<PAGE> 1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 14, 1999
REGISTRATION NO.333-
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
------------------------
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------------
CEPHALON, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 2834 23-2484489
(STATE OR OTHER JURISDICTION OF (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION) CLASSIFICATION NO.)
</TABLE>
145 BRANDYWINE PARKWAY
WEST CHESTER, PA 19380
(610) 344-0200
(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)
------------------------
JOHN E. OSBORN, ESQ.
SENIOR VICE PRESIDENT, GENERAL COUNSEL AND SECRETARY
CEPHALON, INC.
145 BRANDYWINE PARKWAY
WEST CHESTER, PA 19380
(610) 344-0200
(NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE,
OF AGENT FOR SERVICE)
------------------------
COPIES OF ALL COMMUNICATIONS TO:
DAVID R. KING, ESQ.
MORGAN, LEWIS & BOCKIUS LLP
1701 MARKET STREET
PHILADELPHIA, PA 19103
(215) 963-5000
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as
practicable after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [X]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
- ---------------------------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------------------------
PROPOSED
MAXIMUM PROPOSED MAXIMUM
AMOUNT TO BE OFFERING PRICE AGGREGATE OFFERING AMOUNT OF
TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED REGISTERED PER SHARE PRICE(1) REGISTRATION FEE
- ---------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
$3.625 Convertible Exchangeable Preferred Stock.. 2,500,000 shares $50.00 $125,000,000 $36,875.00
- ---------------------------------------------------------------------------------------------------------------------------------
7.25% Convertible Subordinated Debentures..... $125,000,000 -- -- --
- ---------------------------------------------------------------------------------------------------------------------------------
Common Stock, par value $.01 per share........ 6,975,447 shares(2) -- -- --
- ---------------------------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) Estimated solely for the purpose of calculating the registration fee
pursuant to Rule 457(i).
(2) Such number represents the number of shares of Common Stock initially
issuable upon conversion of the Preferred Stock registered hereby and,
pursuant to Rule 416 under the Securities Act of 1933, as amended, such
indeterminable number of shares of Common Stock as may be issued from time
to time upon conversion of the Preferred Stock by reason of adjustment of
the conversion price under certain circumstances outlined in this
Prospectus.
------------------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
MAY DETERMINE.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
SUBJECT TO COMPLETION, DATED OCTOBER 14, 1999
PROSPECTUS
CEPHALON, INC.
2,500,000 SHARES OF $3.625 CONVERTIBLE EXCHANGEABLE PREFERRED STOCK
$125,000,000 7.25% CONVERTIBLE SUBORDINATED DEBENTURES
6,975,447 SHARES OF COMMON STOCK
------------------------
Under this prospectus, the selling stockholders named in this prospectus or
in prospectus supplements may offer and sell the preferred stock, the debentures
issued upon the exchange of the preferred stock and the common stock issued upon
conversion of the preferred stock or the debentures. We will not receive any of
the proceeds of sales by the selling stockholders.
The preferred stock was initially issued at a price of $50 per share. Our
common stock is quoted on the Nasdaq National Market under the symbol "CEPH." On
October 13, 1999 the last reported closing price of our common stock was $16.75
per share.
YOU SHOULD READ THIS PROSPECTUS CAREFULLY BEFORE YOU INVEST. SEE RISK
FACTORS BEGINNING ON PAGE 7 OF THIS PROSPECTUS FOR A DISCUSSION OF THE MATERIAL
RISKS INVOLVED IN INVESTING IN THE SECURITIES.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS ACCURATE OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY CHANGE. WE MAY
NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER
TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE
SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.
------------------------
THE DATE OF THIS PROSPECTUS IS , 1999
<PAGE> 3
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Prospectus Summary.......................................... 1
Risk Factors................................................ 7
Use of Proceeds............................................. 16
Ratio of Earnings to Fixed Charges and Preferred Stock
Dividends................................................. 16
Dividend Policy............................................. 16
Description of Preferred Stock.............................. 17
Description of Debentures................................... 29
Certain Federal Income Tax Consequences..................... 35
Selling Stockholders........................................ 44
Plan of Distribution for the Resale of the Securities....... 45
About this Prospectus....................................... 46
Where You Can Find More Information......................... 46
Forward-Looking Statements.................................. 47
Legal Opinion............................................... 47
Experts..................................................... 47
</TABLE>
i
<PAGE> 4
PROSPECTUS SUMMARY
Because this is a summary, it does not contain all of the details that may
be important to you. You should read this entire prospectus carefully before you
invest.
CEPHALON
Cephalon, Inc. is a biopharmaceutical company dedicated to the discovery,
development and marketing of products to treat neurological disorders and
cancer.
In December 1998, we received approval from the United States Food and Drug
Administration to market PROVIGIL(R), generically called modafinil, Tablets
[C-IV] for treating excessive daytime sleepiness associated with narcolepsy.
PROVIGIL is Cephalon's first approved product in the United States. We initiated
sales of PROVIGIL in the United States in February 1999 with a field sales force
of 45 representatives calling on neurologists and sleep specialists. In June
1999, we entered into a collaboration agreement with Abbott Laboratories, Inc.
to market and further develop GABITRIL(R), generically called tiagabine
hydrochloride, which is a treatment for epilepsy. In connection with this
collaboration, we have recently doubled the size of our United States sales
force to 90 representatives.
We began marketing PROVIGIL in the United Kingdom in March 1998 and in the
Republic of Ireland in February 1999 through our United Kingdom-based sales
organization. We recently initiated promotion of PROVIGIL in Austria.
Additionally, we have rights to commercialize PROVIGIL in Italy and Switzerland,
and applications seeking marketing approval have been filed in those countries.
We also have commercial rights to PROVIGIL in Mexico and we are collaborating
with a corporate partner in Japan to commercialize PROVIGIL in that country.
We have initiated clinical studies exploring the utility of PROVIGIL in
treating excessive daytime sleepiness and fatigue associated with disorders
other than narcolepsy, such as obstructive sleep apnea and multiple sclerosis.
If these studies show that PROVIGIL is useful in treating patients with these
disorders, we intend to perform the additional clinical studies that are
necessary to apply for regulatory approval to market PROVIGIL for these
indications. We also intend to conduct exploratory studies for PROVIGIL in a
number of different disorders, such as depression and attention deficit and
hyperactivity disorder. Our future success is highly dependent on the commercial
success of PROVIGIL in the United States. The "Risk Factors" section on page 7
of this prospectus contains more information about our dependence on PROVIGIL.
We have significant research programs that focus on discovering and
developing treatments for neurological disorders such as Parkinson's disease,
Alzheimer's disease and stroke, and cancers, including prostate and pancreatic
cancers, among others.
Neurodegenerative disorders are characterized by the death of neurons, the
specialized conducting cells of the nervous system. Oncological disorders are
characterized by the uncontrolled proliferation of cells that form tumors. We
utilize our technical expertise in molecular biology, molecular pharmacology,
biochemistry, cell biology, tumor biology and chemistry to develop products in
both of these areas. Our primary research strategy has focused on understanding
the signaling mechanisms within the cell that lead to cell survival and cell
death. This understanding may allow medicinal chemical approaches toward
creating novel, small, orally active, synthetic molecules, so called signal
transduction modulators, which enhance the survival of neurons or which lead to
the death of cancerous cells.
We have formed alliances with TAP Holdings, Inc. for the development of
signal transduction modulators to treat cancers, including prostate and
pancreatic cancers, and H. Lundbeck A/S for the development of signal
transduction modulators to treat neurodegenerative disorders, including
Parkinson's and Alzheimer's disease. TAP is currently conducting Phase I
clinical studies with two molecules, one of
1
<PAGE> 5
which is administered orally and one of which is administered intravenously.
Cephalon and Lundbeck have recently initiated a Phase I clinical study with an
orally administered molecule.
In February 1997, Cephalon and Chiron Corporation submitted a new drug
application to the FDA for approval to market MYOTROPHIN(R) for the treatment of
amyotrophic lateral sclerosis, which is still pending. A similar application in
Europe has been withdrawn. Cephalon cannot predict whether the FDA's conditions
for approval can be met, and the prospects for regulatory approval of MYOTROPHIN
remain highly uncertain.
Cephalon, Inc., headquartered in West Chester, PA, currently markets
pharmaceutical products in five countries, including PROVIGIL and GABITRIL in
the United States.
2
<PAGE> 6
SECURITIES TO BE OFFERED
This prospectus relates to the offer and sale by the selling stockholders
of the following securities:
- 2,500,000 Shares of $3.625 Convertible Exchangeable Preferred Stock
- $125,000,000 7.25% Convertible Subordinated Debentures
- 6,975,447 Shares of Common Stock.
We issued and sold the preferred stock in August 1999 to the initial
purchasers in transactions that were exempt from the registration requirements
imposed by the Securities Act of 1933, as amended. The initial purchasers
reasonably believed that the persons to whom they resold the preferred stock
were "qualified institutional buyers" or QIBs, as defined in Rule 144A under the
Securities Act. Prior to the date of this prospectus, the preferred stock was
eligible for trading on the Private Offerings, Resale and Trading through
Automated Linkages, or PORTAL Market. The preferred stock resold under this
prospectus are no longer eligible for trading on the PORTAL Market.
The following table outlines the key features of the securities:
Securities Offered............ 2,500,000 shares of $3.625 convertible
exchangeable preferred stock, par value $0.01
per share.
Dividends..................... Dividends will be cumulative from the date of
original issue at the annual rate of $3.625 per
share of preferred stock, payable quarterly on
the fifteenth day of February, May, August and
November, commencing November 15, 1999. Any
dividends must be declared by our Board of
Directors and must come from funds which are
legally available for dividend payments.
Conversion Rights............. Unless we redeem or exchange the preferred
stock, the preferred stock can be converted at
your option at any time into shares of common
stock at an initial conversion price of $17.92
(equivalent to a conversion rate of
approximately 2.79 shares of common stock for
each share of preferred stock). The initial
conversion price with respect to the preferred
stock is subject to adjustment in certain
events, including a non-stock fundamental
change or a common stock fundamental change,
which are explained in more detail on page 20
under "Description of Preferred
Stock -- Conversion Rights -- Conversion Price
Adjustment -- Merger, Consolidation or Sale of
Assets."
Liquidation Preference........ $50 per share of preferred stock, plus accrued
and unpaid dividends.
Optional Redemption........... On or after August 17, 2001, we may redeem the
preferred stock, in whole or in part, at our
option, at the following redemption prices
together with accrued dividends:
<TABLE>
<CAPTION>
YEAR REDEMPTION PRICE
---- ----------------
<S> <C> <C>
2001.............................. $52.900
2002.............................. 52.538
2003.............................. 52.175
2004.............................. 51.822
2005.............................. 51.450
2006.............................. 51.088
2007.............................. 50.725
</TABLE>
3
<PAGE> 7
<TABLE>
<CAPTION>
YEAR REDEMPTION PRICE
---- ----------------
<S> <C> <C>
2008.............................. 50.363
Thereafter........................ 50.000
</TABLE>
See "Description of Preferred Stock -- Optional
Redemption."
Voting Rights................. Except as provided by law and in other limited
situations described in this prospectus, you
will not be entitled to any voting rights.
However, you will, among other things, be
entitled to vote as a separate class to elect
two directors if we have not paid the
equivalent of six or more quarterly dividends,
whether or not consecutive. These voting rights
will continue until we pay the full accrued but
unpaid dividends on the preferred stock.
Exchange Provisions........... At our option, we may exchange the preferred
stock in whole, but not in part, on any
dividend payment date beginning on August 15,
2000 for our 7.25% convertible subordinated
debentures. If we elect to exchange the
preferred stock for debentures, the exchange
rate will be $50 principal amount of debentures
for each share of preferred stock. The
debentures, if issued, will mature ten years
after the exchange date.
Debentures.................... The debentures, if issued, will have the
following terms:
Interest Rate............ The debentures will have an interest rate of
7.25% per year. Interest will be payable on
February 15 and August 15 of each year,
beginning on the first interest payment date
after the exchange date.
Redemption............... On or after August 17, 2001 we may redeem the
debentures at the redemption prices listed in
this prospectus, plus accrued interest.
Maturity................. The debentures will mature ten years after the
exchange date.
Conversion............... The debentures may be converted at any time
prior to maturity into common stock at the same
conversion price applicable to the preferred
stock.
Subordination............ The debentures will be subordinated to all of
our senior indebtedness. Neither we nor our
subsidiaries are limited or prohibited by the
indenture from issuing debt.
Use of Proceeds............... See "Use of Proceeds."
Transfer Restrictions......... The preferred stock, the debentures issuable
upon exchange of the preferred stock and the
common stock issuable upon conversion of the
preferred stock and the debentures have not
been registered under the Securities Act. The
preferred stock is being offered and sold only
by "qualified institutional buyers," as defined
in Rule 144A under the Securities Act. The
preferred stock may not be offered or sold
within the United States or to or for the
account or benefit of United States persons
except pursuant to an exemption from, in a
transaction not subject to or in compliance
with the registration requirements of the
Securities Act.
4
<PAGE> 8
Registration Rights........... We have filed with the Securities and Exchange
Commission a shelf registration statement, of
which this prospectus forms a part, with
respect to:
- the resale of the preferred stock;
- the debentures issuable upon exchange
of the preferred stock; and
- the common stock issuable upon
conversion of the preferred stock and
the debentures.
We have agreed to keep the shelf registration
statement effective until two years from the
latest date of initial issuance of the
preferred stock. We will be required to pay
liquidated damages to the holders of the
preferred stock, the debentures issuable upon
exchange of the preferred stock or the common
stock issuable upon conversion of the preferred
stock and the debentures, as the case may be,
under certain circumstances if we are not in
compliance with our registration obligations.
Trading....................... The preferred stock sold in the initial private
placement currently trades in The Portal
Market. However, preferred stock sold pursuant
to this prospectus will no longer be eligible
to trade in The Portal Market. Our common stock
is traded on the Nasdaq National Market under
the symbol "CEPH."
Risk Factors.................. An investment in the preferred stock involves a
high degree of risk. See "Risk Factors" on
pages 7 through 15 for a discussion of certain
factors that should be considered in evaluating
an investment in the preferred stock.
5
<PAGE> 9
FORWARD-LOOKING STATEMENTS
Our disclosure and analysis in this prospectus contain some forward-looking
statements. Forward-looking statements give our current expectations or
forecasts of future events. You can identify these statements by the fact that
they do not relate strictly to historical or current facts. Such statements may
include words such as "anticipate," "estimate, "expect," "project," "intend,"
"plan," "believe" and other words and terms of similar meaning in connection
with any discussion of future operating or financial performance. In particular,
these include statements relating to present or anticipated scientific progress,
development of potential pharmaceutical products, timing of clinical trials,
future revenues and expenses, capital expenditures, funding requirements,
research and development expenditures, future financing and collaborations,
personnel, manufacturing requirements and capabilities, the impact of Year 2000,
and other statements regarding matters that are not historical facts or
statements of current condition.
Any or all of our forward-looking statements in this prospectus may turn
out to be wrong. They can be affected by inaccurate assumptions we might make or
by known or unknown risks and uncertainties. Many factors mentioned in our
discussion in this prospectus will be important in determining future results.
Consequently, no forward-looking statement can be guaranteed. Actual future
results may vary materially.
We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise.
You are advised, however, to consult any additional disclosures we make in our
10-Q, 8-K and 10-K reports to the SEC. Also note that we provide a cautionary
discussion of risks and uncertainties relevant to our business under "Risk
Factors" on page 7 of this prospectus. These are factors that we think could
cause our actual results to differ materially from expected results. Other
factors besides those listed here could also adversely affect us. This
discussion is provided as permitted by the Private Securities Litigation Reform
Act of 1995.
6
<PAGE> 10
RISK FACTORS
You should carefully consider the following risk factors and the other
information presented in this prospectus before deciding to invest in the shares
of preferred stock.
DURING THE NEXT SEVERAL YEARS WE WILL BE VERY DEPENDENT ON THE COMMERCIAL
SUCCESS OF PROVIGIL, AND WE MAY BE UNABLE TO ATTAIN PROFITABILITY ON SALES OF
PROVIGIL.
At our present level of operations, we may not be able to attain
profitability if physicians prescribe PROVIGIL only for those who are diagnosed
narcoleptics, and we may not be able to promote PROVIGIL outside of this
approved use. In December 1998, the FDA approved PROVIGIL for use by those
suffering from excessive daytime sleepiness associated with narcolepsy. The
market for use of PROVIGIL in narcolepsy patients is relatively small; it is
limited to approximately 125,000 persons in the United States, of which we
estimate between 30,000 and 45,000 currently are seeking treatment from a
physician. We have initiated clinical studies to examine whether or not PROVIGIL
is effective and safe when used to treat disorders other than narcolepsy, but we
do not know whether these studies will in fact demonstrate safety and efficacy,
or if they do, whether we will succeed in receiving regulatory approval to
market PROVIGIL for additional disorders. If the results of these studies are
negative, or if adverse experiences are reported in these clinical studies or
otherwise in connection with the use of PROVIGIL by patients, this could
undermine physician and patient comfort with the product, could limit the
commercial success of the product and could even impact the acceptance of
PROVIGIL in the narcolepsy market. Even if the results of these studies are
positive, the impact on sales of PROVIGIL may be negligible unless we are able
to obtain FDA approval to expand the authorized use of PROVIGIL to include
treatment for conditions other than excessive daytime sleepiness associated with
narcolepsy. FDA regulations restrict our ability to communicate the results of
additional clinical studies to patients and physicians without first obtaining
from the FDA approval to expand the authorized uses for this product. As a
result, it may be several years before we have significant sales revenue from
PROVIGIL beyond that attributable to prescriptions for diagnosed narcoleptics.
In addition, the following factors could limit the rate and level of market
acceptance of PROVIGIL:
- the effectiveness of our sales and marketing efforts relative to those of
our competitors;
- the availability and level of reimbursement for PROVIGIL by third-party
payors, including federal, state and foreign government agencies; and
- the occurrence of any side effects, adverse reactions or misuse (or
unfavorable publicity relating thereto) stemming from the use of
PROVIGIL.
We have described these and other factors in more detail below.
Our lack of experience selling pharmaceuticals, together with significant
competition, may impact our ability to effectively market and sell PROVIGIL in
the United States.
In the United States and elsewhere, PROVIGIL faces significant competition
in the marketplace since narcolepsy is currently treated with several drugs, all
of which have been available for a number of years and many of which are
available in inexpensive generic forms. Thus, we will need to demonstrate to
physicians and third party payors that the premium paid for PROVIGIL is
reasonable and appropriate in light of the safety and efficacy of the product
and the related health care benefits to the patient.
As PROVIGIL is used commercially, unintended side effects, adverse reactions or
incidents of misuse may appear that could result in additional regulatory
controls and reduce sales of PROVIGIL.
Until recently, the use of PROVIGIL has been limited to clinical trial
patients under controlled conditions and under the care of expert physicians. We
cannot predict whether the widespread commercial use of PROVIGIL will produce
undesirable or unintended side effects that have not been evident in our
clinical trials to date. As PROVIGIL becomes more widely utilized by significant
numbers of patients who
7
<PAGE> 11
could take multiple medications, adverse drug interactions could occur that are
difficult to predict. Additionally, incidents of product misuse may occur. These
events, among others, could result in litigation and additional regulatory
controls, including withdrawal of the product from the market.
The efforts of government entities and third party payors to contain or reduce
the costs of health care may adversely affect our sales and limit the
commercial success of PROVIGIL.
In certain foreign markets, pricing or profitability of pharmaceutical
products is subject to governmental control. In the United States, there have
been, and we expect there will continue to be, various federal and state
proposals to implement similar government controls. The commercial success of
PROVIGIL could be limited if federal or state governments adopt any such
proposals. In addition, in both the United States and elsewhere, sales of
pharmaceutical products depend in part on the availability of reimbursement to
the consumer from third party payors, such as government and private insurance
plans. Third party payors increasingly challenge the prices charged for
products, and limit reimbursement levels offered to consumers for such products.
If third party payors focus their cost control efforts on PROVIGIL, this could
impair the commercial success of the product.
We may not be able to maintain market exclusivity for PROVIGIL, and therefore
potential competitors may develop competing products, which could result in a
decrease in sales and market share, could cause us to reduce prices to compete
successfully, and may prevent PROVIGIL from being a commercial success.
We hold exclusive license rights to a composition-of-matter patent covering
modafinil as the active drug substance in PROVIGIL; this patent was to have
expired in 1998 in the United States, but we have applied for a patent extension
that, if granted, would run through November 18, 2001. In addition, we own a
United States patent covering the particle size of modafinil which issued in
1997. However, we may not succeed in obtaining any extension for the
composition-of-matter patent, and we cannot guarantee that any of our patents
will be found to be valid if their validity is challenged by a third party, or
that these patents (or any other patent owned or licensed by us) would prevent a
potential competitor from developing competing products or product formulations
that avoid infringement. See "Business -- Patents and Proprietary Technologies."
In the United States, the Orphan Drug Act provides incentives to drug
manufacturers to develop and manufacture drugs for the treatment of rare
disorders. The FDA has granted orphan drug status to PROVIGIL for its use in the
treatment of excessive daytime sleepiness associated with narcolepsy. The grant
of orphan drug status to PROVIGIL allows us a seven-year period of marketing
exclusivity for the product in that indication. While the marketing exclusivity
provided by the orphan drug law should prevent other sponsors from obtaining
approval of the same compound for the same indication (unless the other sponsor
can demonstrate clinical superiority), it would not prevent approval of the
compound for other indications that otherwise are non-exclusive, nor approval of
other kinds of compounds for the same indication.
8
<PAGE> 12
Manufacturing, supply and distribution problems could create supply disruptions
that would damage commercial prospects for PROVIGIL.
We depend upon Laboratoire L. Lafon as our sole supplier of bulk modafinil
compound, the active drug substance contained in PROVIGIL. Moreover, we depend
upon a single manufacturer that is qualified to manufacture finished PROVIGIL
for commercial purposes. We maintain an inventory of modafinil compound to
protect against supply disruptions.
Additionally, a non-active ingredient used in PROVIGIL is no longer
manufactured or commercially available. At anticipated levels of demand, we have
several years supply of this ingredient. We have prepared a new formulation of
PROVIGIL that does not include the now unavailable ingredient, and could enable
us to qualify additional tablet manufacturers with regulatory authorities.
However, the introduction of any such new formulation requires that we show that
the new formulation is bioequivalent to the current one, and also requires
regulatory approval. If we are unable to obtain approval for a new formulation,
or if demand for the product were to exceed expectations, we could face supply
disruptions that would result in significant costs and delays, undermine
goodwill established with physicians and patients, and damage commercial
prospects for PROVIGIL.
We must comply with all applicable regulatory requirements of the FDA and
foreign authorities, including current Good Manufacturing Practice regulations,
or cGMP. The facilities used to manufacture, store and distribute our products
are subject to inspection by regulatory authorities at any time to determine
compliance with regulations. The regulations are complex, and failure to be in
compliance could lead to remedial action, civil and criminal penalties and
delays in production of material.
We rely on several third parties in the United States to formulate, tablet,
package, distribute, provide customer service activities and accept and process
returns. Although we employ a small number of persons to coordinate and manage
the activities undertaken by these third parties, we have relatively limited
experience in this regard. Any disruption in these activities could impede our
ability to sell PROVIGIL and could reduce sales revenue.
OUR SALES OF PROVIGIL AND FINANCIAL RESULTS WILL FLUCTUATE AND THESE
FLUCTUATIONS MAY ADVERSELY AFFECT OUR STOCK PRICE.
A number of the analysts and investors who follow our stock have developed
models to attempt to forecast future PROVIGIL sales and have established
expectations based upon those models. Forecasting revenue is difficult,
especially when there is little commercial history and when market acceptance of
the product is uncertain. Forecasting is further complicated by the difficulties
in estimating stocking levels at pharmaceutical wholesalers and at retail
pharmacies and in estimating potential product returns. As a result it is likely
that there will be significant fluctuations in quarterly revenues, which may not
meet with market expectations and which may adversely affect our stock price.
Other factors which may cause our quarterly financial results to fluctuate
include the cost of PROVIGIL sales, achievement and timing of research and
development milestones, contract and co-promotion revenues, cost and timing of
clinical trials, marketing and other expenses and manufacturing or supply
disruption.
WE ANTICIPATE WE WILL INCUR CONTINUED LOSSES FOR THE NEXT SEVERAL YEARS.
To date, we have not been profitable. At June 30, 1999, our accumulated
deficit was approximately $305 million. Our losses have resulted principally
from costs incurred in research and development, including clinical trials, and
from selling, general and administrative costs associated with our operations.
We expect to continue to incur significant losses for the next several years.
We cannot be sure that we will ever achieve product revenues from PROVIGIL
or from any of our other product candidates sufficient for us to obtain
profitability. We cannot be sure that we or our collaborators will obtain
required regulatory approvals, or successfully develop, commercialize,
manufacture and market any product candidates.
9
<PAGE> 13
THE RESULTS AND TIMING OF FUTURE CLINICAL TRIALS CANNOT BE PREDICTED AND FUTURE
SETBACKS MAY MATERIALLY AFFECT OUR BUSINESS.
We or our collaborators must demonstrate through preclinical testing and
clinical trials that the product candidate is safe and efficacious. The results
from preclinical testing and early clinical trials may not be predictive of
results obtained in subsequent clinical trials, and we cannot be sure that we or
our collaborators' clinical trials will demonstrate the safety and efficacy
necessary to obtain regulatory approval for any product candidates.
A number of companies in the biotechnology and pharmaceutical industries
have suffered significant setbacks in advanced clinical trials, even after
obtaining promising results in earlier trials. In addition, certain clinical
trials are conducted with patients having the most advanced stages of disease.
During the course of treatment, these patients often die or suffer other medical
effects for reasons that may not be related to the pharmaceutical agent being
tested. Such events can hurt the statistical analysis of clinical trial results.
The completion of clinical trials of our product candidates may be delayed
by many factors. One such factor is the rate of enrollment of patients. Neither
we nor our collaborators can control the rate at which patients present
themselves for enrollment, and we cannot be sure that the rate of patient
enrollment will be consistent with our expectations or be sufficient to enable
clinical trials of our product candidates to be completed in a timely manner.
Any significant delays in, or termination of, clinical trials of our product
candidates may have a material adverse effect on our business.
We cannot be sure that we or our collaborators will be permitted by
regulatory authorities to undertake additional clinical trials for any of our
product candidates, or that if such trials are conducted, any of our product
candidates will prove to be safe and efficacious or will receive regulatory
approvals. Any delays in or termination of our or our collaborator's clinical
trial efforts may have a material adverse effect on our business.
OUR RESEARCH AND DEVELOPMENT ACTIVITIES MAY NOT RESULT IN ANY ADDITIONAL
PHARMACEUTICAL PRODUCTS, WHICH MAY ADVERSELY AFFECT OUR BUSINESS.
We are highly focused on the research and development of potential
pharmaceutical products. These activities include engaging in discovery research
and process development, conducting preclinical and clinical studies, and
seeking regulatory approval in the United States and abroad. In all of these
areas, we have relatively limited resources and compete against major
multinational pharmaceutical companies. Moreover, even if we undertake these
activities in an effective and efficient manner, regulatory approval for the
sale of new pharmaceutical products remains highly uncertain since, in our
industry, the majority of compounds fail to enter clinical studies and the
majority of therapeutic candidates entering clinical studies fail to be
commercialized.
OUR RESEARCH AND DEVELOPMENT AND MARKETING EFFORTS ARE HIGHLY DEPENDENT ON
CORPORATE COLLABORATORS WHO MAY NOT DEVOTE SUFFICIENT TIME, RESOURCES AND
ATTENTION TO OUR PROGRAMS, WHICH MAY ADVERSELY IMPACT OUR EFFORTS TO DEVELOP AND
MARKET POTENTIAL PRODUCTS.
Because we have limited resources, we have entered into a number of
agreements with other pharmaceutical companies. These agreements may call for
our partner to control:
- the supply of bulk or formulated drugs for commercial use or for use in
clinical trials;
- the design and execution of clinical studies;
- the process of obtaining regulatory approval to market the product; and
- the marketing and selling of any approved product.
In each of these areas, our partners may not support fully our research and
commercial interests since our program may well compete for time, attention and
resources with the internal programs of our corporate collaborators. As such, we
cannot be sure that our corporate collaborators will share our perspectives on
the relative importance of our program, that they will commit sufficient
resources to our
10
<PAGE> 14
program to move it forward effectively, or that the program will advance as
rapidly as it might if we had retained complete control of all research,
development, regulatory and commercialization decisions. For example, we rely on
several of these collaborators for the production of compounds and the
manufacture and supply of pharmaceutical products. One of them, Kyowa Hakko, has
informed us that they will not be able to meet our increased requirements of the
compound used in our signal transduction modulator program beyond the year 2000.
We have identified alternative manufacturer and Kyowa Hakko is working with us
to transfer technology to them. We cannot be certain that the new manufacturer
will be able to manufacture such compounds or products in sufficient quantities,
at reasonable prices, and in accordance with cGMP requirements established by
the FDA and other regulatory authorities.
WE EXPERIENCE INTENSE COMPETITION IN OUR FIELDS OF INTEREST, WHICH MAY ADVERSELY
AFFECT OUR BUSINESS.
Large and small companies, academic institutions, governmental agencies,
and other public and private research organizations will continue to conduct
research, seek patent protection, and establish collaborative arrangements for
product development. Products developed by any of these entities may compete
directly with those we develop or sell. Many of these companies and institutions
have substantially greater capital resources, research and development staffs
and facilities than us, and substantially greater experience in conducting
clinical trials, obtaining regulatory approvals and manufacturing and marketing
pharmaceutical products. These entities represent significant competition for
us. In addition, competitors who are developing products for the treatment of
neurological or oncological disorders might succeed in developing technologies
and products that are more effective than any that we develop or sell or that
would render our technology and products obsolete or noncompetitive. Competition
and innovation from these or other sources potentially could materially
adversely affect any sales of products that might be developed or are currently
being sold by us or make them obsolete. Advances in current treatment methods
may also adversely affect the market for such products.
WE MAY NOT BE ABLE TO OBTAIN ADEQUATE PATENT PROTECTION EITHER IN THE UNITED
STATES OR ABROAD, WHICH COULD IMPACT OUR ABILITY TO COMPETE EFFECTIVELY.
We place considerable importance on obtaining patent and trade secret
protection for new technologies, products and processes. We intend to file
applications for patents covering the composition of matter or uses of our drug
candidates or our proprietary processes. We also rely on trade secrets, know-
how and continuing technological advancements to support our competitive
position. Although we have entered into confidentiality and invention rights
agreements with our employees, consultants, advisors and collaborators, we
cannot be sure that such agreements will be honored or that we will be able to
effectively protect our rights to our unpatented trade secrets and know-how.
Moreover, we cannot be sure that others will not independently develop
substantially equivalent proprietary information and techniques or otherwise
gain access to our trade secrets and know-how. In addition, many of our
scientific and management personnel have been recruited from other biotechnology
and pharmaceutical companies where they were conducting research in areas
similar to those that we now pursue. As a result, we could be subject to
allegations of trade secret violations and other claims.
In addition, we could incur substantial costs in defending any patent
infringement suits or in asserting any patent rights, including those licensed
to us by third parties, and in defending suits against us or our employees
relating to ownership of or rights to intellectual property. Such disputes could
substantially delay our drug development or commercialization. The U.S. Patent
and Trademark Office or a private party could institute an interference
proceeding involving us in connection with one or more of our patents or patent
applications. Such proceedings could result in an adverse decision as to
priority of invention, in which case we would not be entitled to a patent on the
invention at issue in the interference proceeding. The PTO or a private party
could also institute reexamination proceedings involving us in connection with
one or more of our patents, and such proceedings could result in an adverse
decision as to the validity or scope of the patents.
11
<PAGE> 15
WE ARE INVOLVED IN A NUMBER OF LEGAL PROCEEDINGS THAT, IF ADVERSELY ADJUDICATED
OR SETTLED, COULD MATERIALLY IMPACT OUR FINANCIAL CONDITION.
Cephalon, a current director and officer, and a former officer, have been
named as defendants in a number of civil actions filed in the U.S. District
Court for the Eastern District of Pennsylvania, all of which have been
consolidated into a single class action. The plaintiff class is comprised of
those persons and entities who purchased Cephalon common stock, or traded in
options to buy or sell Cephalon common stock, during the period June 12, 1995
through and including June 7, 1996. Plaintiffs seek to hold defendants liable
for stock trading losses that stem from alleged violations of the U.S.
securities laws and alleged common law negligent misrepresentation. More
specifically, plaintiffs have alleged that statements made by Cephalon and the
named defendants relating to the results of certain clinical studies of
MYOTROPHIN were misleading. We have vigorously defended this lawsuit and believe
that there are valid defenses against the claims, but the defense of the action
is expensive, and the costs of this defense will reduce the amount of insurance
coverage that might otherwise be available to satisfy claims. Therefore, on June
4, 1999, Cephalon entered into a Stipulation of Settlement providing that
Cephalon pay a total of $17,000,000 in full settlement of this action, inclusive
of attorneys fees and expenses. Of this amount, $7,500,000 will be paid by our
directors' and officers' liability insurance carriers; the remaining $9,500,000
will be paid by Cephalon. We have incurred charges to earnings sufficient to
cover the costs of the proposed settlement. On July 30, 1999, the Court entered
an order approving the settlement and a judgment of dismissal with prejudice,
dismissing all claims against the defendants and the order became final on
August 30, 1999. In addition, a further complaint has been filed with the Court
alleging that Cephalon is liable under common law for misrepresentations
concerning the results of the MYOTROPHIN clinical trials, and that Cephalon and
certain of its current and former officers and directors are liable for the
actions of persons who allegedly traded in Cephalon common stock on the basis of
material inside information. We believe that we have valid defenses to all
claims raised in this action and we have filed a motion to dismiss these claims
which is pending with the Court. Moreover, even if there is a judgment against
us, it will not have a material adverse effect on our financial condition or
results of operations.
Due to our involvement in co-promoting STADOL NS, a product of
Bristol-Myers, we are co-defendant in a product liability action brought against
Bristol-Myers. Although we cannot predict with certainty the outcome of this
litigation, we believe that any expenses or damages that we may incur will be
paid by Bristol-Myers under the indemnification provisions of our co-promotion
agreement. As such, we do not believe that this action will have a material
effect on our financial condition or results of operations.
WE FACE SIGNIFICANT PRODUCT LIABILITY RISKS, WHICH MAY HAVE A NEGATIVE EFFECT ON
OUR FINANCIAL PERFORMANCE.
The administration of drugs to humans, whether in clinical trials or
commercially, can result in product liability claims even if our drugs or a
collaborator's drugs are not actually at fault for causing an injury.
Furthermore, our products may cause, or may appear to have caused, adverse side
effects or potentially dangerous drug interactions that we may not learn about
or understand fully until the drug is actually manufactured and sold for some
time. Product liability claims can be expensive to defend and may result in
large judgments or settlements against us, which could have a negative effect on
our financial performance. We maintain product liability insurance at a
relatively limited level, and as such, claims could exceed our coverage.
Furthermore, we cannot be certain that we will always be able to purchase
sufficient insurance at an affordable price. Even if a product liability claim
is not successful, the adverse publicity and time and expense of defending such
a claim may interfere with our business.
WE MAY NEVER OBTAIN APPROVAL TO MARKET MYOTROPHIN, IT MAY NOT BE COST-EFFECTIVE
TO PURSUE MYOTROPHIN FOR OTHER INDICATIONS, AND THEREFORE WE MAY NEVER DERIVE
REVENUE FROM MYOTROPHIN.
Cephalon and Chiron have withdrawn the joint marketing authorization
application for MYOTROPHIN in Europe for the treatment of ALS. We made this
decision because of comments we received from the European reviewer of the
application concerning the results of our two pivotal ALS studies. These
comments led us to believe that the reviewer would not approve our application.
The
12
<PAGE> 16
withdrawal of our marketing authorization application for MYOTROPHIN in Europe
may negatively affect the FDA approval process for MYOTROPHIN in the United
States.
In May 1998, the FDA issued a letter stating that the NDA application
submitted jointly by Cephalon and Chiron to market MYOTROPHIN in the United
States for the treatment of ALS was "potentially approvable," contingent,
however, upon the submission of additional information from ongoing clinical
studies that demonstrates to the satisfaction of the FDA that MYOTROPHIN is
effective in the treatment of ALS. Cephalon and Chiron have had discussions with
the FDA regarding safety and efficacy data and have submitted information from
the ongoing Treatment Investigational New Drug program. The T-IND program is a
compassionate use program that is neither placebo-controlled nor blinded, and
therefore is not designed to produce evidence of efficacy. We are not planning
to submit additional data to the FDA at this time. The study of MYOTROPHIN in
ALS patients being conducted by Kyowa Hakko in Japan is not under our control.
Results from that study may be available in late 1999 but may not satisfy the
FDA's request for additional information. The prospects for regulatory approval
of MYOTROPHIN continue to be very uncertain in the United States. We will
continue to evaluate the prospects of receiving regulatory approval and, based
on communications with the FDA, may determine to withdraw the new drug
application.
If the information submitted to the FDA to date does not prove to be
sufficient for approval, a new study would be necessary, which would be
expensive and would take years to complete. We are not sure whether the
potential profits from sales of MYOTROPHIN would make an additional study
cost-effective to conduct. Even if an additional study were conducted, the
results of a new study may not be sufficient to obtain regulatory approval. If
MYOTROPHIN were not approved for ALS, we are not sure it would be cost-effective
to pursue MYOTROPHIN for any other indication.
THE VALUE OF OUR COMMON STOCK MAY FLUCTUATE SIGNIFICANTLY DUE TO THE VOLATILITY
OF ITS MARKET PRICE AND TRADING VOLUME AND EXERCISE OF OUTSTANDING WARRANTS,
WHICH MAY IMPACT YOUR DECISION TO BUY, SELL OR CONVERT YOUR PREFERRED STOCK TO
COMMON STOCK.
The market price and trading volume of shares of our common stock are
volatile, and we expect it to continue to be volatile for the foreseeable
future. For example, during the previous 52 weeks, our common stock traded at a
high price of $22.13 and a low price of $4.50. Negative announcements (such as
adverse regulatory decisions, disputes concerning patent or other proprietary
rights, or operating results that fall below the market's expectations) could
trigger significant declines in the price of our common stock. In addition, news
concerning certain external events, such as that concerning our competitors or
changes in government regulations that may impact the biotechnology or
pharmaceutical industries, also could affect the price of our common stock. Such
fluctuations with respect to our common stock may, in turn, have an adverse
effect on the market price of the preferred stock.
OUR DEPENDENCE ON KEY EXECUTIVES AND SCIENTISTS COULD IMPACT THE DEVELOPMENT AND
MANAGEMENT OF OUR BUSINESS.
The nature of our business is such that we are highly dependent upon our
ability to attract and retain qualified scientific, technical and managerial
personnel. There is intense competition for qualified personnel in the
pharmaceutical and biotechnology industries, and we cannot be sure that we will
be able to continue to attract and retain qualified personnel necessary for the
development and management of our business. Our research and development
programs and our business might be harmed by the loss of the services of
existing personnel, as well as the failure to recruit additional key scientific,
technical and managerial personnel in a timely manner. Much of the know-how we
have developed resides in our scientific and technical personnel and is not
readily transferable to other personnel. We do not maintain "key man" life
insurance on any of our employees.
13
<PAGE> 17
WE MAY BE REQUIRED TO INCUR SIGNIFICANT COSTS TO COMPLY WITH ENVIRONMENTAL LAWS
AND REGULATIONS AND OUR COMPLIANCE MAY LIMIT ANY FUTURE PROFITABILITY.
Our research and development activities involve the controlled use of
hazardous, infectious and radioactive materials that could be hazardous to human
health, safety or the environment. We store these materials and various wastes
resulting from their use at our facility pending ultimate use and disposal. We
are subject to a variety of federal, state and local laws and regulations
governing the use, generation, manufacture, storage, handling and disposal of
these materials and wastes resulting from their use, and we may be required to
incur significant costs to comply with both existing and future environmental
laws and regulations.
We believe that although our safety procedures for handling and disposing
of these materials comply with federal, state and local laws and regulations,
the risk of accidental injury or contamination from these materials cannot be
entirely eliminated. In the event of an accident, we could be held liable for
any resulting damages.
IF WE ARE UNABLE TO MAINTAIN CERTAIN CASH BALANCES UNDER THE TERMS OF OUR
REVENUE SHARING NOTES, HOLDERS OF OUR REVENUE SHARING NOTES HAVE THE RIGHT TO AN
INCREASED ROYALTY PERCENTAGE, WHICH WILL INCREASE OUR ROYALTY EXPENSE, AND MAY
HAVE THE RIGHT TO ACCELERATE THE NOTES AND FORECLOSE ON THE SECURITY, WHICH WILL
RESULT IN THE LOSS OF OUR RIGHTS TO PROVIGIL.
The notes contain a number of covenants, including a requirement to
maintain cash, cash equivalent and short-term investment balances of $40,000,000
through December 31, 1999 and $30,000,000 through February 2002 or as long as
the principal remains outstanding. This requirement to maintain cash and cash
equivalent balances may limit our flexibility to use our cash resources for
other corporate purposes. The notes are secured by our licenses, patents and FDA
rights relating to PROVIGIL. The notes also require us to pay a royalty of 6% on
net United States PROVIGIL sales for 5 years, which we may reduce to 4 years
under certain circumstances. If we fail to maintain the required cash balances,
the holders of the notes can declare a default and increase the royalty
percentage to 25% of net United States PROVIGIL sales and, if the default is not
cured within one year, can accelerate the due date of the notes and foreclose on
the security. The holders of the notes can also foreclose on the security if we
fail to pay principal and interest when due or violate certain other covenants.
THE YEAR 2000 ISSUE MAY CAUSE COMPLIANCE FAILURE AND SERVICE INTERRUPTIONS IN
OUR BUSINESS OR OPERATIONS IF CERTAIN OF OUR SUPPLIERS OR VENDORS ARE UNABLE TO
BECOME YEAR 2000 COMPLIANT WHICH MAY CAUSE US TO INCUR ADDITIONAL EXPENSE.
The "Year 2000 Issue" is typically the result of software and firmware
being written using two digits rather than four to define the applicable year.
If our software and firmware with date-sensitive functions are not Year 2000
compliant, these systems may recognize a date using "00" as the year 1900 rather
than the year 2000.
We have completed minor modifications to our computer systems and at this
time we do not expect the Year 2000 Issue to pose a significant internal
operational problem. However, we cannot be sure that the systems of other
companies on which we rely will be compliant on or before January 1, 2000 and
will not have an adverse effect on our operations. We have initiated formal
communication with significant suppliers and third party vendors to determine
the extent to which our operations are vulnerable to those third parties'
failure to remediate their own Year 2000 hardware and software issues.
Significant suppliers or third party vendors that are unable to become Year 2000
compliant could adversely affect our business or operations. We are also
vulnerable to external forces that might generally affect industry and commerce,
such as utility or transportation company Year 2000 compliance failures and
related service interruptions. We have not yet fully developed a comprehensive
contingency plan addressing situations that may result if we are unable to
achieve Year 2000 readiness of our critical operations.
14
<PAGE> 18
ANTI-TAKEOVER PROVISIONS MAY DETER A THIRD PARTY FROM ACQUIRING CEPHALON,
LIMITING OUR STOCKHOLDERS' ABILITY TO PROFIT FROM SUCH A TRANSACTION.
Our Board of Directors has the authority to issue up to 5,000,000 shares of
preferred stock, $0.01 par value, of which 1,000,000 have been reserved for
issuance in connection with our stockholder rights plan, and to determine the
price, rights, preferences and privileges of those shares without any further
vote or action by our stockholders. The preferred stock being offered by this
offering circular was established pursuant to these provisions. While we have no
present intention to issue shares of preferred stock, except as contemplated by
this offering circular, such issuance, while providing desirable flexibility in
connection with possible acquisitions and other corporate purposes, could have
the effect of making it more difficult for a third party to acquire a majority
of our outstanding voting stock.
In addition, we are subject to the anti-takeover provisions of Section 203
of the Delaware Corporation Law, which prohibits us from engaging in a "business
combination" with an "interested stockholder" for a period of three years after
the date of the transaction in which the person becomes an interested
stockholder, unless the business combination is approved in a prescribed manner.
The application of Section 203 could have the effect of delaying or preventing a
change of control of Cephalon. We also have adopted a "poison pill" rights plan
that will dilute the stock ownership of an acquiror of our stock upon the
occurrence of certain events. Section 203, the rights plan, and the provisions
of our certificate of incorporation, our bylaws and Delaware corporate law, may
have the effect of deterring hostile takeovers or delaying or preventing changes
in control of our management, including transactions in which stockholders might
otherwise receive a premium for their shares over then current market prices.
THE LIMITED MARKET FOR PREFERRED STOCK AND DEBENTURES MAY LIMIT INVESTORS'
ABILITY TO SELL THEIR HOLDINGS.
The preferred stock is a new issue of securities for which there is
currently no public market. We cannot be sure that a liquid trading market in
the preferred stock will develop. We are not obligated to list the preferred
stock or the debentures on the Nasdaq National Market System or on a national
securities exchange and we do not intend to do so. We cannot be sure that a
market in the preferred stock or debentures will develop.
YOU SHOULD NOT EXPECT TO RECEIVE DIVIDENDS ON OUR COMMON STOCK.
We have not paid cash dividends on our common stock and we do not expect to
do so in the foreseeable future.
WE MAY NOT BE ABLE TO PAY DIVIDENDS AND OTHER DISTRIBUTIONS ON PREFERRED STOCK,
WHICH COULD IMPAIR THE VALUE OF YOUR INVESTMENT.
Under Delaware law, dividends or distributions to stockholders may be made
only from the surplus of a company, or, in certain situations, from the net
profits for the current fiscal year or the fiscal year before which the dividend
or distribution is declared. Our ability to pay dividends in the future will
depend upon our financial results, liquidity and financial condition. We have no
history of generating positive cash flow or profits to make periodic dividend
payments, and we cannot be sure that we will have the surplus or profit
necessary to pay any dividends. We cannot be sure that we will be able to pay
the quarterly installments of the cumulative annual dividend on the preferred
stock or make any other distributions.
THE TAX CONSEQUENCES OF EXCHANGING PREFERRED STOCK FOR DEBENTURES MAY RESULT IN
TAX LIABILITIES TO INVESTORS.
An exchange of preferred stock for debentures will be a taxable event for
federal income tax purposes which may result in tax liability to the holder
without any corresponding receipt of cash by the holder.
15
<PAGE> 19
USE OF PROCEEDS
We will not receive any of the proceeds from the sale of the securities
covered by this prospectus.
RATIO OF EARNINGS TO FIXED CHARGES
AND PREFERRED STOCK DIVIDENDS
Because of our historic losses, we have experienced a deficiency of
earnings available to cover fixed charges throughout our existence. We did not
declare or pay any dividends on the preferred stock during any of the fiscal
years in the five year period ended December 31, 1999 or in the six months ended
June 30, 1999. For these reasons, we have not provided a ratio of earning to
fixed charges and preferred stock dividends.
We have computed the deficiency of earnings available to cover fixed
charges by adding loss from continuing operations before income taxes minus
fixed charges. Fixed charges consist of interest on all indebtedness and
amortization of discount on all indebtedness.
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, SIX MONTHS
---------------------------------------------------- ENDED JUNE 30,
1998 1997 1996 1995 1994 1999
-------- -------- -------- -------- -------- --------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Deficiency of earnings available
to cover fixed charges........ ($53,533) ($57,218) ($50,999) ($29,891) ($34,639) ($28,052)
======== ======== ======== ======== ======== ========
</TABLE>
DIVIDEND POLICY
We have not paid any dividends on our common stock since our inception and
we do not anticipate paying any dividends on our common stock in the foreseeable
future.
16
<PAGE> 20
DESCRIPTION OF PREFERRED STOCK
The following is a summary of some, but not all, of the terms of the
preferred stock. You should refer to the actual terms of the preferred stock and
the Certificate of Designations filed with the Secretary of State of the State
of Delaware and filed as an exhibit to this registration statement. As used in
this description, the words "we," "us" or "our" do not include any current or
future subsidiary of Cephalon.
GENERAL
Our board of directors has the authority, without stockholder approval, to
issue up to 5,000,000 shares of preferred stock in one or more series and to
determine the rights, privileges and limitations of the preferred stock. Of
these 5,000,000 shares of preferred stock:
- 2,500,000 shares are the $3.625 Convertible Exchangeable Preferred Stock
that we issued in our August 1999 private placement; and
- 1,000,000 shares have been reserved for issuance in connection with our
stockholder rights plan.
Different series of preferred stock may have different rights, privileges and
limitations.
In the description, we refer to our $3.625 Convertible Exchangeable
Preferred stock as the "preferred stock." The shares of preferred stock are duly
and validly issued, fully paid and nonassessable. You will not have any
preemptive rights if we issue other series of preferred stock. The preferred
stock is not subject to any sinking fund. We have no obligation to redeem or
retire the preferred stock. The preferred stock has a perpetual maturity,
subject to your right to convert the preferred stock and our right to exchange
or redeem the preferred stock. Any preferred stock converted, exchanged or
redeemed or acquired by us will, upon cancellation, have the status of
authorized but unissued shares of preferred stock. We will be able to reissue
these cancelled shares of preferred stock.
DIVIDENDS
When and if declared by our board of directors out of the legally available
funds, you will be entitled to receive cash dividends at an annual rate of
$3.625 per share of preferred stock. Dividends will be payable quarterly on
February 15, May 15, August 15 and November 15, beginning November 15, 1999. In
the case of any accrued but unpaid dividends, we will pay dividends at
additional times and for interim periods, if any, as determined by our board of
directors. Dividends on the preferred stock will be cumulative from the issue
date. Dividends will be payable to holders of record as they appear on our stock
books not more than 60 days nor less than 10 days preceding the payment dates,
as fixed by our board of directors. If the preferred stock is called for
redemption on a redemption date between the dividend record date and the
dividend payment date and you do not convert the preferred stock (as described
below), you shall receive the dividend payment together with all other accrued
and unpaid dividends on the redemption date instead of receiving the dividend on
the dividend date. Dividends payable on the preferred stock for any period
greater or less than a full dividend period will be computed on the basis of a
360-day year consisting of twelve 30-day months. Accrued but unpaid dividends
will not bear interest.
If we do not pay or set aside dividends in full on the preferred stock and
any other preferred stock ranking on the same basis as to dividends, all
dividends declared upon shares of the preferred stock and any other preferred
stock will be declared on a pro rata basis. For these purposes, "pro rata" means
that the amount of dividends declared per share on the preferred stock and any
other preferred stock bear to each other will be the same ratio that accrued and
unpaid dividends per share on the shares of the preferred stock and such other
preferred stock bear to each other. Except as described above, we will not be
able to redeem, purchase or otherwise acquire any of our stock ranking on the
same basis as the
17
<PAGE> 21
preferred stock as to dividends or liquidation preferences unless we have paid
or set aside full cumulative dividends, if any, accrued on all outstanding
shares of preferred stock.
Unless we have paid or set aside full cumulative dividends, if any, accrued
on all outstanding shares of preferred stock and any other of our preferred
stock ranking on the same basis as to dividends:
- we may not declare or pay or set aside dividends on common stock or any
other stock ranking junior to the preferred stock as to dividends or
liquidation preferences, excluding dividends or distributions of shares,
options, warrants or rights to purchase common stock or other stock
ranking junior to the preferred stock as to dividends; or
- we will not be able to redeem, purchase or otherwise acquire any of our
other stock ranking junior to the preferred stock as to dividends or
liquidation preferences.
Under Delaware law, we may only make dividends or distributions to our
stockholders from:
- our surplus; or
- the net profits for the current fiscal year or the fiscal year before
which the dividend or distribution is declared under certain
circumstances.
Our ability to pay dividends and make any other distributions in the future will
depend upon our financial results, liquidity and financial condition.
CONVERSION RIGHTS
General
You may convert the preferred stock at any time into a number of shares of
common stock determined by dividing the $50 liquidation preference by the
conversion price of $17.92, subject to adjustment as described below. This
conversion price is equivalent to a conversion rate of approximately 2.79 shares
of common stock for each share of preferred stock. We will not make any
adjustment for accrued or unpaid dividends or for common stock dividends upon
conversion. We will not issue fractional shares of common stock upon conversion.
However, we will instead pay cash for each fractional share based upon the
market price of the common stock on the last business day prior to the
conversion date. If we call the preferred stock for redemption, your right to
convert the preferred stock will expire at the close of business on the next
business day preceding the date fixed for redemption, unless we fail to pay the
redemption price.
In order to convert your shares of preferred stock, you must either:
- deliver your preferred stock certificate at the transfer agent office and
a duly signed and completed notice of conversion, or
- if the preferred stock is held in global form, according to the
procedures set forth below under "Form, Denomination and Registration."
The conversion date will be the date you deliver your preferred stock
certificate and the duly signed and completed notice of conversion to the
transfer agent. You will not be required to pay any taxes or duties on
conversion, but will be required to pay any tax or duty payable as a result of
the common stock upon conversion being issued other than in your name. We will
not issue common stock certificates unless all taxes and duties, if any, have
been paid by the holder.
Conversion Price Adjustment -- General
The conversion price of $17.92 will be adjusted if:
(1) we dividend or distribute common stock on shares of our common
stock;
(2) we subdivide or combine our common stock;
18
<PAGE> 22
(3) we issue to all holders of common stock certain rights or warrants
to purchase our common stock at less than 95% of the lesser of:
- the closing sale price on the issue date of these securities; or
- the average of the closing prices of our common stock for the ten
trading day period ending on the issue date of these securities;
(4) we dividend or distribute to all holders of our common stock
shares of our capital stock or evidences of indebtedness or assets,
excluding:
- those rights, warrants, dividends or distributions referred to in
(1) or (3), or
- dividends and distributions paid exclusively in cash;
(5) we make a dividend or distribution consisting exclusively of cash
to all holders of common stock if the aggregate amount of these
distributions that, combined together with (A) all other all-cash
distributions made within the preceding 12 months for which we made no
adjustment plus (B) any cash and the fair market value of other
consideration payable in any tender offers by us or any of our subsidiaries
for common stock concluded within the preceding 12 months for which we made
no adjustment, exceeds 10% of our market capitalization;
(6) we purchase common stock pursuant to a tender offer made by us or
any of our subsidiaries to the extent that involves an aggregate
consideration that, together with (A) any cash and the fair market value of
any other consideration payable in any other tender offer by us or any of
our subsidiaries for common stock expiring within the preceding 12 months
plus (B) the aggregate amount of the all-cash distributions referred to in
(5) above to all holders of common stock within the preceding 12 months
exceeds 10% of our market capitalization on the expiration of the tender
offer;
(7) payment on a tender offer or exchange offer by a person other than
us or any of our subsidiaries if, as of the closing of the offer, the board
of directors is not recommending rejection of the offer; and
(8) we issue common stock or securities convertible or exchangeable
for common stock at a price or conversion price or exchange price per share
that is less than 95% of the lesser of (A) the closing sale price on the
issue date of the securities or (B) the average of the closing prices of
the common stock for the ten trading day period immediately prior to the
date of issuance of the securities, but excluding issuances:
- pursuant to any plan for our employees, directors or consultants;
- to acquire a business in an arm's-length transaction between us and
an unaffiliated third party;
- in a public offering pursuant to a firm commitment underwriting;
- sales at the market pursuant to a continuous offering stock
program;
- pursuant to the exercise of warrants, rights or options, or upon
conversion of convertible securities, at a fair value and with an
exercise price or conversion price at least equal to the lesser of
(A) the closing sale price on the issue date of the securities or
(B) the average of the closing prices of the common stock for the
ten trading day period immediately prior to the issue date of the
securities at the time of issuance of the warrant, right, option or
convertible security; and
- pursuant to a dividend reinvestment plan or other plan for the
reinvestment of dividends or interest provided that such common
stock is issued at a price at least equal to 95% of the lesser of
(A) the closing sale price on the issue date of the securities or
(B) the
19
<PAGE> 23
average of the closing prices for the ten trading day period
immediately prior to the issue date of the securities.
Instead of making adjustments under (5) above, we may provide that upon
conversion holders will receive, in addition to the common stock issuable upon
conversion, the amount of the distribution referred to in (5) above. We will
only make the adjustment referred to in (7) above if the tender or exchange
offer increases a person's ownership to more than 25% of our outstanding common
stock, and only if the payment per share of common stock exceeds the current
market price of our common stock. We will not make the adjustment referred to in
(7) above if the offering documents disclose our plan to engage in any
consolidation, merger, or transfer of all or substantially all of our properties
to any other U.S. corporation, so long as each share of preferred stock will:
- remain outstanding,
- will be unaffected, or
- will be converted into or exchanged for preferred stock having rights,
preferences and limitations substantially similar, but no less
favorable, to the preferred stock.
For purposes of the above adjustments, "market capitalization" means the product
of the lesser of:
- the closing sale price on the issue date of the securities, or
- the average of the closing prices of the common stock for the ten
trading day period immediately prior to the issue date of the
securities,
multiplied by number of shares of common stock outstanding on the record date
for such distribution.
We may reduce the conversion price of the preferred stock if our board of
directors determines that this decrease would be in the best interests of
Cephalon. Any reduction in the conversion price shall be effective for any
period of at least 20 days. We are required to give 15 days prior notice of any
reduction. We may, at our option, reduce the conversion price if our board of
directors deems it advisable to avoid or diminish any income tax to holders of
common stock resulting from any dividend or distribution of stock or rights to
acquire stock or from any event treated as such for income tax purposes. See
"Certain Federal Income Tax Consequences."
No adjustment will be made in the conversion price unless the adjustment
would require a change of at least 1% in the conversion price. However, any
adjustment less than 1% will be carried forward and taken into account in any
subsequent adjustment. We will not adjust the conversion price for the issuance
of common stock or any securities convertible into or exchangeable for common
stock or carrying the right to purchase any common stock or convertible or
exchangeable securities except as stated above.
Conversion Price Adjustment -- Merger, Consolidation or Sale of Assets
If we are involved in a transaction in which shares of our common stock are
converted into the right to receive other securities, cash or other property, or
a sale or transfer of all or substantially all of our assets under which the
holders of our common stock shall be entitled to receive other securities, cash
or other property, then appropriate provision shall be made so that your
preferred stock will convert into:
(1) if the transaction is a common stock fundamental change (as
defined below), common stock of the kind received by holders of common
stock as a result of common stock fundamental change in accordance with (1)
below under "-- Fundamental Change Conversion Price Adjustments", and
(2) if the transaction is not a common stock fundamental change, and
subject to funds being legally available at conversion, the kind and amount
of the securities, cash or other property that would have been receivable
upon the recapitalization, reclassification, consolidation, merger, sale,
transfer or share exchange by a holder of the number of shares of common
stock issuable upon conversion of the preferred stock immediately prior to
the recapitalization, reclassification, consolidation, merger, sale,
transfer or share exchange, after giving effect to any adjustment in the
20
<PAGE> 24
conversion price in accordance with (2) below under "-- Fundamental Change
Conversion Price Adjustments."
The company formed by the consolidation, merger, asset acquisition or share
acquisition shall provide for this right in its organizational document. This
organizational document shall also provide for adjustments so that the
organizational document shall be as nearly practicably equivalent to adjustments
in this section for events occurring after the effective date of the
organizational document.
The following types of transactions, among others, would be covered by this
adjustment:
(1) we recapitalize or reclassify our common stock, except for:
- a change in par value,
- a change from par value to no par value,
- a change from no par value to par value, or
- a subdivision or combination of our common stock,
(2) we consolidate or merge into any other person, or any merger of
another person into us, except for a merger that does not result in a
reclassification, conversion, exchange or cancellation of common stock.
(3) we sell, transfer or lease all or substantially all of our assets
and holders of our common stock become entitled to receive other
securities, cash or other property, or
(4) we undertake any compulsory share exchange.
Fundamental Change Conversion Price Adjustments. If a fundamental change
occurs, the conversion price will be adjusted as follows:
(1) in the case of a common stock fundamental change, the conversion
price shall be the conversion price after giving effect to any other prior
adjustments effected pursuant to the preceding paragraphs, multiplied by a
fraction, the numerator of which is the purchaser stock price and the
denominator of which is the applicable price. However, in the event of a
common stock fundamental change in which:
(A) 100% of the value of the consideration received by a holder of
our common stock is common stock of the successor, acquiror or other
third party, and cash, if any, paid with respect to any fractional
interests in such common stock resulting from such common stock
fundamental change, and
(B) all of our common stock shall have been exchanged for,
converted into or acquired for, common stock of the successor, acquiror
or other third party, and any cash with respect to fractional interests,
the conversion price shall be the conversion price in effect immediately
prior to such common stock fundamental change multiplied by a fraction, the
numerator of which is one (1) and the denominator of which is the number of
shares of common stock of the successor, acquiror or other third party
received by a holder of one share of our common stock as a result of the
common stock fundamental change; and
(2) in the case of a non-stock fundamental change, the conversion
price shall be the lower of:
(A) the conversion price after giving effect to any other prior
adjustments effected pursuant to the preceding paragraphs, and
21
<PAGE> 25
(B) the product of:
(1) the applicable price, and
(2) a fraction, the numerator of which is $50 and the
denominator of which is (x) the amount of the redemption price for
one share of preferred stock if the redemption date were the date of
the non-stock fundamental change, or the date of the period beginning
on the issue date of the preferred stock and through August 15, 2000
or the twelve-month period commencing August 15, 2000, the product of
107.25% and 106.53%, respectively, times $50 plus (y) any
then-accrued and unpaid distributions on one share of preferred
stock.
You may receive significantly different consideration upon conversion
depending upon whether a fundamental change is a non-stock fundamental change or
a common stock fundamental change. In the event of a non-stock fundamental
change, your preferred stock will convert into stock and other securities or
property or assets, including cash, determined by the number of shares of common
stock receivable upon conversion at the conversion price as adjusted in
accordance with (2) above. In the event of a common stock fundamental change,
under certain circumstances you will receive different consideration depending
on whether you convert your preferred stock on or after the common stock
fundamental change. For example, you will receive common stock if you convert
your preferred stock following a common stock fundamental change in which less
than 100% of the value of the consideration received by a holder of common stock
is common stock of the successor, acquirer or other third party. However, if you
had converted your preferred stock prior to the common stock fundamental change,
you would have received consideration in the form of such common stock as well
as any other securities or assets, including cash, issuable upon conversion of
such preferred stock immediately prior to the common stock fundamental change.
Definitions for the Fundamental Change Adjustment Provision.
"applicable price" means:
- in a non-stock fundamental change in which the holders of common
stock receive only cash, the amount of cash received by a holder of
one share of common stock, and
- in the event of any other fundamental change, the average of the
daily closing price for one share of common stock during the 10
trading days immediately prior to the record date for the
determination of the holders of common stock entitled to receive
cash, securities, property or other assets in connection with the
fundamental change or, if there is no such record date, prior to
the date upon which the holders of common stock shall have the
right to receive such cash, securities, property or other assets.
"common stock fundamental change" means any fundamental change in
which more than 50% of the value, as determined in good faith by our board
of directors, of the consideration received by holders of our common stock
consists of common stock that, for the 10 trading days immediately prior to
such fundamental change, has been admitted for listing or admitted for
listing subject to notice of issuance on a national securities exchange or
quoted on Nasdaq National Market, except that a fundamental change shall
not be a common stock fundamental change unless either:
- we continue to exist after the occurrence of the fundamental change
and the outstanding preferred stock continues to exist as
outstanding preferred stock, or
- not later than the occurrence of the fundamental change, the
outstanding preferred stock is converted into or exchanged for
shares of convertible preferred stock, which convertible preferred
stock has rights, preferences and limitations substantially
similar, but no less favorable, to those of the preferred stock.
"fundamental change" means the occurrence of any transaction or event
or series of transactions or events pursuant to which all or substantially
all of our common stock shall be exchanged for, converted into, acquired
for or shall constitute solely the right to receive cash, securities,
property or
22
<PAGE> 26
other assets, whether by means of an exchange offer, liquidation, tender
offer, consolidation, merger, combination, reclassification,
recapitalization or otherwise. However, for purposes of adjustment of the
conversion price, in the case of any series of transactions or events, the
fundamental change shall be deemed to have occurred when substantially all
of the common stock shall have been exchanged for, converted into or
acquired for, or shall constitute solely the right to receive, such cash,
securities, property or other assets, but the adjustment shall be based
upon the consideration that the holders of our common stock received in the
transaction or event as a result of which more than 50% of our common stock
shall have been exchanged for, converted into or acquired for, or shall
constitute solely the right to receive, such cash, securities, property or
other assets.
"non-stock fundamental change" means any fundamental change other than
a common stock fundamental change.
"purchaser stock price" means the average of the daily closing price
for one share of the common stock received by holders of the common stock
in the common stock fundamental change during the 10 trading days
immediately prior to the date fixed for the determination of the holders of
the common stock entitled to receive such common stock or, if there is no
such date, prior to the date upon which the holders of the common stock
shall have the right to receive such common stock.
LIQUIDATION RIGHTS
In the event of our liquidation, you shall receive a liquidation preference
of $50 per share and all accrued and unpaid dividends through the distribution
date. For purposes of this section, the term "liquidation" refers to either a
liquidation, dissolution or winding up of Cephalon. Holders of any class or
series of preferred stock ranking on the same basis as your preferred stock as
to liquidation shall also be entitled to receive the full respective liquidation
preferences and any accrued and unpaid dividends through the distribution date.
Only after the preferred stock holders have received their liquidation
preference and any accrued and unpaid dividends will we distribute assets to
common stock holders or any of our other stock ranking junior to the shares of
preferred stock upon liquidation. If upon liquidation we do not have enough
assets to pay in full the amounts due on the preferred stock and any other
preferred stock ranking on the same basis with your preferred stock as to
liquidation, you and the holders of such other preferred stock will share
ratably in any such distributions of our assets:
- first in proportion to the liquidation preferences until the preferences
are paid in full, and
- then in proportion to the amounts of accrued but unpaid dividends.
After we pay any liquidation preference and accrued dividends, you will not be
entitled to participate any further in the distribution of our assets. The
following events will not be deemed to be a liquidation of Cephalon:
(1) The sale of all or substantially all of the assets, or
(2) our merger or consolidation into or with any other corporation,
our liquidation, dissolution, winding up or reorganization immediately
followed by a reincorporation of another corporation.
OPTIONAL REDEMPTION
On or after August 17, 2001 we may redeem the preferred stock, out of
legally available funds, in whole or in part, at our option, at the redemption
prices listed below. The redemption price is as follows
23
<PAGE> 27
for the period beginning August 15 of the following years, beginning August 17,
2001 and ending on August 14, 2002 in the case of the first period:
<TABLE>
<CAPTION>
REDEMPTION
YEAR PRICE
- ---- ----------
<S> <C>
2001.............................................. $52.900
2002.............................................. 52.538
2003.............................................. 52.175
2004.............................................. 51.822
2005.............................................. 51.450
2006.............................................. 51.088
2007.............................................. 50.725
2008.............................................. 50.363
</TABLE>
and $50.00 at August 15, 2009 and thereafter. In each case we will pay accrued
and unpaid dividends to, but excluding, the redemption date. We are required to
give notice of redemption not more than 60 and not less than 20 days before the
redemption date.
If we redeem less than all of the shares of preferred stock, we shall
select the shares to be redeemed by lot or pro rata or in some other equitable
manner in our sole discretion. Dividends shall cease to accrue on the preferred
stock to be redeemed on or after the redemption date so long as we have paid or
provided for payment for the redemption price and any accrued and unpaid
dividends to, but excluding, the redemption date. Thereafter, the preferred
stock to be redeemed will not be outstanding and your rights as a holder of such
shares shall cease, except your right to receive the redemption price and
accrued and unpaid dividends, without interest, upon surrender of the preferred
stock certificates.
EXCHANGE PROVISIONS
We may exchange the preferred stock in whole, but not in part, for
debentures on any dividend payment date on or after August 15, 2000 at the rate
of $50 principal amount of debentures for each outstanding share of preferred
stock. Debentures will be issuable in denominations of $1,000 and integral
multiples of $1,000. See "Description of Debentures." If the exchange results in
an amount of debentures that is not an integral multiple of $1,000, we will pay
in cash an amount in excess of the closest integral multiple of $1,000. We will
mail written notice of our intention to exchange the preferred stock to each
record holder not less than 30 nor more than 60 days prior to the exchange date.
We refer to the date fixed for exchange of the preferred stock for
debentures as the "exchange date." On the exchange date, your rights as a
stockholder of Cephalon shall cease. Your shares of preferred stock will no
longer be outstanding, and will only represent the right to receive the
debentures and any accrued and unpaid dividends, without interest. We may not
exercise our option to exchange the preferred stock for the debentures if:
- full cumulative dividends on the preferred stock to the exchange date
have not been paid or set aside for payment, or
- an event of default under the indenture has occurred and is continuing.
The exchange of preferred stock for debentures will be a taxable event, since
holders will be exchanging their preferred stock for debt and we will not make
any related cash payment to the holder. See "Certain Federal Income Tax
Consequences."
VOTING RIGHTS
You will have no voting rights except as described below or as required by
law. Each outstanding share of preferred stock will be entitled to one vote.
Shares held by us or any or our affiliates will not have any voting rights.
24
<PAGE> 28
If we have not paid dividends on the preferred stock or on any outstanding
shares of preferred stock ranking on the same basis as to dividends with the
preferred stock in an aggregate amount equal to at least six quarterly dividends
whether or not consecutive, our board of directors will be increased by two. So
long as dividends remain due and unpaid, holders of the preferred stock voting
separately as a class with holders of preferred stock ranking on the same basis
as to dividends having like voting rights will be entitled to elect two
additional directors at any meeting of stockholders at which directors are to be
elected. These voting rights will terminate when we have declared and either
paid or set aside for payment accrued and unpaid dividends. The terms of office
of all directors so elected will terminate immediately upon the termination of
these voting rights.
In addition, without the vote or consent of as least the majority of
holders of preferred stock, we may not:
- adversely change the rights, preferences and limitations of the
preferred stock by modifying our restated certificate of incorporation
or bylaws, or
- authorize, issue, reclassify, increase the authorized amount, or
authorize or issue any convertible obligation or security or right to
purchase any class of stock that ranks senior to or on the same basis
with the preferred stock as to dividends or distributions of assets
upon liquidation, dissolution or winding up of the stock.
Without the vote or consent of the holders of at least a majority of the
preferred stock we may not:
- enter into a share exchange that affects the preferred stock,
- consolidate with or merge into another entity, or
- permit another entity to consolidate with or merge into us,
unless the preferred stock remains outstanding and unaffected or is converted
into or exchanged for convertible preferred stock of the surviving entity having
rights, preferences and limitations substantially similar, but no less
favorable, to the preferred stock, except for changes that do not affect the
holders of the preferred stock adversely.
In determining a majority under these voting provisions, holders of
preferred stock will vote together with holders of any other preferred stock
that rank on parity as to dividends and that have like voting rights.
REGISTRATION RIGHTS
We entered into a registration rights agreement in connection with our
initial issuance of preferred stock. We are filing this registration statement
pursuant to our obligations under this registration rights agreement. Under the
registration rights agreement, we are required to:
- file, at our expense, with the Commission as promptly as practicable,
a shelf registration statement covering resales of transfer restricted
securities,
- use all reasonable efforts to cause such registration statement to
become effective as promptly as is practicable,
- use all reasonable efforts to keep the registration statement
effective until the earlier of two years after the latest date of
initial issuance or until the shelf registration statement is no
longer required to transfer any transfer restricted securities.
25
<PAGE> 29
When we use the term "transfer restricted securities" in this section we
mean the preferred stock, any debenture issued upon exchange of the preferred
stock, and any common stock issued upon conversion of the preferred stock and
the debentures until the earlier of the following events:
- the date on which the preferred stock, debentures or common stock has
been effectively registered under the Securities Act of 1933 and
disposed of in accordance with the shelf registration statement, or
- the date on which the preferred stock, debentures or common stock is
distributed to the public pursuant to Rule 144 under the Securities
Act of 1933 or is salable pursuant to Rule 144(k) under the Securities
Act of 1933, or
- the date on which the preferred stock, debentures or common stock
ceases to be outstanding.
We will be required to pay liquidated damages if one of the following
"registration defaults" occurs:
- we do not file the shelf registration statement within 60 days after
the closing date of the initial private placement of the preferred
stock,
- the SEC has not declared the shelf registration statement effective
within 180 days after the closing date, or
- the shelf registration statement is declared effective but later
ceases to be effective or usable for a period of time more than 90
days in the aggregate in any period of 365 consecutive days.
If a registration default occurs, we will pay liquidated damages to each
holder of preferred stock, debentures or common stock issued upon conversion
that are transfer restricted securities during the first 90-day period
immediately following the occurrence of the registration default in an amount
equal to an additional one-quarter of one percent (0.25%) per year of the
liquidation amount or principal amount or on an equivalent basis per share for
the common stock. Liquidated damages will increase to one-half of one percent
(0.50%) per year of the liquidation amount or principal amount or an equivalent
amount per week per share for the common stock, in each case, that are transfer
restricted securities for each subsequent 90-day period until the registration
default is cured up to a maximum amount of liquidated damages of 1.25% per year.
Liquidated damages will cease to accrue following the cure of any registration
default. All accrued liquidated damages shall be paid to the holders of
preferred stock on the relevant dividend payment dates. All accrued liquidated
damages shall be paid to holders of debentures and any common stock issued upon
conversion on the relevant interest payment dates. We may suspend the use of the
shelf registration statement in certain circumstances described in the
registration rights agreement if we notify holders of the transfer restricted
securities. However, you will have the right to receive liquidated damages if
the aggregate number of days of suspensions in any year exceeds the periods
described above.
We will provide to each registered holder copies of such prospectus, notify
the holders when the shelf registration statement has become effective and take
certain other actions as are required to permit unrestricted resales of the
transfer restricted securities. We will agree to give notice to all holders of
the filing and effectiveness of the shelf registration statement.
You will need to complete a questionnaire prior to any intended
distribution of transfer restricted securities pursuant to the shelf
registration statement. You may request a copy of this questionnaire from
Cephalon. You are required to complete and deliver the questionnaire prior to
the effectiveness of the shelf registration statement so that you may be named
as selling stockholders in the related prospectus at the time of effectiveness.
Upon receipt of such a completed questionnaire and any other information we may
reasonably request, after effectiveness we will, as promptly as practicable but
in any event within five business days of such receipt, file such amendments to
the shelf registration statements or supplements to the related prospectus as
are necessary to permit a holder to deliver such prospectus to purchasers of
transfer restricted securities, subject to our right to suspend the use of the
prospectus. We will pay liquidated damages if we fail to timely make such filing
or, if such filing is a post-effective amendment of the shelf registration
statement required to be declared effective under the Securities Act of 1933, if
such amendment is not declared effective within 45 days of the filing. If you do
not complete and deliver a
26
<PAGE> 30
questionnaire or provide us with other information we may request, you will not
be named as a selling stockholder in the prospectus and will not be permitted to
sell any transfer restricted securities pursuant to the shelf registration
statement. A holder who sells the transfer restricted securities pursuant to the
shelf registration statement will be required to deliver a prospectus to
purchasers and will be bound by the provisions of the registration rights
agreement.
GLOBAL PREFERRED STOCK
Preferred stock sold pursuant to this registration statement will be
evidenced by a global certificate which will be deposited with, or on behalf of,
DTC and registered in the name of Cede & Co. as DTC's nominee. Except as set
forth below, the global certificate may be transferred, in whole or in part,
only to another nominee of DTC or to a successor of DTC or its nominee.
Purchasers may hold their interests in the global certificate directly
through DTC or indirectly through organizations which are participants in DTC.
Transfers between participants will be effected in the ordinary way in
accordance with DTC rules and will be settled in clearing house funds. The laws
of some states require that certain persons take physical delivery of securities
in definitive form. Consequently, the ability to transfer beneficial interests
in the global certificate to such persons may be limited.
Purchasers may beneficially own interests in the global certificate held by
DTC only through participants, or certain banks, brokers, dealers, trust
companies and other parties that clear through or maintain a custodial
relationship, with a Participant, either directly or indirectly through indirect
participants. So long as Cede & Co., as the nominee of DTC, is the registered
owner of the global certificate, Cede & Co. for all purposes will be considered
the sole holder of the global certificate. Except as provided below, owners of
beneficial interests in the global certificate will not be entitled to have
certificates registered in their names, will not receive or be entitled to
receive physical delivery of certificates in definitive form, and will not be
considered the holders.
Payment of dividends on and the redemption price of the global certificate
will be made to Cede & Co. by wire transfer of immediately available funds.
Neither we, the trustee nor any paying agent will have any responsibility or
liability for any aspect of the records relating to or payments made on account
of beneficial ownership interests in the global certificate or for maintaining,
supervising or reviewing any records relating to such beneficial ownership
interests.
We have been informed by DTC that, with respect to any payment of dividends
on or the redemption price of the global certificate, DTC's practice is to
credit participants' accounts on the payment date with payments in amounts
proportionate to their respective beneficial interests in the preferred stock
represented by the global certificate as shown on the records of DTC, unless DTC
has reason to believe that it will not receive payment on such payment date.
Payments by participants to owners of beneficial interests in preferred stock
represented by the global certificate held through such participants will be the
responsibility of such participants, as is now the case with securities held for
the accounts of customers registered in "street name."
Because DTC can only act on behalf of participants, who in turn act on
behalf of indirect participants and certain banks, the ability of a person
having a beneficial interest in preferred stock represented by the global
certificate to pledge such interest to persons or entities that do not
participate in the DTC system, or otherwise take actions in respect of such
interest, may be affected by the lack of a physical certificate evidencing such
interest.
Neither we, the transfer agent, registrar, paying agent nor conversion
agent will have any responsibility for the performance by DTC or its
participants or indirect participants under the rules and procedures governing
their operations. DTC has advised us that it will take any action permitted to
be taken by a holder of preferred stock only at the direction of one or more
participants to whose account with DTC interests in the global certificate are
credited and only in respect of the amount of shares of the preferred stock
represented by the global certificate as to which the participant has given this
direction.
27
<PAGE> 31
DTC is a limited purpose trust company organized under the laws of the
State of New York, a member of the Federal Reserve System, a "clearing
corporation" within the meaning of the Uniform Commercial Code and a "clearing
agency" registered pursuant to the provisions of Section 17A of the Exchange
Act. DTC was created to hold securities for its participants and to facilitate
the clearance and settlement of securities transactions between participants
through electronic book-entry changes to accounts of its participants, thereby
eliminating the need for physical movement of certificates. participants include
securities brokers and dealers, banks, trust companies and clearing
corporations. Certain participants together with other entities own DTC.
Indirect access to the DTC system is available to others such as banks, brokers,
dealers and trust companies that clear through, or maintain a custodial
relationship with, a participant, either directly or indirectly.
If DTC is at any time unwilling or unable to continue as depositary and a
successor depositary is not appointed by us within 90 days, we will cause
preferred stock to be issued in definitive form in exchange for the global
certificate.
TRANSFER AGENT AND REGISTRAR
StockTrans, Inc. will act as transfer agent and registrar for the preferred
stock.
28
<PAGE> 32
DESCRIPTION OF DEBENTURES
If we elect to issue debentures in exchange for the preferred stock, we
will issue the debentures under an indenture between us and State Street Bank
and Trust Company, as trustee. The following summarizes some, but not all, of
the provisions of the indenture and the debentures. You should refer to the
actual terms of the indenture and the debentures for the definitive terms and
conditions that have been filed as an exhibit to this registration statement. As
used in this description, the words "we," "us" or "our" do not include any
current or future subsidiary of Cephalon.
If we elect to issue debentures for preferred stock, we will issue the
debentures at a rate of $50 principal amount of debentures for each share of
preferred stock that we exchange. The debentures will be general, unsecured,
subordinated obligations of Cephalon. The debentures will be limited to an
aggregate principal amount equal to the aggregate liquidation value of the
outstanding preferred stock, excluding accrued and unpaid dividends payable upon
liquidation. The debentures will mature ten years after the exchange date,
unless earlier converted by a holder or redeemed at our option.
The debentures will be issued only in fully registered form, without
coupons, in denominations of $1,000 and any integral multiple of $1,000. You
will not be required to pay a service charge for registration of transfer or
exchange of the debentures. We may, however, require you to pay any tax or other
governmental charge payable in the transaction.
We will maintain an office in New York, New York where payments will be
made on the debentures and where transfer of debentures will be registrable.
Initially, this office will be an office or agency of the trustee in New York,
New York.
The debentures will be issued in the same form as the preferred stock for
which debentures were exchanged. Any global certificates will be replaced with
one or more global debentures as described above under "Description of Preferred
Stock -- Form, Denomination and Registration." Debentures may be issued in
certificated form in exchange for a global debenture under limited specified
circumstances.
We are not restricted from paying dividends or repurchasing securities
under the indenture. We are not subject to any financial covenants under the
indenture.
INTEREST
The debentures will bear interest at the rate of 7.25% per year. Interest
will be paid on February 15 and August 15 each year to the record holder on the
preceding February 1 and August 1. Interest will be computed on the basis of a
360-day year consisting of twelve 30-day months. We may, at our option, pay
interest in the debentures by check mailed to the holders. However, holders of
more than $2,000,000 in principal amount of debentures will be paid by wire
transfer in immediately available funds at the holder's election.
CONVERSION RIGHTS
Holders may convert their debentures at any time prior to maturity, subject
to prior redemption, at a conversion price of $17.92, subject to adjustment as
described below. Except as described in this section, the conversion provisions
of the debentures will be identical to the conversion provisions of the
preferred stock. See "Description of Preferred Stock -- Conversion Rights." If
you convert your debentures after a record date and prior to the next interest
payment date, you will have to pay us interest unless the debentures have been
called for redemption. We are not required to issue fractional shares of common
stock upon conversion of debentures. Instead, we will pay a cash adjustment
based upon the market price of the common stock on the last business day prior
to the date of conversion. If the debentures are called for redemption, your
conversion rights will expire at the close of business on the business day
preceding the redemption date, unless we default in the payment of the
redemption price.
In order to convert your debentures, you must deliver the debenture at the
specified office of a conversion agent, along with a duly signed and completed
notice of conversion and any interest that may
29
<PAGE> 33
be required as described in the preceding paragraph. The conversion date shall
be the date on which you deliver the debenture, the duly signed and completed
notice of conversion and any required interest payments as described in the
preceding paragraph.
You will not be required to pay any taxes or duties payable for the issue
or delivery of common stock on conversion. You will, however, be required to pay
any tax or duty payable as a result of the issuance of common stock upon
conversion in a name other than your name. We will not issue or deliver common
stock unless all taxes and duties, if any, have been paid by the holder.
SUBORDINATION
The debentures are subordinated to the prior payment in full of all senior
indebtedness as provided in the indenture. Upon any distribution of our assets
upon our dissolution, winding up, liquidation or reorganization, the payments on
the debentures will be subordinated to the prior payment in full of all senior
indebtedness. However, holders of debentures may receive securities that are
subordinated at least to the same extent as the debentures are subordinated to
senior indebtedness and any securities issued in exchange for senior
indebtedness under the indenture.
If the debentures are accelerated as a result of an event of default,
holders of all senior indebtedness will be entitled to payment in full in cash
before the holders of the debentures will be entitled to receive any payment on
the debentures. We are required to promptly notify holders of senior
indebtedness if payment of the debentures is accelerated because of an event of
default.
We may not make any payment on the debentures if:
- a default in the payment of senior indebtedness occurs and is
continuing beyond any period of grace, or
- any other default occurs and is continuing under any designated senior
indebtedness that permits holders of designated senior indebtedness to
accelerate its maturity, and the trustee receives a notice known as a
payment blockage notice from us or any other person permitted to give
such notice under the indenture.
We may resume making payments on the debentures:
- in the case of a payment default, upon the date on which such default
is cured or waived or ceases to exist, and
- in case of any other default, the earlier of the date on which such
other default is cured or waived or ceases to exist or 179 days after
receipt of the payment blockage notice, unless the maturity of any
senior indebtedness is accelerated.
No new period of payment blockage arising due to a default other than a
payment default may be commenced unless:
- 365 days have elapsed since the effectiveness of the immediately prior
payment blockage notice, and
- all scheduled payments on the debentures have been paid in full in
cash.
No default other than a payment default that existed or was continuing on the
date of delivery of any payment blockage notice to the trustee shall be the
basis for a subsequent payment blockage notice.
By reason of the subordination provisions, in the event of our bankruptcy,
dissolution or reorganization, holders of senior indebtedness may receive more,
and holders of the debentures may receive less, than our other creditors. These
subordination provisions will not prevent the occurrence of any event of default
under the indenture.
"senior indebtedness" means the principal, premium, if any, and interest on
any indebtedness of Cephalon, including bankruptcy interest or any other payment
on indebtedness, whether outstanding on the
30
<PAGE> 34
date of the indenture or thereafter created, incurred, assumed, guaranteed or in
effect guaranteed by us including all deferrals or renewals or amendments or
modifications. However, senior indebtedness does not include:
- indebtedness evidenced by the debentures,
- any liability for federal, state, local or other taxes owed or owing
by us,
- our indebtedness to any of our subsidiaries,
- any of our trade payables incurred in the ordinary course of business,
and
- any indebtedness that expressly provides that the indebtedness shall
not be senior in right of payment to, or is on the same basis with, or
is subordinated or junior to, the debentures.
"indebtedness" means:
(1) all obligations:
- for borrowed money,
- evidenced by a note, debenture, bond or other written instrument,
- under a lease required to be capitalized on the balance sheet of
the lessee under generally accepted accounting principles,
- under any lease or related document, including a purchase
agreement, that provides that we are contractually obligated to
purchase or cause a third party to purchase and thereby guarantee a
minimum residual value of the lease property to the lessor and our
obligations under this lease or related document to purchase or to
cause a third party to purchase such leased property,
- letters of credit, bank guarantees or bankers' acceptances,
including reimbursement obligations,
- indebtedness secured by a mortgage, pledge, lien, encumbrance,
charge or adverse claim affecting title in an encumbrance to which
the property or assets of the person are subject,
- the balance of deferred and unpaid purchase price of any property
or assets,
- under interest rate or currency swap agreements, cap, floor and
collar agreements, spot and forward contracts and similar
agreements and arrangements;
(2) any obligation of others of the type described in the preceding
(1) or under (3) below assumed by or guaranteed or in effect guaranteed
through an agreement to purchase; and
(3) any deferrals, renewals or amendments or modifications of (1) and
(2) above.
"designated senior indebtedness" means any particular senior indebtedness
that expressly provides that such senior indebtedness shall be designated senior
indebtedness for purposes of the indenture.
If the trustee or any holder of debentures receives any payment or
distribution of our assets of any kind in contravention of the indenture, then
this payment or distribution will be held by the recipient in trust for the
benefit of the holders of senior indebtedness and will be immediately paid over
or delivered to the holders of senior indebtedness or their representatives.
As of June 30, 1999, we had approximately $40.4 million of indebtedness
outstanding. Neither we not our subsidiaries are limited or prohibited from
incurring additional debt.
OPTIONAL REDEMPTION
On or after August 17, 2001, we may redeem the debentures, in whole or in
part, at our option, at the redemption prices listed below. The redemption
prices, expressed as a percentage of the principal amount,
31
<PAGE> 35
are as follows for the 12-month periods beginning August 15 of the following
years, beginning August 17, 2001 and ending on August 14, 2002 in the case of
the first period.
<TABLE>
<CAPTION>
REDEMPTION
YEAR PRICE
- ---- ----------
<S> <C>
2001.............................................. 105.80%
2002.............................................. 105.08
2003.............................................. 104.35
2004.............................................. 103.64
2005.............................................. 102.90
2006.............................................. 102.18
2007.............................................. 101.45
2008.............................................. 100.73
</TABLE>
and 100% at August 15, 2009 and thereafter. In each case we will pay accrued
interest to, but excluding, the redemption date. If the redemption date is an
interest payment date, we will pay interest to the record holders as of the
relevant record date. We are required to give notice not more than 60 and not
less than 20 days before the redemption date.
If fewer than all the debentures are to be redeemed, the trustee will
select the debentures to be redeemed in principal amounts of $1,000 or multiples
of 1,000 by lot or, in its discretion, on a pro rata basis. If any debenture is
partially redeemed, we will issue a new debenture in principal amount equal to
the unredeemed principal portion. If a portion of a holder's debentures is
selected for partial redemption and the holder converts the debentures, the
converted portion shall be deemed to be taken from the portion selected for
redemption.
No sinking fund is provided for the debentures, which means that we are not
required under the indenture to redeem or retire the debentures periodically.
EVENTS OF DEFAULT AND REMEDIES
The following events are "events of default" under the indenture:
- we fail to pay the principal or premium, if any, on the debentures,
whether or not prohibited by the subordination provisions of the
indenture;
- we fail to pay interest on the debentures when due and this failure
continues for 30 days, whether or not prohibited by the subordination
provisions of the indenture;
- we fail to perform any covenant in the indenture and this failure
continues for 45 days after notice is given in accordance with the
indenture;
- we fail to pay at maturity, including any applicable grace period, in an
amount of indebtedness in excess of $5,000,000 and this failure continues
for 30 days after notice given in accordance with the indenture;
- a default by us on any indebtedness that results in the acceleration of
indebtedness in an amount in excess of $5,000,000, without the
indebtedness being discharged or the acceleration being rescinded or
annulled for 30 days after notice given in accordance with the indenture;
or
- events involving our bankruptcy, insolvency or reorganization.
The trustee is required to give notice to holders of all uncured defaults
known to the trustee within 90 days after the occurrence of the default.
However, the trustee may withhold this notice if it determines in good faith
that it is in the best interest of the holders, except notice of:
- a default in the payment of the principal or premium, if any, or interest
on the debentures, or
- a default in the payment of any redemption obligation.
32
<PAGE> 36
If an event of default has occurred and is continuing, the trustee or the
holders of not less than 25% in aggregate principal amount of outstanding
debentures may declare the principal and premium, if any, on the debentures and
accrued interest on the debentures to be immediately due and payable. However,
if we cure all defaults, except payment defaults on the debentures as a result
of the acceleration, and we meet certain conditions, this acceleration
declaration may be canceled and past defaults may be waived by the holders of a
majority in principal amount of outstanding debentures. If an event of default
resulting from events of bankruptcy, insolvency or reorganization were to occur,
all unpaid principal and accrued interest on outstanding debentures will become
due and payable immediately without any declaration or other act on the part of
the trustee or any holders of debentures, subject to certain limitations.
Holders of a majority in principal amount of the outstanding debentures
may, subject to certain limitations, direct the time, method and place of
conducting any proceeding for any remedy available to the trustee or exercising
any trust or power conferred on the trustee. The trustee shall be entitled to
receive from holders reasonable security or indemnity against any costs,
expenses and liabilities incurred by the trustee. Before you may institute a
proceeding which respect to the indenture, each of the following must occur:
- you must have given the trustee written notice of a continuing event
of default;
- the holders of at least 25% of the aggregate principal amount of all
outstanding debentures must make a written request of the trustee to
take action because of the default;
- holders must have offered reasonable indemnification to the trustee
against the cost, expenses and liabilities of taking action; and
- the trustee must not have taken action for 60 days after the receipt
of such notice and offer of indemnification.
These limitations do not apply to a suit for the enforcement of payment of
the principal of or any premium or interest on a debenture or the right to
convert the debenture in accordance with the indenture.
Generally, the holders of not less than a majority of the aggregate
principal amount of outstanding debentures may waive any default or event of
default, except if:
- we fail to pay principal, premium or interest on any debenture when
due;
- we fail to convert any debenture into common stock; or
- we fail to comply with any of the provisions of the indenture that
would require the consent of the holder of each outstanding debenture
affected.
We will send the trustee annually a statement as to whether we are in
default and the nature of any default under the indenture.
LIMITATION ON MERGER, SALE OR CONSOLIDATION
We may not consolidate with or merge with or into another person or sell,
lease, convey or transfer all or substantially all of its assets a consolidated
basis, whether in a single or series of related transactions, to another person
or group of affiliated persons, unless:
- either (A) we are the surviving entity or (B) the resulting entity is
a U.S. corporation and expressly assumes in writing all of our
obligations under the debentures and the indenture;
- no default or event of default exists or shall occur immediately after
giving effect to the transaction; and
- other specified conditions are satisfied.
33
<PAGE> 37
MODIFICATIONS OF THE INDENTURE
The consent of the holders of a majority in principal amount of outstanding
debentures at the time is required to modify or amend the indenture or any
supplemental indenture. However, a modification or amendment would require the
consent of the holder of each outstanding debenture affected if it would:
- extend the fixed maturity of any debenture;
- reduce the rate or extend the time for payment of interest on any
debenture;
- reduce the principal amount or any premium of any debenture;
- reduce any amount payable upon redemption of any debenture;
- impair or adversely affect a holder's right to institute suit for the
payment on any debenture;
- change the currency in which the debentures are payable;
- impair or adversely change the right to convert the debentures;
- adversely modify the subordination provisions of the debentures; or
- reduce the percentage required to consent to modifications and
amendments.
TAXATION OF DEBENTURES
You should read "Certain Federal Income Tax Consequences" for a discussion
of the federal tax considerations which may apply to you as a debenture holder.
GOVERNING LAW
The indenture and the debentures will be governed by the laws of the State
of New York.
CONCERNING THE TRUSTEE
We have accepted the trustee as the initial paying agent, conversion agent,
registrar and custodian for the debentures. We may maintain deposit accounts and
conduct other banking transactions with the trustee or its affiliates in the
ordinary course of business. In addition, the trustee and its affiliates may in
the future provide banking and other services to us in the ordinary course of
their business. If there is an event of default under the indenture, the trustee
will:
- exercise the rights and powers given to the trustee under the indenture
and
- use the same degree and care and skill in its exercise as a prudent
person would exercise under the circumstances in the conduct of the
person's own affairs.
If the trustee becomes one of our creditors, the indenture and the Trust
Indenture Act of 1939 may limit the trustee from obtaining payment of claims in
certain cases or realizing on certain property received by the trustee.
34
<PAGE> 38
CERTAIN FEDERAL INCOME TAX CONSEQUENCES
The following summary of the material federal income tax consequences of
acquiring and owning the preferred stock and the debentures is based on the
Internal Revenue Code of 1986, as amended (the "Code"), Treasury regulations,
court decisions, and Internal Revenue Service ("IRS") rulings now in effect, all
of which are subject to change. Prospective purchasers should particularly note
that any such change could have retroactive application to the preferred stock
and debentures acquired through this offering. In particular, prospective
purchasers of the preferred stock should be aware that the tax consequences
summarized below do not reflect any changes to existing law contained in H.R.
2488, the "Taxpayer Refund and Relief Act of 1999," passed by the United States
Senate and House of Representatives on August 5, 1999, which if enacted into law
in its current form, could impact the tax consequences of acquiring, holding and
disposing of the preferred stock, the debentures, and the common stock.
This summary assumes that the preferred stock is acquired at its original
offering at its original issue price and that the preferred stock and the
debentures are held as capital assets, within the meaning of section 1221 of the
Code, and does not address all of the tax consequences that may be relevant to
particular shareholders in light of their personal circumstances, or to certain
types of shareholders (such as certain financial institutions, dealers in
securities or commodities, insurance companies, regulated investment companies,
personal holding companies, corporations subject to the alternative minimum tax,
tax-exempt organizations or persons who hold the preferred stock or debentures
as positions in a "straddle" or as part of a "hedging", "conversion" or
"constructive sale" transaction for United States federal income tax purposes).
Also not addressed are the consequences under estate, state, local and foreign
tax laws or the tax consequences to subsequent holders of the preferred stock
and debentures. Prospective purchasers are advised to consult their own tax
advisors regarding the tax consequences of acquiring, holding, or disposing of
the preferred stock or debentures in light of their own investment
circumstances.
CHARACTERIZATION OF PREFERRED STOCK AND DEBENTURES
Under section 385(c) of the Code, our characterization of the preferred
stock as "stock" is binding upon us and all holders of the preferred stock,
other than holders who disclose on their tax returns that they are treating the
preferred stock in a manner inconsistent with such characterization. Although
our characterization of the preferred stock is not binding upon the IRS or any
court, this summary assumes that the preferred stock will be treated in a manner
consistent with our characterization. Holders should be aware that if the
preferred stock is treated as debt for federal income tax purposes, the tax
consequences of acquiring, holding and disposing of the preferred stock will
differ materially from the tax consequences described in this prospectus. The
following discussion assumes that the debentures will be treated as debt for
federal income tax purposes.
DISTRIBUTIONS ON PREFERRED STOCK
Distributions with respect to the preferred stock will constitute
dividends, taxable at ordinary income tax rates, to the extent that we have
current or accumulated earnings and profits for federal income tax purposes.
Dividends paid to corporations will generally be eligible for the
dividends-received deduction under section 243 of the Code, subject to the
limitations contained in sections 246 and 246A of the Code.
In general, the dividends-received deduction is available only if the stock
in respect of which a dividend is paid has been held for at least 46 days during
the 90-day period beginning on the date which is 45 days before the date on
which the stock becomes ex-dividend (the "Ex-dividend Date"), or at least 91
days during the 180-day period beginning on the date which is 90 days before the
Ex-dividend Date in the case of a dividend paid with respect to preferred stock
and which is attributable to a period or periods aggregating more than 366 days.
A taxpayer's holding period for these purposes is reduced by periods during
which the taxpayer's risk of loss with respect to the stock is considered
diminished by reason of the existence of options, contracts to sell or other
similar transactions. It is possible that the IRS may contend that days during
which our redemption right is outstanding or, alternatively, is "in the money"
are not
35
<PAGE> 39
included in an investor's holding period for these purposes. The
dividends-received deduction will not be available to the extent that the
taxpayer is under an obligation to make related payments with respect to
positions in substantially similar or related property. The dividends-received
deduction is limited to specified percentages of the holder's taxable income and
may be reduced or eliminated if the holder has indebtedness "directly
attributable to [its] investment" in the stock. Prospective corporate purchasers
of preferred stock should consult their own tax advisors to determine whether
these limitations might apply to them. In particular, prospective corporate
purchasers of the preferred stock should carefully consider the provisions
contained in the Clinton Administration's Fiscal Year 2000 budget proposal (the
"Proposal"), which may reduce or eliminate entirely the amount of the
dividends-received deduction. It is impossible to predict whether the provisions
contained in the Proposal will be enacted into law in their current form, or the
effective date of such provisions. Prospective corporate purchasers should be
aware, however, that many of the provisions contained in the Proposal have
retroactive effective dates.
If distributions with respect to the shares of preferred stock exceed our
current and accumulated earnings and profits, the excess will be applied against
and reduce the holder's tax basis in the preferred stock. Any amount in excess
of the amount of the dividend and the amount applied against basis will be
treated as capital gain.
EXTRAORDINARY DIVIDENDS
If a corporate holder of preferred stock receives an "extraordinary
dividend" from Cephalon with respect to stock which it has not held for more
than two years before the dividend announcement date, the basis of the preferred
stock will be reduced (but not below zero) by the portion of the dividend which
is not taxable because of the dividends-received deduction. If, because of the
limitation on reducing basis below zero, any amount of the non-taxable portion
of an extraordinary dividend has not been applied to reduce basis, such amount
will be treated as gain from the sale or exchange of stock in the taxable year
in which the extraordinary dividend is received. An "extraordinary dividend" on
the preferred stock would include a dividend that (i) equals or exceeds 5% of
the holder's adjusted tax basis in the stock, treating all dividends having
ex-dividend dates within an 85-day period as one dividend, or (ii) exceeds 20%
of the holder's adjusted tax basis in the stock, treating all dividends having
ex-dividend dates within a 365-day period as one dividend. A holder may elect to
use the fair market value of the stock rather than its adjusted basis for
purposes of applying the 5% or 20% limitation if the holder is able to establish
such fair market value to the satisfaction of the IRS.
Special rules apply with respect to "qualified preferred dividends." A
qualified preferred dividend is any fixed dividend payable with respect to
preferred stock which (i) provides for fixed preferred dividends payable no less
often than annually and (ii) is not in arrears as to dividends when acquired,
provided the actual rate of return, as determined under section 1059(e)(3) of
the Code, on such stock does not exceed 15%. Where a qualified preferred
dividend exceeds the 5% or 20% limitation described above, the extraordinary
dividend rules will not apply if the taxpayer holds the stock for more than five
years. If the taxpayer disposes of the stock before it has been held for more
than five years, the aggregate reduction in basis will not exceed the excess of
the qualified preferred dividends paid on such stock during the period held by
the taxpayer over the qualified preferred dividends that would have been paid
during such period on the basis of the stated rate of return as determined under
section 1059(e)(3) of the Code. The length of time that a taxpayer is deemed to
have held stock for this purpose is determined under principles similar to those
applicable for purposes of the dividends-received deduction discussed above.
REDEMPTION PREMIUM
If (a) preferred stock is, like the preferred stock, redeemable only at the
issuer's option, (b) the facts and circumstances on the issue date indicate that
redemption is more likely than not to occur, and (c) the redemption price of the
preferred stock as of the most likely redemption date exceeds the issue price
(so that there is a "redemption premium"), then the redemption premium may be
taxable as a dividend to the extent of the issuing corporation's current or
accumulated earnings and profits over the period from issuance to the most
likely redemption date. If a redemption premium is subject to the foregoing
36
<PAGE> 40
treatment, a holder of the preferred stock would take the amount of the premium
into income under an economic accrual method similar to the method described
under "Original Issue Discount and Premiums on Debentures" below. Under
applicable Treasury regulations, a redemption premium is not subject to the
foregoing treatment if it will be paid "as a result of changes in economic or
market conditions over which neither the issuer nor the holder has legal or
practical control" and is "solely in the nature of a penalty for premature
redemption." The regulations also provide a "safe harbor," pursuant to which a
redemption will not be treated as likely to occur, as to a given holder, if: (x)
the issuer and the holder are not "related" under certain tests prescribed by
the Code, (y) the issuer is not effectively required or compelled by any plan,
arrangement, or agreement to redeem the stock, and (z) redemption would not
reduce the yield of the stock. Because the foregoing tests are based upon an
evaluation of all facts and circumstances surrounding the issuance and
redemption of preferred stock, the conclusion cannot be entirely certain;
however, it is Cephalon's belief that no part of the premium payable upon
redemption of the preferred stock will be treated as a constructive dividend to
the holders of the preferred stock. It is also possible that upon an actual
redemption, the redemption premium would, together with the other redemption
proceeds, be treated as a dividend for federal income tax purposes. See
"Redemption for Cash," below.
REDEMPTION FOR CASH
A redemption of shares of preferred stock by Cephalon for cash will be
treated as a distribution taxable as a dividend (and, possibly, an
"extraordinary dividend" -- see above) to redeeming shareholders to the extent
of Cephalon's current or accumulated earnings and profits unless the redemption:
- results in a "complete termination" of the shareholder's interest in
Cephalon (within the meaning of section 302(b)(3) of the Code);
- is "substantially disproportionate" (within the meaning of section
302(b)(2)) with respect to the holder; or
- is "not essentially equivalent to a dividend" (within the meaning of
section 302(b)(1)).
Based upon published IRS rulings, the redemption of a stockholder's
preferred stock for cash will be treated as "not essentially equivalent to a
dividend" if, taking into account the constructive ownership rules, (1) the
shareholder does not own shares of any other class in the Company, either
directly or by attribution, and (2) there is a meaningful reduction in the
holder's proportionate interest in Cephalon. In determining whether any of these
tests has been met, shares considered to be owned by the holder by reason of the
constructive ownership rules set forth in section 318 of the Code, as well as
shares actually owned, will be taken into account. If any of the foregoing tests
is met, the redemption of shares of preferred stock for cash will result in
taxable gain or loss equal to the difference between the amount of cash received
(except cash attributable to accrued, unpaid, declared dividends, which will be
taxable as a dividend described above), and the holder's tax basis in the
redeemed shares. Any such gain or loss will be capital gain or loss and will be
long-term capital gain or loss, taxable (in the case of individuals) at a
maximum rate of 20%, if the holding period exceeds one year. It is possible that
the IRS may contend that the holding period of preferred stock does not begin so
long as Cephalon's redemption right is outstanding.
EXCHANGE FOR DEBENTURES
An exchange of shares of preferred stock for debentures would also be
subject to the rules of section 302 of the Code described above. Since a holder
of debentures will be treated under the constructive ownership rules as owning
the common stock into which the debentures are convertible, the exchange would
not by itself satisfy the "complete termination" tests or the "substantially
disproportionate" test described above. The "not essentially equivalent to a
dividend" test could be met only if the exchange were regarded as resulting in a
meaningful reduction in the holder's proportionate interest in Cephalon. If none
of these tests is met, the fair market value of the debentures received upon the
exchange will be taxable as a dividend (and, in the case of a corporate holder,
as an "extraordinary dividend" -- see above) to the extent of Cephalon's current
or accumulated earnings and profits and then would be treated as a
37
<PAGE> 41
return of capital to the extent of the holder's tax basis in the preferred
stock. If the fair market value of the debentures exceeds the amounts treated as
a dividend and as a return of capital, any such excess would be treated as
capital gain.
In the event that receipt of the debentures is taxable as a dividend, the
basis of the debentures will be equal to their fair market value as of the date
of the exchange. If the holder retains any stock in Cephalon, the remaining tax
basis in the preferred stock will be transferred to such retained stock. If the
holder retains no stock in Cephalon, it is unclear whether the remaining tax
basis in the preferred stock would be transferred to the debentures or would be
lost. For purposes of determining the recognition of gain under the
extraordinary dividend basis reduction rules described above, only the basis of
the shares of preferred stock exchanged for the debentures may be taken into
account.
Prospective purchasers should consult their own tax advisors regarding
satisfaction of the section 302 tests in their particular circumstances,
including the possibility that a sale of a part of the holder's preferred stock
or the debentures received might be regarded as reducing the holder's interest
in Cephalon, thereby satisfying one of the tests of section 302(b); in such a
case, the shareholder would recognize capital gain or loss on the exchange. For
purposes of determining gain or loss, the amount realized by a shareholder would
be the issue price of the debentures received (see "Original Issue Discount and
Premium on Debentures"). Any such gain or loss will be capital gain or loss and
will be long-term capital gain or loss, taxable (in the case of individuals) at
a maximum rate of 20%, if the holding period exceeds one year. It is possible
that the IRS may contend that the holding period of preferred stock does not
begin so long as Cephalon's redemption right is outstanding. The installment
method will not be available for reporting such gain in the event that the
preferred stock, the debentures, or the common stock into which the debentures
are convertible are traded or readily tradable on an established securities
market.
ORIGINAL ISSUE DISCOUNT AND PREMIUM ON DEBENTURES
Stated interest on the debentures will be includable in income in
accordance with the holder's method of accounting. There is also a risk that the
debentures will be treated as having original issue discount taxable as interest
income as discussed below.
If the preferred stock is exchanged for debentures at a time when the
stated redemption price at maturity of the debentures exceeds their issue price
by an amount equal to or greater than one-fourth of one percent of the stated
redemption price at maturity multiplied by the number of complete years to
maturity, the debentures will be treated as having original issue discount equal
to the entire amount of such excess.
If the exchange of the preferred stock for debentures satisfies the section
302 tests, different rules apply for determining the issue price of the
debentures depending upon whether the preferred stock or the debentures are or
will be traded on an established securities market. In the event the debentures
are listed on an exchange or are otherwise considered to be traded on an
established securities market under Treasury regulations issued under section
1273 of the Code at any time during the 60-day period ending 30 days after the
date of the exchange, the issue price of the debentures will be their fair
market value as determined as of the date of the exchange. If the debentures are
not listed on an exchange or otherwise considered to be traded on an established
securities market within such time period, but the preferred stock is so listed
or traded, the issue price of the debentures will be the fair market value of
the preferred stock as of the date of the exchange. In the event that neither
the preferred stock nor the debentures are listed on an exchange or otherwise
considered to be traded on an established securities market within the requisite
time period, the issue price of the debentures will be their stated principal
amount, assuming that the debentures bear "adequate stated interest" within the
meaning of section 1274 of the Code. If the debentures do not bear adequate
stated interest, the issue price will be equal to their "imputed principal
amount" as determined under section 1274 of the Code.
A holder of a debenture would generally be required to include in gross
income (irrespective of the holder's method of accounting) a portion of the
original issue discount for each year during which it holds the debenture even
though the cash to which such income is attributable would not be received until
38
<PAGE> 42
maturity or redemption of the debenture. The amount of any original issue
discount included in income for each year would be calculated under a constant
yield to maturity formula that would result in the allocation of less original
issue discount to the early years of the term of the debenture and more original
issue discount to later years.
If the preferred stock is exchanged for debentures whose issue price
exceeds the amount payable at maturity (or earlier call date, if appropriate),
such excess (excluding the amount thereof attributable to the conversion
feature) will be deductible by the holder of the debentures as amortizable bond
premium over the term of the debentures (taking into account earlier call dates,
as appropriate), under a yield to maturity formula, if an election by the
taxpayer under section 171 of the Code is in effect or is made. Such election
would apply to all obligations owned or subsequently acquired by the taxpayer
during or after the taxable year in which the election is made. The amortizable
bond premium will be treated as an offset to stated interest on the debentures
to the extent thereof and any excess will be allowable as a deduction subject to
the following limitation. The amount of any amortized bond premium deduction
will be limited to the excess of the holder's interest income inclusions on the
debenture in prior accrual periods over bond premium deductions allowed the
holder in such prior periods, and any amount in excess of such limitation will
be carried forward as additional bond premium in the next accrual period.
If the exchange of the preferred stock for debentures does not satisfy the
section 302 tests, the issue price of a debenture will be determined based on
whether the preferred stock or the debentures are or will be traded on an
established securities market as described in the third preceding paragraph
above. In the event that the basis of a debenture (its fair market value as of
the exchange) is less than its stated redemption price at maturity, it would
appear that a holder will recognize capital gain upon satisfaction of the
debenture at maturity. In the event that the basis of a debenture exceeds the
amounts payable at maturity, a holder should be able to elect to amortize bond
premium under the rules discussed above.
REDEMPTION OR SALE OF DEBENTURES
Generally a redemption or sale of the debentures will result in taxable
gain or loss equal to the difference between the amount of cash and fair market
value of other property received and the holder's tax basis in the debentures.
To the extent that the amount received is attributable to accrued interest,
however, that amount will be taxed as ordinary income. The tax basis of a holder
who received the debentures in exchange for shares of preferred stock will
generally be equal to the fair market value of the debentures at the time of
exchange plus any original issue discount included in the holder's income or
minus any premium previously allowed as an offset to interest income on the
debentures. Such gain or loss will be capital gain or loss, taxable (in the case
of individuals) at a maximum rate of 20% and will be long-term gain or loss if
the holding period for the debentures exceeds one year.
If the debentures are issued with original issue discount and Cephalon were
found to have had an intention at the time the debentures were issued to call
them before maturity, any gain realized on a sale, exchange or redemption of
debentures prior to the maturity would be considered ordinary income to the
extent of any unamortized original issue discount for the period remaining to
the stated maturity of the debentures. Cephalon cannot predict whether it would
have an intention, when and if the debentures are issued, to call the debentures
before their maturity.
CONVERSION OF PREFERRED STOCK OR DEBENTURES INTO COMMON STOCK
No gain or loss will generally be recognized upon conversion of shares of
preferred stock or debentures into shares of common stock. Gain or loss will be
recognized to the extent of the difference between the cash paid in lieu of
fractional shares of common stock and the basis of the preferred stock or
debentures allocable to such fractional shares, and ordinary income will be
recognized to the extent of the shares of common stock attributable to accrued
interest. Additionally, if the conversion takes place when there is a dividend
arrearage on the preferred stock and the fair market value of the common stock
exceeds the issue price of the preferred stock, a portion of the common stock
received might be treated as a dividend distribution, taxable as ordinary
income. Assuming the conversion is not treated as resulting in
39
<PAGE> 43
the payment of a dividend, the tax basis of the common stock received upon
conversion will be equal to the tax basis of the shares of preferred stock or
the debentures converted (less the amount of basis allocable to any fractional
share of common stock for which cash is received), and the holding period of the
common stock will include the holding period of the shares of preferred stock or
the debentures converted. The tax basis of any common stock treated as a
dividend will be equal to its fair market value on the date of the distribution.
ADJUSTMENT OF CONVERSION PRICE
Holders of preferred stock or debentures may be deemed to have received
constructive distributions where the conversion ratio is adjusted to reflect
property distributions with respect to common stock into which such preferred
stock or debentures are convertible. Adjustments to the conversion price made
pursuant to a bona fide reasonable adjustment formula which has the effect of
preventing the dilution of the interest of the holders of the preferred stock or
debentures, however, will generally not be considered to result in a
constructive distribution of stock. Certain of the possible adjustments provided
in the preferred stock and the debentures may not qualify as being pursuant to a
bona fide reasonable adjustment formula. If such adjustments were made, the
holders of preferred stock or debentures might be deemed to have received
constructive distributions taxable as dividends.
BACKUP WITHHOLDING
Under the backup withholding provisions of the Code and applicable Treasury
regulations, a holder of preferred stock, debentures or common stock may be
subject to backup withholding at the rate of 31% with respect to dividends or
interest paid on, original issue discount accrued with respect to, or the
proceeds of a sale, exchange or redemption of preferred stock, debentures or
common stock, unless (a) such holder is a corporation or comes within certain
other exempt categories and when required demonstrates this fact or (b) provides
a taxpayer identification number, certifies as to no loss of exemption from
backup withholding and otherwise complies with applicable requirements of the
backup withholding rules. The amount of any backup withholding from a payment to
a holder will be allowed as a credit against the holder's federal income tax
liability and may entitle such holder to a refund, provided that the required
information is furnished to the IRS.
SPECIAL TAX RULES APPLICABLE TO FOREIGN HOLDERS
For purposes of the following discussion, a "Foreign Holder" is any holder
who is not (i) a citizen or resident of the United States, (ii) a corporation,
partnership or other entity created or organized in or under the laws of the
United States, any State or any political subdivision thereof, (iii) an estate
the income of which is subject to United States federal income taxation
regardless of source, or (iv) a trust (A) over the administration of which a
court within the United States is able to exercise primary supervision and (B)
all substantial decisions of which one or more United States persons have the
authority to control.
Income received by a Foreign Holder in the form of dividends on preferred
stock or common stock (including amounts distributed on or prior to December 31,
2000, that exceed current and accumulated earnings and profits of Cephalon) or
interest and original issue discount on the debentures will be subject to a
United States federal withholding tax at a 30% rate upon the actual payment of
the dividends, interest or original issue discount except as described below and
except where an applicable tax treaty provides for the reduction or elimination
of such withholding tax. Cephalon and its paying agents may elect with respect
to distributions to Foreign Holders on preferred stock or common stock made
after December 31, 2000, to withhold only against the portion of such
distribution that is reasonably estimated to be made from the current or
accumulated earnings and profits of Cephalon. A Foreign Holder generally will be
taxable in the same manner as a United States corporation or resident with
respect to dividend, interest or original issue discount income if such income
is effectively connected with the conduct of a trade or business in the United
States. Such effectively connected income received by a Foreign Holder that is a
40
<PAGE> 44
corporation may in certain circumstances be subject to an additional "branch
profits tax" at a 30% rate, or if applicable, a lower treaty rate.
Dividends paid to Foreign Holders outside the United States that are
subject to the withholding tax described above will generally be exempt from
United States backup withholding tax and United States information reporting
requirements, other than reporting of dividend payments for purposes of the
withholding tax noted above. The payor of the dividends on or prior to December
31, 2000, may generally rely on a payee's address outside the United States in
determining that the regular withholding tax discussed above applies and
consequently that the backup withholding provisions do not apply.
The payor of dividends after December 31, 2000, may generally presume that
a holder is a Foreign Holder only if it can reliably associate the dividend
payment with a beneficial owner certificate (Form W-8) furnished by the person
whose name is on the certificate or attached to a valid foreign intermediary,
flow-through entity or United States branch withholding certificate. In general,
a Foreign Holder need not furnish a United States taxpayer identification number
to Cephalon or its paying agent unless the Foreign Holder intends to claim the
benefit of a lower treaty rate. In the event that the preferred stock or the
common stock, respectively, is "actively traded" within the meaning of section
1092(d) of the Code and the Treasury regulations thereunder, a Foreign Holder
need not furnish a United States taxpayer identification number to Cephalon or
its paying agent in order to claim the benefit of a lower treaty rate for any
dividends paid thereon. Cephalon cannot anticipate, however, whether the
preferred stock or the common stock will be actively traded at the time any
distribution is made.
Payments of interest and original issue discount on the debentures received
by a Foreign Holder on or prior to December 31, 2000, will not be subject to
United States federal withholding tax provided that (a) the Foreign Holder does
not actually or constructively own 10% or more of the total combined voting
power of all classes of stock of Cephalon entitled to vote, (b) the holder is
not a controlled foreign corporation that is related to Cephalon through stock
ownership, and (c) either (1) the beneficial owner of the debenture, under
penalties of perjury, provides the Company or its agent with its name and
address and certifies that it is not a United States person or (2) a securities
clearing organization, bank or other financial institution that holds customer's
securities in the ordinary course of its trade or business (a "Financial
Institution") certifies to Cephalon or its agent, under penalties of perjury,
that such a statement has been received from the beneficial owner by its or
another financial institution and furnishes to Cephalon or its agent a copy
thereof. Backup withholding and information reporting also generally will not
apply to payments of interest and original discount on or prior to December 31,
2000, if the certification described above is received, provided the payor does
not have actual knowledge that the holder is a United States person.
Payments of interest and original issue discount received by a Foreign
Holder after December 31, 2000, will not be subject to United States federal
withholding tax (or to backup withholding and information reporting) provided
that requirements (a) and (b) of the preceding paragraph are satisfied and, in
general, either (1) Cephalon or its paying agent can reliably associate the
payment with documentation upon which it can rely to treat the payment as made
to a foreign beneficial owner under Treasury regulations issued under section
1441 of the Code; (2) Cephalon or its paying agent can reliably associate the
payment with a withholding certificate from a person claiming to be a
withholding foreign partnership and the foreign partnership can reliably
associate the payment with documentation upon which it can rely to treat the
payment as made to a foreign beneficial owner in accordance with such Treasury
regulations; (3) Cephalon or its paying agent can reliably associate the payment
with a withholding certificate from a person representing to be a "qualified
intermediary" that has assumed primary withholding responsibility under such
Treasury regulations and the qualified intermediary can reliably associate the
payment with documentation upon which it can rely to treat the payment as made
to a foreign beneficial owner in accordance with its agreement with the IRS; or
(4) Cephalon or its paying agent receives a statement, under penalties of
perjury from an authorized representative of a Financial Institution stating
that the Financial Institution has received from the beneficial owner a
withholding certificate described in such Treasury regulations or that it has
received from another Financial Institution a similar statement that it, or
another Financial Institution acting on behalf of the beneficial owner, has
41
<PAGE> 45
received such a withholding certificate from the beneficial owner. In general,
it will not be necessary for a Foreign Holder to obtain or furnish a United
States taxpayer identification number to Cephalon or its paying agent in order
to claim any of the foregoing exemptions from United States withholding tax on
payments of interest and original issue discount.
Provided that Cephalon is not, and has not been, a "United States real
property holding corporation" within the meaning of section 897(c) of the Code,
a Foreign Holder generally will not be subject to United States federal income
or withholding tax on gain realized on the sale or exchange of preferred stock,
common stock, or debentures unless (i) the holder is an individual who is
present in the United States for 183 days or more during the taxable year and as
to whom such gain is from United States sources or (ii) the gain is effectively
connected with a United States trade or business of the holder. Upon a
redemption of the preferred stock for cash or an exchange of preferred stock for
debentures, Cephalon may be required to withhold tax on the entire amount of the
proceeds at a 30% rate or lower treaty rate applicable to dividends unless a
Foreign Holder is able to demonstrate to the satisfaction of Cephalon that such
redemption or exchange satisfies the section 302 tests discussed above with
respect to such Foreign Holder (see "Redemption for Cash" and "Exchange for
Debentures"). In the case of an exchange of preferred stock for debentures, this
would result in a Foreign Holder receiving a reduced principal amount of
debentures.
The payment of the proceeds of the sale of preferred stock, common stock or
debentures to or through the United States office of a broker will be subject to
information reporting and possible backup withholding at a rate of 31% unless
the owner certifies its non-United States status under penalties of perjury or
otherwise establishes an exemption in accordance with applicable Treasury
regulations. The payment of the proceeds of the sale of preferred stock, common
stock or debentures to or through the foreign office of a broker generally will
not be subject to this backup withholding tax. In the case of the payment of
proceeds from the disposition of preferred stock. common stock or debentures
through a foreign office of a broker that is a United States person or a "United
States related person," the applicable Treasury regulations require information
reporting on the payment unless the broker has documentary evidence in its files
that the owner is a non-United States person and the broker has no actual
knowledge to the contrary. For this purpose, a "United States related person" is
(i) a "controlled foreign corporation" for United States federal income tax
purposes, (ii) a foreign person 50% or more of whose gross income from all
sources for a specified period is derived from activities that are effectively
connected with the conduct of a United States trade or business or (iii) with
respect to sales effected after December 31, 2000, a foreign partnership that,
at any time during its taxable year, is 50% or more owned by United States
persons or is engaged in the conduct of a United States trade or business. Any
amounts withheld under the backup withholding rules from a payment to a Foreign
Holder will be allowed as a refund or a credit against such Foreign Holder's
United States federal income tax, provided that the required information is
furnished to the IRS.
42
<PAGE> 46
DESCRIPTION OF CAPITAL STOCK
The majority of the authorized capital stock of Cephalon consists of
100,000,000 shares of common stock, par value $0.01 per share. Holders of shares
of our common stock are entitled to one vote per share on all matters to be
voted upon by the stockholders are not entitled to cumulate votes for the
election of directors. Holders of shares of common stock are entitled to receive
ratably such dividends, if any, as may be declared from time to time by the
Board of Directors out of funds legally available therefor. In the event of
liquidation, dissolution or winding up of Cephalon, the holders of shares of
common stock are entitled to share ratably in all assets remaining after payment
of liabilities, subject to the distribution rights of shares of preferred stock,
if any, then outstanding. Shares of common stock have no preemptive, conversion
or other subscription rights and there are no redemption or sinking fund
provisions applicable to the common stock.
As permitted by the Delaware General Corporation Law, Cephalon's restated
certificate of incorporation provides that our directors shall not be personally
liable to Cephalon or its stockholders for monetary damages for breach of
fiduciary duty as a director, except for liability (i) for any breach of the
director's duty of loyalty to the Cephalon or its stockholders, (ii) for acts of
omissions not in good faith or which involve intentional misconduct or a knowing
violation of law, (iii) under section 174 of the Delaware General Corporation
Law, relating to prohibited dividends or distributions or the repurchase or
redemption of stock, or (iv) for any transaction from which the director derives
an improper personal benefit.
43
<PAGE> 47
SELLING STOCKHOLDERS
We originally issued the preferred stock in transactions exempt from the
registration requirements of the Securities Act to persons that the initial
purchasers believed to be QIBs. As used in this prospectus, the term selling
stockholders includes their transferees, pledgees, donees and their successors.
The selling stockholders may from time to time offer and sell pursuant to this
prospectus any or all of the preferred stock, the debentures, if issued in
exchange for the preferred stock, and the shares of common stock initially
issued or issuable upon conversion of the preferred stock or the debentures, if
issued.
The following table sets forth information regarding (1) the beneficial
ownership of our preferred stock, and the maximum number of preferred stock that
each may offer, (2) the principal amount of debentures that each selling
stockholder would beneficially own if the debentures were exchanged for the
preferred stock, and (3) the number of shares of common stock that each selling
stockholder may sell under this prospectus. Because the selling stockholders may
offer all or a portion of the preferred stock, the debentures, if issued, and
the common stock, if converted, under this prospectus, we cannot estimate the
amount of shares of preferred stock, the debentures, if issued or the common
stock that the selling stockholders will hold upon termination of any sale. The
following table is based upon information furnished to us by the selling
stockholders.
<TABLE>
<CAPTION>
NUMBER OF PRINCIPAL AMOUNT NUMBER OF
SHARES OF PERCENT OF OF DEBENTURES COMMON SHARES
PREFERRED STOCK OUTSTANDING BENEFICIALLY ISSUED UPON
BENEFICIALLY PREFERRED OWNED THAT CONVERSION THAT
NAME OF SELLING STOCKHOLDER OWNED(1) STOCK MAY BE SOLD MAY BE SOLD
- --------------------------- --------------- ----------- ---------------- ---------------
<S> <C> <C> <C> <C>
Deutsche Bank Securities................. 126,300 5.1% $ 6,315,000 352,377
State of Oregon Equity................... 120,000 4.8% $ 6,000,000 334,800
New York Life Insurance Company.......... 105,000 4.2% $ 5,250,000 292,950
Triton Capital Investments, LTD.......... 75,000 3.0% $ 3,750,000 209,250
Highbridge International LLC............. 72,500 2.9% $ 3,625,000 202,275
BNP Arbitrage SNC........................ 61,000 2.4% $ 3,050,000 170,190
Paloma Strategies Securities Limited..... 57,500 2.3% $ 2,875,000 160,425
Tribeca Investments, LLC................. 50,000 2.0% $ 2,500,000 139,500
Kellner, DiLeo & Co., L.P. .............. 50,000 2.0% $ 2,500,000 139,500
NMS Services, Inc. ...................... 47,500 1.9% $ 2,375,000 132,525
New York Life Insurance Annuity
Corporation............................ 35,000 1.4% $ 1,750,000 97,650
TQA Master Fund, Ltd. ................... 32,500 1.3% $ 1,625,000 90,675
JMG Convertible Investments, L.P. ....... 30,000 1.2% $ 1,500,000 83,700
Delaware Pers............................ 24,000 1.0% $ 1,200,000 66,960
TQA Master Plus Fund, Ltd. .............. 22,500 0.9% $ 1,125,000 62,775
Zeneca Holdings Trust.................... 10,550 0.4% $ 527,500 29,435
ICI American Holdings Trust.............. 10,550 0.4% $ 527,500 29,435
Paloma Securities LLC.................... 10,000 0.4% $ 500,000 27,900
Nalco Chemical Company................... 5,400 0.2% $ 270,000 15,066
LDG Limited.............................. 5,000 0.2% $ 250,000 13,950
All other holders........................ 1,549,700 62.0% $ 77,485,000 4,323,663
--------- ----- ------------ ---------
Total............................... 2,500,000 $125,000,000 6,975,444
</TABLE>
- ------------
(1) Beneficial ownership is determined in accordance with the rules of the SEC
and generally includes voting or investment power with respect to
securities.
44
<PAGE> 48
PLAN OF DISTRIBUTION FOR THE RESALE OF THE SECURITIES
A selling stockholder may from time to time, in one or more transactions,
sell all or a portion of the securities on the Nasdaq National Market, in
negotiated transactions, in underwritten transactions or otherwise, at prices
then prevailing or related to the then current market price or at negotiated
prices. The offering price of the securities from time to time will be
determined by a selling stockholder, and with respect to the common stock, at
the time of such determination, may be higher or lower than the market price of
our common stock on the Nasdaq National Market. The securities may be sold
directly or through broker-dealers acting as principal or agent. The methods by
which the securities may be sold include:
- a block trade in which the broker-dealer so engaged will attempt to sell
the securities as agent but may position and resell a portion of the
block as principal to facilitate the transaction;
- purchases by a broker-dealer as principal and resale by such
broker-dealer for its account pursuant to this prospectus;
- ordinary brokerage transactions and transactions in which the broker
solicits purchasers; and
- privately negotiated transactions.
In effecting sales, brokers or dealers engaged by a selling stockholder or
may arrange for other brokers or dealers to participate. These brokers or
dealers may receive commissions or discounts from a selling stockholder as
applicable, in amounts to be negotiated immediately prior to the sale. A selling
stockholder and any underwriters, dealers or agents participating in the
distribution of the shares may be deemed to be "underwriters" within the meaning
of the Securities Act, and any profit on the sale of the securities by a selling
stockholder and any commissions received by any broker-dealers may be deemed to
be underwriting commissions under the Securities Act. In addition, any
securities covered by this prospectus that qualify for sale pursuant to Rule 144
might be sold under Rule 144 rather than pursuant to this prospectus.
Additionally, in connection with the sale of the securities, a selling
stockholder may enter into hedging transactions with broker-dealers and the
broker-dealers may engage in short sales of the securities in the course of
hedging the positions they assume with the selling stockholder. A selling
stockholder may also enter into option or other transactions with broker-dealers
that involve the delivery of the shares to the broker-dealers, who may then
resell or otherwise transfer the shares. A selling stockholder may also loan or
pledge the shares to a broker-dealer and the broker-dealer may sell the
securities so loaned or upon a default may sell or otherwise transfer the
pledged securities.
When a selling stockholder elects to make a particular offer of securities,
we will distribute a prospectus supplement, if required, that will identify any
underwriters, dealers or agents and any discounts, commissions and other terms
constituting compensation from a selling stockholder, as applicable, and any
other required information.
In order to comply with the securities laws of certain states, if
applicable, the securities may be sold only through registered or licensed
brokers or dealers. In addition, in certain states, the securities may not be
sold unless they have been registered or qualified for sale in such state or an
exemption from such registration or qualification requirement is available and
is complied with.
We also have agreed to indemnify the selling stockholders in certain
circumstances, against certain liabilities arising under the Securities Act.
Each selling stockholder has agreed to indemnify us and our directors and
officers who sign the registration statement against certain liabilities,
including liabilities arising under the Securities Act.
We have agreed to pay all costs and expenses relating to the registration
of the shares (other than fees and expenses, if any, of counsel or other
advisors to the selling stockholders). Any commissions, discounts or other fees
payable to broker-dealers in connection with any sale of the securities will be
borne by the selling stockholder selling such shares.
All references to selling stockholders in this Section shall also be deemed
to include any transferees, assignees and pledgees of the selling stockholders.
45
<PAGE> 49
ABOUT THIS PROSPECTUS
You should only rely on the information contained in this prospectus. We
have not authorized anyone to provide you with information different from that
contained in this prospectus. The information contained in this prospectus is
accurate only as of the date of this prospectus, regardless of the time of
delivery of this prospectus or of any sale of common stock.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other
information with the Securities and Exchange Commission. You may read and copy
any reports, statements or other information we file at the SEC's public
reference rooms located at Judiciary Plaza, 450 Fifth Street, N.W., Washington,
D.C. 20549, Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, IL
60661 and 7 World Trade Center, Suite 1300, New York, NY 10048. Please call the
SEC at 1-800-SEC-0330 for further information on the public reference rooms. Our
SEC filings are also available to the public from commercial document retrieval
services and at the web site maintained by the SEC at "http://www.sec.gov."
We have filed a Registration Statement on Form S-3, of which this
prospectus forms a part, to register the resale of the securities with the SEC.
As allowed by SEC rules, this prospectus does not contain all the information
you can find in the Registration Statement or the exhibits to the Registration
Statement.
The SEC allows us to "incorporate by reference" information into this
prospectus, which means that we can disclose important information to you by
referring you to another document filed separately with the SEC. The information
incorporated by reference is deemed to be part of this prospectus, except for
any information superseded by information in this prospectus. This prospectus
incorporates by reference the documents set forth below that we have previously
filed with the SEC. These documents contain important information about us, our
business and our finances.
The documents that we are incorporating by reference are:
- Our Annual Report on Form 10-K for the year ended December 31, 1998, as
amended;
- Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 1999
and June 30, 1999;
- Our Current Reports on Form 8-K filed with the SEC on March 1, 1999, June
14, 1999, July 19, 1999, August 3, 1999, August 18, 1999 and September
28, 1999;
- The description of our common stock that is contained in our Form 8-A
Registration Statement filed with the SEC on March 15, 1991, including
any amendments or reports filed for the purpose of updating such
description; and
- The description of our stockholder rights plan that is contained in our
Form 8-A Registration Statement filed with the SEC on January 20, 1999,
including any amendments or reports filed for the purpose of updating
such description.
Any documents which we file pursuant to Sections 13(a), 13(c), 14 or 15(d)
of the Exchange Act after the date of this prospectus but before the end of any
offering of securities made under this prospectus will also be considered to be
incorporated by reference.
If you request, either orally or in writing, we will provide you with a
copy of any or all documents which are incorporated by reference. We will
provide such documents to you free of charge, but will not include any exhibits,
unless those exhibits are incorporated by reference into the document. You
should address written requests for documents to John E. Osborn, Senior Vice
President and General Counsel, Cephalon, Inc., 145 Brandywine Parkway, West
Chester, PA 19380, (610) 344-0200.
46
<PAGE> 50
FORWARD-LOOKING STATEMENTS
Our disclosure and analysis in this prospectus contains some
forward-looking statements. Forward-looking statements give our current
expectations or forecasts of future events. You can identify these statements by
the fact that they do not relate strictly to historical or current facts. Such
statements may include words such as "anticipate", "estimate", "expect",
"project", "intend", "plan", "believe" and other words and terms of similar
meaning in connection with any discussion of future operating or financial
performance. In particular, these include statements relating to present or
anticipated scientific progress, development of potential pharmaceutical
products, future revenues, capital expenditures, research and development
expenditures, future financing and collaborations, personnel, manufacturing
requirements and capabilities, and other statements regarding matters that are
not historical facts or statements of current condition.
Any or all of our forward-looking statements in this prospectus may turn
out to be wrong. They can be affected by inaccurate assumptions we might make or
by known or unknown risks and uncertainties. Many factors mentioned in our
discussion in this prospectus will be important in determining future results.
Consequently, no forward-looking statement can be guaranteed. Actual future
results may vary materially.
We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise.
You are advised, however, to consult any further disclosures we make in our
10-Q, 8-K and 10-K reports to the SEC. Also note that we provide a cautionary
discussion of risks and uncertainties relevant to our business under "Risk
Factors" on page 5 of this prospectus. These are factors that we think could
cause our actual results to differ materially from expected results. Other
factors besides those listed here could also adversely affect us. This
discussion is provided as permitted by the Private Securities Litigation Reform
Act of 1995.
LEGAL OPINION
Morgan, Lewis & Bockius LLP, Philadelphia, Pennsylvania, will pass on the
validity of the shares.
EXPERTS
The financial statements incorporated by reference in this prospectus and
elsewhere in this registration statement have been audited by Arthur Andersen
LLP, independent public accountants, as indicated in their report with respect
thereto, and are incorporated by reference herein in reliance upon the authority
of said firm as experts in giving said reports.
47
<PAGE> 51
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
CEPHALON, INC.
2,500,000 SHARES OF $3.625 CONVERTIBLE EXCHANGEABLE PREFERRED STOCK
$125,000,000 7.25% CONVERTIBLE SUBORDINATED DEBENTURES
6,975,447 SHARES OF COMMON STOCK
------------------------
PROSPECTUS
------------------------
, 1999
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 52
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The following table shows the estimated expenses of the issuance and
distribution of the securities offered hereby.
<TABLE>
<S> <C>
Commission fee.............................................. $ 36,875.00
Nasdaq listing fee.......................................... 17,500.00
Legal fees, accounting fees and expenses.................... 50,000.00
-----------
Total.................................................. $104,375.00
===========
</TABLE>
All of the amounts shown are estimates except for the fees payable to the
Securities and Exchange Commission and the National Association of Securities
Dealers.
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Section 145 of the Delaware General Corporation Law ("Section 145") permits
indemnification of directors, officers, agents and controlling persons of a
corporation under certain conditions and subject to certain limitations. Article
9 of the Company's ByLaws provides for the indemnification of directors,
officers, employees and agents of the Company to the maximum extent permitted by
the Delaware General Corporation Law. Section 145 empowers a corporation to
indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether
civil, criminal, administrative or investigative, by reason of the fact that he
is or was a director, officer or agent of the corporation or another enterprise
if serving at the request of the corporation. Depending on the character of the
proceeding, a corporation may indemnify against expenses (including attorneys'
fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred in connection with such action, suit or proceeding if the person
indemnified acted in good faith and in respect to any criminal action or
proceeding, had no reasonable cause to believe his conduct was unlawful. In the
case of an action by or in the right of the corporation, no indemnification may
be made with respect to any claim, issue or matter as to which such person shall
have been adjudged to be liable to the corporation unless and only to the extent
that the Court of Chancery or the court in which such action or suit was brought
shall determine that despite the adjudication of liability such person is fairly
and reasonably entitled to indemnity for such expenses which the court shall
deem proper. Section 145 further provides that to the extent a director,
officer, employee or agent of a corporation has been successful in the defense
of any action, suit or proceeding referred to above or in the defense of any
claim, issue or matter therein, he shall be indemnified against expenses
(including attorneys' fees) actually and reasonably incurred by him in
connection therewith.
The Company's Bylaws permit it to purchase insurance on behalf of such
person against any liability asserted against him and incurred by him in any
such capacity, or arising out of his status as such, whether or not the Company
would have the power to indemnify him against such liability under the foregoing
provision of the Bylaws.
II-1
<PAGE> 53
ITEM 16. LIST OF EXHIBITS
The exhibits filed as part of this registration statement are as follows:
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
<C> <S>
4.1* Specimen of Preferred Stock Certificate of Cephalon, Inc.
4.2* Certificate of the Powers, Designations, Preferences and
Rights of the $3.625 Convertible Exchangeable Preferred
Stock filed August 17, 1999.
4.3* Indenture, dated as of August 18, 1999, between Cephalon,
Inc. and State Street Bank and Trust Company, as Trustee.
5.1* Opinion of Morgan, Lewis & Bockius LLP regarding legality of
securities being registered.
12 * Statement Re Computation of Earnings to Fixed Charges and
Preferred Stock Dividends.
23.1* Consent of Morgan, Lewis & Bockius LLP (included in its
opinion filed as Exhibit 5.1 hereto).
23.2* Consent of Arthur Andersen LLP
24.1* Powers of Attorney (included on signature page).
25 * Form T-1, Statement of Eligibility and Qualification of
State Street Bank and Trust Company.
</TABLE>
- ------------
* Filed herewith.
** Previously filed.
ITEM 17. UNDERTAKINGS
The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of the
Registrant pursuant to its Restated Certificates of Incorporation, its By-laws,
or otherwise, the Registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy
as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than
the payment by the Registrant of expenses incurred or paid by a director,
officer or controlling person of the Registrant in successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the Registrant will,
unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against a public policy as expressed in the
Securities Act of 1933 and will be governed by the final adjudication of such
issue.
The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth
in the registration statement;
(iii) To include any material information with respect to the plan
of distribution not previously disclosed in the registration statement
or any material change to such information in the registration
statement;
II-2
<PAGE> 54
Provided, however, that paragraph (1)(i) and (1)(ii) do not apply if the
registration statement is on Form S-3 or Form S-8, and the information
required to be included in a post-effective amendment by those paragraphs
is contained in periodic reports filed by the registrant pursuant to
section 13 or section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the registration statement.
(2) That, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be deemed
to be a registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
termination of the offering.
II-3
<PAGE> 55
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
has duly caused this Registration Statement to be signed on its behalf by the
undersigned thereunto duly authorized, in West Chester, Pennsylvania, on this
14th day of October, 1999.
CEPHALON, INC.
By: /s/ FRANK BALDINO, JR., PH.D.
------------------------------------
Frank Baldino, Jr., Ph.D.
President, Chief Executive Officer
and Director
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated. Each person in so signing also makes,
constitutes and appoints Frank Baldino, Jr. and J. Kevin Buchi, and each of them
acting alone, his true and lawful attorney-in-fact, with full power of
substitution, to execute and cause to be filed with the Securities and Exchange
Commission, any and all amendments or post-effective amendments to this
Registration Statement, with exhibits thereto and other documents in connection
therewith, as the Registrant deems appropriate.
<TABLE>
<CAPTION>
NAME TITLE DATE
---- ----- ----
<S> <C> <C>
By: /s/ FRANK BALDINO, JR., PH.D. President, Chief Executive October 14, 1999
- ---------------------------------------------- Officer and Director
Frank Baldino, Jr., Ph.D. (Principal executive
officer)
By: /s/ WILLIAM P. EGAN Director October 14, 1999
- ----------------------------------------------
William P. Egan
By: /s/ ROBERT J. FEENEY, PH.D. Director October 14, 1999
- ----------------------------------------------
Robert J. Feeney, Ph.D.
By: /s/ MARTYN D. GREENACRE Director October 14, 1999
- ----------------------------------------------
Martyn D. Greenacre
By: /s/ KEVIN E. MOLEY Director October 14, 1999
- ----------------------------------------------
Kevin E. Moley
By: /s/ HORST WITZEL, DR.-ING Director October 14, 1999
- ----------------------------------------------
Horst Witzel, Dr.-Ing
By: /s/ DAVID R. KING Director October 14, 1999
- ----------------------------------------------
David R. King
By: /s/ J. KEVIN BUCHI Senior Vice President, Finance October 14, 1999
- ---------------------------------------------- and Chief Financial Officer
J. Kevin Buchi (Principal financial and
accounting officer)
</TABLE>
II-4
<PAGE> 56
CEPHALON, INC.
REGISTRATION STATEMENT ON FORM S-3
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT PAGE
NUMBER DOCUMENT NUMBER
- ------- -------- ------
<C> <S> <C>
4.1* Specimen of Preferred Stock Certificate of Cephalon,
Inc. .......................................................
4.2* Certificate of the Powers, Designations, Preferences and
Rights of the $3.625 Convertible Exchangeable Preferred
Stock filed August 17, 1999. ...............................
4.3* Indenture, dated as of August 18, 1999, between Cephalon,
Inc. and State Street Bank and Trust Company, as Trustee....
5.1* Opinion of Morgan, Lewis & Bockius LLP......................
12 * Statement Re Computation of Earnings to Fixed Charges and
Preferred Stock Dividends...................................
23.1* Consent of Morgan, Lewis & Bockius LLP (included in its
opinion as Exhibit 5.1 hereto)..............................
23.2* Consent of Arthur Andersen LLP..............................
24.1* Powers of Attorney (included as part of the signature page
of this Registration Statement).............................
25 * Form T-1, Statement of Eligibility and Qualification of
State Street Bank and Trust Company.........................
</TABLE>
- ------------
* Filed herewith
** Previously filed
II-5
<PAGE> 1
EXHIBIT 4.1
Certificate No. No. Shares
Class: Preferred Stock
Series: $3.625 Convertible Exchangeable Preferred Stock CUSIP No. 156708 30 7
CEPHALON, INC.
Incorporated under the laws of the State of Delaware
THIS CERTIFIES THAT
is the owner of
FULLY PAID AND NON-ASSESSABLE SHARES OF $3.625 CONVERTIBLE
EXCHANGEABLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF
CEPHALON, INC.
transferrable on the books of the Company by the holder hereof, in person or by
his attorney, upon surrender of this Certificate properly endorsed. This
Certificate and the shares represented hereby are issued and shall be held
subject to the provisions of the Restated Certificate of Incorporation of the
Company (copies of which are on file with the Transfer Agent and Registrar), to
all of which the holder by acceptance hereof assents. This Certificate is not
valid unless countersigned and registered by the Transfer Agent and Registrar.
The Company will furnish to any stockholder upon request and without
charge a full statement of the designations, voting rights, preferences,
limitations and special rights of the shares of each class and series of stock
authorized to be issued and the authority of the Board of Directors to fix and
determine the designations, voting rights, preferences, limitations and special
rights of the classes and series of stock of the Company. Such request may be
made to the Secretary of Cephalon, Inc. or to the Transfer Agent and Registrar.
IN WITNESS WHEREOF, the said Company has caused this Certificate to be
signed by, or with the facsimile signatures of, its duly authorized officers,
and its seal, or a facsimile thereof, to be hereunto affixed.
Dated:
______________________ _____________________________________
Secretary President and Chief Executive Officer
COUNTERSIGNED AND REGISTERED:
STOCKTRANS, INC.
Transfer Agent and Registrar
By:______________________
Title:
Keep this Certificate in a safe place. If it is lost, stolen or
destroyed the Company will require a bond of indemnity as a condition
to the issuance of a replacement certificate.
[SEAL]
<PAGE> 2
CEPHALON, INC.
THE SECURITY EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE
SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO,
OR FOR THE ACCOUNT OR BENEFIT OF, UNITED STATES PERSONS EXCEPT AS SET FORTH IN
THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (1) REPRESENTS
THAT (A) IT IS A "QUALIFIED INSTITUTIONAL BUYER" (AS DEFINED IN RULE 144A UNDER
THE SECURITIES ACT) OR (B) IT IS AN INSTITUTIONAL "ACCREDITED INVESTOR" (AS
DEFINED IN RULE 501(a)(1), (2), (3) OR (7) UNDER THE SECURITIES ACT)
("INSTITUTIONAL ACCREDITED INVESTOR") OR (C) IT IS NOT A UNITED STATES PERSON
AND IS ACQUIRING THE SECURITY EVIDENCED HEREBY IN AN OFFSHORE TRANSACTION; (2)
AGREES THAT IT WILL NOT, WITHIN TWO YEARS AFTER THE ORIGINAL ISSUANCE OF THE
SECURITY EVIDENCED HEREBY, RESELL OR OTHERWISE TRANSFER THE SECURITY EVIDENCED
HEREBY OR THE COMMON STOCK ISSUABLE UPON CONVERSION OF SUCH SECURITY WITHIN THE
UNITED STATES OR TO OR FOR THE ACCOUNT OR BENEFIT OF UNITED STATES PERSONS
EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) TO A QUALIFIED
INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, (C)
TO AN INSTITUTIONAL ACCREDITED INVESTOR THAT, PRIOR TO SUCH TRANSFER FURNISHES
TO STOCKTRANS, INC., AS THE TRANSFER AGENT, A SIGNED LETTER CONTAINING CERTAIN
REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THE
SECURITY EVIDENCED HEREBY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM SUCH
TRANSFER AGENT), (D) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY
RULE 144 UNDER THE SECURITIES ACT (IF AVAILABLE) OR (E) PURSUANT TO A
REGISTRATION STATEMENT WHICH HAS BEEN DECLARED EFFECTIVE UNDER THE SECURITIES
ACT (AND WHICH CONTINUES TO BE EFFECTIVE AT THE TIME OF SUCH TRANSFER); AND (3)
AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THE SECURITY EVIDENCED HEREBY
IS TRANSFERRED (OTHER THAN A TRANSFER PURSUANT TO CLAUSE 2(E) ABOVE), IT WILL
FURNISH TO STOCKTRANS, INC., AS TRANSFER AGENT, A NOTICE SUBSTANTIALLY SIMILAR
TO THIS LEGEND. IN CONNECTION WITH ANY TRANSFER OF THE SECURITY EVIDENCED HEREBY
WITHIN TWO YEARS AFTER THE ORIGINAL ISSUANCE OF SUCH SECURITY (OTHER THAN A
TRANSFER PURSUANT TO CLAUSE 2(E) ABOVE), THE HOLDER MUST CHECK THE APPROPRIATE
BOX SET FORTH ON THE REVERSE HEREOF RELATING TO THE MANNER OF SUCH TRANSFER AND
SUBMIT THIS CERTIFICATE TO THE TRANSFER AGENT. IF THE PROPOSED TRANSFEREE IS A
PURCHASER WHO IS NOT A UNITED STATES PERSON OR AN INSTITUTIONAL ACCREDITED
INVESTOR, THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO STOCKTRANS, INC.,
AS THE TRANSFER AGENT, SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION
AS CEPHALON MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE
PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THIS LEGEND WILL BE REMOVED
UPON THE EARLIER OF THE TRANSFER OF THE SECURITY EVIDENCED HEREBY PURSUANT TO
CLAUSE 2(E) ABOVE OR THE EXPIRATION OF TWO YEARS FROM THE ORIGINAL ISSUANCE OF
THE SECURITY EVIDENCED HEREBY.
2
<PAGE> 3
CONVERSION NOTICE
StockTrans, Inc.
The undersigned registered owner of the Preferred Stock hereby irrevocably
exercises the option to convert the Preferred Stock, or the portion hereof below
designated, into shares of Common Stock in accordance with the terms of the
Certificate of Designation, and directs that the shares issuable and deliverable
upon such conversion, together with any check in payment for fractional shares
and any Preferred Stock representing any unconverted amount of shares hereof, be
issued and delivered to the registered holder hereof unless a different name has
been indicated below. If shares or any portion of the Preferred Stock not
converted are to be issued in the name of a person other than the undersigned,
the undersigned will pay all taxes payable with respect thereto.
Dated:______________________
______________________
Signature(s)
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks, stock
brokers and loan associations and credit
unions) with membership in an approved
signature guarantee medallion program
pursuant to Securities and Exchange
Commission Rule 17AD-15 if shares of Common
Stock issued, or Preferred Stock to be
delivered, other than to and in the name of
registered holder.
______________________
Signature Guarantee
Fill in for registration of shares if to be
issued, and Preferred Stock if to be
delivered, other than to and in the name of
the registered holder:
______________________
(Name)
______________________
(Address)
______________________
(City, State and Zip Code)
Print name and address
Number of shares to be
converted (if less than all):
_________________________________
Social Security or Other Taxpayer
Identification Number
NOTICE: The signature on the conversion notice, or the assignment must
correspond with the name as written upon the face of the Preferred Stock in
every particular without alteration or enlargement or any change whatever.
3
<PAGE> 4
For value received ______________________ hereby sell(s), assign(s) and
transfer(s) unto ______________________ (Please insert social security or
Taxpayer Identification Number of assignee) the Preferred Stock, and hereby
irrevocably constitutes and appoints ______________________ attorney to transfer
the said Preferred Stock on the books of the Company, with full power of
substitution in the premises.
In connection with any transfer of the Preferred Stock within the
United States or to, or for the account or benefit of, U.S. persons occurring
within two years of the original issuance of such Preferred Stock (unless such
Preferred Stock is being transferred pursuant to a registration statement that
has been declared effective under the Securities Act), the undersigned confirms
that such Preferred Stock is being transferred;
[ ] To Cephalon, Inc. or a subsidiary thereof; or
[ ] Pursuant to and in compliance with Rule 144A under the Securities Act
of 1933, as amended; or
[ ] To an Institutional Accredited Investor pursuant to and in compliance
with the Securities Act of 1933, as amended; or
[ ] Pursuant to and in compliance with Rule 144 under the Securities Act
of 1933, as amended;
and unless the box below is checked, the undersigned confirms that such
Preferred Stock is not being transferred to an "affiliate" of the Company as
defined in Rule 144 under the Securities Act of 1933, as amended (an
"Affiliate").
[ ] The transferee is an Affiliate of the Company.
Dated:______________________
____________________________
Signature(s)
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks, stock
brokers, savings and loan associations and
credit unions) with membership in an
approved signature guarantee medallion
program pursuant to Securities and Exchange
Commission Rule 17AD-15 if shares of Common
Stock are to be issued, or Preferred Stock
to be delivered, other than to and in the
name of the registered holder.
______________________
Signature Guarantee
NOTICE: The signature on the conversion notice, or the assignment must
correspond with the name as written upon the Preferred Stock in every particular
without alteration or enlargement or any change whatsoever.
4
<PAGE> 1
EXHIBIT 4.2
CERTIFICATE OF THE POWERS, DESIGNATIONS,
PREFERENCES AND RIGHTS OF THE
$3.625 CONVERTIBLE EXCHANGEABLE PREFERRED STOCK
($0.01 PAR VALUE)
(CUMULATIVE DIVIDEND, LIQUIDATION PREFERENCE $50 PER SHARE)
OF
CEPHALON, INC.
PURSUANT TO SECTION 151(g) OF THE GENERAL CORPORATION LAW
OF THE STATE OF DELAWARE
THE UNDERSIGNED, being the Secretary of Cephalon, Inc., a Delaware
corporation (the "Company"), DOES HEREBY CERTIFY that, pursuant to the
provisions of Section 151(g) of the General Corporation Law of the State of
Delaware, the following resolutions were duly adopted by the Board of Directors
of the Company and a Committee thereof, and pursuant to authority conferred upon
the Board of Directors by the provisions of the Certificate of Incorporation of
the Company, as amended (the "Certificate of Incorporation") and, in the case of
the Committee, by express resolution of the Board of Directors, the Board of
Directors of the Company and the Committee adopted resolutions fixing the
designation and the relative powers, preferences, rights, qualifications,
limitations and restrictions of such stock. These composite resolutions are as
follows:
RESOLVED, that pursuant to authority expressed granted to and vested in
the Board of Directors of the Company by the provisions of the Certificate of
Incorporation, the issuance of a series of preferred stock, par value $0.01 per
share, which shall consist of up to 2,500,000 of the 5,000,000 shares of
preferred stock which the Company now has authority to issue, be, and the same
hereby is, authorized, and the Board hereby fixes the powers, designations,
preferences and relative, participating, optional and other special rights, and
the qualifications, limitations and restrictions thereof (in addition to the
powers, designations, preferences and relative, participating, optional or other
special rights, and the qualifications, limitations or restrictions thereof, set
forth in the Certificate of Incorporation which may be applicable to the
preferred stock of this series) as follows:
1. Number of Shares and Designation. 2,500,000 shares of the preferred
stock, par value $0.01 per share, of the Company are hereby constituted as a
series of the preferred stock designated as $3.625 Convertible Exchangeable
Preferred Stock (the "Preferred Stock").
2. Definitions. For purposes of the Preferred Stock, in addition to
those terms otherwise defined herein, the following terms shall have the
meanings indicated:
-1-
<PAGE> 2
"Affiliate" of any specified person shall mean any other person
directly or indirectly controlling or controlled by or under direct or indirect
common control with such specified person. For the purposes of this definition,
"control," when used with respect to any specified person means the power to
direct or cause the direction of the management and policies of such person,
directly or indirectly, whether through the ownership of voting securities, by
contract or otherwise; and the terms "controlling" and "controlled" have
meanings correlative to the foregoing.
"Applicable Price" shall have the meaning specified in Section 7(j).
"Board of Directors" shall mean the Board of Directors of the Company
or a committee of such Board duly authorized to act for it hereunder.
"Board Resolution" means a copy of a resolution certified by the
Secretary or an Assistant Secretary of the Company to have been duly adopted by
the Board of Directors and to be in full force and effect on the date of such
certification, and delivered to the Transfer Agent.
"Business Day" means each Monday, Tuesday, Wednesday, Thursday and
Friday which is not a day on which the banking institutions in The City of New
York, New York or Philadelphia, Pennsylvania are authorized or obligated by law
or executive order to close or be closed.
"Commission" shall mean the Securities and Exchange Commission.
"Common Stock" shall mean the class of capital stock of the Company
designated as Common Stock, par value $.01 per share, at the date hereof.
Subject to the provisions of Section 7(e), shares issuable on conversion of the
Preferred Stock shall include only shares of such class or shares of any class
or classes resulting from any reclassification or reclassifications thereof and
which have no preference in respect of dividends or of amounts payable in the
event of any voluntary or involuntary liquidation, dissolution or winding up of
the Company and which are not subject to redemption by the Company; provided
that if at any time there shall be more than one such resulting class, the
shares of each such class then so issuable shall be substantially in the
proportion which the total number of shares of such class resulting from all
such reclassifications bears to the total number of shares of all such classes
resulting from all such reclassifications.
"Common Stock Fundamental Change" shall have the meaning specified in
Section 7(j).
"Company" shall mean Cephalon, Inc., a Delaware corporation, and, shall
include its successors and assigns.
"Conversion Price" shall have the meaning specified in Section 7(a).
-2-
<PAGE> 3
"Custodian" shall mean State Street Bank and Trust Company, as
custodian with respect to the Global Certificate, or any successor entity
thereto.
"Debentures" shall mean the Company's 7.25% Convertible Subordinated
Debentures, issued under an Indenture, dated as of August 18, 1999 between the
Company and State Street Bank and Trust Company, as trustee (the "Indenture").
"Depositary" means, with respect to the Preferred Stock issuable or
issued in the form of a Global Certificate, the person specified in Section 13
as the Depositary with respect to the Preferred Stock, until a successor shall
have been appointed and become such pursuant to the applicable provisions of
this Certificate, and thereafter, "Depositary" shall mean or include such
successor. The foregoing sentence shall likewise apply to any subsequent
successor or successors.
"Dividend Payment Date" shall have the meaning specified in Section
3(a).
"Dividend Payment Record Date" shall have the meaning specified in
Section 3(a).
"Dividend Periods" shall mean quarterly dividend periods commencing on
the fifteenth day of February, May, August and November of each year and ending
on and including the day preceding the fifteenth day of the next succeeding
Dividend Period (other than the initial Dividend Period which shall commence on
the Issue Date and end on and include November 14, 1999).
"Exchange Act" means the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder.
"Exchange Date" shall have the meaning specified in Section 10(b).
"Fundamental Change" shall have the meaning specified in Section 7(j).
"Global Certificate" shall have the meaning specified in Section 13(a).
"holder," "holder of shares of Preferred Stock," or "holder of the
Preferred Stock," as applied to any share of Preferred Stock, or other similar
terms (but excluding the term "beneficial holder"), shall mean any person in
whose name at the time a particular share of Preferred Stock is registered on
the Company's stock records, which shall include the books of the Transfer Agent
in respect of the Company and any stock transfer books of the Company.
"Institutional Accredited Investor" means an institutional "accredited
investor" within the meaning of Rule 501(a)(1), (2), (3) or (7) under the
Securities Act.
"Issue Date" shall mean the first date on which shares of the Preferred
Stock are issued.
-3-
<PAGE> 4
"Officers' Certificate", when used with respect to the Company, shall
mean a certificate signed by (a) one of the President, the Chief Executive
Officer, Executive or Senior Vice President or any Vice President (whether or
not designated by a number or numbers or word added before or after the title
"Vice President") and (b) by one of the Treasurer or any Assistant Treasurer,
Secretary or any Assistant Secretary or Controller of the Company, which is
delivered to the Transfer Agent.
"Non-Stock Fundamental Change" shall have the meaning specified in
Section 7(j).
"QIB" means a "qualified institutional buyer" as defined in Rule 144A.
"Purchaser Stock Price" shall have the meaning specified in Section
7(j).
"person" shall mean a corporation, an association, a partnership, an
individual, a joint venture, a joint stock company, a trust, a limited liability
company, an unincorporated organization or a government or an agency or a
political subdivision thereof.
"Reference Market Price" shall have the meaning specified in Section
7(j).
"Restricted Preferred Stock" shall have the meaning specified in
Section 13(c).
"Rule 144A" means Rule 144A as promulgated under the Securities Act, or
any successor rule.
"Rule 144(k)" means Rule 144(k) as promulgated under the Securities
Act, or any successor rule.
"Securities Act" means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.
"Subsidiary" means a corporation more than 50% of the outstanding
voting stock of which is owned, directly or indirectly, by the Company or by one
or more other Subsidiaries, or by the Company and one or more other
Subsidiaries. For the purposes of this definition, "voting stock" means stock
which ordinarily has voting power for the election of directors, whether at all
times or only so long as no senior class of stock has such voting power by
reason of any contingency.
"Trading Day" has the meaning specified in Section 7(d)(ix).
"Transfer Agent" means StockTrans, Inc. or such other agent or agents
of the Company as may be designated by the Board of Directors of the Company as
the transfer agent for the Preferred Stock.
-4-
<PAGE> 5
The definitions of certain other terms are specified in Section 7.
3. Dividends.
(a) Holders of the Preferred Stock are entitled to receive, when, as
and if declared by the Board of Directors, out of the funds of the Company
legally available therefor, cash dividends at the annual rate of $3.625 per
share of Preferred Stock, payable in equal quarterly installments on February
15, May 15, August 15 and November 15 (each a "Dividend Payment Date"),
commencing November 15, 1999 (and, in the case of any accrued but unpaid
dividends, at such additional times and for such interim periods, if any, as
determined by the Board of Directors). If November 15, 1999 or any other
Dividend Payment Date shall be on a day other than a Business Day, then the
Dividend Payment Date shall be on the next succeeding Business Day. Dividends on
the Preferred Stock will be cumulative from the Issue Date, whether or not in
any Dividend Period or Periods there shall be funds of the Company legally
available for the payment of such dividends and whether or not such dividends
are declared, and will be payable to holders of record as they appear on the
stock books of the Company on such record dates (each such date, a "Dividend
Payment Record Date"), which shall be not more than 60 days nor less than 10
days preceding the Dividend Payment Dates thereof, as shall be fixed by the
Board of Directors. Dividends on the Preferred Stock shall accrue (whether or
not declared) on a daily basis from the Issue Date, and accrued dividends for
each Dividend Period shall accumulate to the extent not paid on the Dividend
Payment Date first following the Dividend Period for which they accrue. As used
herein, the term "accrued" with respect to dividends includes both accrued and
accumulated dividends.
(b) The amount of dividends payable per share for each full Dividend
Period for the Preferred Stock shall be computed by dividing the annual dividend
rate by four (rounded down to the nearest one one-hundredth (1/100) of one
cent). The amount of dividends payable for the initial Dividend Period on the
Preferred Stock, or any other period shorter or longer than a full Dividend
Period on the Preferred Stock, shall be computed on the basis of a 360-day year
consisting of twelve 30-day months. Holders of shares of Preferred Stock called
for redemption on a redemption date falling between the close of business on a
Dividend Payment Record Date and the opening of business on the corresponding
Dividend Payment Date shall, in lieu of receiving such dividend on the Dividend
Payment Date fixed therefor, receive such dividend payment together with all
other accrued and unpaid dividends on the date fixed for redemption (unless such
holders convert such shares in accordance with Section 7 hereof). Holders of
shares of Preferred Stock shall not be entitled to any dividends, whether
payable in cash, property or stock, in excess of cumulative dividends, as herein
provided. No interest, or sum of money in lieu of interest, shall be payable in
respect of any dividend payment or payments on the Preferred Stock which may be
in arrears.
(c) So long as any shares of Preferred Stock are outstanding, no
dividends, except as described in the next succeeding sentence, shall be
declared or paid or set apart for payment on any class or series of stock of the
Company ranking, as to dividends, on a parity with the Preferred Stock, for any
period unless full cumulative dividends have been
-5-
<PAGE> 6
or contemporaneously are declared and paid or declared and a sum sufficient for
the payment thereof set apart for such payment on the Preferred Stock for all
Dividend Periods terminating on or prior to the applicable Dividend Payment
Date. When dividends are not paid in full or a sum sufficient for such payment
is not set apart, as aforesaid, upon the shares of Preferred Stock and any other
class or series of stock ranking on a parity as to dividends with Preferred
Stock, all dividends declared upon shares of Preferred Stock and all dividends
declared upon such other stock shall be declared pro rata so that the amounts of
dividends per share declared on the Preferred Stock and such other stock shall
in all cases bear to each other the same ratio that accrued dividends per share
on the shares of Preferred Stock and on such other stock bear to each other.
(d) So long as any shares of the Preferred Stock are outstanding, no
other stock of the Company ranking on a parity with the Preferred Stock as to
dividends or upon liquidation, dissolution or winding up shall be redeemed,
purchased or otherwise acquired for any consideration (or any monies be paid to
or made available for a sinking fund or otherwise for the purchase or redemption
of any shares of any such stock) by the Company or any Subsidiary (except for
repurchases from employees and consultants) unless (i) the full cumulative
dividends, if any, accrued on all outstanding shares of Preferred Stock shall
have been paid or set apart for payment for all past Dividend Periods and (ii)
sufficient funds shall have been set apart for the payment of the dividend for
the current Dividend Period with respect to the Preferred Stock.
(e) So long as any shares of the Preferred Stock are outstanding, no
dividends (other than dividends or distributions paid in shares of, or options,
warrants or rights to subscribe for or purchase shares of, Common Stock or other
stock ranking junior to the Preferred Stock, as to dividends and upon
liquidation, dissolution or winding up) shall be declared or paid or set apart
for payment and no other distribution shall be declared or made or set apart for
payment, in each case upon the Common Stock or any other stock of the Company
ranking junior to the Preferred Stock as to dividends or upon liquidation,
dissolution or winding up, nor shall any Common Stock nor any other such stock
of the Company ranking junior to the Preferred Stock as to dividends or upon
liquidation, dissolution or winding up be redeemed, purchased or otherwise
acquired for any consideration (or any monies be paid to or made available for a
sinking fund or otherwise for the purchase or redemption of any shares of any
such stock) by the Company or any Subsidiary (except by conversion into or
exchange for stock of the Company ranking junior to the Preferred Stock as to
dividends and upon liquidation, dissolution or winding up) unless, in each case
(i) the full cumulative dividends, if any, accrued on all outstanding shares of
Preferred Stock and any other stock of the Company ranking on a parity with the
Preferred Stock as to dividends shall have been paid or set apart for payment
for all past Dividend Periods and all past dividend periods with respect to such
other stock and (ii) sufficient funds shall have been set apart for the payment
of the dividend for the current Dividend Period with respect to the Preferred
Stock and for the current dividend period with respect to any other stock of the
Company ranking on a parity with the Preferred Stock as to dividends.
-6-
<PAGE> 7
4. Liquidation Preference.
(a) In the event of any voluntary or involuntary dissolution,
liquidation or winding up of the Company (for the purposes of this Section 4, a
"Liquidation"), before any distribution of assets shall be made to the holders
of Common Stock or the holders of any other stock of the Company that ranks
junior to the Preferred Stock upon Liquidation, the holder of each share of
Preferred Stock then outstanding shall be entitled to be paid out of the assets
of the Company available for distribution to its shareholders, an amount equal
to liquidation preference of $50 per share plus all dividends accrued and unpaid
on such share up to the date of distribution of the assets of the Company to the
holders of Preferred Stock, and the holders of any class or series of preferred
stock ranking on a parity with the Preferred Stock as to Liquidation shall be
entitled to receive the full respective liquidation preferences (including any
premium) to which they are entitled and shall receive all accrued and unpaid
dividends with respect to their respective shares through and including the date
of distribution.
(b) If upon any Liquidation of the Company, the assets available for
distribution to the holders of Preferred Stock and any other stock of the
Company ranking on a parity with the Preferred Stock upon Liquidation which
shall then be outstanding shall be insufficient to pay the holders of all
outstanding shares of Preferred Stock and all other such parity stock the full
amounts (including all dividends accrued and unpaid) of the liquidating
distribution to which they shall be entitled, then the holders of each series of
such stock will share ratably in any such distribution of assets first in
proportion to their respective liquidation preferences until such preferences
are paid in full, and then in proportion to their respective amounts of accrued
but unpaid dividends. After payment of any such liquidating preference and
accrued dividends, the holders of shares of the Preferred Stock will not be
entitled to any further participation in any distribution of assets by the
Company.
(c) For purposes of this Section 4, a Liquidation shall not include (i)
any consolidation or merger of the Company with or into any other corporation,
(ii) any liquidation, dissolution, winding up or reorganization of the Company
immediately followed by reincorporation as another corporation or (iii) a sale
or other disposition of all or substantially all of the Company's assets to
another corporation unless in connection therewith the Liquidation of the
Company is specifically approved by all requisite corporate action.
(d) The holder of any shares of Preferred Stock shall not be entitled
to receive any payment owed for such shares under this Section 4 until such
holder shall cause to be delivered to the Company (i) the certificate(s)
representing such shares of Preferred Stock and (ii) transfer instrument(s)
satisfactory to the Company and sufficient to transfer such shares of Preferred
Stock to the Company free of any adverse interest. No interest shall accrue on
any payment upon Liquidation after the due date thereof.
5. Redemption at the Option of the Company.
-7-
<PAGE> 8
(a) Preferred Stock may not be redeemed by the Company prior to August
17, 2001, on or after which the Company, at its option, may redeem the shares of
Preferred Stock, in whole or in part, out of funds legally available therefor,
at any time or from time to time, subject to the notice provisions and
provisions for partial redemption described below, during the period beginning
on August 15 of the years shown below (beginning on August 17, 2001 and ending
on August 14, 2002, in the case of the first such period), at the following
redemption prices per share plus an amount equal to accrued and unpaid
dividends, if any, to (but excluding) the date fixed for redemption, whether or
not earned or declared:
<TABLE>
<CAPTION>
REDEMPTION
YEAR PRICE
---------- ----------
<S> <C>
2001 $52.900
2002 52.538
2003 52.175
2004 51.822
2005 51.450
2006 51.088
2007 50.725
2008 50.363
</TABLE>
and $50 at August 15, 2009 and thereafter; provided that, if the applicable
redemption date is a Dividend Payment Date, the quarterly payment of dividends
becoming due on such date shall be payable to the holders of such shares of
Preferred Stock registered as such on the relevant record date subject to the
terms and provisions of Section 3.
No sinking fund, mandatory redemption or other similar provision shall
apply to the Preferred Stock.
(b) In case the Company shall desire to exercise the right to redeem
the shares of Preferred Stock, in whole or in part, pursuant to Section 5(a), it
shall fix a date for redemption, and it, or at its request (which must be
received by the Transfer Agent at least ten (10) Business Days prior to the date
the Transfer Agent is requested to give notice as described below unless a
shorter period is agreed to by the Transfer Agent), the Transfer Agent in the
name of and at the expense of the Company, shall mail or cause to be mailed a
notice of such redemption at least twenty (20) and not more than sixty (60) days
prior the date fixed for redemption to the holders of the shares of Preferred
Stock so to be redeemed at their last addresses as the same appear on the
Company's stock records (provided that if the Company shall give such notice, it
shall also give such notice, and notice of the shares of Preferred Stock to be
redeemed, to the Transfer Agent). Such mailing shall be by first class mail. The
notice if mailed in the manner herein provided shall be conclusively presumed to
have been duly given, whether or not the holder receives such notice. In any
case, failure to give such notice by mail or any defect in the notice to the
holder of any share of Preferred Stock designated for redemption shall not
-8-
<PAGE> 9
affect the validity of the proceedings for the redemption of any other share of
Preferred Stock.
Each such notice of redemption shall specify the number of shares of
Preferred Stock to be redeemed, the date fixed for redemption, the redemption
price at which such shares of Preferred Stock are to be redeemed, the place or
places of payment, that payment will be made upon presentation and surrender of
the certificate or certificates representing such shares of Preferred Stock,
that dividends accrued to (but excluding) the date fixed for redemption will be
paid as specified in said notice, and that on and after said date dividends
thereon or on the portion thereof to be redeemed will cease to accrue. Such
notice shall also state the current Conversion Price and the date on which the
right to convert such shares of Preferred Stock into Common Stock will expire.
On or prior to the redemption date specified in the notice of
redemption given as provided in this Section 5(b), the Company will deposit with
a bank or trust company having an office or agency in the Borough of Manhattan,
City of New York and having a combined capital and surplus of at least
$50,000,000 (the "Deposit Bank") an amount of money sufficient to redeem on the
redemption date all the shares of Preferred Stock so called for redemption
(other than those theretofore surrendered for conversion into Common Stock) at
the appropriate redemption price, together with accrued dividends to (but
excluding) the date fixed for redemption; provided that if such payment is made
on the redemption date it must be received by the Deposit Bank by 10:00 a.m. New
York City time, on such date. If any shares of Preferred Stock called for
redemption are converted pursuant hereto, any money deposited with the Deposit
Bank or so segregated and held in trust for the redemption of such shares of
Preferred Stock shall be paid to the Company upon its request, or, if then held
by the Company shall be discharged from such trust. The Company shall be
entitled to make any deposit of funds contemplated by this Section 5 under
arrangements designed to permit such funds to generate interest or other income
for the Company, and the Company shall be entitled to receive all interest and
other income earned by any funds while they shall be deposited as contemplated
by this Section 5, provided that the Company shall maintain on deposit funds
sufficient to satisfy all payments which the deposit arrangement shall have been
established to satisfy. If the conditions precedent to the disbursement of any
funds deposited by the Company pursuant to this Section 5 shall not have been
satisfied within two years after the establishment of such funds, then (i) such
funds shall be returned to the Company upon its request; (ii) after such return,
such funds shall be free of any trust which shall have been impressed upon them;
(iii) the person entitled to the payment for which such funds shall have been
originally intended shall have the right to look only to the Company for such
payment, subject to applicable escheat laws; and (iv) the trustee which shall
have held such funds shall be relieved of any responsibility for such funds upon
the return of such funds to the Company.
If fewer than all the outstanding shares of Preferred Stock are to be
redeemed, shares to be redeemed shall be selected by the Company from
outstanding shares of Preferred Stock not previously called for redemption by
lot or pro rata (as near as may be) or by any other equitable method determined
by the Company in its sole discretion.
-9-
<PAGE> 10
(c) If notice of redemption has been given as above provided, on and
after the date fixed for redemption (unless the Company shall default in the
payment of the redemption price, together with accrued and unpaid dividends to
(but excluding) said date), dividends on such shares of Preferred Stock so
called for redemption shall cease to accrue and such shares of Preferred Stock
shall be deemed no longer outstanding and the holders thereof shall have no
right in respect of such shares of Preferred Stock except the right to receive
the redemption price thereof and accrued and unpaid dividends to (but excluding)
the date fixed for redemption, without interest thereon. On presentation and
surrender of the certificate or certificates representing such shares of
Preferred Stock at a place of payment specified in said notice, such shares of
Preferred Stock to be redeemed shall be redeemed by the Company at the
applicable redemption price, together with dividends accrued thereon to (but
excluding) the date fixed for redemption; provided that, if the applicable
redemption date is a Dividend Payment Date, the quarterly payment of dividends
becoming due on such date shall be payable to the holders of such shares of
Preferred Stock registered as such on the relevant record date subject to the
terms and provisions of Section 3.
If fewer than all the shares of Preferred Stock represented by any
certificate are redeemed, a new certificate shall be issued representing the
unredeemed shares without cost to the holder thereof.
(d) In connection with any redemption of Preferred Stock, the Company
may arrange for the purchase and conversion of any Preferred Stock by an
agreement with one or more investment bankers or other purchasers to purchase
such Preferred Stock by paying to the Deposit Bank in trust for the holders of
Preferred Stock, on or before the date fixed for redemption, an amount not less
than the applicable redemption price, together with dividends accrued to (but
excluding) the date fixed for redemption, of such Preferred Stock.
Notwithstanding anything to the contrary contained in this Section 5, the
obligation of the Company to pay the redemption price of such Preferred Stock,
together with dividends accrued to (but excluding) the date fixed for
redemption, shall be deemed to be satisfied and discharged to the extent such
amount is so paid by such purchasers. If such an agreement is entered into, a
copy of which will be filed with the Deposit Bank prior to the date fixed for
redemption, any certificate representing the Preferred Stock so converted not
duly surrendered for conversion by the holders thereof may, at the option of the
Company, be deemed, to the fullest extent permitted by law, acquired by such
purchasers from such holders and (notwithstanding anything to the contrary
contained in Section 7) surrendered by such purchasers for conversion, all as of
immediately prior to the close of business on the date fixed for redemption (and
the right to convert any such Preferred Stock shall be deemed to have been
extended through such time), subject to payment of the above amount as
aforesaid. At the direction of the Company, the Deposit Bank shall hold and
dispose of any such amount paid to it in the same manner as it would monies
deposited with it by the Company for the redemption of Preferred Stock.
6. Shares to Be Retired. Any share of Preferred Stock converted,
redeemed or otherwise acquired by the Company shall be retired and canceled and
shall upon
-10-
<PAGE> 11
cancellation be restored to the status of authorized but unissued shares of
preferred stock, subject to reissuance by the Board of Directors as shares of
preferred stock of one or more series.
7. Conversion. Holders of shares of Preferred Stock shall have the
right to convert all or a portion of such shares (including fractions of such
shares) into shares of Common Stock, as follows:
(a) Subject to and upon compliance with the provisions of this Section
7, a holder of shares of Preferred Stock shall have the right, at the holder's
option, at any time after the Issue Date (except that, with respect to shares of
Preferred Stock which shall be called for redemption, such right shall terminate
at the close of business on the next Business Day preceding the date fixed for
redemption of such shares of Preferred Stock unless the Company shall default in
payment due upon redemption thereof) to convert any of such shares (or a portion
thereof) into that number of fully paid and non-assessable shares of Common
Stock (as such shares shall then be constituted) obtained by dividing $50.00 by
the Conversion Price, as adjusted in accordance with this Section 7, by
surrender of the certificate or certificates representing such share of
Preferred Stock so to be converted in the manner provided in Section 7(b). As
used herein, the initial "Conversion Price" shall mean the dollar amount
obtained by dividing $50.00 by 2.79. If a part of a share of Preferred Stock is
converted, then the Company will convert such share into the appropriate number
of shares of Common Stock (subject to Section 7(c)) and issue a certificate
representing a fractional share of Preferred Stock evidencing the remaining
interest of such holder. A holder of the Preferred Stock is not entitled to any
rights of a holder of Common Stock until such holder has converted his Preferred
Stock to Common Stock, and only to the extent such Preferred Stock is deemed to
have been converted to Common Stock under this Section 7.
(b) In order to exercise the conversion right, the holder of the
Preferred Stock to be converted shall surrender the certificate or certificates
(with the Conversion Notice, the form of which is set forth in Section 14(a), on
the reverse of the certificate or certificates duly completed) representing the
number of shares to be so converted, duly endorsed, at an office or agency of
the Transfer Agent in the Borough of Manhattan, City of New York, and shall give
written notice of conversion to the office or agency that the holder elects to
convert such number of shares of Preferred Stock specified in said notice. Such
notice shall also state the name or names (with address) in which the
certificate or certificates for shares of Common Stock which shall be of Common
Stock issuable on such conversion shall be issued, and shall be accompanied by
transfer taxes, if required pursuant to Section 7(f). Each such share of
Preferred Stock surrendered for conversion shall, unless the shares of Common
Stock issuable on conversion are to be issued in the same name in which such
share of Preferred Stock is registered, be duly endorsed by, or be accompanied
by instruments of transfer in form satisfactory to the Company duly executed by,
the holder or his duly authorized attorney.
As promptly as practicable after satisfaction of the requirements for
conversion set forth above, the Company shall issue and shall deliver to such
holder or, if shares of
-11-
<PAGE> 12
Common Stock issuable on conversion are to be issued in a name other than that
in which such share of Preferred Stock to be converted is registered (as if such
transfer were a transfer of the share of Preferred Stock so converted), to such
other person, at the office or agency of the Transfer Agent in the Borough of
Manhattan, City of New York, the certificate or certificates representing the
number of shares of Common Stock issuable upon the conversion of such share of
Preferred Stock or a portion thereof in accordance with the provisions of this
Section 7 and a check or cash in respect of any fractional interest in respect
of a share of Common Stock arising upon such conversion, as provided in Section
7(c) (which payment, if any, shall be paid no later than five Business Days
after satisfaction of the requirements for conversion set forth above).
Each conversion shall be deemed to have been effected on the date on
which the requirements set forth above in this Section 7(b) have been satisfied
as to such share of Preferred Stock so converted, and the person in whose name
any certificate or certificates for the shares of Common Stock shall be issuable
upon such conversion shall be deemed to have become on said date the holder of
record of the shares represented thereby; provided, however, that if any such
surrender occurs on any date when the stock transfer books of the Company shall
be closed, the conversion shall be effected on the next succeeding day on which
such stock transfer books are open, and the person in whose name the
certificates are to be issued shall be the record holder thereof for all
purposes, but such conversion shall be at the Conversion Price in effect on the
date upon which certificate or certificates representing such shares of
Preferred Stock shall be surrendered. All shares of Common Stock delivered upon
conversion of the Preferred Stock will, upon delivery, be duly authorized,
validly issued and fully paid and nonassessable.
In the case of any share of Preferred Stock which is converted after
any record date with respect to the payment of a dividend on the Preferred Stock
and prior to the close of business on the Business Day prior to the next
succeeding Dividend Payment Date, the dividend due on such Dividend Payment Date
shall be payable on such Dividend Payment Date to the holder of record of such
share as of such preceding record date notwithstanding such conversion; provided
that shares of Preferred Stock surrendered for conversion during the period
between the close of business on any record date with respect to the payment of
a dividend on the Preferred Stock and prior to the close of business on the
Business Day prior to the next succeeding Dividend Payment Date must (except in
the case of shares of Preferred Stock which have been called for redemption and
a notice of redemption has been sent to the holders of Preferred Stock pursuant
to Section 5(b)) be accompanied by payment in funds acceptable to the Company of
an amount equal to the dividend payable on such Dividend Payment Date on the
shares of Preferred Stock being surrendered for conversion. The Transfer Agent
shall not be required to accept for conversion any shares of Preferred Stock not
accompanied by any payment required by the preceding sentence. Except as
provided in this paragraph, no payment or adjustment shall be made upon any
conversion on account of any dividends accrued on shares of Preferred Stock
surrendered for conversion or on account of any dividends on the Common Stock
issued upon conversion.
-12-
<PAGE> 13
(c) In connection with the conversion of any shares of Preferred Stock,
a portion of such shares may be converted; however, no fractional shares of
Common Stock or scrip representing fractional shares shall be issued upon
conversion of the Preferred Stock. If any fractional share of stock otherwise
would be issuable upon the conversion of the Preferred Stock, the Company shall
make an adjustment therefor in cash at the current market value thereof to the
holder of the Preferred Stock. The current market value of a share of Common
Stock shall be the Closing Price on the first Trading Day immediately preceding
the day on which the Preferred Stock (or a specified portion thereof) is deemed
to have been converted and such Closing Price shall be determined as provided in
Section 7(d)(ix). If more than one share (or fraction thereof) shall be
surrendered for conversion at one time by the same holder, the number of full
shares of Common Stock issuable upon conversion thereof shall be computed on the
basis of the aggregate number of shares of Preferred Stock so surrendered.
(d) The Conversion Price shall be adjusted from time to time by the
Company as follows:
(i) In case the Company shall hereafter pay a dividend or make a
distribution to all holders of the outstanding Common Stock in shares
of Common Stock, the Conversion Price in effect at the opening of
business on the date following the date fixed for the determination of
shareholders entitled to receive such dividend or other distribution
shall be reduced by multiplying such Conversion Price by a fraction of
which the numerator shall be the number of shares of Common Stock
outstanding at the close of business on the Record Date (as defined in
Section 7(d)(ix)) fixed for such determination and the denominator
shall be the sum of such number of shares and the total number of
shares constituting such dividend or other distribution, such reduction
to become effective immediately prior to the opening of business on the
day following the Record Date. If any dividend or distribution of the
type described in this Section 7(d)(i) is declared but not so paid or
made, the Conversion Price shall again be adjusted to the Conversion
Price which would then be in effect if such dividend or distribution
had not been declared.
(ii) In case the Company shall issue rights or warrants to all holders
of its outstanding shares of Common Stock entitling them (for a period
expiring within forty-five (45) days after the date fixed for the
determination of shareholders entitled to receive such rights or
warrants) to subscribe for or purchase shares of Common Stock at a
price per share less than 95% of the Current Market Price (as defined
in Section 7(d)(ix)) on the Record Date fixed for the determination of
shareholders entitled to receive such rights or warrants, the
Conversion Price shall be adjusted so that the same shall equal the
price determined by multiplying the Conversion Price in effect at the
opening of business on the date after such Record Date by a fraction of
which the numerator shall be the number of shares of Common Stock
outstanding at the close of business on the Record Date plus the number
of shares which the aggregate offering price of the total number of
shares so offered would purchase at such Current Market Price, and of
which the
-13-
<PAGE> 14
denominator shall be the number of shares of Common Stock outstanding
on the close of business on the Record Date plus the total number of
additional shares of Common Stock so offered for subscription or
purchase. Such adjustment shall become effective immediately after the
opening of business on the day following the Record Date fixed for
determination of shareholders entitled to receive such rights or
warrants. To the extent that shares of Common Stock are not delivered
pursuant to such rights or warrants, upon the expiration or termination
of such rights or warrants the Conversion Price shall be readjusted to
the Conversion Price which would then be in effect had the adjustments
made upon the issuance of such rights or warrants been made on the
basis of delivery of only the number of shares of Common Stock actually
delivered. In the event that such rights or warrants are not so issued,
the Conversion Price shall again be adjusted to be the Conversion Price
which would then be in effect if such date fixed for the determination
of shareholders entitled to receive such rights or warrants had not
been fixed. In determining whether any rights or warrants entitle the
holders to subscribe for or purchase shares of Common Stock at less
than 95% of such Current Market Price, and in determining the aggregate
offering price of such shares of Common Stock, there shall be taken
into account any consideration received for such rights or warrants,
the value of such consideration, if other than cash, to be determined
by the Board of Directors.
(iii) In case the outstanding shares of Common Stock shall be
subdivided into a greater number of shares of Common Stock, the
Conversion Price in effect at the opening of business on the day
following the day upon which such subdivision becomes effective shall
be proportionately reduced, and conversely, in case outstanding shares
of Common Stock shall be combined into a smaller number of shares of
Common Stock, the Conversion Price in effect at the opening of business
on the day following the day upon which such combination becomes
effective shall be proportionately increased, such reduction or
increase, as the case may be, to become effective immediately after the
opening of business on the day following the day upon which such
subdivision or combination becomes effective.
(iv) In case the Company shall, by dividend or otherwise, distribute to
all holders of its Common Stock shares of any class of capital stock of
the Company (other than any dividends or distributions to which Section
7(d)(i) applies) or evidences of its indebtedness, cash or other assets
(including securities, but excluding (1) any rights or warrants
referred to in Section 7(d)(ii) or (2) dividends and distributions paid
exclusively in cash (the foregoing hereinafter in this Section 7(d)(iv)
called the "Securities")), then, in each such case, the Conversion
Price shall be reduced so that the same shall be equal to the price
determined by multiplying the Conversion Price in effect immediately
prior to the close of business on the Record Date (as defined in
Section 7(d)(ix)) with respect to such distribution by a fraction of
which the numerator shall be the Current Market Price (determined as
provided in Section 7(d)(ix)) on such date less the fair market value
(as determined by the Board of Directors, whose determination shall
-14-
<PAGE> 15
be conclusive and described in a Board Resolution) on such date of the
portion of the Securities so distributed applicable to one share of
Common Stock and the denominator shall be such Current Market Price,
such reduction to become effective immediately prior to the opening of
business on the day following the Record Date; provided, however, that
in the event the then fair market value (as so determined) of the
portion of the Securities so distributed applicable to one share of
Common Stock is equal to or greater than the Current Market Price on
the Record Date, in lieu of the foregoing adjustment, adequate
provision shall be made so that each holder of the Preferred Stock
shall have the right to receive upon conversion of the Preferred Stock
(or any portion thereof) the amount of Securities such holder would
have received had such holder converted such Preferred Stock (or
portion thereof) immediately prior to such Record Date. In the event
that such dividend or distribution is not so paid or made, the
Conversion Price shall again be adjusted to be the Conversion Price
which would then be in effect if such dividend or distribution had not
been declared. If the Board of Directors determines the fair market
value of any distribution for purposes of this Section 7(d)(iv) by
reference to the actual or when issued trading market for any
securities comprising all or part of such distribution, it must in
doing so consider the prices in such market over the same period (the
"Reference Period") used in computing the Current Market Price pursuant
to Section 7(d)(ix) to the extent possible, unless the Board of
Directors in a board resolution determines in good faith that
determining the fair market value during the Reference Period would not
be in the best interest of the holder of the Preferred Stock.
In the event that the Company implements a shareholders' rights plan (a
"New Rights Plan") or amends any existing shareholders' rights plan (as
amended, an "Amended Rights Plan" and together with any New Rights
Plan, a "Rights Plan"), such Rights Plan shall provide that upon
conversion of the Preferred Stock the holders will receive, in addition
to the Common Stock issuable upon such conversion, the rights under
such Rights Plan (notwithstanding the occurrence of an event causing
such rights to separate from the Common Stock at or prior to the time
of conversion). Any distribution of rights or warrants pursuant to the
Rights Plan complying with the requirements set forth in the
immediately preceding sentence of this paragraph shall not constitute a
distribution of rights or warrants for purposes of this Section 7(d).
Rights or warrants distributed by the Company to all holders of Common
Stock entitling the holders thereof to subscribe for or purchase shares
of the Company's capital stock (either initially or under certain
circumstances), which rights or warrants, until the occurrence of a
specified event or events ("Trigger Event"): (i) are deemed to be
transferred with such shares of Common Stock; (ii) are not exercisable;
and (iii) are also issued in respect of future issuances of Common
Stock, shall be deemed not to have been distributed for purposes of
this Section 7(d)(iv) (and no adjustment to the Conversion Price under
this Section 7(d)(iv) will be required) until the occurrence of the
earliest Trigger Event. If such right or warrant is subject to
subsequent events, upon the
-15-
<PAGE> 16
occurrence of which such right or warrant shall become exercisable to
purchase different securities, evidences of indebtedness or other
assets or entitle the holder to purchase a different number or amount
of the foregoing or to purchase any of the foregoing at a different
purchase price, then the occurrence of each such event shall be deemed
to be the date of issuance and record date with respect to a new right
or warrant (and a termination or expiration of the existing right or
warrant without exercise by the holder thereof). In addition, in the
event of any distribution (or deemed distribution) of rights or
warrants, or any Trigger Event or other event (of the type described in
the preceding sentence) with respect thereto, that resulted in an
adjustment to the Conversion Price under this Section 7(d)(iv), (1) in
the case of any such rights or warrants which shall all have been
redeemed or repurchased without exercise by any holders thereof, the
Conversion Price shall be readjusted upon such final redemption or
repurchase to give effect to such distribution or Trigger Event, as the
case may be, as though it were a cash distribution, equal to the per
share redemption or repurchase price received by a holder of Common
Stock with respect to such rights or warrants (assuming such holder had
retained such rights or warrants), made to all holders of Common Stock
as of the date of such redemption or repurchase, and (2) in the case of
such rights or warrants all of which shall have expired or been
terminated without exercise, the Conversion Price shall be readjusted
as if such rights and warrants had never been issued.
For purposes of this Section 7(d)(iv) and Sections 7(d)(i) and (ii),
any dividend or distribution to which this Section 7(d)(iv) is
applicable that also includes shares of Common Stock to which 7(d)(i)
applies, or rights or warrants to subscribe for or purchase shares of
Common Stock to which Section 7(d)(ii) applies (or both), shall be
deemed instead to be (1) a dividend or distribution of the evidences of
indebtedness, assets, shares of capital stock, rights or warrants other
than such shares of Common Stock to which Section 7(d)(i) applies or
rights or warrants to which Section 7(d)(ii) applies (and any
Conversion Price reduction required by this Section 7(d)(iv) with
respect to such dividend or distribution shall then be made)
immediately followed by (2) a dividend or distribution of such shares
of Common Stock or such rights or warrants (and any further Conversion
Price reduction required by Sections 7(d)(i) and (ii) with respect to
such dividend or distribution shall then be made) except (A) the Record
Date of such dividend or distribution shall be substituted as "the date
fixed for the determination of shareholders entitled to receive such
dividend or other distribution", "Record Date fixed for such
determination" and "Record Date" within the meaning of Section 7(d)(i)
and as "the date fixed for the determination of shareholders entitled
to receive such rights or warrants", "the Record Date fixed for the
determination of the shareholders entitled to receive such rights or
warrants" and "such Record Date" within the meaning of Section
7(d)(ii), and (B) any shares of Common Stock included in such dividend
or distribution shall not be deemed "outstanding at the close of
business on the date fixed for such determination" within the meaning
of Section 7(d)(i).
-16-
<PAGE> 17
(v) In case the Company shall, by dividend or otherwise, distribute to
all holders of its Common Stock cash (excluding any cash that is
distributed upon a merger or consolidation to which Section 7(e)
applies or as part of a distribution referred to in Section 7(d)(iv)),
in an aggregate amount that, combined together with (1) the aggregate
amount of any other such distributions to all holders of its Common
Stock made exclusively in cash within the twelve (12) months preceding
the date of payment of such distribution, and in respect of which no
adjustment pursuant to this Section 7(d)(v) has been made, and (2) the
aggregate of any cash plus the fair market value (as determined by the
Board of Directors, whose determination shall be conclusive and
described in a Board Resolution) of consideration payable in respect of
any tender offer by the Company or any of its subsidiaries for all or
any portion of the Common Stock concluded within the twelve (12) months
preceding the date of payment of such distribution, and in respect of
which no adjustment pursuant to Section 7(d)(vi) has been made, exceeds
10.0% of the product of the Current Market Price (determined as
provided in Section 7(d)(ix)) on the Record Date with respect to such
distribution times the number of shares of Common Stock outstanding on
such date, then, and in each such case, immediately after the close of
business on such date, the Conversion Price shall be reduced so that
the same shall equal the price determined by multiplying the Conversion
Price in effect immediately prior to the close of business on such
Record Date by a fraction (i) the numerator of which shall be equal to
the Current Market Price on the Record Date less an amount equal to the
quotient of (x) the excess of such combined amount over such 10.0% and
(y) the number of shares of Common Stock outstanding on the Record Date
and (ii) the denominator of which shall be equal to the Current Market
Price on such date, provided, however, that in the event the portion of
the cash so distributed applicable to one share of Common Stock is
equal to or greater than the Current Market Price of the Common Stock
on the Record Date, in lieu of the foregoing adjustment, adequate
provision shall be made so that each holder of the Preferred Stock
shall have the right to receive upon conversion of shares of Preferred
Stock the amount of cash such holder would have received had such
holder converted such shares immediately prior to such Record Date. In
the event that such dividend or distribution is not so paid or made,
the Conversion Price shall again be adjusted to be the Conversion Price
which would then be in effect if such dividend or distribution had not
been declared. Any cash distribution to all holders of Common Stock as
to which the Company makes the election permitted by Section 7(d)(xv)
and as to which the Company has complied with the requirements of such
Section shall be treated as not having been made for all purposes of
this Section 7(d)(v).
(vi) In case a tender offer made by the Company or any of Subsidiary
for all or any portion of the Common Stock shall expire and such tender
offer (as amended upon the expiration thereof) shall require the
payment to shareholders (based on the acceptance (up to any maximum
specified in the terms of the tender offer) of Purchased Shares (as
defined below)) of an aggregate consideration having a fair market
value (as determined by the Board of Directors, whose determination
shall
-17-
<PAGE> 18
be conclusive and described in a Board Resolution) that combined
together with (1) the aggregate of the cash plus the fair market value
(as determined by the Board of Directors, whose determination shall be
conclusive and described in a Board Resolution), as of the expiration
of such tender offer, of consideration payable in respect of any other
tender offers, by the Company or any of its subsidiaries for all or any
portion of the Common Stock expiring within the twelve (12) months
preceding the expiration of such tender offer and in respect of which
no adjustment pursuant to this Section 7(d)(vi) has been made and (2)
the aggregate amount of any distributions to all holders of the
Company's Common Stock made exclusively in cash within twelve (12)
months preceding the expiration of such tender offer and in respect of
which no adjustment pursuant to Section 7(d)(v) has been made, exceeds
10.0% of the product of the Current Market Price (determined as
provided in Section 7(d)(ix)) as of the last time (the "Expiration
Time") tenders could have been made pursuant to such tender offer (as
it may be amended) times the number of shares of Common Stock
outstanding (including any tendered shares) on the Expiration Time,
then, and in each such case, immediately prior to the opening of
business on the day after the date of the Expiration Time, the
Conversion Price shall be adjusted so that the same shall equal the
price determined by multiplying the Conversion Price in effect
immediately prior to close of business on the date of the Expiration
Time by a fraction of which the numerator shall be the number of shares
of Common Stock outstanding (including any tendered shares) on the
Expiration Time multiplied by the Current Market Price of the Common
Stock on the Trading Day next succeeding the Expiration Time and the
denominator shall be the sum of (x) the fair market value (determined
as aforesaid) of the aggregate consideration payable to shareholders
based on the acceptance (up to any maximum specified in the terms of
the tender offer) of all shares validly tendered and not withdrawn as
of the Expiration Time (the shares deemed so accepted, up to any such
maximum, being referred to as the "Purchased Shares") and (y) the
product of the number of shares of Common Stock outstanding (less any
Purchased Shares) at the Expiration Time and the Current Market Price
of the Common Stock on the Trading Day next succeeding the Expiration
Time, such reduction (if any) to become effective immediately prior to
the opening of business on the day following the Expiration Time. In
the event that the Company is obligated to purchase shares pursuant to
any such tender offer, but the Company is permanently prevented by
applicable law from effecting any such purchases or all such purchases
are rescinded, the Conversion Price shall again be adjusted to be the
Conversion Price which would then be in effect if such tender offer had
not been made. If the application of this Section 7(d)(vi) to any
tender offer would result in an increase in the Conversion Price, no
adjustment shall be made for such tender offer under this Section
7(d)(vi). Any cash distribution to all holders of Common Stock as to
which the Company has made the election permitted by Section 7(d)(xv)
and as to which the Company has complied with the requirements of such
Section shall be treated as not having been made for all purposes of
this Section 7(d)(vi).
-18-
<PAGE> 19
(vii) In case of a tender or exchange offer made by a person other than
the Company or any Subsidiary for an amount which increases the
offeror's ownership of Common Stock to more than 25% of the Common
Stock outstanding and shall involve the payment by such person of
consideration per share of Common Stock having a fair market value (as
determined by the Board of Directors, whose determination shall be
conclusive, and described in a resolution of the Board of Directors) at
the last time (the "Tender Expiration Time") tenders or exchanges may
be made pursuant to such tender or exchange offer (as it shall have
been amended)) that exceeds the Current Market Price of the Common
Stock on the Trading Day next succeeding the Tender Expiration Time,
and in which, as of the Tender Expiration Time the Board of Directors
is not recommending rejection of the offer, the Conversion Price shall
be reduced so that the same shall equal the price determined by
multiplying the Conversion Price in effect immediately prior to the
Tender Expiration Time by a fraction of which the numerator shall be
the number of shares of Common Stock outstanding (including any
tendered or exchanged shares) on the Tender Expiration Time multiplied
by the Current Market Price of the Common Stock on the Trading Day next
succeeding the Tender Expiration Time and the denominator shall be the
sum of (x) the fair market value (determined as aforesaid) of the
aggregate consideration payable to shareholders based on the acceptance
(up to any maximum specified in the terms of the tender or exchange
offer) of all shares validly tendered or exchanged and not withdrawn as
of the Tender Expiration Time (the shares deemed so accepted, up to any
such maximum, being referred to as the "Tender Purchased Shares") and
(y) the product of the number of shares of Common Stock outstanding
(less any Tender Purchased Shares) on the Tender Expiration Time and
the Current Market Price of the Common Stock on the Trading Day next
succeeding the Tender Expiration Time, such reduction to become
effective immediately prior to the opening of business on the day
following the Tender Expiration Time. In the event that such person is
obligated to purchase shares pursuant to any such tender or exchange
offer, but such person is permanently prevented by applicable law from
effecting any such purchases or all such purchases are rescinded, the
Conversion Price shall again be adjusted to be the Conversion Price
which would then be in effect if such tender or exchange offer had not
been made. Notwithstanding the foregoing, the adjustment described in
this Section 7(d)(vii) shall not be made if, as of the Tender
Expiration Time, the offering documents with respect to such offer
disclose a plan or intention to cause the Company to engage in any
consolidation or merger of the Company with or into any other
corporation or corporations (whether or not affiliated with the
Company), or successive consolidations or mergers in which the Company
or its successor or successors shall be a party or parties, or any
sale, conveyance or lease (or successive sales, conveyances or leases)
of all or substantially all of the property of the Company, to any
other corporation (whether or not affiliated with the Company),
authorized to acquire and operate the same and which shall be organized
under the laws of the United States of America, any state thereof or
the District of Columbia; provided, however, that each share of
Preferred Stock shall remain outstanding, or unaffected or shall be
converted into or exchanged for
-19-
<PAGE> 20
convertible exchangeable preferred stock of the corporation (if other
than the Company) formed by such consolidation, or into which the
Company shall have been merged, or by the corporation which shall have
acquired or leased such property having powers, preferences and
relative, participating, optional or other rights and qualifications,
limitations and restrictions substantially similar to (but no less
favorable than) a share of Preferred Stock.
(viii) In case the Company shall issue Common Stock or securities
convertible into, or exchangeable for, Common Stock at a price per
share (or having a conversion or exchange price per share) that is less
than 95% of the Current Market Price on the date of issuance of such
securities (but excluding, among other things, issuances: (a) pursuant
to any bona fide plan for the benefit of employees or directors of or
consultants to the Company now or hereafter in effect; (b) to acquire
all or any portion of a business in an arm's-length transaction between
the Company and an unaffiliated third party including, if applicable,
issuances upon exercise of options or warrants assumed in connection
with such an acquisition; (c) in a bona fide public offering pursuant
to a firm commitment underwriting (or a similar type of offering made
pursuant to Rule 144A and/or Regulation S under the Securities Act) or
sales at the market pursuant to a continuous offering stock program;
(d) pursuant to the exercise of warrants, rights (including, without
limitation, earnout rights) or options, or upon the conversion of
convertible securities, which are issued and outstanding on the date
hereof, or which may be issued in the future at fair value and with an
exercise price or conversion price at least equal to the Current Market
Price at the date of issuance of such securities; and (e) pursuant to a
dividend reinvestment plan or other plan hereafter adopted for the
reinvestment of dividends or interest provided that such Common Stock
is issued at a price at least equal to 95% of the Current Market Price
of the Common Stock at the time of such issuance), the Conversion Price
shall be adjusted so that the same shall equal the price determined by
multiplying (i) the Conversion Price on the day immediately prior to
such date of issuance by (ii) a fraction, the numerator of which shall
be the sum of (A) the number of shares of Common Stock outstanding on
such date and (B) the number of additional shares of Common Stock which
the aggregate consideration receivable by the Company for the total
number of shares of Common Stock so issued (or into which the
convertible securities may convert) would purchase at the Current
Market Price as of the trading day immediately preceding the date of
the public announcement of the actual terms including the pricing
terms) of such issuance (or if there is no such public announcement
prior to the effective date of such issuance, such effective date) and
the denominator of which shall be the sum of (1) the number of shares
of Common Stock outstanding on such date and (2) the number of shares
of Common Stock issued (or into which the convertible securities may
convert). An adjustment made pursuant to this paragraph (viii) shall be
made on the next Business Day following the date on which any such
issuance is made and shall be effective retroactively immediately after
the close of business on such date. For purposes of this paragraph
(viii), the aggregate consideration receivable by the Company in
connection with the issuance of
-20-
<PAGE> 21
shares of Common Stock or of securities convertible into shares of
Common Stock shall be deemed to be equal to the sum of the aggregate
offering price (before deduction of underwriting discounts or
commissions and expenses payable to third parties) of all such
securities plus the minimum aggregate amount, if any, payable upon
conversion of any such convertible securities into shares of Common
Stock.
(ix) For purposes of this Section 7, the following terms shall have the
meaning indicated:
(1) "Closing Price" with respect to any securities on
any day shall mean the closing sale price regular way on such
day or, in case no such sale takes place on such day, the
average of the reported closing bid and asked prices, regular
way, in each case on the Nasdaq National Market or New York
Stock Exchange, as applicable, or, if such security is not
listed or admitted to trading on such Nasdaq National Market
or New York Stock Exchange, on the principal national security
exchange or quotation system on which such security is quoted
or listed or admitted to trading, or, if not quoted or listed
or admitted to trading on any national securities exchange or
quotation system, the average of the closing bid and asked
prices of such security on the over-the-counter market on the
day in question as reported by the National Quotation Bureau
Incorporated, or a similar generally accepted reporting
service, or if not so available, in such manner as furnished
by any New York Stock Exchange member firm selected from time
to time by the Board of Directors for that purpose, or a price
determined in good faith by the Board of Directors, whose
determination shall be conclusive and described in a Board
Resolution.
(2) "Current Market Price" shall mean the lesser of
(a) the Closing Price per share of Common Stock on the date in
question and (b) the average of the daily Closing Prices per
share of Common Stock for the ten (10) consecutive Trading
Days immediately prior to the date in question; provided,
however, that (1) if the "ex" date (as hereinafter defined)
for any event (other than the issuance or distribution or
Fundamental Change requiring such computation) that requires
an adjustment to the Conversion Price pursuant to Section
7(d)(i), (ii), (iii), (iv), (v), (vi), (vii) or (viii) occurs
during such ten (10) consecutive Trading Days, the Closing
Price for each Trading Day prior to the "ex" date for such
other event shall be adjusted by multiplying such Closing
Price by the same fraction by which the Conversion Price is so
required to be adjusted as a result of such other event, (2)
if the "ex" date for any event (other than the issuance or
distribution or Fundamental Change requiring such computation)
that requires an adjustment to the Conversion Price pursuant
to Section 7(d)(i), (ii), (iii), (iv), (v), (vi), (vii) or
(viii) occurs on or after the "ex" date for the issuance or
distribution or Fundamental Change requiring such computation
and prior to the day in
-21-
<PAGE> 22
question, the Closing Price for each Trading Day on and after
the "ex" date for such other event shall be adjusted by
multiplying such Closing Price by the reciprocal of the
fraction by which the Conversion Price is so required to be
adjusted as a result of such other event, and (3) if the "ex"
date for the issuance, distribution or Fundamental Change
requiring such computation is prior to the day in question,
after taking into account any adjustment required pursuant to
clause (1) or (2) of this proviso, the Closing Price for each
Trading Day on or after such "ex" date shall be adjusted by
adding thereto the amount of any cash and the fair market
value (as determined by the Board of Directors in a manner
consistent with any determination of such value for purposes
of Section 7(d)(iv), (vi) or (vii) whose determination shall
be conclusive and described in a Board Resolution) of the
evidences of indebtedness, shares of capital stock or assets
being distributed applicable to one share of Common Stock as
of the close of business on the day before such "ex" date. For
purposes of any computation under Sections 7(d)(vi) or (vii),
the Current Market Price of the Common Stock on any date shall
be deemed to be the average of the daily Closing Prices per
share of Common Stock for such day and the next two succeeding
Trading Days; provided, however, that if the "ex" date for any
event (other than the tender offer requiring such computation)
that requires an adjustment to the Conversion Price pursuant
to Section 7(d)(i), (ii), (iii), (iv), (v), (vi), (vii) or
(viii) occurs on or after the Expiration Time or the Tender
Expiration Time, as the case may be, for the tender or
exchange offer requiring such computation and prior to the day
in question, the Closing Price for each Trading Day on and
after the "ex" date for such other event shall be adjusted by
multiplying such Closing Price by the reciprocal of the
fraction by which the Conversion Price is so required to be
adjusted as a result of such other event. For purposes of this
paragraph, the term "ex" date, (1) when used with respect to
any issuance or distribution or Fundamental Change, means the
first date on which the Common Stock trades regular way on the
relevant exchange or in the relevant market from which the
Closing Price was obtained without the right to receive such
issuance or distribution, (2) when used with respect to any
subdivision or combination of shares of Common Stock, means
the first date on which the Common Stock trades regular way on
such exchange or in such market after the time at which such
subdivision or combination becomes effective, and (3) when
used with respect to any tender or exchange offer means the
first date on which the Common Stock trades regular way on
such exchange or in such market after the Expiration Time or
Tender Expiration Time, as the case may be, of such offer.
Notwithstanding the foregoing, whenever successive adjustments
to the Conversion Price are called for pursuant to this
Section 7(d), such adjustments shall be made to the Current
Market Price as may be necessary or appropriate to effectuate
the intent of this Section 7(d) and to avoid unjust or
inequitable results as determined in good faith by the Board
of Directors.
-22-
<PAGE> 23
(3) "fair market value" shall mean the amount which a
willing buyer would pay a willing seller in an arm's length
transaction.
(4) "Record Date" shall mean, with respect to any
dividend, distribution or other transaction or event in which
the holders of Common Stock have the right to receive any
cash, securities or other property or in which the Common
Stock (or other applicable security) is exchanged for or
converted into any combination of cash, securities or other
property, the date fixed for determination of shareholders
entitled to receive such cash, securities or other property
(whether such date is fixed by the Board of Directors or by
statute, contract or otherwise).
(5) "Trading Day" shall mean (x) if the applicable
security is quoted on the Nasdaq National Market, a day on
which trades may be made thereon or (y) if the applicable
security is listed or admitted for trading on the New York
Stock Exchange or another national security exchange, a day on
which the New York Stock Exchange or another national security
exchange is open for business or (z) if the applicable
security is not so listed, admitted for trading or quoted, any
day other than a Saturday or Sunday or a day on which banking
institutions in the State of New York are authorized or
obligated by law or executive order to close.
(x) The Company may make such reductions in the Conversion Price, in
addition to those required by Sections 7(d)(i), (ii), (iii), (iv), (v),
(vi), (vii) and (viii), as the Board of Directors considers to be
advisable to avoid or diminish any income tax to holders of Common
Stock or rights to purchase Common Stock resulting from any dividend or
distribution of stock (or rights to acquire stock) or from any event
treated as such for income tax purposes.
(xi) To the extent permitted by applicable law, the Company from time
to time may reduce the Conversion Price by any amount for any period of
time if the period is at least twenty (20) days, the reduction is
irrevocable during the period and the Board of Directors shall have
made a determination that such reduction would be in the best interests
of the Company, which determination shall be conclusive and described
in a Board Resolution. Whenever the Conversion Price is reduced
pursuant to the preceding sentence, the Company shall mail to each
holder of the Preferred Stock at his last address appearing on the
Company's stock records a notice of the reduction at least fifteen (15)
days prior to the date the reduced Conversion Price takes effect, and
such notice shall state the reduced Conversion Price and the period
during which it will be in effect.
No adjustment in the Conversion Price shall be required unless such
adjustment would require an increase or decrease of at least 1% in such
price; provided, however, that any adjustments which by reason of this
Section 7(d)(xi) are not required to be made shall be carried forward
and taken into account in any
-23-
<PAGE> 24
subsequent adjustment. All calculations under Section 7 shall be made
by the Company and shall be made to the nearest cent or to the nearest
one hundredth of a share, as the case may be. No adjustment need be
made for a change in the par value or no par value of the Common Stock.
(xii) Whenever the Conversion Price is adjusted as herein provided, the
Company shall promptly file with the Transfer Agent an Officers'
Certificate setting forth the Conversion Price after such adjustment
and setting forth a brief statement of the facts requiring such
adjustment. Promptly after delivery of such certificate, the Company
shall prepare a notice of such adjustment of the Conversion Price
setting forth the adjusted Conversion Price and the date on which each
adjustment becomes effective and shall mail such notice of such
adjustment of the Conversion Price to each holder of the Preferred
Stock at his last address appearing on the Company's stock records,
within twenty (20) days of the effective date of such adjustment.
Failure to deliver such notice shall not effect the legality or
validity of any such adjustment.
(xiii) In any case in which this Section 7(d) provides that an
adjustment shall become effective immediately after a Record Date for
an event, the Company may defer until the occurrence of such event (i)
issuing to the holder of any share of Preferred Stock converted after
such Record Date and before the occurrence of such event the additional
shares of Common Stock issuable upon such conversion by reason of the
adjustment required by such event over and above the Common Stock
issuable upon such conversion before giving effect to such adjustment
and (ii) paying to such holder of Preferred Stock any amount in cash in
lieu of any fraction pursuant to Section 7(c).
(xiv) For purposes of this Section 7(d), the number of shares of Common
Stock at any time outstanding shall not include shares held in the
treasury of the Company but shall include shares issuable in respect of
scrip certificates issued in lieu of fractions of shares of Common
Stock. The Company will not pay any dividend or make any distribution
on shares of Common Stock held in the treasury of the Company.
(xv) In lieu of making any adjustment to the Conversion Price pursuant
to Section 7(d)(v), the Company may elect to reserve an amount of cash
for distribution to the holders of the Preferred Stock upon the
conversion of the Preferred Stock so that any such holder converting
Preferred Stock will receive upon such conversion, in addition to the
shares of Common Stock and other items to which such holder is
entitled, the full amount of cash which such holder would have received
if such holder had, immediately prior to the Record Date for such
distribution of cash, converted its Preferred Stock into Common Stock,
together with any interest accrued with respect to such amount, in
accordance with this Section 7(d)(xv). The Company may make such
election by providing an Officers' Certificate to the Transfer Agent to
such effect on or prior to the payment date for any such distribution
and depositing with the Deposit Bank (as
-24-
<PAGE> 25
defined in Section 5(b)) on or prior to such date an amount of cash
equal to the aggregate amount the holders of the Preferred Stock would
have received if such holders had, immediately prior to the Record Date
for such distribution, converted all of the Preferred Stock into Common
Stock, with irrevocable instructions and authority to the Deposit Bank
that such funds be applied in the manner set forth in this Section
7(d)(xv). The Company shall instruct the Deposit Bank to invest any
such funds so deposited in marketable obligations issued or fully
guaranteed by the United States government with a maturity not more
than three (3) months from the date of issuance. Upon conversion of the
Preferred Stock by a holder, the holder will be entitled to receive, in
addition to the Common Stock issuable upon conversion, an amount of
cash equal to the amount such holder would have received if such holder
had, immediately prior to the Record Date for such distribution,
converted its Preferred Stock into Common Stock, along with such
holder's pro rata share of any accrued interest earned as a consequence
of the investment of such funds. Promptly after making an election
pursuant to this Section 7(d)(xv), the Company shall give or shall
cause to be given notice to all holders of the Preferred Stock of such
election, which notice shall state the amount of cash such holders
shall be entitled to receive (excluding interest) upon conversion of
the Preferred Stock as a consequence of the Company having made such
election.
(e) In the event that the Company shall be a party to any transaction
(including, without limitation (a) any recapitalization or reclassification of
shares of Common Stock (other than a change in par value, or from par value to
no par value, or from no par value to par value, or as a result of a subdivision
or combination of Common Stock), (b) any consolidation of the Company with, or
merger of the Company into, any other person, or any merger of another person
into the Company (other than a merger that does not result in a
reclassification, conversion, exchange or cancellation of Common Stock), (c) any
sale, transfer or lease of all or substantially all of the assets of the Company
or (d) any compulsory share exchange) pursuant to which either shares of Common
Stock shall be converted into the right to receive other securities, cash or
other property, or, in the case of a sale or transfer of all or substantially
all of the assets of the Company, the holders of Common Stock shall be entitled
to receive other securities, cash or other property, then appropriate provision
shall be made so that the holder of each share of Preferred Stock then
outstanding shall have the right thereafter to convert such Preferred Stock only
into: (x) in the case of any such transaction that does not constitute a Common
Stock Fundamental Change (as defined in Section 7(j)) and subject to funds being
legally available for such purpose under applicable law at the time of such
conversion, the kind and amount of the securities, cash or other property that
would have been receivable upon such recapitalization, reclassification,
consolidation, merger, sale, transfer or share exchange by a holder of the
number of shares of Common Stock issuable upon conversion of such share of
Preferred Stock immediately prior to such recapitalization, reclassification,
consolidation, merger, sale, transfer or share exchange, after giving effect, in
the case of any Non-Stock Fundamental Change (as defined in Section 7(j)), to
any adjustment in the Conversion Price in accordance with Section 7(i)(i), and
(y) in the case of any such transaction that constitutes a Common
-25-
<PAGE> 26
Stock Fundamental Change, common stock of the kind received by holders of Common
Stock as a result of such Common Stock Fundamental Change in an amount
determined in accordance with Section 7(i)(ii). The company formed by such
consolidation or resulting from such merger or that acquires such assets or that
acquires the Company's shares, as the case may be, shall make provision in its
certificate or articles of incorporation or other constituent document to
establish such right. Such certificate or articles of incorporation or other
constituent document shall provide for adjustments that, for events subsequent
to the effective date of such certificate or articles of incorporation or other
constituent document, shall be as nearly equivalent as may be practicable to the
relevant adjustments provided for in this Section 7. The above provisions shall
similarly apply to successive transactions of the type described in this Section
7(e).
(f) The issue of stock certificates representing the shares of Common
Stock on conversions of the Preferred Stock shall be made without charge to the
converting holder of the Preferred Stock for any tax in respect of the issue
thereof. The Company shall not, however, be required to pay any tax which may be
payable in respect of any transfer involved in the issue and delivery of stock
in any name other than the name in which the shares of Preferred Stock with
respect to which such shares of Common Stock are issued are registered, and the
Company shall not be required to issue or deliver any such stock certificate
unless and until the person or persons requesting the issue thereof shall have
paid to the Company the amount of such tax or shall have established to the
satisfaction of the Company that such tax has been paid.
(g) The Company covenants that all shares of Common Stock which may be
delivered upon conversion of shares of Preferred Stock will upon delivery be
duly and validly issued and fully paid and non-assessable, free of all liens and
charges and not subject to any preemptive rights.
The Company covenants that it will at all times reserve and keep
available, free from preemptive rights, out of the aggregate of its authorized
but unissued shares of Common Stock or its issued shares of Common Stock held in
its treasury, or both, a sufficient number of shares of Common Stock for the
purpose of effecting conversions of shares of Preferred Stock not theretofore
converted into Common Stock. For purposes of this reservation of Common Stock,
the number of shares of Common Stock which shall be deliverable upon the
conversion of all outstanding shares of Preferred Stock shall be computed as if
at the time of computation all outstanding shares of Preferred stock were held
by a single holder. The issuance of shares of Common Stock upon conversion of
shares of Preferred Stock is authorized in all respects.
The Company shall from time to time, in accordance with the laws of the
State of Delaware, use its best efforts to increase the authorized number of
shares of Common Stock if at any time the number of shares of authorized and
unissued Common Stock shall not be sufficient to permit the conversion of all
the then outstanding shares of Preferred Stock.
-26-
<PAGE> 27
Before taking any action which would cause an adjustment reducing the
Conversion Price below the then par value, if any, of the shares of Common Stock
issuable upon conversion of the Preferred Stock, the Company will take all
corporate action which may, in the opinion of its counsel, be necessary in order
that the Company may validly and legally issue shares of such Common Stock at
such adjusted Conversion Price.
The Company covenants that if any shares of Common Stock to be provided
for the purpose of conversion of the Preferred Stock hereunder require
registration with or approval of any governmental authority under any Federal or
State law before such shares may be validly issued upon conversion, the Company
will in good faith and as expeditiously as possible endeavor to secure such
registration or approval, as the case may be.
The Company further covenants that if at any time the Common Stock
shall be listed on the Nasdaq National Market or any other national securities
exchange or automated quotation system the Company will, if permitted by the
rules of such exchange or automated quotation system, list and keep listed, so
long as the Common Stock shall be so listed on such exchange or automated
quotation system, all Common Stock issuable upon conversion of the Preferred
Stock.
(h) In case:
(i) the Company shall declare a dividend (or any other distribution) on
its Common Stock (that would require an adjustment in the Conversion
Price pursuant to Section 7(d)); or
(ii) the Company shall authorize the granting to the holders of its
Common Stock of rights or warrants to subscribe for or purchase any
share of any class or any other rights or warrants; or
(iii) of any reclassification of the Common Stock of the Company (other
than a subdivision or combination of its outstanding Common Stock, or a
change in par value, or from par value to no par value, or from no par
value to par value), or of any consolidation or merger to which the
Company is a party and for which approval of any shareholders of the
Company is required, or of the sale or transfer of all or substantially
all of the assets of the Company; or
(iv) of the voluntary or involuntary dissolution, liquidation or
winding-up of the Company; the Company shall cause to be filed with
the Transfer Agent and to be mailed to each holder of the Preferred
Stock at his address appearing on the Company's stock records, as
promptly as possible but in any event at least fifteen days prior to
the applicable date hereinafter specified, a notice stating (x) the
date on which a record is to be taken for the purpose of such dividend,
distribution or rights or warrants, or, if a record is not to be taken,
the date as of which the holders of Common Stock of record to be
entitled to such dividend, distribution or
-27-
<PAGE> 28
rights are to be determined, or (y) the date on which such
reclassification, consolidation, merger, sale, transfer, dissolution,
liquidation or winding-up is expected to become effective or occur, and
the date as of which it is expected that holders of Common Stock of
record shall be entitled to exchange their Common Stock for securities
or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer, dissolution, liquidation or
winding-up. Failure to give such notice, or any defect therein, shall
not affect the legality or validity of such dividend, distribution,
reclassification, consolidation, merger, sale, transfer, dissolution,
liquidation or winding-up.
(i) Notwithstanding any other provisions in this Section 7 to the
contrary, if any Fundamental Change (as defined in Section 7(j)) occurs, then
the Conversion Price in effect with be adjusted immediately after such
Fundamental Change as described below. In addition, in the event of a Common
Stock Fundamental Change, shares of Preferred Stock shall thereafter be
convertible solely into common stock of the kind received by holders of Common
Stock as the result of such Common Stock Fundamental Change.
For purposes of calculating any adjustment to be made pursuant to this
Section 7(i) in the event of a Fundamental Change, immediately after such
Fundamental Change (and for such purposes a Fundamental Change shall be deemed
to occur on the earlier of (a) the occurrence of such Fundamental Change and (b)
the date, if any, fixed for determination of shareholders entitled to receive
the cash, securities, property or other assets distributable in such Fundamental
Change to holders of the Common Stock):
(i) in the case of a Non-Stock Fundamental Change, the Conversion Price
of the Preferred Stock immediately following such Non-Stock Fundamental
Change shall be the lower of (A) the Conversion Price in effect
immediately prior to such Non-Stock Fundamental Change, but after
giving effect to any other prior adjustments effected pursuant to this
Section 7, and (B) the product of (1) the Applicable Price (as defined
in Section 7(j)) and (2) a fraction, the numerator of which is $50 and
the denominator of which is (x) the amount of the redemption price for
one share of Preferred Stock if the redemption date were the date of
such Non-Stock Fundamental Change (or the date of the period commencing
on the first date of original issuance of the Preferred Stock and
through August 14, 2000 or the twelve-month period commencing August
15, 2000, the product of 107.25% and 106.53%, respectively, times $50)
plus (y) any then-accrued and unpaid distributions on one share of
Preferred Stock; and
(ii) in the case of a Common Stock Fundamental Change, the Conversion
Price of the Preferred Stock immediately following such Common Stock
Fundamental Change shall be the Conversion Price in effect immediately
prior to such Common Stock Fundamental Change, but after giving effect
to any other prior adjustments effected pursuant to this Section 7,
multiplied by a fraction, the numerator of which is the Purchaser Stock
Price (as defined in Section 7(j)) and the denominator of which is the
Applicable Price; provided, however, that in the event of a Common
Stock Fundamental Change in which (A) 100% of the value
-28-
<PAGE> 29
of the consideration received by a holder of Common Stock is common
stock of the successor, acquiror or other third party (and cash, if
any, paid with respect to any fractional interests in such common stock
resulting from such Common Stock Fundamental Change) and (B) all of the
Common Stock shall have been exchanged for, converted into or acquired
for, common stock of the successor, acquiror or other third party (and
any cash with respect to fractional interests), the Conversion Price of
the Preferred Stock immediately following such Common Stock Fundamental
Change shall be the Conversion Price in effect immediately prior to
such Common Stock Fundamental Change multiplied by a fraction, the
numerator of which is one (1) and the denominator of which is the
number of shares of common stock of the successor, acquiror or other
third party received by a holder of one share of Common Stock as a
result of such Common Stock Fundamental Change.
(j) The following definitions shall apply to terms used in this Section
7:
(i) The term "Applicable Price" means (i) in the event of a Non-Stock
Fundamental Change in which the holders of Common Stock receive only
cash, the amount of cash received by a holder of one share of Common
Stock and (ii) in the event of any other Fundamental Change, the
average of the daily Closing Price (determined as provided in Section
7(d)(ix)(1)) for one share of Common Stock during the 10 Trading Days
(determined as provided in the Section 7(d)(ix)(5)) immediately prior
to the record date for the determination of the holders of Common Stock
entitled to receive cash, securities, property or other assets in
connection with such Fundamental Change or, if there is no such record
date, prior to the date upon which the holders of Common Stock shall
have the right to receive such cash, securities, property or other
assets. The Closing Price on any Trading Day may be subject to
adjustment as provided in Section 7(d)(ix).
(ii) The term "Common Stock Fundamental Change" means any Fundamental
Change in which more than 50% of the value (as determined in good faith
by the Board of Directors of the Company) of the consideration received
by holders of Common Stock consists of common stock that, for the 10
Trading Days immediately prior to such Fundamental Change, has been
admitted for listing or admitted for listing subject to notice of
issuance on a national securities exchange or quoted on Nasdaq National
Market, provided, however, that a Fundamental Change shall not be a
Common Stock Fundamental Change unless either (i) the Company continues
to exist after the occurrence of such Fundamental Change and the
outstanding Preferred Stock continues to exist as outstanding Preferred
Stock, or (ii) not later than the occurrence of such Fundamental
Change, the outstanding Preferred Stock is converted into or exchanged
for shares of convertible preferred stock, which convertible preferred
stock has powers, preferences and relative, participating optional or
other rights, and qualifications, limitations and restrictions
substantially similar (but no less favorable) to those of the Preferred
Stock.
-29-
<PAGE> 30
(iii) The term "Fundamental Change" means the occurrence of any
transaction or event or series of transactions or events pursuant to
which all or substantially all of the Common Stock shall be exchanged
for, converted into, acquired for or shall constitute solely the right
to receive cash, securities, property or other assets (whether by means
of an exchange offer, liquidation, tender offer, consolidation, merger,
combination, reclassification, recapitalization or otherwise);
provided, however, in the case of any such series of transactions or
events, for purposes of adjustment of the Conversion Price, such
Fundamental Change shall be deemed to have occurred when substantially
all of the Common Stock shall have been exchanged for, converted into
or acquired for, or shall constitute solely the right to receive, such
cash, securities, property or other assets, but the adjustment shall be
based upon the consideration that the holders of the Common Stock
received in the transaction or event as a result of which more than 50%
of the Common Stock shall have been exchanged for, converted into or
acquired for, or shall constitute solely the right to receive, such
cash, securities, property or other assets.
(iv) The term "Non-Stock Fundamental Change" means any Fundamental
Change other than a Common Stock Fundamental Change.
(v) The term "Purchaser Stock Price" means, with respect to any Common
Stock Fundamental Change, the average of the daily Closing Price for
one share of the common stock received by holders of the Common Stock
in such Common Stock Fundamental Change during the 10 Trading Days
immediately prior to the date fixed for the determination of the
holders of the Common Stock entitled to receive such common stock or,
if there is no such date, prior to the date upon which the holders of
the Common Stock shall have the right to receive such common stock.
8. Ranking. Any class or classes of stock of the Company shall be
deemed to rank:
(a) prior to the Preferred Stock, as to dividends or as to distribution
of assets upon liquidation, dissolution or winding up, if the holders of such
class shall be entitled to the receipt of dividends or of amounts distributable
upon liquidation, dissolution or winding up, as the case may be, in preference
or priority to the holders of Preferred Stock.
(b) on a parity with the Preferred Stock, as to dividends or as to
distribution of assets upon liquidation, dissolution or winding up, whether or
not the dividend rates, Dividend Payment Dates or redemption or liquidation
prices per share thereof be different from those of the Preferred Stock, if the
holders of such class of stock and the Preferred Stock shall be entitled to the
receipt of dividends or of amounts distributable upon liquidation, dissolution
or winding up, as the case may be, in proportion to their respective amounts of
accrued and unpaid dividends per share or liquidation prices, without preference
or priority of one over the other; and
-30-
<PAGE> 31
(c) junior to the Preferred Stock, as to dividends or as to the
distribution of assets upon liquidation, dissolution or winding up, if such
stock shall be Common Stock or if the holder of Preferred Stock shall be
entitled to receipt of dividends or of amounts distributable upon liquidation,
dissolution or winding up, as the case may be, in preference or priority to the
holders of shares of such stock.
9. Voting Rights.
(a) The holders of the Preferred Stock will not have any voting rights
except as set forth below or as otherwise from time to time required by law. In
connection with any right to vote, each holder of the Preferred Stock will have
one vote for each share of Preferred Stock held. Any shares of Preferred Stock
held by the Company or any entity controlled by the Company shall not have
voting rights hereunder and shall not be counted in determining the presence of
a quorum.
(b) Whenever dividends on the Preferred Stock or on any outstanding
shares of preferred stock ranking on parity as to dividends with the Preferred
Stock shall be in arrears in an aggregate amount equal to at least six quarterly
dividends (whether or not consecutive), (i) the number of members of the Board
of Directors of the Company shall be increased by two, effective as of the time
of election of such directors as hereinafter provided and (ii) the holders of
the Preferred Stock (voting separately as a class with the holders of preferred
stock ranking on parity as to dividends with the Preferred Stock on which like
voting rights have been conferred and are exercisable, without regard to series)
will have the exclusive right to vote for and elect such two additional
directors of the Company at any meeting of shareholders of the Company at which
directors are to be elected held during the period such dividends remain in
arrears. The right of the holders of the Preferred Stock to vote for such two
additional directors shall terminate when all accrued and unpaid dividends on
the Preferred Stock and all other affected classes or series of preferred stock
ranking on parity as to dividends with the Preferred Stock have been declared
and paid or set apart for payment. The holders of the Preferred Stock voting as
a class shall have the right to remove without cause at any time and replace any
directors such holders shall have elected pursuant to this Section 9. If the
office of any director elected by the holders of Preferred Stock voting as a
class becomes vacant by reason of death, resignation, retirement,
disqualification, removal from office or otherwise, the remaining director
elected by the holders of Preferred Stock (together with any other series of
preferred stock ranking on a parity with the Preferred Stock and upon which like
voting rights have been conferred and are exercisable) voting as a class may
choose a successor who shall hold office for the unexpired term in respect of
which such vacancy occurred. The term of office of all directors so elected
shall terminate immediately upon the termination of the right of the holders of
the Preferred Stock to vote for such directors, and the number of directors of
the Board of Directors of the Company shall immediately thereafter be reduced by
two.
The foregoing right of the holders of the Preferred Stock with respect
to the election of two directors may be exercised at any annual meeting of
shareholders or at any special meeting of shareholders held for such purpose. If
the right to elect directors
-31-
<PAGE> 32
shall have accrued to the holders of the Preferred Stock more than ninety (90)
days preceding the date established for the next annual meeting of shareholders,
the President of the Company shall, within twenty (20) days after the delivery
to the Company at its principal office of a written request for a special
meeting signed by the holders of at least 10% of all outstanding shares of
Preferred Stock, call a special meeting of the holders of the Preferred Stock to
be held within sixty (60) days after the delivery of such request for the
purpose of electing such additional directors.
(c) So long as the Preferred Stock is outstanding, the Company shall
not, without the affirmative vote or consent of the holders of at least a
majority (unless a higher percentage shall then be required by applicable law)
of all outstanding shares of Preferred Stock voting separately as a class with
the holders of preferred stock ranking on parity as to dividends with the
Preferred Stock on which like voting rights have been conferred and are
exercisable, without regard to series, (i) amend, alter or repeal any provision
of the Certificate of Incorporation (including, without limitation, these
resolutions) or the Bylaws of the Company so as to affect adversely the relative
rights, preferences, qualifications, limitations or restrictions of the
Preferred Stock, or (ii) create, authorize or issue, or reclassify any
authorized stock of the Company into, or increase the authorized amount of, any
class or series of the Company's capital stock ranking senior to or on parity
with the Preferred Stock as to dividends or as to distributions of assets upon
liquidation, dissolution or winding up of the Company, whether voluntary or
involuntary, or any obligation or security convertible into shares of such a
class or series. In addition, so long as the Preferred Stock is outstanding, the
Company shall not, without the affirmative vote or consent of the holders of at
least a majority (unless a higher percentage shall then be required by
applicable law) of all outstanding shares of Preferred Stock voting separately
as a class with the holders of preferred stock ranking on parity as to dividends
with the Preferred Stock on which like voting rights have been conferred and are
exercisable, without regard to series, enter into a share exchange pursuant to
which the Preferred Stock would be exchanged for any other securities or merge
or consolidate with or into any other person or permit any other person to merge
or consolidate with or into the Company, unless in such case each share of
Preferred Stock shall remain outstanding or unaffected or shall be converted
into or exchanged for convertible exchangeable preferred stock of the surviving
entity having voting rights, preferences, limitations or special rights thereof
substantially similar (but no less favorable) to a share of Preferred Stock. A
class vote on the part of the Preferred Stock shall, without limitation,
specifically not be deemed to be required (except as otherwise required by law
or resolution of the Company's Board of Directors) in connection with (a) the
authorization, issuance or increase in the authorized amount of any shares of
capital stock ranking junior to or on parity with the Preferred Stock both as to
the payment of dividends and as to distribution of assets upon liquidation,
dissolution or winding up of the Company, whether voluntary or involuntary, when
and if issued, including Common Stock; or (b) the authorization, issuance or
increase in the amount of any bonds, mortgages, debentures or other obligations
of the Company (other than those that may be covered by clause (ii) of the
preceding sentence).
-32-
<PAGE> 33
The holders of Preferred Stock shall also be entitled to vote on
certain amendments or supplements to the Indenture establishing the Debentures,
for which the Preferred Stock may be exchanged, as described in Section 10
hereof, and provided in Article XI of such Indenture.
10. Exchange.
(a) The Preferred Stock shall be exchangeable, in whole but not in
part, at the option of the Company on any Dividend Payment Date beginning August
15, 2000, for the Debentures at the rate of $50 principal amount of Debentures
for each share of Preferred Stock outstanding at the time of exchange; provided
that the Debentures will be issuable in denominations of $1,000 and integral
multiples thereof. If the exchange results in an amount of Debentures that is
not an integral multiple of $1,000, the amount in excess of the closest integral
multiple of $1,000 will be paid in cash by the Company.
(b) The Company will mail to each record holder of the Preferred Stock
written notice of its intention to exchange the Preferred Stock for the
Debentures no less than 30 nor more than 60 days prior to the date of the
exchange (the "Exchange Date"). The notice shall specify the Exchange Date, the
place or places where certificates for shares of the Preferred Stock are to be
surrendered for Debentures and shall state that dividends on Preferred Stock
will cease to accrue on and after the Exchange Date.
(c) If the Company has caused the Debentures to be authenticated on or
prior to the Exchange Date and has complied with the other provisions of this
Section 10, then, notwithstanding that any certificates for shares of Preferred
Stock have not been surrendered for exchange, on the Exchange Date dividends
shall cease to accrue on the Preferred Stock and at the close of business on the
Exchange Date the holders of the Preferred Stock shall cease to be shareholders
with respect to the Preferred Stock and shall have no interest in or other
claims against the Company by virtue thereof and shall have no voting or other
rights with respect to the Preferred Stock, except the right to receive the
Debentures issuable upon such exchange and the right to accumulated and unpaid
dividends, without interest thereon, upon surrender (and endorsement, if
required by the Company) of their certificates, and the shares evidenced thereby
shall no longer be deemed outstanding for any purpose. The Company will cause
the Debentures to be authenticated on or before the Exchange Date, and the
Company will pay interest on the Debentures at the rate and on the dates
specified in such Indenture from and after the Exchange Date.
(d) Notwithstanding the foregoing, if notice of exchange has been given
pursuant to this Section 10 and any holder of shares of Preferred Stock shall,
prior to the close of business on the Exchange Date, give written notice to the
Company pursuant to Section 7 of the conversion of any or all of the shares held
by the holder (accompanied by a certificate or certificates for such shares,
duly endorsed or assigned to the Company), then the exchange shall not become
effective as to the shares to be converted and the conversion shall become
effective as provided in Section 7.
-33-
<PAGE> 34
(e) The Debentures will be delivered to the persons entitled thereto
upon surrender to the Company or its agent appointed for that purpose of the
certificates for the shares of Preferred Stock being exchanged therefor.
(f) Notwithstanding the other provisions of this Section 10, if on the
Exchange Date the Company has not paid full cumulative dividends on the
Preferred Stock (or set aside a sum therefor) or an Event of Default under the
Indenture shall have occurred and be continuing, the Company may not exchange
the Preferred Stock for the Debentures and any notice previously given pursuant
to this Section 10 shall be of no effect.
(g) Prior to the Exchange Date, the Company will comply with any
applicable securities and blue sky laws with respect to the exchange of the
Preferred Stock for the Debentures.
(h) Dividends with respect to the shares of Preferred Stock to be
exchanged which are due on the quarterly Dividend Payment Date on which the
exchange is effected will be mailed to holders in the regular course.
11. Record Holders. The Company and the Transfer Agent may deem and
treat the record holder of any shares of Preferred Stock as the true and lawful
owner thereof for all purposes and neither the Company nor the Transfer Agent
shall be affected by any notice to the contrary.
12. Notice. Except as may otherwise be provided for herein, all notices
referred to herein shall be in writing, and all notices hereunder shall be
deemed to have been given upon receipt, in the case of a notice of conversion
given to the Company as contemplated in Section 7(b) hereof, or, in all other
cases, upon the earlier of receipt of such notice or three Business Days after
the mailing of such notice if sent by registered mail (unless first-class mail
shall be specifically permitted for such notice under the terms of this
resolution) with postage prepaid, addressed, if to the Company, to its offices
at 145 Brandywine Parkway, West Chester, PA 19380 (Attention: Chief Financial
Officer) or to an agent of the Company designated as permitted by this
certificate, or, if to any holder of the Preferred Stock, to such holder at the
address of such holder of the Preferred Stock as listed in the Company's stock
records or to such other address as the Company or holder, as the case may be,
shall have designated by notice similarly given.
13. Restrictions on Transfer.
(a) So long as the shares of Preferred Stock are eligible for
book-entry settlement with the Depositary, or unless otherwise required by law,
all shares of Preferred Stock that are so eligible may be represented by a
Preferred Stock certificate in global form (the "Global Certificate") registered
in the name of the Depositary or the nominee of the Depositary, except as
otherwise specified below. The transfer and exchange of beneficial interests in
the Global Certificate shall be effected through the
-34-
<PAGE> 35
Depositary in accordance with this Certificate and the procedures of the
Depositary therefor.
Shares of Preferred Stock that upon initial issuance are not owned by
Institutional Accredited Investors will be represented by one or more Global
Certificates. Transfers of interests in a Global Certificate will be made in
accordance with the standing instructions and procedures of the Depository and
its participants. The Transfer Agent shall make appropriate endorsements to
reflect increases or decreases in the Global Certificate as set forth on the
face of the Global Certificate to reflect any such transfers.
Except as provided below, beneficial owners of an interest in a Global
Certificate shall not be entitled to have certificates registered in their
names, will not receive or be entitled to receive physical delivery of
certificates in definitive form and will not be considered holders of such
Global Certificates.
(b) So long as the shares of Preferred Stock are eligible for
book-entry settlement, or unless otherwise required by law, upon any transfer of
a definitive Preferred Stock certificate to a QIB in accordance with Rule 144A,
and upon receipt of the definitive Preferred Stock certificate or Preferred
Stock certificates being so transferred, together with a certification,
substantially in the form of the reverse of the certificate, from the transferor
that the transfer is being made in compliance with Rule 144A (or other evidence
satisfactory to the Transfer Agent), the Transfer Agent shall make an
endorsement on the Global Certificate to reflect an increase in the aggregate
amount of the Preferred Stock represented by the Global Certificate, the
Transfer Agent shall cancel such definitive Preferred Stock certificate or
Preferred Stock certificates in accordance with the standing instructions and
procedures of the Depositary and the aggregate amount of Preferred Stock
represented by the Global Certificate will be increased accordingly; provided
that no definitive Preferred Stock certificate, or portion thereof, in respect
of which the Company or an Affiliate of the Company held any beneficial interest
shall be included in such Global Certificate until such definitive Preferred
Stock certificate is freely tradable in accordance with Rule 144(k); provided
further that the Transfer Agent shall issue Preferred Stock certificates in
definitive form upon any transfer of a beneficial interest in any Global
Certificate to the Company or any Affiliate of the Company.
Upon any sale or transfer of Preferred Stock to an Institutional
Accredited Investor (other than pursuant to a registration statement that has
been declared effective under the Securities Act), such Institutional Accredited
Investor shall, prior to such sale or transfer, furnish to the Company and/or
the Transfer Agent a signed letter containing representations and agreements
relating to certain restrictions on transfer, the form of which is available
from the Transfer Agent upon request, and shall check the appropriate box on the
form of Assignment Form on the reverse of such certificate, the form of which is
set forth in Section 14(b).
Any Global Certificate may be endorsed with or have incorporated in the
text thereof such legends or recitals or changes not inconsistent with the
provisions of this
-35-
<PAGE> 36
Certificate as may be required by the custodian, the Depositary, by the New York
Stock Exchange or by the National Association of Securities Dealers, Inc. in
order for the shares of Preferred Stock to be tradeable on The Portal Market or
as may be required for the shares of Preferred Stock to be tradeable on any
other market developed for trading of securities pursuant to Rule 144A or
required to comply with any applicable law or any regulation thereunder or with
the rules and regulations of any securities exchange upon which the shares of
Preferred Stock may be listed or traded or to conform with any usage with
respect thereto, or to indicate any special limitations or restrictions to which
any particular shares of Preferred Stock are subject.
(c) Every share of Preferred Stock that bears or is required under this
Section 13(c) to bear the legend set forth in this Section 13(c) (together with
any Common Stock issued upon conversion of the Preferred Stock and required to
bear the legend set forth in Section 13(d), collectively, the "Restricted
Preferred Stock") shall be subject to the restrictions on transfer set forth in
this Section 13(c) (including those set forth in the legend set forth below)
unless such restrictions on transfer shall be waived by written consent of the
Company, and the holder of each such Restricted Preferred Stock, by such
holder's acceptance thereof, agrees to be bound by all such restrictions on
transfer. As used in Sections 13(c) and 13(d), the term "transfer" encompasses
any sale, pledge, transfer or other disposition whatsoever of any Restricted
Preferred Stock.
Until two (2) years after the original issue date of any Preferred
Stock, any certificate evidencing such Preferred Stock (and all securities
issued in exchange therefor or substitution thereof, other than Common Stock, if
any, issued upon conversion therefor, which shall bear the legend set forth in
Section 13(d), if applicable) shall bear a legend in substantially the following
form, unless such Preferred Stock has been sold pursuant to a registration
statement that has been declared effective under the Securities Act (and which
continues to be effective at the time of such transfer), or unless otherwise
agreed by the Company in writing, with written notice thereof to the Transfer
Agent:
THE SECURITY EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE
SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT AS
SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE
HOLDER (1) REPRESENTS THAT (A) IT IS A "QUALIFIED INSTITUTIONAL BUYER"
(AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) OR (B) IT IS AN
INSTITUTIONAL "ACCREDITED INVESTOR" (AS DEFINED IN RULE 501(A)(1), (2),
(3) OR (7) UNDER THE SECURITIES ACT) ("INSTITUTIONAL ACCREDITED
INVESTOR"); (2) AGREES THAT IT WILL NOT, WITHIN TWO YEARS AFTER THE
ORIGINAL ISSUANCE OF THE SECURITY EVIDENCED HEREBY, RESELL OR OTHERWISE
TRANSFER THE SECURITY EVIDENCED HEREBY OR THE COMMON STOCK ISSUABLE
UPON CONVERSION OF SUCH
-36-
<PAGE> 37
SECURITY EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) TO A
QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE
SECURITIES ACT, (C) TO AN INSTITUTIONAL ACCREDITED INVESTOR THAT, PRIOR
TO SUCH TRANSFER, FURNISHES TO STOCKTRANS, INC., AS TRANSFER AGENT, A
SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS
RELATING TO THE RESTRICTIONS ON TRANSFER OF THE SECURITY EVIDENCED
HEREBY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM SUCH TRANSFER
AGENT), (D) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY
RULE 144 UNDER THE SECURITIES ACT (IF AVAILABLE) OR (E) PURSUANT TO A
REGISTRATION STATEMENT WHICH HAS BEEN DECLARED EFFECTIVE UNDER THE
SECURITIES ACT (AND WHICH CONTINUES TO BE EFFECTIVE AT THE TIME OF SUCH
TRANSFER); AND (3) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM
THE SECURITY EVIDENCED HEREBY IS TRANSFERRED (OTHER THAN A TRANSFER
PURSUANT TO CLAUSE 2(E) ABOVE), IT WILL FURNISH TO STOCKTRANS, INC., AS
TRANSFER AGENT, A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN
CONNECTION WITH ANY TRANSFER OF THE SECURITY EVIDENCED HEREBY WITHIN
TWO YEARS AFTER THE ORIGINAL ISSUANCE OF SUCH SECURITY (OTHER THAN A
TRANSFER PURSUANT TO CLAUSE 2(E) ABOVE), THE HOLDER MUST CHECK THE
APPROPRIATE BOX SET FORTH ON THE REVERSE HEREOF RELATING TO THE MANNER
OF SUCH TRANSFER AND SUBMIT THIS CERTIFICATE TO THE TRANSFER AGENT. IF
THE PROPOSED TRANSFEREE IS AN INSTITUTIONAL ACCREDITED INVESTOR, THE
HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO STOCKTRANS, INC., AS
TRANSFER AGENT, SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER
INFORMATION AS THE COMPANY MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH
TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A
TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT. THIS LEGEND WILL BE REMOVED UPON THE EARLIER OF THE
TRANSFER OF THE SECURITY EVIDENCED HEREBY PURSUANT TO CLAUSE 2(E) ABOVE
OR UPON THE EXPIRATION OF TWO YEARS FROM THE ORIGINAL ISSUANCE OF THE
SECURITY EVIDENCED HEREBY.
Any Preferred Stock (or share of stock issued in exchange or
substitution therefor) as to which such restrictions on transfer shall have
expired in accordance with their terms or as to the conditions for removal of
the foregoing legend set forth therein have been satisfied may, upon surrender
of such Preferred Stock for exchange to the Transfer Agent in accordance with
the provisions of this Section 13, be exchanged for new Preferred
-37-
<PAGE> 38
Stock, of like tenor and aggregate amount, which shall not bear the restrictive
legend required by this Section 13(c).
Notwithstanding any other provisions of this Certificate (other than
the provisions set forth in this Section 13(c)), a Global Certificate may not be
transferred as a whole except by the Depositary to a nominee of the Depositary
or by a nominee of the Depositary to the Depositary or another nominee to a
successor Depositary or a nominee of such successor Depositary.
The Depositary shall be a clearing agency registered under the Exchange
Act. The Company initially appoints The Depository Trust Company to act as
Depositary with respect to the Global Certificates. Initially, the Global
Certificate shall be issued to the Depositary, registered in the name of Cede &
Co., as the nominee of the Depositary, and deposited with a custodian for Cede &
Co.
If at any time the Depositary for a Global Certificate notifies the
Company that it is unwilling or unable to continue as Depositary for such Global
Certificate, the Company may appoint a successor Depositary with respect to such
Global Certificate. If a successor Depositary for the Preferred Stock is not
appointed by the Company within 90 days after the Company receives such notice,
the Company will execute, and the Transfer Agent will authenticate and deliver,
Preferred Stock in certificated form, in an aggregate principal amount equal to
the principal amount of the Global Certificate, in exchange for such Global
Certificate.
Preferred Stock in definitive form issued in exchange for all or a part
of a Global Certificate pursuant to this Section 13 shall be registered in such
names and in such authorized denominations as the Depositary, pursuant to
instructions from its direct or indirect participants or otherwise, shall
instruct the Transfer Agent. Upon execution and authentication, the Transfer
Agent shall deliver such Preferred Stock in certificated form to the Persons in
whose names such Preferred Stock in definitive form are so registered.
At such time as all interests in a Global Certificate have been
redeemed, converted, exchanged, repurchased or canceled for Preferred Stock in
definitive form, or transferred to a transferee who receives Preferred Stock in
definitive form, such Global Certificate shall be, upon receipt thereof,
canceled by the Transfer Agent in accordance with standing procedures and
instructions existing between the custodian and Depositary. At any time prior to
such cancellation, if any interest in a Global Certificate is exchanged for
Preferred Stock in certificated form, redeemed, converted, exchanged,
repurchased by the Company or canceled, or transferred for part of a Global
Certificate, the principal amount of such Global Certificate shall, in
accordance with the standing procedures and instructions existing between the
custodian and the Depositary, be reduced or increased, as the case may be, and
an endorsement shall be made on such Global Certificate, by the Transfer Agent
or the custodian, at the direction of the Transfer Agent, to reflect such
reduction or increase.
-38-
<PAGE> 39
(d) Until two (2) years after the original issuance date of any
Preferred Stock, any stock certificate representing Common Stock issued upon
conversion of a share of Preferred Stock shall bear a legend in substantially
the following form, unless such Common Stock has been sold pursuant to a
registration statement that has been declared effective under the Securities Act
(and which continues to be effective at the time of such transfer) or such
Common Stock has been issued upon conversion of Preferred Stock that have been
transferred pursuant to a registration statement that has been declared
effective under the Securities Act, or unless otherwise agreed by the Company in
writing with written notice thereof to the transfer agent for the Common Stock:
THE COMMON STOCK EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE
U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY
STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD EXCEPT AS SET
FORTH IN THE FOLLOWING SENTENCE. THE HOLDER HEREOF AGREES THAT UNTIL
THE EXPIRATION OF TWO YEARS AFTER THE ORIGINAL ISSUANCE OF THE SECURITY
UPON THE CONVERSION OF WHICH THE COMMON STOCK EVIDENCED HEREBY WAS
ISSUED, (1) IT WILL NOT RESELL OR OTHERWISE TRANSFER THE COMMON STOCK
EVIDENCED HEREBY EXCEPT (A) THE COMPANY OR ANY SUBSIDIARY THEREOF, (B)
TO A "QUALIFIED INSTITUTIONAL BUYER" (AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT) IN COMPLIANCE WITH RULE 144A, (C) TO AN INSTITUTIONAL
"ACCREDITED INVESTOR" (AS DEFINED IN RULE 501(A)(1), (2), (3) OR (7)
UNDER THE SECURITIES ACT) THAT, PRIOR TO SUCH TRANSFER, FURNISHES TO
STOCKTRANS, INC., AS TRANSFER AGENT, A SIGNED LETTER CONTAINING CERTAIN
REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER
OF THE COMMON STOCK EVIDENCED HEREBY (THE FORM OF WHICH LETTER CAN BE
OBTAINED FROM SUCH TRANSFER AGENT), (D) PURSUANT TO THE EXEMPTION FROM
REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF
AVAILABLE), OR (E) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BEEN
DECLARED EFFECTIVE UNDER THE SECURITIES ACT (AND WHICH CONTINUES TO BE
EFFECTIVE AT THE TIME OF SUCH TRANSFER); (2) PRIOR TO ANY SUCH TRANSFER
(OTHER THAN A TRANSFER PURSUANT TO CLAUSE 1(E) ABOVE), IT WILL FURNISH
TO STOCKTRANS, INC., AS TRANSFER AGENT, SUCH CERTIFICATIONS, LEGAL
OPINIONS OR OTHER INFORMATION AS THE COMPANY MAY REASONABLE REQUIRE TO
CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
THE SECURITIES ACT AND (3) IT WILL
-39-
<PAGE> 40
DELIVER TO EACH PERSON TO WHOM THE SECURITY EVIDENCED HEREBY IS
TRANSFERRED (OTHER THAN A TRANSFER PURSUANT TO CLAUSE 1(E) ABOVE) A
NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. THIS LEGEND WILL BE
REMOVED UPON THE EARLIER OF THE TRANSFER OF THE COMMON STOCK EVIDENCED
HEREBY PURSUANT TO CLAUSE 1(E) ABOVE OR THE EXPIRATION OF TWO YEARS
FROM THE ORIGINAL ISSUANCE OF THE SECURITY UPON THE CONVERSION OF WHICH
THE COMMON STOCK EVIDENCED HEREBY WAS ISSUED.
Any such Common Stock as to which such restrictions on transfer shall
have expired in accordance with their terms or as to which the conditions for
removal of the foregoing legend set forth therein have been satisfied may, upon
surrender of the certificates representing such shares of Common Stock for
exchange in accordance with the procedures of the transfer agent for the Common
Stock, be exchanged for a new certificate or certificates for a like number of
shares of Common Stock, which shall not bear the restrictive legend required by
this Section 13(d).
(e) Any Preferred Stock or Common Stock issued upon the conversion or
exchange of a Security that, prior to the expiration of the holding period
applicable to sales thereof under Rule 144(k) under the Securities Act (or any
successor provision), is purchased or owned by the Company or any Affiliate
thereof may not be resold by the Company or such Affiliate unless registered
under the Securities Act or resold pursuant to an exemption from the
registration requirements of the Securities Act in a transaction which results
in such Preferred Stock or Common Stock, as the case may be, no longer being
"restricted securities" (as defined under Rule 144).
(f) Notwithstanding any provision of Section 13 to the contrary, in the
event Rule 144(k) as promulgated under the Securities Act (or any successor
rule) is amended to change the two-year period under Rule 144(k) (or the
corresponding period under any successor rule), from and after receipt by the
Transfer Agent of the Officers' Certificate and Opinion of Counsel provided for
in this Section 13(f), (i) the references in the first sentence of the second
paragraph of Section 13(c) to "two (2) years" and in the restrictive legend set
forth in such paragraph to "TWO YEARS" shall be deemed for all purposes hereof
to be references to such changed period, (ii) the references in the first
paragraph of Section 13(d) to "two (2) years" and in the restrictive legend set
forth in such paragraph to "TWO YEARS" shall be deemed for all purposes hereof
to be references to such changed period and (iii) all corresponding references
in the Preferred Stock and the restrictive legends thereon shall be deemed for
all purposes hereof to be references to such changed period, provided that such
changes shall not become effective if they are otherwise prohibited by, or would
otherwise cause a violation of, the then-applicable federal securities laws. As
soon as practicable after the Company has knowledge of the effectiveness of any
such amendment to change the two-year period under Rule 144(k) (or the
corresponding period under any successor rule), unless such changes would
otherwise be prohibited by, or would otherwise cause a violation of, the
then-applicable
-40-
<PAGE> 41
securities law, the Company shall provide to the Trustee an Officers'
Certificate and Opinion of Counsel informing the Transfer Agent of the
effectiveness of such amendment and the effectiveness of the foregoing changes
to Sections 13(c) and 13(d) and the Preferred Stock. The provisions of this
Section 13(f) will not be effective until such time as the Opinion of Counsel
and Officers' Certificate have been received by the Trustee hereunder. This
Section 13(f) shall apply to successive amendments to Rule 144(k) (or any
successor rule) changing the holding period thereunder.
14. Form of Notice of Conversion; Form of Assignment.
(a) The following is the form of Conversion Notice to be set forth on
the reverse of the Preferred Stock certificate:
-41-
<PAGE> 42
[FORM OF CONVERSION NOTICE]
CONVERSION NOTICE
To: _________________________
The undersigned registered owner of the Preferred Stock hereby
irrevocably exercises the option to convert the Preferred Stock, or the portion
hereof below designated, into shares of Common Stock in accordance with the
terms of the Certificate of Designation, and directs that the shares issuable
and deliverable upon such conversion, together with any check in payment for
fractional shares and any Preferred Stock representing any unconverted amount of
shares hereof, be issued and delivered to the registered holder hereof unless a
different name has been indicated below. If shares or any portion of the
Preferred Stock not converted are to be issued in the name of a person other
than the undersigned, the undersigned will pay all transfer taxes payable with
respect thereto.
Dated:_________________________
_________________________
_________________________
Signature(s)
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks, stock
brokers, savings and loan associations and
credit unions) with membership in an
approved signature guarantee medallion
program pursuant to Securities and Exchange
Commission Rule 17AD-15 if shares of Common
Stock are to be issued, or Preferred Stock
to be delivered, other than to and in the
name of the registered holder.
Signature Guarantee
Fill in for registration of shares if to be
issued, and Preferred Stock if to be
delivered, other than to and in the name of
the registered holder:
-42-
<PAGE> 43
_________________________
(Name)
_________________________
(Street Address)
_________________________
(City, State and Zip Code)
Please print name and address
Number of shares to be converted
(if less than all):
_________________________________
Social Security or Other Taxpayer
Identification Number
(b) The following is the form of Assignment to be set forth on the
reverse of the Preferred Stock certificate:
[FORM OF ASSIGNMENT]
For value received __________________________ hereby sell(s), assign(s)
and transfer(s) unto _________________________ (Please insert social security or
Taxpayer Identification Number of assignee) the Preferred Stock, and hereby
irrevocably constitutes and appoints ________________________ attorney to
transfer the said Preferred Stock on the books of the Company, with full power
of substitution in the premises.
In connection with any transfer of the Preferred Stock occurring within
two years of the original issuance of such Preferred Stock (unless such
Preferred Stock is being transferred pursuant to a registration statement that
has been declared effective under the Securities Act), the undersigned confirms
that such Preferred Stock is being transferred:
[ ] To Cephalon, Inc., or a subsidiary thereof; or
[ ] Pursuant to and in compliance with Rule 144A under the Securities Act
of 1933, as amended; or
[ ] To an Institutional Accredited Investor pursuant to and in compliance
with the Securities Act of 1933, as amended; or
[ ] Pursuant to and in compliance with Rule 144 under the Securities Act of
1933, as amended;
and unless the box below is checked, the undersigned confirms that such
Preferred Stock is not being transferred to an "affiliate" of the Company as
defined in Rule 144 under the Securities Act of 1933, as amended (an
"Affiliate").
-43-
<PAGE> 44
[ ] The transferee is an Affiliate of the Company.
Dated:_________________________
Signature(s)
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks, stock
brokers, savings and loan associations and
credit unions) with membership in an
approved signature guarantee medallion
program pursuant to Securities and Exchange
Commission Rule 17AD-15 if shares of Common
Stock are to be issued, or Preferred Stock
to be delivered, other than to and in the
name of the registered holder.
Signature Guarantee
NOTICE: The signature on the conversion notice, or the assignment must
correspond with the name as written upon the face of the Preferred Stock in
every particular without alteration or enlargement or any change whatever.
----------------------
-44-
<PAGE> 45
IN WITNESS WHEREOF, the Company has caused this certificate to be
signed and attested this August 16, 1999.
CEPHALON, INC.
By: /s/ John E. Osborn
------------------------
Name: John E. Osborn
Title: Secretary
Attest:
/s/ J. Kevin Buchi
- ----------------------------------
Name: J. Kevin Buchi
Title: Senior Vice President,
Chief Financial Officer
-45-
<PAGE> 1
EXHIBIT 4.3
CEPHALON, INC.
AND
STATE STREET BANK AND TRUST COMPANY
as Trustee
INDENTURE
Dated as of August 18, 1999
7.25% Convertible Subordinated Debentures
<PAGE> 2
CROSS REFERENCE SHEET*
Between
Provisions of Trust Indenture Act of 1939 and Indenture, dated as of
August 18, 1999, between Cephalon, Inc. and State Street Bank and Trust Company,
as Trustee, providing for the 7.25% Convertible Subordinated Debentures:
<TABLE>
<CAPTION>
Section of the Act Section of Indenture
---------------------------------------- -----------------------
<S> <C>
310(a)(1) and (2)........................................ 8.9
310(a)(3) and (4)........................................ Inapplicable
310(b)................................................... 8.8 and 8.10(b) and (d)
310(c)................................................... Inapplicable
311(a)................................................... 8.13
311(b)................................................... 8.13
311(c)................................................... Inapplicable
312(a)................................................... 6.1 and 6.2(a)
312(b)................................................... 6.2(b)
312(c)................................................... 6.2(c)
313(a)................................................... 6.3(a)
313(b)(1)................................................ Inapplicable
313(b)(2)................................................ 6.3(a)
313(c)................................................... 6.3(a)
313(d)................................................... 6.3(b)
314(a)................................................... 6.4
314(b)................................................... Inapplicable
314(c)(1) and (2)........................................ 16.5
314(c)(3)................................................ Inapplicable
314(d)................................................... Inapplicable
314(e)................................................... 16.5
314(f)................................................... Inapplicable
315(a), (c) and (d)...................................... 8.1
315(b)................................................... 7.8
</TABLE>
- --------------
* This Cross Reference Sheet is not part of the Indenture.
<PAGE> 3
<TABLE>
<S> <C>
315(e)................................................... 7.9
316(a)(1)................................................ 7.7
316(a)(2)................................................ Not required
316(a)(last sentence).................................... 9.4
316(b)................................................... 11.2
317(a)................................................... 7.2
317(b)................................................... 5.4 and 13.2
318(a)................................................... 16.8
</TABLE>
<PAGE> 4
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
ARTICLE I DEFINITIONS.......................................................................................... 1
Section 1.1 Definitions...................................................................................... 1
ARTICLE II ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF DEBENTURES............................... 9
Section 2.1 Designation, Amount and Issue of Debentures...................................................... 9
Section 2.2 Form of Debentures............................................................................... 9
Section 2.3 Date and Denomination of Debentures; Maturity; Payments of Interest.............................. 10
Section 2.4 Execution of Debentures.......................................................................... 12
Section 2.5 Exchange and Registration of Transfer of Debentures.............................................. 13
Section 2.6 Mutilated, Destroyed, Lost or Stolen Debentures.................................................. 20
Section 2.7 Temporary Debentures............................................................................. 21
Section 2.8 Cancellation of Debentures Paid, Etc............................................................. 21
ARTICLE III REDEMPTION OF DEBENTURES............................................................................. 22
Section 3.1 Redemption Prices................................................................................ 22
Section 3.2 Notice of Redemption; Selection of Debentures.................................................... 22
Section 3.3 Payment of Debentures Called for Redemption...................................................... 23
Section 3.4 Conversion Arrangement on Call for Redemption.................................................... 24
ARTICLE IV SUBORDINATION OF DEBENTURES.......................................................................... 25
Section 4.1 Agreement of Subordination....................................................................... 25
Section 4.2 Payments to Debentureholders..................................................................... 25
Section 4.3 Subrogation of Debentures........................................................................ 28
Section 4.4 Authorization by Debentureholders................................................................ 29
Section 4.5 Notice to Trustee................................................................................ 29
Section 4.6 Trustee's Relation to Senior Indebtedness........................................................ 30
Section 4.7 No Impairment of Subordination................................................................... 31
Section 4.8 Certain Conversions Deemed Payment............................................................... 31
Section 4.9 Article Applicable to Paying Agents.............................................................. 31
Section 4.10 Senior Indebtedness Entitled to Rely............................................................ 32
ARTICLE V PARTICULAR COVENANTS OF THE COMPANY.................................................................. 32
Section 5.1 Payment of Principal, Premium and Interest....................................................... 32
Section 5.2 Maintenance of Office or Agency.................................................................. 32
Section 5.3 Appointments to Fill Vacancies in Trustee's Office............................................... 33
</TABLE>
<PAGE> 5
<TABLE>
<S> <C>
Section 5.4 Provisions as to Paying Agent.................................................................... 33
Section 5.5 Existence........................................................................................ 34
Section 5.6 [RESERVED]....................................................................................... 34
Section 5.7 [RESERVED]....................................................................................... 34
Section 5.8 Stay, Extension and Usury Laws................................................................... 34
Section 5.9 Compliance Certificate........................................................................... 34
Section 5.10 Further Instruments and Acts.................................................................... 35
Section 5.11 Rule 144A Information Requirement............................................................... 35
ARTICLE VI DEBENTUREHOLDERS' LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE................................... 35
Section 6.1 Debentureholders' Lists.......................................................................... 35
Section 6.2 Preservation and Disclosure of Lists............................................................. 36
Section 6.3 Reports by Trustee............................................................................... 36
Section 6.4 Reports by Company............................................................................... 36
ARTICLE VII DEFAULTS AND REMEDIES................................................................................ 37
Section 7.1 Events of Default................................................................................ 37
Section 7.2 Payments of Debentures on Default; Suit Therefor................................................. 39
Section 7.3 Application of Monies Collected by Trustee....................................................... 41
Section 7.4 Proceedings by Debentureholder................................................................... 42
Section 7.5 Proceedings by Trustee........................................................................... 42
Section 7.6 Remedies Cumulative and Continuing............................................................... 43
Section 7.7 Direction of Proceedings and Waiver of Defaults by Majority of Debentureholders.................. 43
Section 7.8 Notice of Defaults............................................................................... 43
Section 7.9 Undertaking to Pay Costs......................................................................... 44
Section 7.10 Delay or Omission Not Waiver.................................................................... 44
ARTICLE VIII CONCERNING THE TRUSTEE............................................................................ 44
Section 8.1 Duties and Responsibilities of Trustee........................................................... 44
Section 8.2 Reliance on Documents, Opinions, Etc............................................................. 46
Section 8.3 No Responsibility for Recitals, Etc.............................................................. 47
Section 8.4 Trustee, Paying Agents, Conversion Agents or Registrar May Own Debentures........................ 47
Section 8.5 Monies to Be Held in Trust....................................................................... 47
Section 8.6 Compensation and Expenses of Trustee............................................................. 47
Section 8.7 Officers' Certificate as Evidence................................................................ 48
Section 8.8 Conflicting Interests of Trustee................................................................. 48
</TABLE>
-ii-
<PAGE> 6
<TABLE>
<S> <C>
Section 8.9 Eligibility of Trustee........................................................................... 48
Section 8.10 Resignation or Removal of Trustee............................................................... 49
Section 8.11 Acceptance by Successor Trustee................................................................. 50
Section 8.12 Succession by Merger, Etc....................................................................... 50
Section 8.13 Limitation on Rights of Trustee as Creditor..................................................... 51
ARTICLE IX CONCERNING THE DEBENTUREHOLDERS...................................................................... 51
Section 9.1 Action by Debentureholders....................................................................... 51
Section 9.2 Proof of Execution by Debentureholders........................................................... 52
Section 9.3 Who Are Deemed Absolute Owners................................................................... 52
Section 9.4 Company-Owned Debentures Disregarded............................................................. 52
Section 9.5 Revocation of Consents; Future Holders Bound..................................................... 53
ARTICLE X DEBENTUREHOLDERS' MEETINGS........................................................................... 53
Section 10.1 Purpose of Meetings............................................................................. 53
Section 10.2 Call of Meetings by Trustee..................................................................... 53
Section 10.3 Call of Meetings by Company or Debentureholders................................................. 54
Section 10.4 Qualifications for Voting....................................................................... 54
Section 10.5 Regulations..................................................................................... 54
Section 10.6 Voting.......................................................................................... 55
Section 10.7 No Delay of Rights by Meeting................................................................... 55
ARTICLE XI SUPPLEMENTAL INDENTURES.............................................................................. 56
Section 11.1 Supplemental Indentures Without Consent of Debentureholders..................................... 56
Section 11.2 Supplemental Indentures with Consent of Debentureholders........................................ 57
Section 11.3 Effect of Supplemental Indentures............................................................... 58
Section 11.4 Notation on Debentures.......................................................................... 58
Section 11.5 Evidence of Compliance of Supplemental Indenture to Be Furnished Trustee........................ 58
ARTICLE XII MERGER, SALE OR CONSOLIDATION........................................................................ 59
Section 12.1 Limitation on Merger, Sale or Consolidation..................................................... 59
Section 12.2 Successor Corporation to Be Substituted......................................................... 59
ARTICLE XIII SATISFACTION AND DISCHARGE OF INDENTURE........................................................... 60
Section 13.1 Discharge of Indenture.......................................................................... 60
Section 13.2 Deposited Monies to Be Held in Trust by Trustee................................................. 60
</TABLE>
-iii-
<PAGE> 7
<TABLE>
<S> <C>
Section 13.3 Paying Agent to Repay Monies Held............................................................... 61
Section 13.4 Return of Unclaimed Monies...................................................................... 61
Section 13.5 Reinstatement................................................................................... 61
ARTICLE XIV IMMUNITY OF INCORPORATORS, SHAREHOLDERS, OFFICERS AND DIRECTORS................................... 61
Section 14.1 Indenture and Debentures Solely Corporate Obligations........................................... 61
ARTICLE XV CONVERSION OF DEBENTURES............................................................................. 62
Section 15.1 Right to Convert................................................................................ 62
Section 15.2 Exercise of Conversion Privilege; Issuance of Common Stock on Conversion; No Adjustment for
Interest or Dividends................................................................................ 62
Section 15.3 Cash Payments in Lieu of Fractional Shares...................................................... 64
Section 15.4 Conversion Price................................................................................ 64
Section 15.5 Adjustment of Conversion Price.................................................................. 64
Section 15.6 Reclassification, Consolidation, Merger or Sale................................................. 75
Section 15.7 Taxes on Shares Issued.......................................................................... 76
Section 15.8 Reservation of Shares; Shares to Be Fully Paid; Listing of Common Stock......................... 76
Section 15.9 Responsibility of Trustee....................................................................... 77
Section 15.10 Notice to Holders Prior to Certain Actions..................................................... 78
Section 15.11 Adjustments to Conversion Price in the Event of a Fundamental Change........................... 78
ARTICLE XVI MISCELLANEOUS PROVISIONS.......................................................................... 81
Section 16.1 Provisions Binding on Company's Successors...................................................... 81
Section 16.2 Official Acts by Successor Corporation.......................................................... 81
Section 16.3 Addresses for Notices, Etc...................................................................... 81
Section 16.4 Governing Law................................................................................... 82
Section 16.5 Evidence of Compliance with Conditions Precedent; Certificates to Trustee....................... 82
Section 16.6 Legal Holidays.................................................................................. 82
Section 16.7 No Security Interest Created.................................................................... 82
Section 16.8 Trust Indenture Act............................................................................. 82
Section 16.9 Benefits of Indenture........................................................................... 83
Section 16.10 Table of Contents, Headings, Etc............................................................... 83
Section 16.11 Authenticating Agent........................................................................... 83
Section 16.12 Execution in Counterparts...................................................................... 84
Exhibit A Form of Debenture
</TABLE>
-iv-
<PAGE> 8
Exhibit B Form of Institutional Accredited Investor Letter
-v-
<PAGE> 9
INDENTURE, dated as of August 18, 1999, between Cephalon, Inc., a
Delaware corporation (hereinafter sometimes called the "Company", as more fully
set forth in Section 1.1), and State Street Bank and Trust Company, a
Massachusetts trust corporation (hereinafter sometimes called the "Trustee", as
more fully set forth in Section 1.1).
W I T N E S S E T H:
WHEREAS, for its lawful corporate purposes, the Company has duly
authorized the issue of its 7.25% Convertible Subordinated Debentures
(hereinafter sometimes called the "Debentures"), in an aggregate principal
amount not to exceed $125,000,000 and, to provide the terms and conditions upon
which the Debentures are to be authenticated, issued and delivered, the Company
has duly authorized the execution and delivery of this Indenture; and
WHEREAS, the Debentures, the certificate of authentication to be borne
by the Debentures, a form of assignment, and a form of conversion notice to be
borne by the Debentures are to be substantially in the forms hereinafter
provided for; and
WHEREAS, all acts and things necessary to make the Debentures, when
executed by the Company and authenticated and delivered by the Trustee or a duly
authorized authenticating agent, as in this Indenture provided, the valid,
binding and legal obligations of the Company, and to constitute these presents a
valid agreement according to its terms, have been done and performed, and the
execution of this Indenture and the issue hereunder of the Debentures have in
all respects been duly authorized.
NOW, THEREFORE, THIS INDENTURE WITNESSETH:
That in order to declare the terms and conditions upon which the
Debentures are to be authenticated, issued and delivered, and in consideration
of the premises and of the purchase and acceptance of the Debentures by the
holders thereof, the Company covenants and agrees with the Trustee for the equal
and proportionate benefit of the respective holders from time to time of the
Debentures (except as otherwise provided below), as follows:
ARTICLE I
DEFINITIONS
Section 1.1. Definitions. Each of the terms defined in this
Section 1.1 (except as herein otherwise expressly provided or unless the context
otherwise requires) for all purposes of this Indenture and of any indenture
supplemental hereto shall have the respective meanings specified in this Section
1.1. Each of the terms used in this Indenture, which are defined in the Trust
Indenture Act or which are by reference therein defined in the Securities Act
(except as herein otherwise expressly provided or unless the context otherwise
requires) shall have the meanings assigned to such term in said Trust Indenture
Act and in said Securities Act as in force at the date of the execution of this
Indenture. The words "herein," "hereof," "hereunder," and words of
<PAGE> 10
similar import refer to this Indenture as a whole and not to any particular
Article, Section or other Subdivision. The terms defined in this Article include
the plural as well as the singular.
Additional Interest: The term "Additional Interest" shall have the
meaning specified in Section 2.3.
Affiliate: The term "Affiliate" of any specified person shall mean any
other person directly or indirectly controlling or controlled by or under direct
or indirect common control with such specified person. For the purposes of this
definition, "control," when used with respect to any specified person means the
power to direct or cause the direction of the management and policies of such
person, directly or indirectly, whether through the ownership of voting
securities, by contract or otherwise; and the terms "controlling" and
"controlled" have meanings correlative to the foregoing.
Applicable Price: The term "Applicable Price" shall have the meaning
specified in Section 15.11(b).
Board of Directors: The term "Board of Directors" shall mean the Board
of Directors of the Company or a committee of such Board duly authorized to act
for it hereunder.
Board Resolution: The term "Board Resolution" means a copy of a
resolution certified by the Secretary or an Assistant Secretary of the Company
to have been duly adopted by the Board of Directors and to be in full force and
effect on the date of such certification, and delivered to the Trustee.
Business Day: The term "Business Day" means each Monday, Tuesday,
Wednesday, Thursday and Friday which is not a day on which the banking
institutions in The City of New York or the city in which the Corporate Trust
Office is located are authorized or obligated by law or executive order to close
or be closed.
Commission: The term "Commission" shall mean the Securities and
Exchange Commission.
Common Stock: The term "Common Stock" shall mean any stock of any class
of the Company which has no preference in respect of dividends or of amounts
payable in the event of any voluntary or involuntary liquidation, dissolution or
winding up of the Company and which is not subject to redemption by the Company.
Subject to the provisions of Section 15.6, however, shares issuable on
conversion of Debentures shall include only shares of the class designated as
common stock of the Company at the date of this Indenture or shares of any class
or classes resulting from any reclassification or reclassifications thereof and
which have no preference in respect of dividends or of amounts payable in the
event of any voluntary or involuntary liquidation, dissolution or winding up of
the Company and which are not subject to redemption by the Company; provided
that if at any time there shall be more than one such resulting class, the
shares of each such class then so issuable shall be substantially in the
proportion which the
-2-
<PAGE> 11
total number of shares of such class resulting from all such reclassifications
bears to the total number of shares of all such classes resulting from all such
reclassifications.
Common Stock Fundamental Change: The term "Common Stock Fundamental
Change" shall have the meaning specified in Section 15.11(b).
Company: The term "Company" shall mean Cephalon, Inc., a Delaware
corporation, and subject to the provisions of Article XII, shall include its
successors and assigns.
Conversion Price: The term "Conversion Price" shall have the meaning
specified in Section 15.4.
Corporate Trust Office: The term "Corporate Trust Office," or other
similar term, shall mean the office of the Trustee at which at any particular
time its corporate trust business shall be principally administered, which
office is, at the date as of which this Indenture is dated, located at 2 Avenue
de Lafayette, 5th floor, Boston, MA 02111-1724, Attention: Corporate Trust
Department (Cephalon, Inc., 7.25% Convertible Subordinated Debentures).
Custodian: The term "Custodian" means State Street Bank and Trust
Company, as custodian with respect to the Debentures in global form, or any
successor entity thereto.
Debenture or Debentures: The terms "Debenture" or "Debentures" shall
mean any Debenture or Debentures, as the case may be, authenticated and
delivered under this Indenture.
Debentureholder; holder: The terms "Debentureholder" or "holder" as
applied to any Debenture, or other similar terms (but excluding the term
"beneficial holder"), shall mean any person in whose name at the time a
particular Debenture is registered on the Debenture register.
Debenture register: The term "Debenture register" shall have the
meaning specified in Section 2.5.
default: The term "default" shall mean any event that is, or after
notice or passage of time, or both, would be, an Event of Default.
Depositary: The term "Depositary" means, with respect to the Debentures
issuable or issued in whole or in part in global form, the person specified in
Section 2.5(d) as the Depositary with respect to such Debentures, until a
successor shall have been appointed and become such pursuant to the applicable
provisions of this Indenture, and thereafter, "Depositary" shall mean or include
such successor.
Designated Senior Indebtedness: The term "Designated Senior
Indebtedness" means any particular Senior Indebtedness in which the instrument
creating or evidencing the same or the assumption or guarantee thereof (or
related agreements or documents to which the Company is a party) expressly
provides that such Senior Indebtedness shall be "Designated Senior
-3-
<PAGE> 12
Indebtedness" for purposes of this Indenture (provided that such instrument,
agreement or other document may place limitations and conditions on the right of
such Senior Indebtedness to exercise the rights of Designated Senior
Indebtedness).
Event of Default: The term "Event of Default" shall mean any event
specified in Section 7.1 continued for the period of time, if any, and after the
giving of notice, if any, therein designated.
Exchange Act: The term "Exchange Act" means the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder.
Exchange Date: The term "Exchange Date" shall mean the date on which
the Debentures are issued in exchange for all of the outstanding shares of
Preferred Stock.
Fundamental Change: The term "Fundamental Change" shall have the
meaning specified in Section 15.11(b).
Global Debenture: The term "Global Debenture" shall have the meaning
specified in Section 2.5(b).
Indebtedness: The term "Indebtedness" means, with respect to any
person, all obligations, whether or not contingent, of such person (i) (a) for
borrowed money, whether or not evidenced by a note, debenture, bond, or other
written instrument, (b) evidenced by a note, debenture, bond or other written
instrument, (c) under a lease required to be capitalized on the balance sheet of
the lessee under generally accepted accounting principles or under any lease or
related document (including a purchase agreement) that provides that the Company
is contractually obligated to purchase or cause a third party to purchase and
thereby guarantee a minimum residual value of the lease property to the lessor
and the obligations of the Company under such lease or related document to
purchase or to cause a third party to purchase such leased property, (d) in
respect of letters of credit, bank guarantees or bankers' acceptances (including
reimbursement obligations with respect to any of the foregoing), (e) with
respect to Indebtedness secured by a mortgage, pledge, lien, encumbrance, charge
or adverse claim affecting title in an encumbrance to which the property or
assets of such person are subject, whether or not the obligation secured thereby
shall have been assumed by or shall otherwise be such person's legal liability,
(f) in respect of the balance of deferred and unpaid purchase price of any
property or assets, (g) under interest rate or currency swap agreements, cap,
floor and collar agreements, spot and forward contracts and similar agreements
and arrangements; (ii) with respect to any obligation of others of the type
described in the preceding clause (i) or under clause (iii) below assumed by or
guaranteed in any manner by such person or in effect guaranteed by such person
through an agreement to purchase (including, without limitation, "take or pay"
and similar arrangements), contingent or otherwise (and the obligations of such
person under any such assumptions, guarantees or other such arrangements); and
(iii) any and all Indebtedness constituting deferrals, renewals, extensions,
refinancings and refundings of, or amendments, modifications or supplements to,
any of the foregoing.
-4-
<PAGE> 13
Indenture: The term "Indenture" shall mean this instrument as
originally executed or, if amended or supplemented as herein provided, as so
amended or supplemented.
Initial Purchasers: The term "Initial Purchasers" means BancBoston
Robertson Stephens, Inc., SG Cowen Securities Corporation, Hambrecht & Quist and
U.S. Bancorp Piper Jaffray.
Institutional Accredited Investor: The term "Institutional Accredited
Investor" shall mean an institutional "accredited investor" within the meaning
of Rule 501(a)(1), (2), (3) or (7) under the Securities Act.
Non-Stock Fundamental Change: The term "Non-Stock Fundamental Change"
shall have the meaning specified in Section 15.11(b).
Officers' Certificate: The term "Officers' Certificate", when used with
respect to the Company, shall mean a certificate signed by (a) one of the
President, the Chief Executive Officer, Executive or Senior Vice President or
any Vice President (whether or not designated by a number or numbers or word
added before or after the title "Vice President") and (b) by one of the
Treasurer or any Assistant Treasurer, Secretary or any Assistant Secretary or
Controller of the Company, which is delivered to the Trustee. Each such
certificate shall include the statements provided for in Section 16.5 if and to
the extent required by the provisions of such Section.
Opinion of Counsel: The term "Opinion of Counsel" shall mean an opinion
in writing signed by legal counsel, who may be an employee of or counsel to the
Company, or other counsel acceptable to the Trustee, which is delivered to the
Trustee. Each such opinion shall include the statements provided for in Section
16.5 if and to the extent required by the provisions of such Section.
outstanding: The term "outstanding," when used with reference to
Debentures, shall, subject to the provisions of Section 9.4, mean, as of any
particular time, all Debentures authenticated and delivered by the Trustee under
this Indenture, except
(a) Debentures theretofore canceled by the Trustee or
delivered to the Trustee for cancellation;
(b) Debentures, or portions thereof, for the payment, or
redemption of which monies in the necessary amount shall have been
deposited in trust pursuant hereto with the Trustee or with any paying
agent (other than the Company) or shall have been set aside and
segregated in trust by the Company (if the Company shall act as its own
paying agent); provided that if such Debentures are to be redeemed
prior to the maturity thereof, notice of such redemption shall have
been given as provided in Section 3.2, or provision satisfactory to the
Trustee shall have been made for giving such notice;
-5-
<PAGE> 14
(c) Debentures in lieu of which, or in substitution for
which, other Debentures shall have been authenticated and delivered
pursuant to the terms of Section 2.6 unless proof satisfactory to the
Trustee is presented that any such Debentures are held by bona fide
holders in due course; and
(d) Debentures converted into Common Stock pursuant to
Article XV and Debentures deemed not outstanding pursuant to Section
3.2.
Payment Blockage Notice: The term "Payment Blockage Notice" has the
meaning specified in Section 4.2.
Person: The term "person" shall mean a corporation, a limited liability
company, an association, a partnership, an individual, a joint venture, a joint
stock company, a trust, an unincorporated organization or a government or an
agency or a political subdivision thereof.
Portal Market: The term "Portal Market" shall mean The Portal Market
operated by the National Association of Securities Dealers, Inc. or any
successor thereto.
Predecessor Debenture: The term "Predecessor Debenture" of any
particular Debenture shall mean every previous Debenture evidencing all or a
portion of the same debt as that evidenced by such particular Debenture; and,
for the purposes of this definition, any Debenture authenticated and delivered
under Section 2.6 in lieu of a lost, destroyed or stolen Debenture shall be
deemed to evidence the same debt as the lost, destroyed or stolen Debenture that
it replaces.
Preferred Stock: The term "Preferred Stock" shall mean the $3.625
Convertible Exchangeable Preferred Stock, par value $0.01 per share, of the
Company.
Purchaser Stock Price: The term "Purchaser Stock Price" shall have the
meaning specified in Section 15.11(b).
QIB: The term "QIB" shall mean a "qualified institutional buyer" as
defined in Rule 144A.
Registration Default: The term "Registration Default" shall have the
meaning set forth in Section 3 of the Registration Rights Agreement.
Registration Rights Agreement: The term "Registration Rights Agreement"
means that certain Registration Rights Agreement, dated as of August 18, 1999,
between the Company and the Initial Purchasers.
Representative: The term "Representative" means the (a) indenture
trustee or other trustee, agent or representative for any Senior Indebtedness or
(b) with respect to any Senior Indebtedness that does not have any such trustee,
agent or other representative, (i) in the case of
-6-
<PAGE> 15
such Senior Indebtedness issued pursuant to an agreement providing for voting
arrangements as among the holders or owners of such Senior Indebtedness, any
holder or owner of such Senior Indebtedness acting with the consent of the
required persons necessary to bind such holders or owners of such Senior
Indebtedness and (ii) in the case of all other such Senior Indebtedness, the
holder or owner of such Senior Indebtedness.
Responsible Officer: The term "Responsible Officer", when used with
respect to the Trustee, shall mean an officer of the Trustee assigned to the
Corporate Trust Office, and any officer of the Trustee to whom such matter is
referred to because of his knowledge of and familiarity with the particular
subject.
Restricted Securities: The term "Restricted Securities" has the meaning
specified in Section 2.5(d).
Rule 144: The term "Rule 144" shall mean Rule 144 as promulgated under
the Securities Act.
Rule 144A: The term "Rule 144A" shall mean Rule 144A as promulgated
under the Securities Act.
Securities Act: The term "Securities Act" means the Securities Act of
1933, as amended, and the rules and regulations promulgated thereunder.
Senior Indebtedness: The term "Senior Indebtedness" means the principal
of, premium, if any, and interest on, rent under, and any other amounts payable
on or in or in respect of the Company's (i) 11% Revenue Sharing Senior Secured
Notes due 2002, in the initial aggregate principal amount of $30,000,000; (ii)
Equipment Leases under the Master Lease Agreement dated as of February 1, 1994
with General Electric Capital Corporation, as amended from time to time; (iii)
Note, dated March 30, 1995, in the original principal amount of $6,900,000
payable to the order of The Variable Annuity Life Insurance Company; (iv) Note,
dated March 30, 1995, in the original principal amount of $2,000,000 payable to
the order of The Pennsylvania Industrial Development Authority; (v) Note, dated
March 30, 1995, in the original principal amount of $10,000,000 payable to the
order of The Commonwealth of Pennsylvania; and (vi) any other Indebtedness of
the Company (including, without limitation, any interest accruing after the
filing of a petition by or against the Company under any bankruptcy law, whether
or not allowed as a claim after such filing in any proceeding under such
bankruptcy law), whether outstanding on the date of this Indenture or thereafter
created, incurred, assumed, guaranteed or in effect guaranteed by the Company
(including all deferrals, renewals, extensions or refundings of, or amendments,
modifications or supplements to the foregoing); provided, however, that Senior
Indebtedness does not include (v) Indebtedness evidenced by the Debentures, (w)
any liability for federal, state, local or other taxes owed or owing by the
Company, (x) Indebtedness of the Company to any subsidiary of the Company, (y)
any trade payables of the Company incurred in the ordinary course of business,
and (z) any indebtedness in which the instrument creating or evidencing the same
or the assumption or guarantee thereof (or related agreements or documents to
which the
-7-
<PAGE> 16
Company is a party) expressly provides that such Indebtedness shall not be
senior in right of payment to, or is pari passu with, or is subordinated or
junior to, the Debentures.
Subsidiary: The term "Subsidiary" means a corporation more than 50% of
the outstanding voting stock of which is owned, directly or indirectly, by the
Company or by one or more other Subsidiaries, or by the Company and one or more
other Subsidiaries. For the purposes of this definition, "voting stock" means
stock which ordinarily has voting power for the election of directors, whether
at all times or only so long as no senior class of stock has such voting power
by reason of any contingency.
Trading Day: The term "Trading Day" has the meaning specified in
Section 15.5(i)(5).
Transfer Restricted Securities: The term "Transfer Restricted
Securities" shall have the meaning set forth in Section 1 of the Registration
Rights Agreement.
Trust Indenture Act: The term "Trust Indenture Act" shall mean the
Trust Indenture Act of 1939, as amended, as it was in force at the date of
execution of this Indenture, except as provided in Sections 11.3 and 15.6;
provided, however, that in the event the Trust Indenture Act of 1939 is amended
after the date hereof, the term "Trust Indenture Act" shall mean, to the extent
required by such amendment, the Trust Indenture Act of 1939 as so amended.
Trustee: The term "Trustee" shall mean State Street Bank and Trust
Company and its successors and any corporation resulting from or surviving any
consolidation or merger to which it or its successors may be a party and any
successor trustee at the time serving as successor trustee hereunder.
The definitions of certain other terms are as specified in Article XV.
-8-
<PAGE> 17
ARTICLE II
ISSUE, DESCRIPTION, EXECUTION, REGISTRATION
AND EXCHANGE OF DEBENTURES
Section 2.1 Designation, Amount and Issue of Debentures. The
Debentures shall be designated as "7.25% Convertible Subordinated Debentures."
Debentures not to exceed the aggregate principal amount of $100,000,000 (or
$125,000,000 if the over-allotment option set forth in Section 7 of the Purchase
Agreement dated August 13, 1999 (as amended from time to time by the parties
thereto) by and between the Company and the Initial Purchasers is exercised in
full) (except pursuant to Sections 2.5, 2.6, 3.3 and 15.2) upon the execution of
this Indenture, or from time to time thereafter, may be executed by the Company
and delivered to the Trustee for authentication, and the Trustee shall thereupon
authenticate and deliver said Debentures upon the written order of the Company,
signed by the Company's (a) President, Executive or Senior Vice President or any
Vice President (whether or not designated by a number or numbers or word or
words added before or after the title "Vice President") and (b) Treasurer or
Assistant Treasurer or its Secretary or any Assistant Secretary, without any
further action by the Company hereunder, provided, however that said Debentures
may not be executed, delivered or authenticated unless and until (i) the Company
may legally issue said Debentures in accordance with the Delaware General
Corporation Law, as amended, and (ii) the Trustee shall have received an
Officer's Certificate and Opinion of Counsel in accordance with Section 16.5.
The Debentures may only be issued upon the exchange of all outstanding Preferred
Stock.
Section 2.2. Form of Debentures. The Debentures and the Trustee's
certificate of authentication to be borne by such Debentures shall be
substantially in the form set forth in Exhibit A, which is incorporated in and
made a part of this Indenture.
Any of the Debentures may have such letters, numbers or other marks of
identification and such notations, legends and endorsements as the officers
executing the same may approve (execution thereof to be conclusive evidence of
such approval) and as are not inconsistent with the provisions of this
Indenture, or as may be required to comply with any law or with any rule or
regulation made pursuant thereto or with any rule or regulation of any
securities exchange or automated quotation system on which the Debentures may be
listed or designated for issuance, or to conform to usage.
Any Global Debenture shall represent such of the outstanding Debentures
as shall be specified therein and shall provide that it shall represent the
aggregate amount of outstanding Debentures from time to time endorsed thereon
and that the aggregate amount of outstanding Debentures represented thereby may
from time to time be increased or reduced to reflect transfers or exchanges
permitted hereby. Any endorsement of a Global Debenture to reflect the amount of
any increase or decrease in the amount of outstanding Debentures represented
thereby shall be made by the Trustee or the Custodian, at the direction of the
Trustee, in such manner and upon instructions given by the holder of such
Debentures in accordance with this Indenture.
-9-
<PAGE> 18
Payment of principal of and interest and premium, if any (including any
redemption price), on any Global Debenture shall be made to the holder of such
Debenture.
The terms and provisions contained in the form of Debenture attached as
Exhibit A hereto shall constitute, and are hereby expressly made, a part of this
Indenture and to the extent applicable, the Company and the Trustee, by their
execution and delivery of this Indenture, expressly agree to such terms and
provisions and to be bound thereby.
Section 2.3. Date and Denomination of Debentures; Maturity;
Payments of Interest. The Debentures shall be issuable in registered form
without coupons in denominations of $1,000 principal amount and integral
multiples thereof. Every Debenture shall be dated the date of its authentication
and, except as provided in this Section, shall bear interest, payable
semiannually on February 15 and August 15, of each year, commencing on the first
such date after the Exchange Date, from the most recent date to which interest
has been paid or duly provided for, or if no interest has been paid or duly
provided for on the Debentures, from the Exchange Date, until payment of the
principal sum has been made or fully provided for. The Debentures will mature on
the tenth year anniversary of the Exchange Date, unless earlier converted or
redeemed. Notwithstanding the foregoing, when there is no existing default in
the payment of interest on the Debentures, all Debentures authenticated by the
Trustee after the close of business on the record date (as defined in this
Section 2.3) for any interest payment date (February 15 or August 15, as the
case may be) and prior to such interest payment date shall be dated the date of
authentication but shall bear interest from such interest payment date,
provided, however, that if and to the extent that the Company shall default in
interest due on such interest payment date then any such Debenture shall bear
interest from the February 15 or the August 15, as the case may be, immediately
preceding the date of such Debenture to which interest has been paid or duly
provided for or, if no interest has been paid or duly provided for on the
Debentures, from the Exchange Date.
The person in whose name any Debenture (or its Predecessor Debenture)
is registered at the close of business on any record date with respect to any
interest payment date (including any Debenture that is converted after the
record date and on or before the interest payment date) shall be entitled to
receive the interest payable on such interest payment date notwithstanding the
cancellation of such Debenture upon any transfer, exchange or conversion
subsequent to the record date and on or prior to such interest payment date.
Interest may, at the option of the Company, be paid by check mailed to the
address of such person on the registry kept for such purposes; provided that,
with respect to any holder of Debentures with an aggregate principal amount
equal to or in excess of $2,000,000, at the request of such holder in writing to
the Company, interest on such holder's Debentures shall be paid by wire transfer
in immediately available funds in accordance with the wire transfer instruction
supplied by such holder to the Trustee and paying agent (if different from
Trustee). Interest payable with respect to Debentures held in the form of a
Global Debenture shall be paid to the Depositary by wire transfer in immediately
available funds in accordance with the applicable procedures of the Depositary.
The term "record date" with respect to any interest payment date shall mean the
February 1 or August 1 preceding said February 15 or August 15.
-10-
<PAGE> 19
Interest on the Debentures shall be computed on the basis of a 360-day
year comprised of twelve 30-day months.
Any interest on any Debenture which is payable, but is not punctually
paid or duly provided for, on any said February 15 or August 15 (herein called
"Defaulted Interest") shall forthwith cease to be payable to the Debentureholder
on the relevant record date by virtue of his having been such Debentureholder;
and such Defaulted Interest shall be paid by the Company, at its election in
each case, as provided in clause (1) or (2) below:
(1) The Company may elect to make payment of any Defaulted
Interest to the persons in whose names the Debentures (or their respective
Predecessor Debentures) are registered at the close of business on a special
record date for the payment of such Defaulted Interest, which shall be fixed in
the following manner. The Company shall notify the Trustee in writing of the
amount of Defaulted Interest to be paid on each Debenture and the date of the
payment (which shall be not less than twenty-five (25) days after the receipt by
the Trustee of such notice, unless the Trustee shall consent to an earlier
date), and at the same time the Company shall deposit with the Trustee an amount
of money equal to the aggregate amount to be paid in respect of such Defaulted
Interest or shall make arrangements satisfactory to the Trustee for such deposit
prior to the date of the proposed payment, such money when deposited to be held
in trust for the benefit of the persons entitled to such Defaulted Interest as
in this clause provided. Thereupon the Trustee shall fix a special record date
for the payment of such Defaulted Interest which shall be not more than fifteen
(15) days and not less than ten (10) days prior to the date of the proposed
payment and not less than ten (10) days after the receipt by the Trustee of the
notice of the proposed payment. The Trustee shall promptly notify the Company of
such special record date and, in the name and at the expense of the Company,
shall cause notice of the proposed payment of such Defaulted Interest and the
special record date therefor to be mailed, first-class postage prepaid, to each
Debentureholder as of such special record date at his address as it appears in
the Debenture register, not less than ten (10) days prior to such special record
date. Notice of the proposed payment of such Defaulted Interest and the special
record date therefor having been so mailed, such Defaulted Interest shall be
paid to the persons in whose names the Debentures (or their respective
Predecessor Debentures) were registered at the close of business on such special
record date and shall no longer be payable pursuant to the following clause (2).
(2) The Company may make payment of any Defaulted Interest in
any other lawful manner not inconsistent with the requirements of any securities
exchange or automated quotation system on which the Debentures may be listed or
designated for issuance, and upon such notice as may be required by such
exchange or automated quotation system, if, after notice given by the Company to
the Trustee of the proposed payment pursuant to this clause, such manner of
payment shall be deemed practicable by the Trustee.
In the event of a Registration Default, the Company will pay additional
interest ("Additional Interest") to each holder of Debentures that are Transfer
Restricted Securities,
-11-
<PAGE> 20
during the first 90-day period immediately following the occurrence of such
Registration Default in an amount equal to an additional one-quarter of one
percent (0.25%) per annum of the principal amount of Debentures held by such
holder. The rate of accrual of the Additional Interest will increase to one-half
of one percent (0.50%) per annum of the principal amount of the Debenture
constituting Transfer Restricted Securities for each subsequent 90-day period
until the applicable registration statement is filed, declared effective or
becomes available for effecting sales of securities, up to a maximum of
Additional Interest of 1.25% per annum of the principal amount of the Debentures
constituting Transfer Restricted Securities. Following the cure of a
Registration Default, Additional Interest will cease to accrue with respect to
such Registration Default (without in any way limiting the effect of any
subsequent Registration Default). All Additional Interest shall accrue and be
paid to the holders of Debentures in the manner, in all respects, as interest on
the Debentures under this Indenture. The Company shall notify the Trustee within
one Business Day after each and every date on which a Registration Default
occurs. In no event shall the Company be required to pay Additional Interest in
excess of the applicable maximum amount set forth above, regardless of whether
one or multiple Registration Defaults shall exist. All of the Company's
obligations set forth in this paragraph which are unsatisfied to any extent with
respect to any Debenture constituting a Transfer Restricted Security at the time
such Debenture ceases to be a Transfer Restricted Security shall survive until
such time as all such obligations with respect to such Debenture have been
satisfied in full.
Section 2.4 Execution of Debentures. The Debentures shall be signed in
the name and on behalf of the Company by the facsimile signature of its
President, its Chief Executive Officer, any of its Executive or Senior Vice
Presidents, or any of its Vice Presidents (whether or not designated by a number
or numbers or word or words added before or after the title "Vice President")
and attested by the manual or facsimile signature of its Secretary or any of its
Assistant Secretaries (which may be printed, engraved or otherwise reproduced
thereon, by facsimile or otherwise). Only such Debentures as shall bear thereon
a certificate of authentication substantially in the form set forth on the form
of Debenture attached as Exhibit A hereto, manually executed by the Trustee (or
an authenticating agent appointed by the Trustee as provided by Section 16.11),
shall be entitled to the benefits of this Indenture or be valid or obligatory
for any purpose. Such certificate by the Trustee (or such an authenticating
agent) upon any Debenture executed by the Company shall be conclusive evidence
that the Debenture so authenticated has been duly authenticated and delivered
hereunder and that the holder is entitled to the benefits of this Indenture.
In case any officer of the Company who shall have signed any of the
Debentures shall cease to be such officer before the Debentures so signed shall
have been authenticated and delivered by the Trustee, or disposed of by the
Company, such Debentures nevertheless may be authenticated and delivered or
disposed of as though the person who signed such Debentures had not ceased to be
such officer of the Company; and any Debenture may be signed on behalf of the
Company by such persons as, at the actual date of the execution of such
Debenture, shall be the proper officers of the Company, although at the date of
the execution of this Indenture any such person was not such an officer.
-12-
<PAGE> 21
Section 2.5 Exchange and Registration of Transfer of Debentures.
(a) The Company shall cause to be kept at the Corporate Trust
Office a register (the register maintained in such office and in any other
office or agency of the Company designated pursuant to Section 5.2 being herein
sometimes collectively referred to as the "Debenture register") in which,
subject to such reasonable regulations as it may prescribe, the Company shall
provide for the registration of Debentures and of transfers of Debentures. Such
register shall be in written form or in any form capable of being converted into
written form within a reasonable period of time. The Trustee is hereby initially
appointed "Debenture registrar" for the purpose of registering Debentures and
transfers of Debentures as herein provided. The Company may appoint one or more
co-registrars in accordance with Section 5.2. There shall be only one Debenture
register.
Upon surrender for registration of transfer of any Debenture
to the Debenture registrar or any co-registrar, and satisfaction of the
requirements for such transfer set forth in this Section 2.5, the Company shall
execute, and the Trustee shall authenticate and deliver, in the name of the
designated transferee or transferees, one or more new Debentures of any
authorized denominations and of a like aggregate principal amount.
Debentures may be exchanged for other Debentures of any
authorized denominations and of a like aggregate principal amount, upon
surrender of the Debentures to be exchanged at any such office or agency.
Whenever any Debentures are so surrendered for exchange, the Company shall
execute, and the Trustee shall authenticate and deliver, the Debentures which
the Debentureholder making the exchange is entitled to receive, bearing
registration numbers not contemporaneously outstanding.
All Debentures presented or surrendered for registration of
transfer or for exchange shall (if so required by the Company, the Trustee, the
Debenture registrar or any co-registrar) be duly endorsed, or be accompanied by
a written instrument or instruments of transfer in form satisfactory to the
Company and duly executed, by the Debentureholder thereof or his attorney duly
authorized in writing.
No service charge shall be charged to the Debentureholder for
any exchange or registration of transfer of Debentures, but the Company may
require payment of a sum sufficient to cover any tax, assessments or other
governmental charges that may be imposed in connection therewith.
None of the Company, the Trustee, the Debenture registrar or
any co-registrar shall be required to exchange or register a transfer of (a) any
Debentures for a period of fifteen (15) days next preceding any selection of
Debentures to be redeemed or (b) any Debentures called for redemption or, if a
portion of any Debenture is selected or called for redemption, such portion
thereof selected or called for redemption or (c) any Debentures surrendered for
conversion or, if a portion of any Debenture is surrendered for conversion, such
portion thereof surrendered for conversion.
-13-
<PAGE> 22
All Debentures issued upon any transfer or exchange of
Debentures in accordance with this Indenture shall be the valid obligations of
the Company, evidencing the same debt, and entitled to the same benefits under
this Indenture as the Debentures surrendered upon such registration of transfer
or exchange.
(b) So long as the Debentures are eligible for book-entry
settlement with the Depositary, or unless otherwise required by law, all
Debentures that are so eligible may be represented by a Debenture or Debentures
in global form (the "Global Debenture" or "Global Debentures") registered in the
name of the Depositary or the nominee of the Depositary, except as otherwise
specified below. The transfer and exchange of beneficial interests in the Global
Debenture shall be effected through the Depositary in accordance with this
Indenture and the procedures of the Depositary therefor.
Debentures that upon initial issuance are not owned by
Institutional Accredited Investors will be represented by one or more Global
Debentures. Transfers of interests in a Global Debenture will be made in
accordance with the standing instructions and procedures of the Depository and
its participants. The Transfer Agent shall make appropriate endorsements to
reflect increases or decreases in the Global Debenture as set forth on the face
of the Global Debenture to reflect any such transfers.
Except as provided below, beneficial owners of an interest
in a Global Debenture shall not be entitled to have certificates registered in
their names, will not receive or be entitled to receive physical delivery of
certificates in definitive form and will not be considered holders of such
Global Debentures.
(c) So long as the Debentures are eligible for book-entry
settlement, or unless otherwise required by law, upon any transfer of a
definitive Debenture to a QIB in accordance with Rule 144A, and upon receipt of
the definitive Debenture or Debentures being so transferred, together with a
certification, substantially in the form of the reverse of the certificate, from
the transferor that the transfer is being made in compliance with Rule 144A (or
other evidence satisfactory to the Trustee), the Trustee shall make an
endorsement on the Global Debenture to reflect an increase in the aggregate
amount of the Debentures represented by the Global Debenture, the Trustee shall
cancel such definitive Debenture or Debentures in accordance with the standing
instructions and procedures of the Depositary and the aggregate principal amount
of Debentures represented by the Global Debenture will be increased accordingly;
provided that no definitive Debenture, or portion thereof, in respect of which
the Company or an Affiliate of the Company held any beneficial interest shall be
included in such Global Debenture until such definitive Debenture is freely
tradable in accordance with Rule 144(k); provided further that the Trustee shall
issue Debentures in definitive form upon any transfer of a beneficial interest
in any Global Debenture to the Company or any Affiliate of the Company.
Upon any sale or transfer of Debentures to an Institutional
Accredited Investor (other than pursuant to a registration statement that has
been declared effective under the
-14-
<PAGE> 23
Securities Act), such Institutional Accredited Investor shall, prior to such
sale or transfer, furnish to the Company and/or the Trustee a signed letter
containing representations and agreements relating to certain restrictions on
transfer, the form of which is set forth in Exhibit B hereto, and, in the case
of a Debenture in definitive form, shall check the appropriate box on the form
of Assignment on the reverse of such Debenture.
Any Global Debenture may be endorsed with or have incorporated
in the text thereof such legends or recitals or changes not inconsistent with
the provisions of this Indenture as may be required by the Custodian, the
Depositary, by the New York Stock Exchange or by the National Association of
Securities Dealers, Inc. in order for the Debentures to be tradeable on The
Portal Market or as may be required for the Debentures to be tradeable on any
other market developed for trading of securities pursuant to Rule 144A or
required to comply with any applicable law or any regulation thereunder or with
the rules and regulations of any securities exchange upon which the Debentures
may be listed or traded or to conform with any usage with respect thereto, or to
indicate any special limitations or restrictions to which any particular
Debentures are subject.
(d) Every Debenture that bears or is required under this
Section 2.5(d) to bear the legend set forth in this Section 2.5(d) (together
with any Common Stock issued upon conversion of the Debentures and required to
bear the legend set forth in Section 2.5(e), collectively, the "Restricted
Securities") shall be subject to the restrictions on transfer set forth in this
Section 2.5(d) (including those set forth in the legend set forth below) unless
such restrictions on transfer shall be waived by written consent of the Company,
and the holder of each such Restricted Securities by such holder's acceptance
thereof, agrees to be bound by all such restrictions on transfer. As used in
Sections 2.5(d) and 2.5(e), the term "transfer" encompasses any sale, pledge,
transfer or other disposition whatsoever of any Restricted Securities.
Until two years after the original issue date of the Preferred
Stock, any certificate evidencing any Debenture issued upon exchange of the
Preferred Stock pursuant to this Indenture (and all securities issued in
exchange therefor or substitution thereof, other than Common Stock, if any,
issued upon conversion therefor, which shall bear the legend set forth in
Section 2.5(e), if applicable) shall bear a legend in substantially the
following form, unless such Debenture has been sold pursuant to a registration
statement that has been declared effective under the Securities Act (and which
continues to be effective at the time of such transfer), or unless otherwise
agreed by the Company in writing, with written notice thereof to the Trustee:
THE DEBENTURE EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE
SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD WITHIN
THE UNITED STATES OR TO, OR FOR, THE ACCOUNT OR BENEFIT OF, U.S.
PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS
ACQUISITION HEREOF, THE HOLDER (1) REPRESENTS THAT (A) IT IS A
-15-
<PAGE> 24
"QUALIFIED INSTITUTIONAL BUYER" (AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT), (B) IT IS AN INSTITUTIONAL "ACCREDITED INVESTOR" (AS
DEFINED IN RULE 501(a)(1), (2), (3) OR (7) UNDER THE SECURITIES ACT)
("INSTITUTIONAL ACCREDITED INVESTOR") OR (C) IT IS NOT A U.S. PERSON
AND IS ACQUIRING THE DEBENTURE EVIDENCED HEREBY IN AN OFFSHORE
TRANSACTION; (2) AGREES THAT IT WILL NOT, WITHIN TWO YEARS AFTER THE
ORIGINAL ISSUANCE OF THE PREFERRED STOCK OF WHICH THE DEBENTURE
EVIDENCED HEREBY HAS BEEN ISSUED UPON EXCHANGE THEREFOR, RESELL OR
OTHERWISE TRANSFER THE DEBENTURE EVIDENCED HEREBY OR THE COMMON STOCK
ISSUABLE UPON CONVERSION OF SUCH DEBENTURE EXCEPT (A) TO THE COMPANY OR
ANY SUBSIDIARY THEREOF, (B) TO A QUALIFIED INSTITUTIONAL BUYER IN
COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, (C) TO AN
INSTITUTIONAL ACCREDITED INVESTOR THAT, PRIOR TO SUCH TRANSFER,
FURNISHES TO THE TRUSTEE, A SIGNED LETTER CONTAINING CERTAIN
REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER
OF THE DEBENTURE EVIDENCED HEREBY (THE FORM OF WHICH LETTER CAN BE
OBTAINED FROM SUCH TRUSTEE), (D) PURSUANT TO THE EXEMPTION FROM
REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF
AVAILABLE) OR (E) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BEEN
DECLARED EFFECTIVE UNDER THE SECURITIES ACT (AND WHICH CONTINUES TO BE
EFFECTIVE AT THE TIME OF SUCH TRANSFER); AND (3) AGREES THAT IT WILL
DELIVER TO EACH PERSON TO WHOM THE DEBENTURE EVIDENCED HEREBY IS
TRANSFERRED (OTHER THAN A TRANSFER PURSUANT TO CLAUSE 2(E)) A NOTICE
SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN CONNECTION WITH ANY
TRANSFER OF THE DEBENTURE EVIDENCED HEREBY WITHIN TWO YEARS AFTER THE
ORIGINAL ISSUANCE OF THE PREFERRED STOCK OF WHICH THE DEBENTURE
EVIDENCED HEREBY HAS BEEN ISSUED UPON EXCHANGE THEREFOR (OTHER THAN A
TRANSFER PURSUANT TO CLAUSE 2(E)), THE HOLDER MUST CHECK THE
APPROPRIATE BOX SET FORTH ON THE REVERSE HEREOF RELATING TO THE MANNER
OF SUCH TRANSFER AND SUBMIT THIS CERTIFICATE TO THE TRUSTEE. IF THE
PROPOSED TRANSFEREE IS A PURCHASER WHO IS NOT A U.S. PERSON OR IS AN
INSTITUTIONAL ACCREDITED INVESTOR, THE HOLDER MUST, PRIOR TO SUCH
TRANSFER, FURNISH TO THE TRUSTEE, SUCH CERTIFICATIONS, LEGAL OPINIONS
OR OTHER INFORMATION AS THE COMPANY MAY REASONABLY REQUIRE TO CONFIRM
THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A
TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT. THIS LEGEND WILL BE REMOVED UPON THE EARLIER
-16-
<PAGE> 25
OF THE TRANSFER OF THE DEBENTURE EVIDENCED HEREBY PURSUANT TO CLAUSE
2(E) ABOVE OR THE EXPIRATION OF TWO YEARS FROM THE ORIGINAL ISSUANCE OF
THE PREFERRED STOCK OF WHICH THE DEBENTURE EVIDENCED HEREBY HAS BEEN
ISSUED UPON EXCHANGE THEREFOR.
Any Debenture (or security issued in exchange or substitution
therefor) as to which such restrictions on transfer shall have expired in
accordance with their terms or as to the conditions for removal of the foregoing
legend set forth therein have been satisfied may, upon surrender of such
Debenture for exchange to the Trustee in accordance with the provisions of this
Section 2.5(d), be exchanged for new Debenture or Debentures, of like tenor and
aggregate amount, which shall not bear the restrictive legend required by this
Section 2.5(d).
Notwithstanding any other provisions of this Indenture (other
than the provisions set forth in this Section 2.5(d)), a Global Debenture may
not be transferred as a whole except by the Depositary to a nominee of the
Depositary or by a nominee of the Depositary to the Depositary or another
nominee to a successor Depositary or a nominee of such successor Depositary.
The Depositary shall be a clearing agency registered under the
Exchange Act. The Company initially appoints The Depository Trust Company to act
as Depositary with respect to the Global Debentures. Initially, the Global
Debenture shall be issued to the Depositary, registered in the name of Cede &
Co., as the nominee of the Depositary, and deposited with the Custodian for Cede
& Co.
If at any time the Depositary for a Global Debenture notifies
the Company that it is unwilling or unable to continue as Depositary for such
Global Debenture, the Company may appoint a successor Depositary with respect to
such Global Debenture. If a successor Depositary for the Debentures is not
appointed by the Company within 90 days after the Company receives such notice,
the Company will execute, and the Trustee will authenticate and deliver,
Debentures in certificated form, in an aggregate principal amount equal to the
principal amount of the Global Debenture, in exchange for such Global Debenture.
Debentures in definitive form issued in exchange for all or a
part of a Global Debenture pursuant to this Section 2.5(d) shall be registered
in such names and in such authorized denominations as the Depositary, pursuant
to instructions from its direct or indirect participants or otherwise, shall
instruct the Trustee. Upon execution and authentication, the Trustee shall
deliver such Debentures in certificated form to the persons in whose names such
Debentures in definitive form are so registered.
At such time as all interests in a Global Debenture have been
redeemed, converted, exchanged, repurchased or canceled for Debentures in
definitive form, or transferred to a transferee who receives Debentures in
definitive form, such Global Debenture shall be,
-17-
<PAGE> 26
upon receipt thereof, canceled by the Trustee in accordance with standing
procedures and instructions existing between the Custodian and Depositary. At
any time prior to such cancellation, if any interest in a Global Debenture is
exchanged for Debentures in certificated form, redeemed, converted, exchanged,
repurchased by the Company or canceled, or transferred for part of a Global
Debenture, the principal amount of such Global Debenture shall, in accordance
with the standing procedures and instructions existing between the Custodian and
the Depositary, be reduced or increased, as the case may be, and an endorsement
shall be made on such Global Debenture, by the Trustee or the Custodian, at the
direction of the Trustee, to reflect such reduction or increase.
(e) Until two years after the original issue date of the
Preferred Stock, any stock certificate representing Common Stock issued upon
conversion of a Debenture pursuant to this Indenture shall bear a legend in
substantially the following form, unless such Common Stock has been sold
pursuant to a registration statement that has been declared effective under the
Securities Act (and which continues to be effective at the time of such
transfer) or such Common Stock has been issued upon conversion of a Debenture
that has been transferred pursuant to a registration statement that has been
declared effective under the Securities Act, or unless otherwise agreed by the
Company in writing with written notice thereof to the transfer agent for the
Common Stock:
THE COMMON STOCK EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE
U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY
STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD
WITHIN THE UNITED STATES OR TO, OR FOR, THE ACCOUNT OR BENEFIT OF, U.S.
PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. THE HOLDER
HEREOF AGREES THAT UNTIL THE EXPIRATION OF TWO YEARS AFTER THE ORIGINAL
ISSUANCE OF THE PREFERRED STOCK OF WHICH THE COMMON STOCK ISSUABLE UPON
CONVERSION OF THE DEBENTURE ISSUED IN EXCHANGE FOR SUCH PREFERRED STOCK
HEREBY WAS ISSUED, (1) IT WILL NOT RESELL OR OTHERWISE TRANSFER THE
COMMON STOCK EVIDENCED HEREBY WITHIN THE UNITED STATES OR TO, OR FOR
ACCOUNT OR BENEFIT OF, U.S. PERSONS, EXCEPT (A) TO THE COMPANY OR ANY
SUBSIDIARY THEREOF, (B) TO A "QUALIFIED INSTITUTIONAL BUYER" (AS
DEFINED IN RULE 144A UNDER THE SECURITIES ACT) IN COMPLIANCE WITH RULE
144A, (C) TO AN INSTITUTIONAL "ACCREDITED INVESTOR" (AS DEFINED IN RULE
501(a)(1), (2), (3) OR (7) UNDER THE SECURITIES ACT) THAT, PRIOR TO
SUCH TRANSFER, FURNISHES TO STOCKTRANS, INC., AS TRANSFER AGENT, A
SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS
RELATING TO THE RESTRICTIONS ON TRANSFER OF THE COMMON STOCK EVIDENCED
HEREBY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM SUCH TRANSFER
AGENT), (D) PURSUANT TO THE EXEMPTION FROM
-18-
<PAGE> 27
REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF
AVAILABLE), OR (E) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BEEN
DECLARED EFFECTIVE UNDER THE SECURITIES ACT (AND WHICH CONTINUES TO BE
EFFECTIVE AT THE TIME OF SUCH TRANSFER); (2) PRIOR TO SUCH TRANSFER
(OTHER THAN A TRANSFER PURSUANT TO CLAUSE 1(E) ABOVE), IT WILL FURNISH
TO STOCKTRANS, INC., AS TRANSFER AGENT, SUCH CERTIFICATIONS, LEGAL
OPINIONS OR OTHER INFORMATION AS THE COMPANY MAY REASONABLE REQUIRE TO
CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
THE SECURITIES ACT; AND (3) IT WILL DELIVER TO EACH PERSON TO WHOM THE
COMMON STOCK EVIDENCED HEREBY IS TRANSFERRED (OTHER THAN A TRANSFER
PURSUANT TO CLAUSE 1(E) ABOVE) A NOTICE SUBSTANTIALLY SIMILAR TO THIS
LEGEND. THIS LEGEND WILL BE REMOVED UPON THE EARLIER OF THE TRANSFER OF
THE COMMON STOCK EVIDENCED HEREBY PURSUANT TO CLAUSE 1(E) ABOVE OR THE
EXPIRATION OF TWO YEARS FROM THE ORIGINAL ISSUANCE OF THE PREFERRED
STOCK OF WHICH THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE
DEBENTURE ISSUED IN EXCHANGE FOR SUCH PREFERRED STOCK HEREBY WAS
ISSUED.
Any such Common Stock as to which such restrictions on
transfer shall have expired in accordance with their terms or as to which the
conditions for removal of the foregoing legend set forth therein have been
satisfied may, upon surrender of the certificates representing such shares of
Common Stock for exchange in accordance with the procedures of the transfer
agent for the Common Stock, be exchanged for a new certificate or certificates
for a like number of shares of Common Stock, which shall not bear the
restrictive legend required by this Section 2.5(e).
(f) Any Debenture or Common Stock issued upon the conversion
or exchange of a Debenture that, prior to the expiration of the holding period
applicable to sales thereof under Rule 144(k) under the Securities Act (or any
successor provision), is purchased or owned by the Company or any Affiliate
thereof may not be resold by the Company or such Affiliate unless registered
under the Securities Act or resold pursuant to an exemption from the
registration requirements of the Securities Act in a transaction which results
in such Debenture or Common Stock, as the case may be, no longer being
"restricted securities" (as defined under Rule 144).
(g) Notwithstanding any provision of Section 2.5 to the
contrary, in the event Rule 144(k) as promulgated under the Securities Act (or
any successor rule) is amended to change the two-year period under Rule 144(k)
(or the corresponding period under any successor rule), from and after receipt
by the Trustee of the Officers' Certificate and Opinion of Counsel provided for
in this Section 2.5(g), (i) the references in the first sentence of the second
-19-
<PAGE> 28
paragraph of Section 2.5(d) to "two (2) years" and in the restrictive legend set
forth in such paragraph to "TWO YEARS" shall be deemed for all purposes hereof
to be references to such changed period, (ii) the references in the first
paragraph of Section 2.5(e) to "two (2) years" and in the restrictive legend set
forth in such paragraph to "TWO YEARS" shall be deemed for all purposes hereof
to be references to such changed period and (iii) all corresponding references
in the Debentures and the restrictive legends thereon shall be deemed for all
purposes hereof to be references to such changed period, provided that such
changes shall not become effective if they are otherwise prohibited by, or would
otherwise cause a violation of, the then-applicable federal securities laws. As
soon as practicable after the Company has knowledge of the effectiveness of any
such amendment to change the two-year period under Rule 144(k) (or the
corresponding period under any successor rule), unless such changes would
otherwise be prohibited by, or would otherwise cause a violation of, the
then-applicable securities law, the Company shall provide to the Trustee an
Officers' Certificate and Opinion of Counsel informing the Trustee of the
effectiveness of such amendment and the effectiveness of the foregoing changes
to Sections 2.5(d) and 2.5(e) and the Debentures. The provisions of this Section
2.5(g) will not be effective until such time as the Opinion of Counsel and
Officers' Certificate have been received by the Trustee hereunder. This Section
2.5(g) shall apply to successive amendments to Rule 144(k) (or any successor
rule) changing the holding period thereunder.
Section 2.6 Mutilated, Destroyed, Lost or Stolen Debentures. In case
any Debenture shall become mutilated or be destroyed, lost or stolen, the
Company in its discretion may execute, and upon its request the Trustee or an
authenticating agent appointed by the Trustee shall authenticate and deliver, a
new Debenture, bearing a number not contemporaneously outstanding, in exchange
and substitution for the mutilated Debenture, or in lieu of and in substitution
for the Debenture so destroyed, lost or stolen. In every case the applicant for
a substituted Debenture shall furnish to the Company, to the Trustee and, if
applicable, to such authenticating agent such security or indemnity as may be
required by them to save each of them harmless for any loss, liability, cost or
expense caused by or connected with such substitution, and, in every case of
destruction, loss or theft, the applicant shall also furnish to the Company, to
the Trustee and, if applicable, to such authenticating agent evidence to their
satisfaction of the destruction, loss or theft of such Debenture and of the
ownership thereof.
The Trustee or such authenticating agent may authenticate any such
substituted Debenture and deliver the same upon the receipt of such security or
indemnity as the Trustee, the Company and, if applicable, such authenticating
agent may require. Upon the issuance of any substituted Debenture, the Company
may require the payment of a sum sufficient to cover any tax or other
governmental charge that may be imposed in relation thereto and any other
expenses connected therewith. In case any Debenture which has matured or is
about to mature or has been called for redemption or is about to be converted
into Common Stock shall become mutilated or be destroyed, lost or stolen, the
Company may, instead of issuing a substitute Debenture, pay or authorize the
payment of or convert or authorize the conversion of the same (without surrender
thereof except in the case of a mutilated Debenture), as the case may be, if the
applicant for such payment or conversion shall furnish to the Company, to the
Trustee and,
-20-
<PAGE> 29
if applicable, to such authenticating agent such security or indemnity as may be
required by them to save each of them harmless for any loss, liability, cost or
expense caused by or connected with such substitution, and, in case of
destruction, loss or theft, evidence satisfactory to the Company, the Trustee
and, if applicable, any paying agent or conversion agent of the destruction,
loss or theft of such Debenture and of the ownership thereof.
Every substitute Debenture issued pursuant to the provisions of this
Section 2.6 by virtue of the fact that any Debenture is destroyed, lost or
stolen shall constitute an additional contractual obligation of the Company,
whether or not the destroyed, lost or stolen Debenture shall be found at any
time, and shall be entitled to all the benefits of (but shall be subject to all
the limitations set forth in) this Indenture equally and proportionately with
any and all other Debentures duly issued hereunder. To the extent permitted by
law, all Debentures shall be held and owned upon the express condition that the
foregoing provisions are exclusive with respect to the replacement or payment or
conversion of mutilated, destroyed, lost or stolen Debentures and shall preclude
any and all other rights or remedies notwithstanding any law or statute existing
or hereafter enacted to the contrary with respect to the replacement or payment
or conversion of negotiable instruments or other securities without their
surrender.
Section 2.7 Temporary Debentures. Pending the preparation of definitive
Debentures or any Global Debenture, the Company may execute and the Trustee or
an authenticating agent appointed by the Trustee shall, upon written request of
the Company, authenticate and deliver temporary Debentures (printed or
lithographed). Temporary Debentures shall be issuable in any authorized
denomination, and substantially in the form of the definitive Debentures but
with such omissions, insertions and variations as may be appropriate for
temporary Debentures, all as may be determined by the Company. Every such
temporary Debenture shall be executed by the Company and authenticated by the
Trustee or such authenticating agent upon the same conditions and in
substantially the same manner, and with the same effect, as the definitive
Debentures. Without unreasonable delay the Company will execute and deliver to
the Trustee or such authenticating agent definitive Debentures and thereupon any
or all temporary Debentures may be surrendered in exchange therefor, at each
office or agency maintained by the Company pursuant to Section 5.2 and the
Trustee or such authenticating agent shall authenticate and deliver in exchange
for such temporary Debentures an equal aggregate principal amount of definitive
Debentures. Such exchange shall be made by the Company at its own expense and
without any charge therefor. Until so exchanged, the temporary Debentures shall
in all respects be entitled to the same benefits and subject to the same
limitations under this Indenture as definitive Debentures authenticated and
delivered hereunder.
Section 2.8 Cancellation of Debentures Paid, Etc. All Debentures
surrendered for the purpose of payment, redemption, conversion, exchange or
registration of transfer, shall, if surrendered to the Company or any paying
agent or any Debenture registrar or any conversion agent, be surrendered to the
Trustee and promptly canceled by it, or, if surrendered to the Trustee, shall be
promptly canceled by it, and no Debentures shall be issued in lieu thereof
except as expressly permitted by any of the provisions of this Indenture. Upon
written
-21-
<PAGE> 30
instructions of the Company, the Trustee shall destroy canceled Debentures and,
after such destruction, shall, if requested by the Company, deliver a
certificate of such destruction to the Company. If the Company shall acquire any
of the Debentures, such acquisition shall not operate as a redemption or
satisfaction of the indebtedness represented by such Debentures unless and until
the same are delivered to the Trustee for cancellation.
ARTICLE III
REDEMPTION OF DEBENTURES
Section 3.1 Redemption Prices. The Company may, at its option, redeem
all or from time to time any part of the Debentures on any date prior to
maturity, upon notice as set forth in Section 3.2, and at the optional
redemption prices set forth in the form of Debenture attached as Exhibit A
hereto, together with accrued interest, if any, to, but excluding, the date
fixed for redemption, provided, however, that no such redemption shall be
effected before August 17, 2001.
Section 3.2 Notice of Redemption; Selection of Debentures. In case the
Company shall desire to exercise the right to redeem all or, as the case may be,
any part of the Debentures pursuant to Section 3.1, it shall fix a date for
redemption, and it, or at its request (which must be received by the Trustee at
least ten (10) Business Days prior to the date the Trustee is requested to give
notice as described below unless a shorter period is agreed to by the Trustee),
the Trustee in the name of and at the expense of the Company, shall mail or
cause to be mailed a notice of such redemption at least twenty (20) and not more
than sixty (60) days prior to the date fixed for redemption to the holders of
Debentures so to be redeemed as a whole or in part at their last addresses as
the same appear on the Debenture register (provided that if the Company shall
give such notice, it shall also give such notice, and notice of the Debentures
to be redeemed, to the Trustee). If fewer than all the Debentures are to be
redeemed, the Company will give the Trustee written notice in the form of an
Officers' Certificate not fewer than thirty-five (35) days (or such shorter
period of time as may be acceptable to the Trustee) prior to the redemption date
as to the aggregate principal amount of Debentures to be redeemed. Such mailing
shall be by first class mail. The notice if mailed in the manner herein provided
shall be conclusively presumed to have been duly given, whether or not the
holder receives such notice. In any case, failure to give such notice by mail or
any defect in the notice to the holder of any Debenture designated for
redemption as a whole or in part shall not affect the validity of the
proceedings for the redemption of any other Debenture.
Each such notice of redemption shall specify the aggregate principal
amount of Debentures to be redeemed, the date fixed for redemption, the
redemption price at which Debentures are to be redeemed, the CUSIP number or
numbers for the Debentures to be redeemed, the place or places of payment, that
payment will be made upon presentation and surrender of such Debentures, that
interest accrued to, but excluding, the date fixed for redemption will be paid
as specified in said notice, and that on and after said date interest
-22-
<PAGE> 31
thereon or on the portion thereof to be redeemed will cease to accrue. Such
notice shall also state the current Conversion Price and the date on which the
right to convert such Debentures or portions thereof into Common Stock will
expire. If fewer than all the Debentures are to be redeemed, the notice of
redemption shall identify the Debentures to be redeemed. In case any Debenture
is to be redeemed in part only, the notice of redemption shall state the portion
of the principal amount thereof to be redeemed and shall state that on and after
the date fixed for redemption, upon surrender of such Debenture, a new Debenture
or Debentures in principal amount equal to the unredeemed portion thereof will
be issued.
On or prior to the redemption date specified in the notice of
redemption given as provided in this Section 3.2, the Company will deposit with
the Trustee or with one or more paying agents (or, if the Company is acting as
its own paying agent, set aside, segregate and hold in trust as provided in
Section 5.4) an amount of money sufficient to redeem on the redemption date all
the Debentures (or portions thereof) so called for redemption (other than those
theretofore surrendered for conversion into Common Stock) at the appropriate
redemption price, together with accrued interest to, but excluding, the date
fixed for redemption; provided that if such payment is made on the redemption
date it must be received by the Trustee or paying agent, as the case may be, by
10:00 a.m. New York City time, on such date. If any Debenture called for
redemption is converted pursuant hereto, any money deposited with the Trustee or
any paying agent or so segregated and held in trust for the redemption of such
Debenture shall be paid to the Company upon its request, or, if then held by the
Company shall be discharged from such trust.
If fewer than all the Debentures are to be redeemed, the Trustee shall
select the Debentures or portions thereof to be redeemed (in principal amounts
of $1,000 or integral multiples thereof), by lot or, in its sole discretion, on
a pro rata basis. If any Debenture selected for partial redemption is converted
in part after such selection, the converted portion of such Debenture shall be
deemed (so far as may be) to be the portion to be selected for redemption. The
Debentures (or portions thereof) so selected shall be deemed duly selected for
redemption for all purposes hereof, notwithstanding that any such Debenture is
converted as a whole or in part before the mailing of the notice of redemption.
Upon any redemption of less than all Debentures, the Company and the
Trustee may (but need not) treat as outstanding any Debentures surrendered for
conversion during the period of fifteen (15) days next preceding the mailing of
a notice of redemption and may (but need not) treat as not outstanding any
Debenture authenticated and delivered during such period in exchange for the
unconverted portion of any Debenture converted in part during such period.
Section 3.3 Payment of Debentures Called for Redemption. If notice of
redemption has been given as above provided, the Debentures or portion of
Debentures with respect to which such notice has been given shall, unless
converted into Common Stock pursuant to the terms hereof, become due and payable
on the date and at the place or places stated in such notice at the applicable
redemption price, together with interest accrued to, but excluding, the date
fixed for redemption, and on and after said date (unless the Company shall
default in the
-23-
<PAGE> 32
payment of such Debentures at the redemption price, together with interest
accrued to, but excluding, said date) interest on the Debentures or portion of
Debentures so called for redemption shall cease to accrue and such Debentures
shall cease after the close of business on the Business Day next preceding the
date fixed for redemption to be convertible into Common Stock and, except as
provided in Sections 8.5 and 13.4, to be entitled to any benefit or security
under this Indenture, and the holders thereof shall have no right in respect of
such Debentures except the right to receive the redemption price thereof and
unpaid interest to, but excluding, the date fixed for redemption. On
presentation and surrender of such Debentures at a place of payment in said
notice specified, the said Debentures or the specified portions thereof to be
redeemed shall be paid and redeemed by the Company at the applicable redemption
price, together with interest accrued thereon to, but excluding, the date fixed
for redemption; provided that, if the applicable redemption date is an interest
payment date, the semi-annual payment of interest becoming due on such date
shall be payable to the holders of such Debentures registered as such on the
relevant record date subject to the terms and provisions of Section 2.3 hereof.
Upon presentation of any Debenture redeemed in part only, the Company
shall execute and the Trustee shall authenticate and deliver to the holder
thereof, at the expense of the Company, a new Debenture or Debentures, of
authorized denominations, in principal amount equal to the unredeemed portion of
the Debentures so presented.
Notwithstanding the foregoing, the Trustee shall not redeem any
Debentures or mail any notice of optional redemption during the continuance of a
default in payment of interest or premium on the Debentures or of any Event of
Default of which, in the case of any Event of Default other than under Section
7.1(a) or (b), a Responsible Officer of the Trustee has knowledge. If any
Debenture called for redemption shall not be so paid upon surrender thereof for
redemption, the principal and premium, if any, shall, until paid or duly
provided for, bear interest from the date fixed for redemption at the rate borne
by the Debenture and such Debenture shall remain convertible into Common Stock
until the principal and premium, if any, shall have been paid or duly provided
for.
Section 3.4 Conversion Arrangement on Call for Redemption. In
connection with any redemption of Debentures, the Company may arrange for the
purchase and conversion of any Debentures by an agreement with one or more
investment bankers or other purchasers to purchase such Debentures by paying to
the Trustee in trust for the Debentureholders, on or before the date fixed for
redemption, an amount not less than the applicable redemption price, together
with interest accrued to the date fixed for redemption, of such Debentures.
Notwithstanding anything to the contrary contained in this Article III, the
obligation of the Company to pay the redemption price of such Debentures,
together with interest accrued to, but excluding, the date fixed for redemption,
shall be deemed to be satisfied and discharged to the extent such amount is so
paid by such purchasers. If such an agreement is entered into, a copy of which
will be filed with the Trustee prior to the date fixed for redemption, any
Debentures not duly surrendered for conversion by the holders thereof may, at
the option of the Company, be deemed, to the fullest extent permitted by law,
acquired by such purchasers from such
-24-
<PAGE> 33
holders and (notwithstanding anything to the contrary contained in Article XV)
surrendered by such purchasers for conversion, all as of immediately prior to
the close of business on the date fixed for redemption (and the right to convert
any such Debentures shall be deemed to have been extended through such time),
subject to payment of the above amount as aforesaid. At the direction of the
Company, the Trustee shall hold and dispose of any such amount paid to it in the
same manner as it would monies deposited with it by the Company for the
redemption of Debentures. Without the Trustee's prior written consent, no
arrangement between the Company and such purchasers for the purchase and
conversion of any Debentures shall increase or otherwise affect any of the
powers, duties, responsibilities or obligations of the Trustee as set forth in
this Indenture, and the Company agrees to indemnify the Trustee from, and hold
it harmless against, any loss, liability or expense arising out of or in
connection with any such arrangement for the purchase and conversion of any
Debentures between the Company and such purchasers to which the Trustee has not
consented in writing, including the costs and expenses incurred by the Trustee
in the defense of any claim or liability arising out of or in connection with
the exercise or performance of any of its powers, duties, responsibilities or
obligations under this Indenture.
ARTICLE IV
SUBORDINATION OF DEBENTURES
Section 4.1 Agreement of Subordination. The Company covenants and
agrees, and each holder of Debentures issued hereunder by his acceptance thereof
likewise covenants and agrees, that all Debentures shall be issued subject to
the provisions of this Article IV; and each person holding any Debenture,
whether upon original issue or upon transfer, assignment or exchange thereof,
accepts and agrees to be bound by such provisions.
The payment of the principal of, premium, if any, and interest
(including Additional Interest, if any) on all Debentures (including, but not
limited to, the redemption price with respect to the Debentures to be redeemed,
as provided in this Indenture) issued hereunder shall, to the extent and in the
manner hereinafter set forth, be subordinated and subject in right of payment to
the prior payment in full in cash or other payment satisfactory to holders of
Senior Indebtedness of all Senior Indebtedness.
No provision of this Article IV shall prevent the occurrence of any
default or Event of Default hereunder.
Section 4.2 Payments to Debentureholders. No payment shall be made with
respect to the principal of, or premium, if any, or interest (including
Additional Interest, if any) on the Debentures (including, but not limited to,
the redemption price with respect to the Debentures to be redeemed, as provided
in this Indenture), except payments and distributions made by the Trustee as
permitted by the first or second paragraph of Section 4.5, if:
-25-
<PAGE> 34
(a) a default in the payment of principal, premium, interest,
rent or other obligations due on any Senior Indebtedness occurs and is
continuing (or, in the case of Senior Indebtedness for which there is a period
of grace, in the event of such a default that continues beyond the period of
grace, if any, specified in the instrument or lease evidencing such Senior
Indebtedness), unless and until such default shall have been cured or waived or
shall have ceased to exist; or
(b) a default, other than a payment default, on a Designated
Senior Indebtedness occurs and is continuing that then permits holders of such
Designated Senior Indebtedness to accelerate its maturity and the Trustee
receives a notice of the default (a "Payment Blockage Notice") from the Company
or holder or Representative of Designated Senior Indebtedness.
If the Trustee receives any Payment Blockage Notice pursuant
to clause (b) above, no subsequent Payment Blockage Notice shall be effective
for purposes of this Section unless and until (A) at least 365 days shall have
elapsed since the effectiveness of the immediately prior Payment Blockage
Notice, and (B) all scheduled payments of principal, premium, if any, and
interest (including Additional Interest, if any) on the Debentures that have
come due have been paid in full in cash. No nonpayment default that existed or
was continuing on the date of delivery of any Payment Blockage Notice to the
Trustee shall be, or be made, the basis for a subsequent Payment Blockage
Notice.
The Company may and shall resume payments on and distributions
in respect of the Debentures upon the earlier of:
(1) the date upon which the default is cured or waived or
ceases to exist, or
(2) in the case of a default referred to in clause (b) above,
the earlier of (x) the date such default is cured or waived or ceases to exist
and (y) 179 days pass after notice is received if the maturity of such
Designated Senior Indebtedness has not been accelerated,
unless this Article IV otherwise prohibits the payment or distribution at the
time of such payment or distribution.
Upon any payment by the Company, or distribution of assets of
the Company of any kind or character, whether in cash, property or securities,
to creditors upon any dissolution or winding-up or total or partial liquidation
or reorganization of the Company, whether voluntary or involuntary or in
bankruptcy, insolvency, receivership or other proceedings, all amounts due or to
become due upon all Senior Indebtedness shall first be paid in full, in cash or
other payment satisfactory to the holders of Senior Indebtedness or payment
thereof provided for in cash or other payment satisfactory to the holders of
Senior Indebtedness, before any payment is made on account of the principal (and
premium, if any) or
-26-
<PAGE> 35
interest (including Additional Interest, if any) on the Debentures (except
payments made pursuant to Article XIII from monies deposited with the Trustee
pursuant thereto prior to the happening of such dissolution, winding-up,
liquidation or reorganization or bankruptcy, insolvency, receivership or other
such proceedings); and upon any such dissolution or winding-up or liquidation or
reorganization or bankruptcy, insolvency, receivership or other such
proceedings, any payment by the Company, or distribution of assets of the
Company of any kind or character, whether in cash, property or securities, to
which the holders of the Debentures or the Trustee under this Indenture would be
entitled, except for the provision of this Article IV, shall (except as
aforesaid) be paid by the Company or by any receiver, trustee in bankruptcy,
liquidating trustee, agent or other person making such payment or distribution,
or by the holders of the Debentures or by the Trustee under this Indenture if
received by them or it, directly to the holders of Senior Indebtedness (pro rata
to such holders on the basis of the respective amounts of Senior Indebtedness
held by such holders or as otherwise required by law or a court order) or their
respective Representative or Representatives, as their respective interests may
appear, to the extent necessary to pay all Senior Indebtedness in full in cash
or other payment satisfactory to holders of Senior Indebtedness after giving
effect to any concurrent payment or distribution to or for the holders of Senior
Indebtedness, before any payment or distribution is made to the holders of the
Debentures or to the Trustee under this Indenture.
In the event of the acceleration of the Debentures pursuant to
Article VII, no payment or distribution shall be made to the Trustee or any
holder of Debentures in respect of the principal of, premium, if any, or
interest (including Additional Interest, if any) on the Debentures (including,
but not limited to, the redemption price with respect to the Debentures called
for redemption in accordance with Section 3.2), except payments and
distributions made by the Trustee as permitted by the first or second paragraph
of Section 4.5, until all Senior Indebtedness has been paid in full in cash or
other payment satisfactory to the holders of Senior Indebtedness or such
acceleration is rescinded in accordance with the terms of this Indenture. If
payment of the Debentures is accelerated pursuant to Article VII, the Company
shall promptly notify holders of Senior Indebtedness of such acceleration.
In the event that, notwithstanding the foregoing, any payment
or distribution of assets of the Company of any kind or character, whether in
cash, property or securities (including, without limitation, by way of set-off
or otherwise), prohibited by the foregoing, shall be received by the Trustee
under this Indenture or by any holders of the Debentures before all Senior
Indebtedness is paid in full in cash or other payment satisfactory to holders of
Senior Indebtedness, or provision is made for in cash or other payment
satisfactory to holders of Senior Indebtedness, such payment or distribution
shall be held by the recipient or recipients in trust for the benefit of, and
shall be paid over or delivered to, the holders of Senior Indebtedness or their
respective Representative or Representatives, or to the trustee or trustees
under any indenture pursuant to which any instruments evidencing any Senior
Indebtedness may have been issued, as their respective interests may appear, as
calculated by the Company, for application to the payment of all Senior
Indebtedness
-27-
<PAGE> 36
remaining unpaid to the extent necessary to pay all Senior Indebtedness in full
in cash or other payment satisfactory to the holders of Senior Indebtedness,
after giving effect to any concurrent payment or distribution (or provision
therefor) to or for the holders of such Senior Indebtedness.
For purposes of this Article IV, the words "cash, property or
securities" shall not be deemed to include shares of stock of the Company as
reorganized or readjusted, or securities of the Company or any other corporation
provided for by a plan of reorganization or readjustment, the payment of which
is subordinated (at least to the extent provided in this Article IV with respect
to the Debentures) to the payment of all Senior Indebtedness which may at the
time be outstanding; provided that (i) the Senior Indebtedness is assumed by the
new corporation, if any, resulting from such reorganization or adjustment, and
(ii) the rights of the holders of Senior Indebtedness (other than leases which
are not assumed by the Company or by the new corporation, as the case may be)
are not, without the consent of such holders, altered by such reorganization or
readjustment. The consolidation of the Company with, or the merger of the
Company into, another corporation or the liquidation or dissolution of the
Company following the conveyance or transfer of its property as an entirety, or
substantially as an entirety, to another corporation upon the terms and
conditions provided for in Article XII shall not be deemed a dissolution,
winding-up, liquidation or reorganization for the purposes of this Section 4.2
if such other corporation shall, as a part of such consolidation, merger,
conveyance or transfer, comply with the conditions stated in Article XII.
Nothing in this Section 4.2 shall apply to claims of, or
payments to, the Trustee under or pursuant to Section 8.6. This Section 4.2
shall be subject to the further provisions of Section 4.5.
Section 4.3 Subrogation of Debentures. Subject to the payment in full
of all Senior Indebtedness, the rights of the holders of the Debentures shall be
subrogated to the extent of the payments or distributions made to the holders of
such Senior Indebtedness pursuant to the provisions of this Article IV (equally
and ratably with the holders of all indebtedness of the Company which by its
express terms is subordinated to other indebtedness of the Company to
substantially the same extent as the Debentures are subordinated and is entitled
to like rights of subrogation) to the rights of the holders of Senior
Indebtedness to receive payments or distributions of cash, property or
securities of the Company applicable to the Senior Indebtedness until the
principal of (and premium, if any) and interest (including Additional Interest,
if any) on the Debentures shall be paid in full; and, for the purposes of such
subrogation, no payments or distributions to the holders of the Senior
Indebtedness of any cash, property or securities to which the holders of the
Debentures or the Trustee would be entitled except for the provisions of this
Article IV, and no payment over pursuant to the provisions of this Article IV,
to or for the benefit of the holders of Senior Indebtedness by holders of the
Debentures or the Trustee, shall, as between the Company, its creditors other
than holders of Senior Indebtedness, and the holders of the Debentures, be
deemed to be a payment by the Company to or on account of the Senior
Indebtedness; and no payments or distributions of cash, property or securities
to or for the benefit of the holders of the Debentures pursuant to the
-28-
<PAGE> 37
subrogation provisions of this Article IV, which would otherwise have been paid
to the holders of Senior Indebtedness shall be deemed to be a payment by the
Company to or for the account of the Debentures. It is understood that the
provisions of this Article IV are and are intended solely for the purposes of
defining the relative rights of the holders of the Debentures, on the one hand,
and the holders of the Senior Indebtedness, on the other hand.
Nothing contained in this Article IV or elsewhere in this Indenture or
in the Debentures is intended to or shall impair, as among the Company, its
creditors other than the holders of Senior Indebtedness, and the holders of the
Debentures, the obligation of the Company, which is absolute and unconditional,
to pay to the holders of the Debentures the principal of (and premium, if any)
and interest (including Additional Interest, if any) on the Debentures as and
when the same shall become due and payable in accordance with their terms, or is
intended to or shall affect the relative rights of the holders of the Debentures
and creditors of the Company other than the holders of the Senior Indebtedness,
nor shall anything herein or therein prevent the Trustee or the holder of any
Debenture from exercising all remedies otherwise permitted by applicable law
upon default under this Indenture, subject to the rights, if any, under this
Article IV of the holders of Senior Indebtedness in respect of cash, property or
securities of the Company received upon the exercise of any such remedy.
Upon any payment or distribution of assets of the Company referred to
in this Article IV, the Trustee, subject to the provisions of Section 8.1, and
the holders of the Debentures shall be entitled to rely upon any order or decree
made by any court of competent jurisdiction in which such bankruptcy,
dissolution, winding-up, liquidation or reorganization proceedings are pending,
or a certificate of the receiver, trustee in bankruptcy, liquidating trustee,
agent or other person making such payment or distribution, delivered to the
Trustee or to the holders of the Debentures, for the purpose of ascertaining the
persons entitled to participate in such distribution, the holders of the Senior
Indebtedness and other indebtedness of the Company, the amount thereof or
payable thereon, the amount or amounts paid or distributed thereon and all other
facts pertinent thereto or to this Article IV.
Section 4.4 Authorization by Debentureholders. Each holder of a
Debenture by his acceptance thereof authorizes and directs the Trustee on his
behalf to take such action as may be necessary or appropriate to effectuate the
subordination provided in this Article IV and appoints the Trustee his
attorney-in-fact for any and all such purposes.
Section 4.5 Notice to Trustee. The Company shall give prompt written
notice in the form of an Officers' Certificate to a Responsible Officer of the
Trustee and to any paying agent of any fact known to the Company which would
prohibit the making of any payment of monies to or by the Trustee or any paying
agent in respect of the Debentures pursuant to the provisions of this Article
IV. Notwithstanding the provisions of this Article IV or any other provision of
this Indenture, the Trustee shall not be charged with knowledge of the existence
of any Senior Indebtedness or of any default or event of default with respect to
any Senior Indebtedness or of any other facts which would prohibit the making of
any payment of monies to or by the Trustee in respect of the Debentures pursuant
to the provisions of this Article IV, unless and until a
-29-
<PAGE> 38
Responsible Officer of the Trustee shall have received written notice thereof at
the Corporate Trust Office from the Company (in the form of an Officers'
Certificate) or a holder or holders or Representative of Senior Indebtedness who
shall have been certified by the Company or otherwise established to the
reasonable satisfaction of the Trustee to be such holder or Representative; and
before the receipt of any such written notice, the Trustee, subject to the
provisions of Section 8.1, shall be entitled in all respects to assume that no
such facts exist; provided that if on a date at least two (2) Business Days
prior to the date upon which by the terms hereof any such monies may become
payable for any purpose (including, without limitation, the payment of the
principal of, or premium, if any, or interest on any Debenture), the Trustee
shall not have received with respect to such monies the notice provided for in
this Section 4.5, then, anything herein contained to the contrary
notwithstanding, the Trustee shall have full power and authority to receive such
monies and to apply the same to the purpose for which they were received, and
shall not be affected by any notice to the contrary which may be received by it
on or after such prior date.
Notwithstanding anything to the contrary hereinbefore set forth,
nothing shall prevent (a) any payment by the Company or the Trustee to the
Debentureholders of amounts in connection with a redemption of Debentures if (i)
notice of such redemption has been given to the holders of Debentures pursuant
to Article III prior to the receipt by the Trustee of written notice as
aforesaid, and (ii) such notice of redemption is given not earlier than sixty
(60) days before the redemption date, or (b) any payment by the Trustee to the
Debentureholders of monies deposited with it pursuant to Section 13.1.
The Trustee, subject to the provisions of Section 8.1, shall be
entitled to rely on the delivery to it of a written notice by a person
representing himself to be a holder of Senior Indebtedness (or a Representative
on behalf of such holder) to establish that such notice has been given by a
holder of Senior Indebtedness or a Representative on behalf of any such holder
or holders. In the event that the Trustee determines in good faith that further
evidence is required with respect to the right of any person as a holder of
Senior Indebtedness to participate in any payment or distribution pursuant to
this Article IV, the Trustee may request such person to furnish evidence to the
reasonable satisfaction of the Trustee as to the amount of Senior Indebtedness
held by such person, the extent to which such person is entitled to participate
in such payment or distribution and any other facts pertinent to the rights of
such person under this Article IV, and if such evidence is not furnished the
Trustee may defer any payment to such person pending judicial determination as
to the right of such person to receive such payment.
Section 4.6 Trustee's Relation to Senior Indebtedness. The Trustee and
any agent of the Company or the Trustee in its individual capacity shall be
entitled to all the rights set forth in this Article IV in respect of any Senior
Indebtedness at any time held by it, to the same extent as any other holder of
Senior Indebtedness, and nothing in Section 8.13 or elsewhere in this Indenture
shall deprive the Trustee or any such agent of any of its rights as such holder.
Nothing in this Article IV shall apply to claims of, or payments to, the Trustee
under or pursuant to Section 8.6.
-30-
<PAGE> 39
With respect to the holders of Senior Indebtedness, the Trustee
undertakes to perform or to observe only such of its covenants and obligations
as are specifically set forth in this Article IV, and no implied covenants or
obligations with respect to the holders of Senior Indebtedness shall be read
into this Indenture against the Trustee. The Trustee shall not be deemed to owe
any fiduciary duty to the holders of Senior Indebtedness and, subject to the
provisions of Sections 4.2, 4.5 and 8.1, the Trustee shall not be liable to any
holder of Senior Indebtedness if it shall pay over or deliver to holders of
Debentures, the Company or any other person money or assets to which any holder
of Senior Indebtedness shall be entitled by virtue of this Article IV or
otherwise.
Section 4.7 No Impairment of Subordination. No right of any present or
future holder of any Senior Indebtedness to enforce subordination as herein
provided shall at any time in any way be prejudiced or impaired by any act or
failure to act on the part of the Company or by any act or failure to act, in
good faith, by any such holder, or by any noncompliance by the Company with the
terms, provisions and covenants of this Indenture, regardless of any knowledge
thereof which any such holder may have or otherwise be charged with.
Section 4.8 Certain Conversions Deemed Payment. For the purposes of
this Article only, (1) the issuance and delivery of junior securities upon
conversion of Debentures in accordance with Article XV shall not be deemed to
constitute a payment or distribution on account of the principal of (or premium,
if any) or interest on Debentures or on account of the purchase or other
acquisition of Debentures, and (2) the payment, issuance or delivery of cash
(except in satisfaction of fractional shares pursuant to Section 15.3), property
or securities (other than junior securities) upon conversion of a Debenture
shall be deemed to constitute payment on account of the principal of such
Debenture. For the purposes of this Section, the term "junior securities" means
(a) shares of any stock of any class of the Company and (b) securities of the
Company which are subordinated in right of payment to all Senior Indebtedness
which may be outstanding at the time of issuance or delivery of such securities
to substantially the same extent as, or to a greater extent than, the Debentures
are so subordinated as provided in this Article. Nothing contained in this
Article or elsewhere in this Indenture or in the Debentures is intended to or
shall impair, as among the Company, its creditors other than holders of Senior
Indebtedness and the holders of the Debentures, the right, which is absolute and
unconditional, of the holder of any Debenture to convert such Debenture in
accordance with Article XV.
Section 4.9 Article Applicable to Paying Agents. If at any time any
paying agent other than the Trustee shall have been appointed by the Company and
be then acting hereunder, the term "Trustee" as used in this Article shall
(unless the context otherwise requires) be construed as extending to and
including such paying agent within its meaning as fully for all intents and
purposes as if such paying agent were named in this Article in addition to or in
place of the Trustee; provided, however, that the first paragraph of Section 4.5
shall not apply to the Company or any Affiliate of the Company if it or such
Affiliate acts as paying agent.
-31-
<PAGE> 40
Section 4.10 Senior Indebtedness Entitled to Rely. The holders of
Senior Indebtedness (including, without limitation, Designated Senior
Indebtedness) shall have the right to rely upon this Article IV, and no
amendment or modification of the provisions contained herein shall diminish the
rights of such holders unless such holders shall have agreed in writing thereto.
ARTICLE V
PARTICULAR COVENANTS OF THE COMPANY
Section 5.1 Payment of Principal, Premium and Interest. The
Company covenants and agrees that it will duly and punctually pay or cause to be
paid the principal of and premium, if any, and interest (including Additional
Interest, if any) on each of the Debentures at the places, at the respective
times and in the manner provided herein and in the Debentures.
Section 5.2 Maintenance of Office or Agency. The Company will
maintain in the Borough of Manhattan, The City of New York, an office or agency
where the Debentures may be surrendered for registration of transfer or exchange
or for presentation for payment or for conversion or redemption and where
notices and demands to or upon the Company in respect of the Debentures and this
Indenture may be served. The Company will give prompt written notice to the
Trustee of the location, and any change in the location, of such office or
agency not designated or appointed by the Trustee. If at any time the Company
shall fail to maintain any such required office or agency or shall fail to
furnish the Trustee with the address thereof, such presentations, surrenders,
notices and demands may be made or served at the Corporate Trust Office, or the
office or agency of the Trustee or an Affiliate of the Trustee, in the Borough
of Manhattan, The City of New York.
The Company may also from time to time designate one or more other
offices or agencies where the Debentures may be presented or surrendered for any
or all such purposes and may from time to time rescind such designations;
provided that no such designation or rescission shall in any manner relieve the
Company of its obligation to maintain an office or agency in the Borough of
Manhattan, The City of New York, for such purposes. The Company will give prompt
written notice to the Trustee of any such designation or rescission and of any
change in the location of any such other office or agency.
The Company hereby initially designates the Trustee as paying agent,
Debenture registrar, Custodian and conversion agent. The Corporate Trust Office
and the office or agency of the Trustee in the Borough of Manhattan, The City of
New York (which shall initially be State Street Bank and Trust Company, N.A., an
Affiliate of the Trustee, located at 61 Broadway, 15th floor, New York, New York
10006) shall be considered as one such office or agency of the Company for each
of the aforesaid purposes.
-32-
<PAGE> 41
So long as the Trustee is the Debenture registrar, the Trustee agrees
to mail, or cause to be mailed, the notices set forth in Section 8.10(a) and the
third paragraph of Section 8.11.
Section 5.3 Appointments to Fill Vacancies in Trustee's Office.
The Company, whenever necessary to avoid or fill a vacancy in the office of
Trustee, will appoint, in the manner provided in Section 8.10, a Trustee, so
that there shall at all times be a Trustee hereunder.
Section 5.4 Provisions as to Paying Agent.
(a) If the Company shall appoint a paying agent other
than the Trustee, the Company will cause such paying agent to execute and
deliver to the Trustee an instrument in which such agent shall agree with the
Trustee, subject to the provisions of this Section 5.4:
(1) that it will hold all sums held by it as such
agent for the payment of the principal of and premium, if any, or interest on
the Debentures (whether such sums have been paid to it by the Company or by any
other obligor on the Debentures) in trust for the benefit of the holders of the
Debentures;
(2) that it will give the Trustee notice of any
failure by the Company (or by any other obligor on the Debentures) to make any
payment of the principal of and premium, if any, or interest on the Debentures
when the same shall be due and payable; and
(3) that at any time during the continuance of an
Event of Default, upon request of the Trustee, it will forthwith pay to the
Trustee all sums so held in trust.
The Company shall, on or before each due date of the
principal of, premium, if any, or interest on the Debentures, deposit with the
paying agent a sum sufficient to pay such principal, premium, if any, or
interest, and (unless such paying agent is the Trustee) the Company will
promptly notify the Trustee of any failure to take such action, provided that if
such deposit is made on the due date, such deposit must be received by the
paying agent by 10:00 a.m., New York City time, on such date.
(b) If the Company shall act as its own paying agent, it
will, on or before each due date of the principal of, premium, if any, or
interest on the Debentures, set aside, segregate and hold in trust for the
benefit of the holders of the Debentures a sum sufficient to pay such principal,
premium, if any, or interest so becoming due and will notify the Trustee of any
failure to take such action and of any failure by the Company (or any other
obligor under the Debentures) to make any payment of the principal of, premium,
if any, or interest on the Debentures when the same shall become due and
payable.
(c) Anything in this Section 5.4 to the contrary
notwithstanding, the Company may, at any time, for the purpose of obtaining a
satisfaction and discharge of this Indenture, or for any other reason, pay or
cause to be paid to the Trustee all sums held in trust
-33-
<PAGE> 42
by the Company or any paying agent hereunder as required by this Section 5.4,
such sums to be held by the Trustee upon the trusts herein contained and upon
such payment by the Company or any paying agent to the Trustee, the Company or
such paying agent shall be released from all further liability with respect to
such sums.
(d) Anything in this Section 5.4 to the contrary
notwithstanding, the agreement to hold sums in trust as provided in this Section
5.4 is subject to Sections 13.3 and 13.4.
Section 5.5 Existence. Subject to Article XII, the Company will
do or cause to be done all things necessary to preserve and keep in full force
and effect its existence.
Section 5.6 [RESERVED]
Section 5.7 [RESERVED]
Section 5.8 Stay, Extension and Usury Laws. The Company covenants
(to the extent that it may lawfully do so) that it shall not at any time insist
upon, plead, or in any manner whatsoever claim or take the benefit or advantage
of, any stay, extension or usury law or other law which would prohibit or
forgive the Company from paying all or any portion of the principal of, premium,
if any, or interest on the Debentures as contemplated herein, wherever enacted,
now or at any time hereafter in force, or which may affect the covenants or the
performance of this Indenture; and the Company (to the extent it may lawfully do
so) hereby expressly waives all benefit or advantage of any such law, and
covenants that it will not, by resort to any such law, hinder, delay or impede
the execution of any power herein granted to the Trustee, but will suffer and
permit the execution of every such power as though no such law has been enacted.
Section 5.9 Compliance Certificate. The Company shall deliver to
the Trustee, within 120 days after the end of each fiscal year of the Company
(beginning with the fiscal year in which the Exchange Date falls), an Officers'
Certificate, stating whether or not to the best knowledge of the signers thereof
the Company is in default in the performance and observance of any of the terms,
provisions and conditions of this Indenture (without regard to any period of
grace or requirement of notice provided hereunder) and, if the Company shall be
in default, specifying all such defaults and the nature and status thereof of
which they may have knowledge.
The Company will deliver to the Trustee, forthwith upon becoming aware
of any default in the performance or observance of any covenant, agreement or
condition contained in this Indenture, or any Event of Default, an Officers'
Certificate specifying with particularity such default or Event of Default and
further stating what action the Company has taken, is taking or proposes to take
with respect thereto.
-34-
<PAGE> 43
Any notice required to be given under this Section 5.9 shall be
delivered to the Trustee at its Corporate Trust Office.
Section 5.10 Further Instruments and Acts. Upon request of the
Trustee, the Company will execute and deliver such further instruments and do
such further acts as may be reasonably necessary or proper to carry out more
effectively the purposes of this Indenture.
Section 5.11 Rule 144A Information Requirement. Within the period
prior to the expiration of the holding period applicable to sales of Debentures
or Common Stock issued upon conversion thereof under Rule 144(k) under the
Securities Act (or any successor provision), the Company covenants and agrees
that it shall, during any period in which it is not subject to Section 13 or
15(d) under the Exchange Act, make available to any holder or beneficial holder
of Debentures or any Common Stock issued upon conversion thereof, in each case
which continue to be Restricted Securities, in connection with any sale thereof
and any prospective purchaser of Debentures or such Common Stock from such
holder or beneficial holder, the information required pursuant to Rule
144A(d)(4) under the Securities Act upon the request of any holder or beneficial
holder of the Debentures or such Common Stock and it will take such further
action as any holder or beneficial holder of such Debentures or such Common
Stock may reasonably request, all to the extent required from time to time to
enable such holder or beneficial holder to sell its Debentures or Common Stock
without registration under the Securities Act within the limitation of the
exemption provided by Rule 144A, as such rule may be amended from time to time.
Upon the request of any holder or any beneficial holder of the Debentures or
such Common Stock, the Company will deliver to such holder a written statement
as to whether it has complied with such requirements.
ARTICLE VI
DEBENTUREHOLDERS' LISTS AND REPORTS BY THE COMPANY
AND THE TRUSTEE
Section 6.1 Debentureholders' Lists. The Company covenants and
agrees that it will furnish or cause to be furnished to the Trustee,
semi-annually, not more than fifteen (15) days after each February 1 and August
1 in each year beginning with the immediately succeeding February 1 or August 1
after the Exchange Date, and at such other times as the Trustee may request in
writing, within thirty (30) days after receipt by the Company of any such
request (or such lesser time as the Trustee may reasonably request in order to
enable it to timely provide any notice to be provided by it hereunder), a list
in such form as the Trustee may reasonably require of the names and addresses of
the holders of Debentures as of a date not more than fifteen (15) days (or such
other date as the Trustee may reasonably request in order to so provide any such
notices) prior to the time such information is furnished, except that no such
list need be furnished so long as the Trustee is acting as Debenture registrar.
-35-
<PAGE> 44
Section 6.2 Preservation and Disclosure of Lists.
(a) The Trustee shall preserve, in as current a form as
is reasonably practicable, all information as to the names and addresses of the
holders of Debentures contained in the most recent list furnished to it as
provided in Section 6.1 or maintained by the Trustee in its capacity as
Debenture registrar, if so acting. The Trustee may destroy any list furnished to
it as provided in Section 6.1 upon receipt of a new list so furnished.
(b) The rights of Debentureholders to communicate with
other holders of Debentures with respect to their rights under this Indenture or
under the Debentures and the corresponding rights and duties of the Trustee,
shall be as provided by the Trust Indenture Act.
(c) Every Debentureholder, by receiving and holding the
same, agrees with the Company and the Trustee that neither the Company nor the
Trustee nor any agent of either of them shall be held accountable by reason of
any disclosure of information as to names and addresses of holders of Debentures
made pursuant to the Trust Indenture Act.
Section 6.3 Reports by Trustee.
(a) Within 60 days after May 1 of each year commencing
with the year in which the Exchange Date falls, the Trustee shall transmit to
holders of Debentures such reports dated as of May 1 of the year in which such
reports are made concerning the Trustee and its actions under this Indenture as
may be required pursuant to Section 313 of the Trust Indenture Act at the times
and in the manner provided pursuant thereto.
(b) A copy of such report shall, at the time of such
transmission to holders of Debentures, be filed by the Trustee with each stock
exchange or automated quotation system upon which the Debentures are listed,
with the Commission and with the Company. The Company will notify the Trustee
when the Debentures are listed on any stock exchange or automated quotation
system and when any such listing is discontinued.
Section 6.4 Reports by Company.
(a) The Company (and any obligor upon the Debentures)
shall file with the Trustee and the Commission, and transmit to holders of
Debentures, such information, documents and other reports and such summaries
thereof, as may be required pursuant to the Trust Indenture Act at the times and
in the manner provided pursuant to such Act; provided that any such information,
documents or reports required to be filed with the Commission pursuant to
Section 13 or 15(d) of the Exchange Act shall be filed with the Trustee within
15 days after the same is so required to be filed with the Commission.
(b) The Company will deliver to the Trustee (a) as soon
as available and in any event within ninety (90) days after the end of each
fiscal year of the Company (i) a consolidated balance sheet of the Company and
its subsidiaries as of the end of such fiscal year
-36-
<PAGE> 45
and the related consolidated statements of operations, stockholders' equity and
cash flows for such fiscal year, all reported on by an independent public
accountant of nationally recognized standing and (ii) a report containing a
management's discussion and analysis of the financial condition and results of
operations and a description of the business and properties of the Company and
(b) as soon as available and in any event within forty-five (45) days after the
end of each of the first three quarters of each fiscal year of the Company (i)
an unaudited consolidated management's discussion and analysis of the financial
condition and results of operations of the Company for such quarter; provided
that the foregoing statements and reports shall not be required for any fiscal
year or quarter, as the case may be, with respect to which the Company files or
expects to file with the Trustee an annual report or quarterly report, as the
case may be, pursuant to Section 6.4(a). The Trustee shall have no liability as
regards the substance of the information provided by the Company or its agents
pursuant to this Section 6.4.
ARTICLE VII
DEFAULTS AND REMEDIES
Section 7.1 Events of Default. In case one or more of the
following Events of Default (whatever the reason for such Event of Default and
whether it shall be voluntary or involuntary or be effected by operation of law
or pursuant to any judgment, decree or order of any court or any order, rule or
regulation of any administrative or governmental body) shall have occurred and
be continuing:
(a) default in the payment of the principal of and
premium, if any, on any of the Debentures as and when the same shall become due
and payable either at maturity or in connection with any redemption, by
declaration or otherwise, whether or not such payment is prohibited by the
provisions of Article IV; or
(b) default in the payment of any installment of interest
(including Additional Interest, if any), upon any of the Debentures as and when
the same shall become due and payable, and continuance of such default for a
period of thirty (30) days, whether or not such payment is prohibited by the
provisions of Article IV; or
(c) failure on the part of the Company duly to observe or
perform any other of the covenants or agreements on the part of the Company in
the Debentures or in this Indenture (other than a covenant or agreement a
default in whose performance or whose breach is elsewhere in this Section
specifically dealt with) continued for a period of forty-five (45) days after
the date on which written notice of such failure, requiring the Company to
remedy the same, shall have been given to the Company by the Trustee, or to the
Company and a Responsible Officer of the Trustee by the holders of at least 25%
in aggregate principal amount of the outstanding Debentures at the time
outstanding determined in accordance with Section 9.4; or
-37-
<PAGE> 46
(d) failure by the Company to make any payment at
maturity, including any applicable grace period, in respect of Indebtedness, in
an amount in excess of $5,000,000 or the equivalent thereof in any other
currency or composite currency and such failure shall have continued for thirty
(30) days after written notice thereof shall have been given to the Company by
the Trustee or to the Company and a Responsible Officer of the Trustee or to the
Company and a Responsible Officer of the Trustee by the holders of at least 25%
in aggregate principal amount of the outstanding Debentures at the time
outstanding determined in accordance with Section 9.4; or
(e) a default by the Company with respect to any
Indebtedness which default results in the acceleration of Indebtedness in an
amount in excess of $5,000,000 or the equivalent thereof in any other currency
or composite currency without such Indebtedness having been discharged or such
acceleration having been cured, waived, rescinded or annulled for a period of
thirty (30) days after written notice thereof shall have been given to the
Company by the Trustee or to the Company and a Responsible Officer of the
Trustee by the holders of at least 25% in aggregate principal amount of the
outstanding Debentures at the time outstanding determined in accordance with
Section 9.4; or
(f) the Company shall commence a voluntary case or other
proceeding seeking liquidation, reorganization or other relief with respect to
itself or its debts under any bankruptcy, insolvency or other similar law now or
hereafter in effect or seeking the appointment of a trustee, receiver,
liquidator, custodian or other similar official of it or any substantial part of
its property, or shall consent to any such relief or to the appointment of or
taking possession by any such official in an involuntary case or other
proceeding commenced against it, or shall make a general assignment for the
benefit of creditors, or shall fail generally to pay its debts as they become
due; or
(g) an involuntary case or other proceeding shall be
commenced against the Company seeking liquidation, reorganization or other
relief with respect to it or its debts under any bankruptcy, insolvency or other
similar law now or hereafter in effect or seeking the appointment of a trustee,
receiver, liquidator, custodian or other similar official of it or any
substantial part of its property, and such involuntary case or other proceeding
shall remain undismissed and unstayed for a period of ninety (90) consecutive
days;
then, and in each and every such case (other than an Event of Default specified
in Section 7.1(f) or (g)), unless the principal of all of the Debentures shall
have already become due and payable, either the Trustee or the holders of not
less than 25% in aggregate principal amount of the Debentures then outstanding
hereunder determined in accordance with Section 9.4, by notice in writing to the
Company (and to the Trustee if given by Debentureholders), may declare the
principal of and premium, if any, on all the Debentures and the interest accrued
thereon (including Additional Interest, if any) to be due and payable
immediately, and upon any such declaration the same shall become and shall be
immediately due and payable, anything in this Indenture or in the Debentures
contained to the contrary
-38-
<PAGE> 47
notwithstanding. If an Event of Default specified in Section 7.1(f) or (g)
occurs and is continuing, the principal of and premium, if any, on all the
Debentures and the interest accrued thereon shall be immediately due and
payable. This provision, however, is subject to the conditions that if, at any
time after the principal of the Debentures shall have been so declared due and
payable, and before any judgment or decree for the payment of the monies due
shall have been obtained or entered as hereinafter provided, the Company shall
pay or shall deposit with the Trustee a sum sufficient to pay all matured
installments of interest (including Additional Interest, if any) upon all
Debentures and the principal of and premium, if any, on any and all Debentures
which shall have become due otherwise than by acceleration (with interest on
overdue installments of interest (including Additional Interest, if any) (to the
extent that payment of such interest is enforceable under applicable law) and on
such principal and premium, if any, at the rate borne by the Debentures, to the
date of such payment or deposit) and amounts due to the Trustee pursuant to
Section 8.6, and if any and all defaults under this Indenture, other than the
nonpayment of principal of and premium, if any, and accrued interest (including
Additional Interest, if any) on Debentures which shall have become due by
acceleration, shall have been cured or waived pursuant to Section 7.7, then and
in every such case the holders of a majority in aggregate principal amount of
the Debentures then outstanding, by written notice to the Company and to the
Trustee, may waive all defaults or Events of Default and rescind and annul such
declaration and its consequences; but no such waiver or rescission and annulment
shall extend to or shall affect any subsequent default or Event of Default, or
shall impair any right consequent thereon. The Company shall notify the
Responsible Officer of the Trustee, promptly upon becoming aware thereof, of any
Event of Default.
In case the Trustee shall have proceeded to enforce any right under
this Indenture and such proceedings shall have been discontinued or abandoned
because of such waiver or rescission and annulment or for any other reason or
shall have been determined adversely to the Trustee, then and in every such case
the Company, the holders of Debentures, and the Trustee shall be restored
respectively to their several positions and rights hereunder, and all rights,
remedies and powers of the Company, the holders of Debentures, and the Trustee
shall continue as though no such proceeding had been instituted.
Section 7.2 Payments of Debentures on Default; Suit Therefor. The
Company covenants that (a) in case default shall be made in the payment by the
Company of any installment of interest (including Additional Interest, if any)
upon any of the Debentures as and when the same shall become due and payable,
and such default shall have continued for a period of thirty (30) days, or (b)
in case default shall be made in the payment of the principal of or premium, if
any, on any of the Debentures as and when the same shall have become due and
payable, whether at maturity of the Debentures or in connection with any
redemption, by declaration under this Indenture or otherwise, then, upon demand
of the Trustee, the Company will pay to the Trustee, for the benefit of the
holders of the Debentures, the whole amount that then shall have become due and
payable on all such Debentures for principal and premium, if any, or interest
(including Additional Interest, if any), or both, as the case may be, with
interest upon the overdue principal and premium, if any, and (to the extent that
payment of such
-39-
<PAGE> 48
interest is enforceable under applicable law) upon the overdue installments of
interest (including Additional Interest, if any) at the rate borne by the
Debentures; and, in addition thereto, such further amount as shall be sufficient
to cover the costs and expenses of collection, including reasonable compensation
to the Trustee, its agents, attorneys and counsel, and any expenses or
liabilities incurred by the Trustee hereunder other than through its negligence
or bad faith. Until such demand by the Trustee, the Company may pay the
principal of and premium, if any, and interest (including Additional Interest,
if any) on the Debentures to the registered holders, whether or not the
Debentures are overdue.
In case the Company shall fail forthwith to pay such amounts upon such
demand, the Trustee, in its own name and as trustee of an express trust, shall
be entitled and empowered to institute any actions or proceedings at law or in
equity for the collection of the sums so due and unpaid, and may prosecute any
such action or proceeding to judgment or final decree, and may enforce any such
judgment or final decree against the Company or any other obligor on the
Debentures and collect in the manner provided by law out of the property of the
Company or any other obligor on the Debentures wherever situated the monies
adjudged or decreed to be payable.
In the case there shall be pending proceedings for the bankruptcy or
for the reorganization of the Company or any other obligor on the Debentures
under Title 11 of the United States Code, or any other applicable law, or in
case a receiver, assignee or trustee in bankruptcy or reorganization,
liquidator, sequestrator or similar official shall have been appointed for or
taken possession of the Company or such other obligor, the property of the
Company or such other obligor, or in the case of any other judicial proceedings
relative to the Company or such other obligor upon the Debentures, or to the
creditors or property of the Company or such other obligor, the Trustee,
irrespective of whether the principal of the Debentures shall then be due and
payable as therein expressed or by declaration or otherwise and irrespective of
whether the Trustee shall have made any demand pursuant to the provisions of
this Section 7.2, shall be entitled and empowered, by intervention in such
proceedings or otherwise, to file and prove a claim or claims for the whole
amount of principal, premium, if any, and interest (including Additional
Interest, if any) owing and unpaid in respect of the Debentures, and, in case of
any judicial proceedings, to file such proofs of claim and other papers or
documents as may be necessary or advisable in order to have the claims of the
Trustee and of the Debentureholders allowed in such judicial proceedings
relative to the Company or any other obligor on the Debentures, its or their
creditors, or its or their property, and to collect and receive any monies or
other property payable or deliverable on any such claims, and to distribute the
same after the deduction of any amounts due the Trustee under Section 8.6; and
any receiver, assignee or trustee in bankruptcy or reorganization, liquidator,
custodian or similar official is hereby authorized by each of the
Debentureholders to make such payments to the Trustee, and, in the event that
the Trustee shall consent to the making of such payments directly to the
Debentureholders, to pay to the Trustee any amount due it for reasonable
compensation, expenses, advances and disbursements, including counsel fees
incurred by it up to the date of such distribution. To the extent that such
payment of reasonable compensation, expenses, advances and disbursements out of
the estate in any such proceedings
-40-
<PAGE> 49
shall be denied for any reason, payment of the same shall be secured by a lien
on, and shall be paid out of, any and all distributions, dividends, monies,
securities and other property which the holders of the Debentures may be
entitled to receive in such proceedings, whether in liquidation or under any
plan of reorganization or arrangement or otherwise.
Nothing herein contained shall be deemed to authorize the Trustee to
authorize or consent to or adopt on behalf of any Debentureholder any plan of
reorganization or arrangement affecting the Debentures or the rights of any
Debentureholder, or to authorize the Trustee to vote in respect of the claim of
any Debentureholder in any such proceeding; provided, however, that the Trustee
may, on behalf of the Debentureholders, vote for the election of a trustee in
bankruptcy or similar official and may be a member of the creditor's committee
established with respect to such bankruptcy.
All rights of action and of asserting claims under this Indenture, or
under any of the Debentures, may be enforced by the Trustee without the
possession of any of the Debentures, or the production thereof on any trial or
other proceeding relative thereto, and any such suit or proceeding instituted by
the Trustee shall be brought in its own name as trustee of an express trust, and
any recovery of judgment shall, after provision for the payment of the
reasonable compensation, expenses, disbursements and advances of the Trustee,
its agents and counsel, be for the ratable benefit of the holders of the
Debentures.
Section 7.3 Application of Monies Collected by Trustee. Any
monies collected by the Trustee pursuant to this Article VII shall be applied in
the order following, at the date or dates fixed by the Trustee for the
distribution of such monies, upon presentation of the several Debentures, and
stamping thereon the payment, if only partially paid, and upon surrender
thereof, if fully paid:
First: To the payment of all amounts due the Trustee under
Section 8.6;
Second: Subject to the provisions of Article IV, in case the
principal of the outstanding Debentures shall not have become due and
be unpaid, to the payment of interest on the Debentures in default in
the order of the maturity of the installments of such interest, with
interest (to the extent that such interest has been collected by the
Trustee) upon the overdue installments of interest at the rate borne by
the Debentures, such payments to be made ratably to the persons
entitled thereto;
Third: Subject to the provisions of Article IV, in case the
principal of the outstanding Debentures shall have become due, by
declaration or otherwise, and be unpaid, to the payment of the whole
amount then owing and unpaid upon the Debentures for principal and
premium, if any, and interest, with interest on the overdue principal
and premium, if any, and (to the extent that such interest has been
collected by the Trustee) upon overdue installments of interest at the
rate borne by the Debentures; and in case such monies shall be
insufficient to pay in full the whole amounts so due and unpaid upon
the Debentures, then to the payment of such principal and premium, if
-41-
<PAGE> 50
any, and interest without preference or priority of principal and
premium, if any, over interest, or of interest over principal and
premium, if any, or of any installment of interest over any other
installment of interest, or of any Debenture over any other Debenture,
ratably to the aggregate of such principal and premium, if any, and
accrued and unpaid interest; and
Fourth: Subject to the provisions of Article IV, to the
payment of the remainder, if any, to the Company or any other person
lawfully entitled thereto.
Section 7.4 Proceedings by Debentureholder. No holder of any
Debenture shall have any right by virtue of or by availing of any provision of
this Indenture to institute any suit, action or proceeding in equity or at law
upon or under or with respect to this Indenture, or for the appointment of a
receiver, trustee, liquidator, custodian or other similar official, or for any
other remedy hereunder, unless such holder previously shall have given to the
Trustee written notice of an Event of Default and of the continuance thereof, as
hereinbefore provided, and unless also the holders of not less than 25% in
aggregate principal amount of the Debentures then outstanding shall have made
written request upon the Trustee to institute such action, suit or proceeding in
its own name as Trustee hereunder and shall have offered to the Trustee such
reasonable indemnity as it may require against the costs, expenses and
liabilities to be incurred therein or thereby, and the Trustee for sixty (60)
days after its receipt of such notice, request and offer of indemnity, shall
have neglected or refused to institute any such action, suit or proceeding and
no direction inconsistent with such written request shall have been given to the
Trustee pursuant to Section 7.7; it being understood and intended that no one or
more holders of Debentures shall have any right in any manner whatever by virtue
of, or by availing of, any provision of this Indenture to affect, disturb or
prejudice the rights of any other holders of Debentures, or to obtain or seek to
obtain priority or preference over any other holders or to enforce any right
under this Indenture, except in the manner herein provided and for the equal and
ratable benefit of all the holders of Debentures.
Notwithstanding any other provision of this Indenture and any provision
of any Debenture, the right of any holder of any Debenture to receive payment of
the principal of and premium, if any, and interest on such Debenture, on or
after the respective due dates expressed in such Debenture, or to institute suit
for the enforcement of any such payment on or after such respective dates
against the Company shall not be impaired or affected without the consent of
such holder.
Anything in this Indenture or the Debentures to the contrary
notwithstanding, the holder of any Debenture, without the consent of either the
Trustee or the holder of any other Debenture, in his own behalf and for his own
benefit, may enforce, and may institute and maintain any proceeding suitable to
enforce, his rights of conversion as provided herein.
Section 7.5 Proceedings by Trustee. In case of an Event of
Default, the Trustee may in its discretion proceed to protect and enforce the
rights vested in it by this Indenture by such appropriate judicial proceedings
as the Trustee shall deem most effectual to protect and enforce
-42-
<PAGE> 51
any of such rights, either by suit in equity or by action at law or by
proceeding in bankruptcy or otherwise, whether for the specific enforcement of
any covenant or agreement contained in this Indenture or in aid of the exercise
of any power granted in this Indenture, or to enforce any other legal or
equitable right vested in the Trustee by this Indenture or by law.
Section 7.6 Remedies Cumulative and Continuing. Except as
provided in Section 2.6, all powers and remedies given by this Article VII to
the Trustee or to the Debentureholders shall, to the extent permitted by law, be
deemed cumulative and not exclusive of any thereof or of any other powers and
remedies available to the Trustee or the holders of the Debentures, by judicial
proceedings or otherwise, to enforce the performance or observance of the
covenants and agreements contained in this Indenture, and no delay or omission
of the Trustee or of any holder of any of the Debentures to exercise any right
or power accruing upon any default or Event of Default occurring and continuing
as aforesaid shall impair any such right or power, or shall be construed to be a
waiver of any such default or any acquiescence therein; and, subject to the
provisions of Section 7.4, every power and remedy given by this Article VII or
by law to the Trustee or to the Debentureholders may be exercised from time to
time, and as often as shall be deemed expedient, by the Trustee or by the
Debentureholders.
Section 7.7 Direction of Proceedings and Waiver of Defaults by
Majority of Debentureholders. The holders of a majority in aggregate principal
amount of the Debentures at the time outstanding determined in accordance with
Section 9.4 shall have the right to direct the time, method, and place of
conducting any proceeding for any remedy available to the Trustee or exercising
any trust or power conferred on the Trustee; provided, however, that (a) such
direction shall not be in conflict with any rule of law or with this Indenture,
and (b) the Trustee may take any other action deemed proper by the Trustee which
is not inconsistent with such direction. The holders of a majority in aggregate
principal amount of the Debentures at the time outstanding determined in
accordance with Section 9.4 may on behalf of the holders of all of the
Debentures waive any past default or Event of Default hereunder and its
consequences except (i) a default in the payment of interest or premium, if any,
on, or the principal of, the Debentures, (ii) a failure by the Company to
convert any Debentures into Common Stock or (iii) a default in respect of a
covenant or provision hereof which under Article XI cannot be modified or
amended without the consent of the holders of all Debentures then outstanding
affected thereby. Upon any such waiver the Company, the Trustee and the holders
of the Debentures shall be restored to their former positions and rights
hereunder; but no such waiver shall extend to any subsequent or other default or
Event of Default or impair any right consequent thereon. Whenever any default or
Event of Default hereunder shall have been waived as permitted by this Section
7.7, said default or Event of Default shall for all purposes of the Debentures
and this Indenture be deemed to have been cured and to be not continuing; but no
such waiver shall extend to any subsequent or other default or Event of Default
or impair any right consequent thereon.
Section 7.8 Notice of Defaults. The Trustee shall, within ninety
(90) days after the occurrence of a default, mail to all Debentureholders, as
the names and addresses of such
-43-
<PAGE> 52
holders appear upon the Debenture register, notice of all defaults known to a
Responsible Officer, unless such defaults shall have been cured or waived before
the giving of such notice; and provided that, except in the case of default in
the payment of the principal of, or premium, if any, or interest on any of the
Debentures, the Trustee shall be protected in withholding such notice if and so
long as a trust committee of directors and/or Responsible Officers of the
Trustee in good faith determines that the withholding of such notice is in the
best interests of the Debentureholders.
Section 7.9 Undertaking to Pay Costs. All parties to this
Indenture agree, and each holder of any Debenture by his acceptance thereof
shall be deemed to have agreed, that any court may, in its discretion, require,
in any suit for the enforcement of any right or remedy under this Indenture, or
in any suit against the Trustee for any action taken or omitted by it as
Trustee, the filing by any party litigant in such suit of an undertaking to pay
the costs of such suit and that such court may in its discretion assess
reasonable costs, including reasonable attorneys' fees, against any party
litigant in such suit, having due regard to the merits and good faith of the
claims or defenses made by such party litigant; provided that the provisions of
this Section 7.9 shall not apply to any suit instituted by the Trustee, to any
suit instituted by any Debentureholder, or group of Debentureholders, holding in
the aggregate more than 10% in principal amount of the Debentures at the time
outstanding determined in accordance with Section 9.4, or to any suit instituted
by any Debentureholder for the enforcement of the payment of the principal of or
premium, if any, or interest on any Debenture (including, but not limited to,
the redemption price with respect to the Debentures being redeemed, as provided
in this Indenture) on or after the due date expressed in such Debenture or to
any suit for the enforcement of the right to convert any Debenture in accordance
with the provisions of Article XV.
Section 7.10 Delay or Omission Not Waiver. No delay or omission of
the Trustee or of any holder of any Debenture to exercise any right or remedy
accruing upon any Event of Default shall impair any such right or remedy or
constitute a waiver of any such Event of Default or any acquiescence therein.
Every right and remedy given by this Article or by law to the Trustee or to the
holders of Debentures may be exercised from time to time, and as often as may be
deemed expedient, by the Trustee or by the holders of Debentures, as the case
may be.
ARTICLE VIII
CONCERNING THE TRUSTEE
Section 8.1 Duties and Responsibilities of Trustee. The Trustee,
prior to the occurrence of an Event of Default and after the curing of all
Events of Default which may have occurred, undertakes to perform such duties and
only such duties as are specifically set forth in this Indenture. In case an
Event of Default has occurred (which has not been cured or waived) the Trustee
shall exercise such of the rights and powers vested in it by this Indenture, and
use
-44-
<PAGE> 53
the same degree of care and skill in their exercise, as a prudent person would
exercise or use under the circumstances in the conduct of such person's own
affairs.
No provision of this Indenture shall be construed to relieve the
Trustee from liability for its own negligent action, its own negligent failure
to act or its own willful misconduct, except that
(a) prior to the occurrence of an Event of Default and
after the curing or waiving of all Events of Default which may have occurred:
(1) the duties and obligations of the Trustee shall be
determined solely by the express provisions of this Indenture and the Trust
Indenture Act, and the Trustee shall not be liable except for the performance of
such duties and obligations as are specifically set forth in this Indenture and
no implied covenants or obligations shall be read into this Indenture and the
Trust Indenture Act against the Trustee; and
(2) in the absence of bad faith on the part of the
Trustee, the Trustee may conclusively rely, as to the truth of the statements
and the correctness of the opinions expressed therein, upon any certificates or
opinions furnished to the Trustee and conforming to the requirements of this
Indenture; but, in the case of any such certificates or opinions which by any
provisions hereof are specifically required to be furnished to the Trustee, the
Trustee shall be under a duty to examine the same to determine whether or not
they conform to the requirements of this Indenture;
(b) the Trustee shall not be liable for any error of
judgment made in good faith by a Responsible Officer or Officers of the Trustee,
unless it shall be provided that the Trustee was negligent in ascertaining the
pertinent facts;
(c) the Trustee shall not be liable to any Debentureholder
with respect to any action taken or omitted to be taken by it in good faith in
accordance with the direction of the holders of not less than a majority in
principal amount of the Debentures at the time outstanding determined as
provided in Section 9.4 relating to the time, method and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or
power conferred upon the Trustee, under this Indenture; and
(d) whether or not therein provided, every provision of
this Indenture relating to the conduct or affecting the liability of, or
affording protection to, the Trustee shall be subject to the provisions of this
Section.
None of the provisions contained in this Indenture shall
require the Trustee to expend or risk its own funds or otherwise incur personal
financial liability in the performance of any of its duties or in the exercise
of any of its rights or powers, if there is reasonable ground for believing that
the repayment of such funds or adequate indemnity against such risk or liability
is not reasonably assured to it.
-45-
<PAGE> 54
Section 8.2 Reliance on Documents, Opinions, Etc. Except as otherwise
provided in Section 8.1:
(a) the Trustee may rely and shall be protected in acting
upon any resolution, certificate, statement, instrument, opinion, report,
notice, request, consent, order, bond, Debenture, coupon or other paper or
document believed by it in good faith to be genuine and to have been signed or
presented by the proper party or parties;
(b) any request, direction, order or demand of the Company
mentioned herein shall be sufficiently evidenced by an Officers' Certificate
(unless other evidence in respect thereof be herein specifically prescribed);
and any resolution of the Board of Directors may be evidenced to the Trustee by
a copy thereof certified by the Secretary or an Assistant Secretary of the
Company;
(c) the Trustee may consult with counsel and any advice
or Opinion of Counsel shall be full and complete authorization and protection in
respect of any action taken or omitted by it hereunder in good faith and in
accordance with such advice or Opinion of Counsel;
(d) the Trustee shall be under no obligation to exercise
any of the rights or powers vested in it by this Indenture at the request, order
or direction of any of the Debentureholders pursuant to the provisions of this
Indenture, unless such Debentureholders shall have offered to the Trustee
reasonable security or indemnity against the costs, expenses and liabilities
which may be incurred therein or thereby;
(e) the Trustee shall not be bound to make any
investigation into the facts or matters stated in any resolution, certificate,
statement, instrument, opinion, report, notice, request, direction, consent,
order, bond, debenture or other paper or document, but the Trustee, in its
discretion, may make such further inquiry or investigation into such facts or
matters as it may see fit, and, if the Trustee shall determine to make such
further inquiry or investigation, it shall be entitled to examine the books,
records and premises of the Company, personally or by agent or attorney;
provided, however, that if the payment within a reasonable time to the Trustee
of the costs, expenses or liabilities likely to be incurred by it in the making
of such investigation is, in the opinion of the Trustee, not reasonably assured
to the Trustee by the security afforded to it by the terms of this Indenture,
the Trustee may require reasonable indemnity from the Debentureholders against
such expenses or liability as a condition to so proceeding; the reasonable
expenses of every such examination shall be paid by the Company or, if paid by
the Trustee or any predecessor Trustee, shall be repaid by the Company upon
demand; and
(f) the Trustee may execute any of the trusts or powers
hereunder or perform any duties hereunder either directly or by or through
agents or attorneys and the
-46-
<PAGE> 55
Trustee shall not be responsible for any misconduct or negligence on the part of
any agent or attorney appointed by it with due care hereunder.
In no event shall the Trustee be liable for any consequential loss or damage of
any kind whatsoever (including but not limited to lost profits), even if the
Trustee has been advised of the likelihood of such loss or damage and regardless
of the form of action.
Section 8.3 No Responsibility for Recitals, Etc. The recitals
contained herein and in the Debentures (except in the Trustee's certificate of
authentication) shall be taken as the statements of the Company, and the Trustee
assumes no responsibility for the correctness of the same. The Trustee makes no
representations as to the validity or sufficiency of this Indenture or of the
Debentures. The Trustee shall not be accountable for the use or application by
the Company of any Debentures or the proceeds of any Debentures authenticated
and delivered by the Trustee in conformity with the provisions of this
Indenture.
Section 8.4 Trustee, Paying Agents, Conversion Agents or Registrar May
Own Debentures. The Trustee, any paying agent, any conversion agent or Debenture
registrar, in its individual or any other capacity, may become the owner or
pledgee of Debentures with the same rights it would have if it were not Trustee,
paying agent, conversion agent or Debenture registrar.
Section 8.5 Monies to Be Held in Trust. Subject to the provisions
of Section 13.4, all monies received by the Trustee shall, until used or applied
as herein provided, be held in trust for the purposes for which they were
received. Money held by the Trustee in trust hereunder need not be segregated
from other funds except to the extent required by law. The Trustee shall be
under no liability for interest on any money received by it hereunder except as
may be agreed from time to time by the Company and the Trustee.
Section 8.6 Compensation and Expenses of Trustee. The Company
covenants and agrees to pay to the Trustee from time to time, and the Trustee
shall be entitled to, reasonable compensation for all services rendered by it
hereunder in any capacity (which shall not be limited by any provision of law in
regard to the compensation of a trustee of an express trust), and the Company
will pay or reimburse the Trustee upon its request for all reasonable expenses,
disbursements and advances reasonably incurred or made by the Trustee in
accordance with any of the provisions of this Indenture (including the
reasonable compensation and the expenses and disbursements of its counsel and of
all persons not regularly in its employ) except any such expense, disbursement
or advance as may arise from its negligence or willful misconduct. The Company
also covenants to indemnify the Trustee in any capacity under this Indenture and
its agents and any authenticating agent for, and to hold them harmless against,
any loss, liability or expense incurred without negligence or willful misconduct
on the part of the Trustee or such agent or authenticating agent, as the case
may be, and arising out of or in connection with the acceptance or
administration of this trust or in any other capacity hereunder, including the
costs and expenses of defending themselves against any claim of liability in the
premises. The obligations of the Company under this Section 8.6 to compensate or
indemnify the Trustee and to pay or reimburse the Trustee for expenses,
disbursements and
-47-
<PAGE> 56
advances shall be secured by a lien prior to that of the Debentures upon all
property and funds held or collected by the Trustee as such, except funds held
in trust herewith for the benefit of the holders of particular Debentures prior
to the date of the accrual of such unpaid compensation or indemnifiable claim.
The obligation of the Company under this Section shall survive the satisfaction
and discharge of this Indenture.
When the Trustee and its agents and any authenticating agent incur
expenses or render services after an Event of Default specified in Section
7.1(f) or (g) occurs, the expenses and the compensation for the services are
intended to constitute expenses of administration under any bankruptcy,
insolvency or similar laws.
Section 8.7 Officers' Certificate as Evidence. Except as
otherwise provided in Section 8.1 or Section 8.2, whenever in the administration
of the provisions of this Indenture the Trustee shall deem it necessary or
desirable that a matter be proved or established prior to taking or omitting any
action hereunder, such matter (unless other evidence in respect thereof be
herein specifically prescribed) may, in the absence of negligence, willful
misconduct, recklessness and bad faith on the part of the Trustee, be deemed to
be conclusively proved and established by an Officers' Certificate delivered to
the Trustee, and such Officers' Certificate, in the absence of negligence,
willful misconduct, recklessness and bad faith on the part of the Trustee, shall
be full warrant to the Trustee for any action taken or omitted by it under the
provisions of this Indenture upon the faith thereof.
Section 8.8 Conflicting Interests of Trustee.
(a) If the Trustee has or shall acquire a conflicting
interest within the meaning of the Trust Indenture Act, the Trustee shall either
eliminate such interest or resign, to the extent and in the manner provided by,
and subject to the provisions of, the Trust Indenture Act and this Indenture.
(b) In the event that the Trustee shall fail to comply
with Subsection (a) of this Section 8.8, the Trustee shall transmit notice of
such failure to the holders of Debentures to the extent and in the manner
provided by, and subject to, the provisions of the Trust Indenture Act.
Section 8.9 Eligibility of Trustee. There shall at all times be a
Trustee hereunder which shall be a person that is eligible pursuant to the Trust
Indenture Act to act as such and has a combined capital and surplus (together
with its corporate parent) of at least $50,000,000. If such person publishes
reports of condition at least annually, pursuant to law or to the requirements
of any supervising or examining authority, then for the purposes of this
Section, the combined capital and surplus of such person shall be deemed to be
its combined capital and surplus as set forth in its most recent report of
condition so published. If at any time the Trustee shall cease to be eligible in
accordance with the provisions of this Section, it shall resign immediately in
the manner and with the effect hereinafter specified in this Article.
<PAGE> 57
Section 8.10 Resignation or Removal of Trustee.
(a) The Trustee may at any time resign by giving written
notice of such resignation to the Company and by mailing notice thereof to the
holders of Debentures at their addresses as they shall appear on the Debenture
register. Upon receiving such notice of resignation, the Company shall promptly
appoint a successor trustee by written instrument, in duplicate, executed by
order of the Board of Directors, one copy of which instrument shall be delivered
to the resigning Trustee and one copy to the successor trustee. If no successor
trustee shall have been so appointed and have accepted appointment sixty (60)
days after the mailing of such notice of resignation to the Debentureholders,
the resigning Trustee may petition any court of competent jurisdiction for the
appointment of a successor trustee, or any Debentureholder who has been a bona
fide holder of a Debenture or Debentures for at least six months may, subject to
the provisions of Section 7.9, on behalf of himself and all others similarly
situated, petition any such court for the appointment of a successor trustee.
Such court may thereupon, after such notice, if any, as it may deem proper and
prescribe, appoint a successor trustee.
(b) In case at any time any of the following shall occur:
(1) the Trustee shall fail to comply with Section
8.8(a) after written request therefor by the Company or by any Debentureholder
who has been a bona fide holder of a Debenture or Debentures for at least six
months, or
(2) the Trustee shall cease to be eligible in
accordance with the provisions of Section 8.9 and shall fail to resign after
written request therefor by the Company or by any such Debentureholder, or
(3) the Trustee shall become incapable of acting, or
shall be adjudged bankrupt or insolvent, or a receiver of the Trustee or of its
property shall be appointed, or any public officer shall take charge or control
of the Trustee or of its property or affairs for the purpose of rehabilitation,
conservation or liquidation,
then, in any such case, the Company may remove the Trustee and appoint a
successor trustee by written instrument, in duplicate, executed by order of the
Board of Directors, one copy of which instrument shall be delivered to the
Trustee so removed and one copy to the successor trustee, or, subject to the
provisions of Section 7.9, any Debentureholder who has been a bona fide holder
of a Debenture or Debentures for at least six months may, on behalf of himself
and all others similarly situated, petition any court of competent jurisdiction
for the removal of the Trustee and the appointment of a successor trustee. Such
court may thereupon, after such notice, if any, as it may deem proper and
prescribe, remove the Trustee and appoint a successor trustee.
(c) The holders of a majority in aggregate principal amount of
the Debentures at the time outstanding may at any time remove the Trustee and
nominate a
-49-
<PAGE> 58
successor trustee which shall be deemed appointed as successor trustee unless
within ten (10) days after notice to the Company of such nomination the Company
objects thereto, in which case the Trustee so removed or any Debentureholder,
upon the terms and conditions and otherwise as in Section 8.10(a) provided, may
petition any court of competent jurisdiction for an appointment of a successor
trustee.
(d) Any resignation or removal of the Trustee and appointment
of a successor trustee pursuant to any of the provisions of this Section 8.10
shall become effective upon acceptance of appointment by the successor trustee
as provided in Section 8.11.
Section 8.11 Acceptance by Successor Trustee. Any successor trustee
appointed as provided in Section 8.10 shall execute, acknowledge and deliver to
the Company and to its predecessor trustee an instrument accepting such
appointment hereunder, and thereupon the resignation or removal of the
predecessor trustee shall become effective and such successor trustee, without
any further act, deed or conveyance, shall become vested with all the rights,
powers, duties and obligations of its predecessor hereunder, with like effect as
if originally named as trustee herein; but, nevertheless, on the written request
of the Company or of the successor trustee, the trustee ceasing to act shall,
upon payment of any amounts then due it pursuant to the provisions of Section
8.6, execute and deliver an instrument transferring to such successor trustee
all the rights and powers of the trustee so ceasing to act. Upon request of any
such successor trustee, the Company shall execute any and all instruments in
writing for more fully and certainly vesting in and confirming to such successor
trustee all such rights and powers. Any trustee ceasing to act shall,
nevertheless, retain a lien upon all property and funds held or collected by
such trustee as such, except for funds held in trust for the benefit of holders
of particular Debentures, to secure any amounts then due it pursuant to the
provisions of Section 8.6.
No successor trustee shall accept appointment as provided in this
Section 8.11 unless at the time of such acceptance such successor trustee shall
be qualified under the provisions of Section 8.8 and be eligible under the
provisions of Section 8.9.
Upon acceptance of appointment by a successor trustee as provided in
this Section 8.11, each of the Company and the former trustee shall mail or
cause to be mailed notice of the succession of such trustee hereunder to the
holders of Debentures at their addresses as they shall appear on the Debenture
register. If the Company fails to mail such notice within ten (10) days after
acceptance of appointment by the successor trustee, the successor trustee shall
cause such notice to be mailed at the expense of the Company.
Section 8.12 Succession by Merger, Etc. Any corporation or other entity
into which the Trustee may be merged or converted or with which it may be
consolidated, or any corporation resulting from any merger, conversion or
consolidation to which the Trustee shall be a party, or any corporation or other
entity succeeding to all or substantially all of the corporate trust business of
the Trustee (including the trust created hereunder), shall be the successor to
the Trustee hereunder without the execution or filing of any paper or any
further
-50-
<PAGE> 59
act on the part of any of the parties hereto, provided that in the case of any
corporation succeeding to all or substantially all of the trust business of the
Trustee such corporation shall be qualified under the provisions of Section 8.8
and eligible under the provisions of Section 8.9.
In case at the time such successor to the Trustee shall succeed to the
trusts created by this Indenture, any of the Debentures shall have been
authenticated but not delivered, any such successor to the Trustee may adopt the
certificate of authentication of any predecessor trustee or authenticating agent
appointed by such predecessor trustee, and deliver such Debentures so
authenticated; and in case at that time any of the Debentures shall not have
been authenticated, any successor to the Trustee or an authenticating agent
appointed by such successor trustee may authenticate such Debentures either in
the name of any predecessor trustee hereunder or in the name of the successor
trustee; and in all such cases such certificates shall have the full force which
it is anywhere in the Debentures or in this Indenture provided that the
certificate of the Trustee shall have; provided, however, that the right to
adopt the certificate of authentication of any predecessor Trustee or to
authenticate Debentures in the name of any predecessor Trustee shall apply only
to its successor or successors by merger, conversion or consolidation.
Section 8.13 Limitation on Rights of Trustee as Creditor. If and when
the Trustee shall be or become a creditor of the Company (or any other obligor
upon the Debentures and the Trust Indenture Act is applicable hereto), the
Trustee shall be subject to the provisions of Section 311(a) of the Trust
Indenture Act or, if applicable, Section 311(b) of the Trust Indenture Act
regarding the collection of the claims against the Company (or any such other
obligor).
ARTICLE IX
CONCERNING THE DEBENTUREHOLDERS
Section 9.1 Action by Debentureholders. Whenever in this Indenture it
is provided that the holders of a specified percentage in aggregate principal
amount of the Debentures may take any action (including the making of any demand
or request, the giving of any notice, consent or waiver or the taking of any
other action), the fact that at the time of taking any such action, the holders
of such specified percentage have joined therein may be evidenced (a) by any
instrument or any number of instruments of similar tenor executed by
Debentureholders in person or by agent or proxy appointed in writing, or (b) by
the record of the holders of Debentures voting in favor thereof at any meeting
of Debentureholders duly called and held in accordance with the provisions of
Article X, or (c) by a combination of such instrument or instruments and any
such record of such a meeting of Debentureholders. Whenever the Company or the
Trustee solicits the taking of any action by the holders of the Debentures, the
Company or the Trustee may fix in advance of such solicitation, a date as the
record date for determining holders entitled to take such action. The record
date shall be not more than fifteen (15) days prior to the date of commencement
of solicitation of such action.
-51-
<PAGE> 60
Section 9.2 Proof of Execution by Debentureholders. Subject to the
provisions of Sections 8.1, 8.2 and 10.5, proof of the execution of any
instrument by a Debentureholder or his agent or proxy shall be sufficient if
made in accordance with such reasonable rules and regulations as may be
prescribed by the Trustee or in such manner as shall be satisfactory to the
Trustee. The holding of Debentures shall be proved by the Debenture register or
by a certificate of the Debenture registrar. The record of any Debentureholders'
meeting shall be proved in the manner provided in Section 10.6.
Section 9.3 Who Are Deemed Absolute Owners. The Company, the Trustee,
any paying agent, any conversion agent and any Debenture registrar may deem the
person in whose name such Debenture shall be registered upon the Debenture
register to be, and may treat him as, the absolute owner of such Debenture
(whether or not such Debenture shall be overdue and notwithstanding any notation
of ownership or other writing thereon) for the purpose of receiving payment of
or on account of the principal of, premium, if any, and interest on such
Debenture, for conversion of such Debenture and for all other purposes; and
neither the Company nor the Trustee nor any paying agent nor any conversion
agent nor any Debenture registrar shall be affected by any notice to the
contrary. All such payments so made to any holder for the time being, or upon
his order, shall be valid, and, to the extent of the sum or sums so paid,
effectual to satisfy and discharge the liability for monies payable upon any
such Debenture.
Section 9.4 Company-Owned Debentures Disregarded. In determining
whether the holders of the requisite aggregate principal amount of Debentures
have concurred in any direction, consent, waiver or other action under this
Indenture, Debentures which are owned by the Company or any other obligor on the
Debentures or by any Affiliate of the Company or any other obligor on the
Debentures shall be disregarded and deemed not to be outstanding for the purpose
of any such determination; provided that for the purposes of determining whether
the Trustee shall be protected in relying on any such direction, consent, waiver
or other action only Debentures which a Responsible Officer of the Trustee knows
are so owned shall be so disregarded. Debentures so owned which have been
pledged in good faith may be regarded as outstanding for the purposes of this
Section 9.4 if the pledgee shall establish to the satisfaction of the Trustee
the pledgee's right to vote such Debentures and that the pledgee is not the
Company, any other obligor on the Debentures or an Affiliate of the Company or
any such other obligor. In the case of a dispute as to such right, any decision
by the Trustee taken upon the advice of counsel shall be full protection to the
Trustee. Upon request of the Trustee, the Company shall furnish to the Trustee
promptly an Officers' Certificate listing and identifying all Debentures, if
any, known by the Company to be owned or held by or for the account of any of
the above described persons; and, subject to Section 8.1, the Trustee shall be
entitled to accept such Officers' Certificate as conclusive evidence of the
facts therein set forth and of the fact that all Debentures not listed therein
are outstanding for the purpose of any such determination.
-52-
<PAGE> 61
Section 9.5 Revocation of Consents; Future Holders Bound. At any time
prior to (but not after) the evidencing to the Trustee, as provided in Section
9.1, of the taking of any action by the holders of the percentage in aggregate
principal amount of the Debentures specified in this Indenture in connection
with such action, any holder of a Debenture which is shown by the evidence to be
included in the Debentures the holders of which have consented to such action
may, by filing written notice with the Trustee at its Corporate Trust Office and
upon proof of holding as provided in Section 9.2, revoke such action so far as
concerns such Debenture. Except as aforesaid, any such action taken by the
holder of any Debenture shall be conclusive and binding upon such holder and
upon all future holders and owners of such Debenture and of any Debentures
issued in exchange or substitution therefor, irrespective of whether any
notation in regard thereto is made upon such Debenture or any Debenture issued
in exchange or substitution therefor.
ARTICLE X
DEBENTUREHOLDERS' MEETINGS
Section 10.1 Purpose of Meetings. A meeting of Debentureholders may be
called at any time and from time to time pursuant to the provisions of this
Article X for any of the following purposes:
(1) to give any notice to the Company or to the Trustee or to
give any directions to the Trustee permitted under this Indenture, or
to consent to the waiving of any default or Event of Default hereunder
and its consequences, or to take any other action authorized to be
taken by Debentureholders pursuant to any of the provisions of Article
VII;
(2) to remove the Trustee and nominate a successor trustee
pursuant to the provisions of Article VIII;
(3) to consent to the execution of an indenture or indentures
supplemental hereto pursuant to the provisions of Section 11.2;
(4) to take any other action authorized to be taken by or on
behalf of the holders of any specified aggregate principal amount of
the Debentures under any other provision of this Indenture or under
applicable law; or
(5) to take any other action authorized by this Indenture or
under applicable law.
Section 10.2 Call of Meetings by Trustee. The Trustee may at any time
call a meeting of Debentureholders to take any action specified in Section 10.1,
to be held at such time and at such place in the Borough of Manhattan, The City
of New York, as the Trustee
-53-
<PAGE> 62
shall determine. Notice of every meeting of the Debentureholders, setting forth
the time and the place of such meeting and in general terms the action proposed
to be taken at such meeting and the establishment of any record date pursuant to
Section 9.1, shall be mailed to holders of Debentures at their addresses as they
shall appear on the Debenture register. Such notice shall also be mailed to the
Company. Such notices shall be mailed not less than twenty (20) nor more than
ninety (90) days prior to the date fixed for the meeting.
Any meeting of Debentureholders shall be valid without notice if the
holders of all Debentures then outstanding are present in person or by proxy or
if notice is waived before or after the meeting by the holders of all Debentures
outstanding, and if the Company and the Trustee are either present by duly
authorized representatives or have, before or after the meeting, waived notice.
Section 10.3 Call of Meetings by Company or Debentureholders. In case
at any time the Company, pursuant to a resolution of its Board of Directors, or
the holders of at least 10% in aggregate principal amount of the Debentures then
outstanding, shall have requested the Trustee to call a meeting of
Debentureholders, by written request setting forth in reasonable detail the
action proposed to be taken at the meeting, and the Trustee shall not have
mailed the notice of such meeting within twenty (20) days after receipt of such
request, then the Company or such Debentureholders may determine the time and
the place for such meeting and may call such meeting to take any action
authorized in Section 10.1, by mailing notice thereof as provided in Section
10.2.
Section 10.4 Qualifications for Voting. To be entitled to vote at any
meeting of Debentureholders a person shall (a) be a holder of one or more
Debentures on the record date pertaining to such meeting or (b) be a person
appointed by an instrument in writing as proxy by a holder of one or more
Debentures. The only persons who shall be entitled to be present or to speak at
any meeting of Debentureholders shall be the persons entitled to vote at such
meeting and their counsel and any representatives of the Trustee and its counsel
and any representatives of the Company and its counsel.
Section 10.5 Regulations. Notwithstanding any other provisions of this
Indenture, the Trustee may make such reasonable regulations as it may deem
advisable for any meeting of Debentureholders, in regard to proof of the holding
of Debentures and of the appointment of proxies, and in regard to the
appointment and duties of inspectors of votes, the submission and examination of
proxies, certificates and other evidence of the right to vote, and such other
matters concerning the conduct of the meeting as it shall think fit.
The Trustee shall, by an instrument in writing, appoint a temporary
chairman of the meeting, unless the meeting shall have been called by the
Company or by Debentureholders as provided in Section 10.3, in which case the
Company or the Debentureholders calling the meeting, as the case may be, shall
in like manner appoint a temporary chairman. A permanent chairman and a
permanent secretary of the meeting shall be elected by vote of the holders of a
-54-
<PAGE> 63
majority in principal amount of the Debentures represented at the meeting and
entitled to vote at the meeting.
Subject to the provisions of Section 9.4, at any meeting each
Debentureholder or proxyholder shall be entitled to one vote for each $1,000
principal amount of Debentures held or represented by him; provided, however,
that no vote shall be cast or counted at any meeting in respect of any Debenture
challenged as not outstanding and ruled by the chairman of the meeting to be not
outstanding. The chairman of the meeting shall have no right to vote other than
by virtue of Debentures held by him or instruments in writing as aforesaid duly
designating him as the proxy to vote on behalf of other Debentureholders. Any
meeting of Debentureholders duly called pursuant to the provisions of Section
10.2 or 10.3 may be adjourned from time to time by the holders of a majority of
the aggregate principal amount of Debentures represented at the meeting, whether
or not constituting a quorum, and the meeting may be held as so adjourned
without further notice.
Section 10.6 Voting. The vote upon any resolution submitted to any
meeting of Debentureholders shall be by written ballot on which shall be
subscribed the signatures of the holders of Debentures or of their
representatives by proxy and the principal amount of the Debentures held or
represented by them. The permanent chairman of the meeting shall appoint two
inspectors of votes who shall count all votes cast at the meeting for or against
any resolution and who shall make and file with the secretary of the meeting
their verified written reports in duplicate of all votes cast at the meeting. A
record in duplicate of the proceedings of each meeting of Debentureholders shall
be prepared by the secretary of the meeting and there shall be attached to said
record the original reports of the inspectors of votes on any vote by ballot
taken thereat and affidavits by one or more persons having knowledge of the
facts setting forth a copy of the notice of the meeting and showing that said
notice was mailed as provided in Section 10.2. The record shall show the
principal amount of the Debentures voting in favor of or against any resolution.
The record shall be signed and verified by the affidavits of the permanent
chairman and secretary of the meeting and one of the duplicates shall be
delivered to the Company and the other to the Trustee to be preserved by the
Trustee, the latter to have attached thereto the ballots voted at the meeting.
Any record so signed and verified shall be conclusive evidence of the
matters therein stated.
Section 10.7 No Delay of Rights by Meeting. Nothing in this Article X
contained shall be deemed or construed to authorize or permit, by reason of any
call of a meeting of Debentureholders or any rights expressly or impliedly
conferred hereunder to make such call, any hindrance or delay in the exercise of
any right or rights conferred upon or reserved to the Trustee or to the
Debentureholders under any of the provisions of this Indenture or of the
Debentures.
-55-
<PAGE> 64
ARTICLE XI
SUPPLEMENTAL INDENTURES
Section 11.1 Supplemental Indentures Without Consent of
Debentureholders. The Company, when authorized by the resolutions of the Board
of Directors, and the Trustee may from time to time and at any time enter into
an indenture or indentures supplemental hereto for one or more of the following
purposes:
(a) to make provision with respect to the conversion rights of
the holders of Debentures pursuant to the requirements of Section 15.6;
(b) subject to Article IV, to convey, transfer, assign,
mortgage or pledge to the Trustee as security for the Debentures, any property
or assets;
(c) to evidence the succession of another corporation to the
Company, or successive successions, and the assumption by the successor
corporation of the covenants, agreements and obligations of the Company pursuant
to Article XII;
(d) to add to the covenants of the Company such further
covenants, restrictions or conditions as the Board of Directors and the Trustee
shall consider to be for the benefit of the holders of Debentures, and to make
the occurrence, or the occurrence and continuance, of a default in any such
additional covenants, restrictions or conditions a default or an Event of
Default permitting the enforcement of all or any of the several remedies
provided in this Indenture as herein set forth; provided, however, that in
respect of any such additional covenant, restriction or condition such
supplemental indenture may provide for a particular period of grace after
default (which period may be shorter or longer than that allowed in the case of
other defaults) or may provide for an immediate enforcement upon such default or
may limit the remedies available to the Trustee upon such default;
(e) to provide for the issuance under this Indenture of
Debentures in coupon form (including Debentures registrable as to principal
only) and to provide for exchange of such Debentures with the Debentures issued
hereunder in fully registered form and to make all appropriate changes for such
purpose;
(f) to cure any ambiguity or to correct or supplement any
provision contained herein or in any supplemental indenture which may be
defective or inconsistent with any other provision contained herein or in any
supplemental indenture, or to make such other provisions in regard to matters or
questions arising under this Indenture which shall not materially adversely
affect the interests of the holders of the Debentures;
(g) to evidence and provide for the acceptance of appointment
hereunder by a successor Trustee with respect to the Debentures; or
-56-
<PAGE> 65
(h) to modify, eliminate or add to the provisions of this
Indenture to such extent as shall be necessary to effect the qualifications of
this Indenture under the Trust Indenture Act, or under any similar federal
statute hereafter enacted.
The Trustee is hereby authorized to join with the Company in the
execution of any such supplemental indenture, to make any further appropriate
agreements and stipulations which may be therein contained and to accept the
conveyance, transfer and assignment of any property thereunder, but the Trustee
shall not be obligated to, but may in its discretion, enter into any
supplemental indenture which affects the Trustee's own rights, duties or
immunities under this Indenture or otherwise.
Any supplemental indenture authorized by the provisions of this Section
11.1 may be executed by the Company and the Trustee without the consent of the
holders of any of the Debentures at the time outstanding, notwithstanding any of
the provisions of Section 11.2.
Section 11.2 Supplemental Indentures with Consent of Debentureholders.
With the consent (evidenced as provided in Article IX) of the holders of not
less than a majority in aggregate principal amount of the Debentures at the time
outstanding (determined in accordance with Section 9.4), the Company, when
authorized by the resolutions of the Board of Directors, and the Trustee may
from time to time and at any time enter into an indenture or indentures
supplemental hereto for the purpose of adding any provisions to or changing in
any manner or eliminating any of the provisions of this Indenture or any
supplemental indenture or of modifying in any manner the rights of the holders
of the Debentures; provided, however, that no such supplemental indenture shall
(i) extend the fixed maturity of any Debenture, or reduce the rate or extend the
time of payment of interest thereon, or reduce the principal amount thereof or
premium, if any, thereon, or reduce any amount payable on redemption thereof, or
impair or adversely affect the right of any Debentureholder to institute suit
for the payment thereof, or make the principal thereof or interest or premium,
if any, thereon payable in any coin or currency other than that provided in the
Debentures, or change or impair the right to convert the Debentures into Common
Stock subject to the terms set forth herein in any respect adverse to the holder
thereof, including Section 15.6, or modify the provisions of this Indenture with
respect to the subordination of the Debentures in a manner adverse to the
Debentureholders, without the consent of the holder of each Debenture so
affected, or (ii) reduce the aforesaid percentage of Debentures, the holders of
which are required to consent to any such supplemental indenture, without the
consent of the holders of all Debentures then outstanding or reduce the
percentage of Debentures, the holders of which are required to consent to any
waiver or modify any of the provisions of this Section or Section 7.7, except to
increase any such percentage or to provide that certain of the provisions of
this Indenture cannot be modified or waived without the consent of the holder of
each outstanding Debenture.
Up to and prior to the close of business on the Exchange Date, only the
holders of shares of Preferred Stock shall be entitled to vote on any amendments
or supplements to this Indenture as provided above.
-57-
<PAGE> 66
Upon the request of the Company, accompanied by a copy of the
resolutions of the Board of Directors certified by its Secretary or Assistant
Secretary authorizing the execution of any such supplemental indenture, and upon
the filing with the Trustee of evidence of the consent of Debentureholders as
aforesaid, the Trustee shall join with the Company in the execution of such
supplemental indenture unless such supplemental indenture affects the Trustee's
own rights, duties or immunities under this Indenture or otherwise, in which
case the Trustee may in is discretion, but shall not be obligated to, enter into
such supplemental indenture.
It shall not be necessary for the consent of the Debentureholders under
this Section 11.2 to approve the particular form of any proposed supplemental
indenture, but it shall be sufficient if such consent shall approve the
substance thereof.
Section 11.3 Effect of Supplemental Indentures. Any supplemental
indenture executed pursuant to the provisions of this Article XI shall comply
with the Trust Indenture Act, as then in effect. Upon the execution of any
supplemental indenture pursuant to the provisions of this Article XI, this
Indenture shall be and be deemed to be modified and amended in accordance
therewith and the respective rights, limitation of rights, obligations, duties
and immunities under this Indenture of the Trustee, the Company and the holders
of Debentures shall thereafter be determined, exercised and enforced hereunder
subject in all respects to such modifications and amendments and all the terms
and conditions of any such supplemental indenture shall be and be deemed to be
part of the terms and conditions of this Indenture for any and all purposes.
Section 11.4 Notation on Debentures. Debentures authenticated and
delivered after the execution of any supplemental indenture pursuant to the
provisions of this Article XI may bear a notation in form approved by the
Trustee as to any matter provided for in such supplemental indenture. If the
Company or the Trustee shall so determine, new Debentures so modified as to
conform, in the opinion of the Trustee and the Board of Directors, to any
modification of this Indenture contained in any such supplemental indenture may,
at the Company's expense, be prepared and executed by the Company, authenticated
by the Trustee (or an authenticating agent duly appointed by the Trustee
pursuant to Section 16.11) and delivered in exchange for the Debentures then
outstanding, upon surrender of such Debentures then outstanding.
Section 11.5 Evidence of Compliance of Supplemental Indenture to Be
Furnished Trustee. The Trustee, subject to the provisions of Sections 8.1 and
8.2, may receive an Officers' Certificate and an Opinion of Counsel as
conclusive evidence that any supplemental indenture executed pursuant hereto
complies with the requirements of this Article XI.
-58-
<PAGE> 67
ARTICLE XII
MERGER, SALE OR CONSOLIDATION
Section 12.1 Limitation on Merger, Sale or Consolidation. The Company
shall not consolidate with or merge with or into another person or sell, lease,
convey or transfer all or substantially all of its assets (computed on a
consolidated basis), whether in a single transaction or a series of related
transactions, to another person or group of affiliated persons, unless (i)
either (A) in the case of a consolidation or merger, the Company is the
surviving entity or (B) the resulting, surviving or transferee entity is a
corporation organized under the laws of the United States, any state thereof or
the District of Columbia and expressly assumes by supplemental indenture all of
the obligations of the Company in connection with the Debentures and the
Indenture; (ii) no default or Event of Default shall exist or shall occur
immediately before or after giving effect on a pro forma basis to such
transaction; and (iii) the Company has delivered to the Trustee an Officers'
Certificate and an Opinion of Counsel, each stating that such consolidation,
merger, sale, lease, conveyance or transfer and, if a supplemental indenture is
required, such supplemental indenture comply with the Indenture and that all
conditions precedent relating to such transactions have been satisfied.
Section 12.2 Successor Corporation to Be Substituted In case of any
such consolidation, merger, sale, conveyance or lease and upon the assumption by
the successor corporation, by supplemental indenture, executed and delivered to
the Trustee and satisfactory in form to the Trustee, of the due and punctual
payment of the principal of and premium, if any, and interest on all of the
Debentures and the due and punctual performance of all of the covenants and
conditions of this Indenture to be performed by the Company, such successor
corporation shall succeed to and be substituted for the Company, with the same
effect as if it had been named herein as the party of the first part. Such
successor corporation thereupon may cause to be signed, and may issue either in
its own name or in the name of Cephalon, Inc. any or all of the Debentures
issuable hereunder which theretofore shall not have been signed by the Company
and delivered to the Trustee; and, upon the order of such successor corporation
instead of the Company and subject to all the terms, conditions and limitations
in this Indenture prescribed, the Trustee shall authenticate and shall deliver,
or cause to be authenticated and delivered, any Debentures which previously
shall have been signed and delivered by the officers of the Company to the
Trustee for authentication, and any Debentures which such successor corporation
thereafter shall cause to be signed and delivered to the Trustee for that
purpose. All the Debentures so issued shall in all respects have the same legal
rank and benefit under this Indenture as the Debentures theretofore or
thereafter issued in accordance with the terms of this Indenture as though all
of such Debentures had been issued at the date of the execution hereof. In the
event of any such consolidation, merger, sale or conveyance (but not in the
event of such lease), the person named as the "Company" in the first paragraph
of this Indenture, or any successor which shall thereafter have become such in
the manner prescribed in this Article XII and which shall have transferred its
rights and obligations hereunder to another successor in the manner prescribed
in this Article XII, may be dissolved, wound up and
-59-
<PAGE> 68
liquidated at any time thereafter and such person shall be released from its
liabilities as obligor and maker of the Debentures and from its obligations
under this Indenture.
In case of any such consolidation, merger, sale, conveyance or lease,
such changes in phraseology and form (but not in substance) may be made in the
Debentures thereafter to be issued as may be appropriate.
ARTICLE XIII
SATISFACTION AND DISCHARGE OF INDENTURE
Section 13.1 Discharge of Indenture. When (a) the Company shall deliver
to the Trustee for cancellation all Debentures theretofore authenticated (other
than any Debentures which have been destroyed, lost or stolen and in lieu of or
in substitution for which other Debentures shall have been authenticated and
delivered) and not theretofore canceled, or (b) all the Debentures not
theretofore canceled or delivered to the Trustee for cancellation shall have
become due and payable, or are by their terms to become due and payable within
one year or are to be called for redemption within one year under arrangements
satisfactory to the Trustee for the giving of notice of redemption, and the
Company shall irrevocably deposit with the Trustee, in trust, funds sufficient
to pay at maturity or upon redemption of all of the Debentures (other than any
Debentures which shall have been mutilated, destroyed, lost or stolen and in
lieu of or in substitution for which other Debentures shall have been
authenticated and delivered) not theretofore canceled or delivered to the
Trustee for cancellation, including principal and premium, if any, and interest
due or to become due to such date of maturity or redemption date, as the case
may be, and if in either case the Company shall also pay or cause to be paid all
other sums payable hereunder by the Company, then this Indenture shall cease to
be of further effect (except as to (i) remaining rights of registration of
transfer, substitution and exchange and conversion of Debentures and maintenance
of an office therefor, (ii) rights hereunder of Debentureholders to receive
payments of principal of and premium, if any, and interest on, the Debentures
and the other rights, duties and obligations of Debentureholders, as
beneficiaries hereof with respect to the amounts, if any, so deposited with the
Trustee and (iii) the rights, obligations and immunities of the Trustee
hereunder), and the Trustee, on demand of the Company accompanied by an
Officers' Certificate and an Opinion of Counsel as required by Section 16.5 and
at the cost and expense of the Company, shall execute proper instruments
acknowledging satisfaction of and discharging this Indenture; the Company,
however, hereby agreeing to reimburse the Trustee for any costs or expenses
thereafter reasonably and properly incurred by the Trustee and to compensate the
Trustee for any services thereafter reasonably and properly rendered by the
Trustee in connection with this Indenture or the Debentures.
Section 13.2 Deposited Monies to Be Held in Trust by Trustee. Subject
to Section 13.4, all monies deposited with the Trustee pursuant to Section 13.1
shall be held in trust and applied by it to the payment, notwithstanding the
provisions of Article IV, either directly or through any paying agent (including
the Company if acting as its own paying
-60-
<PAGE> 69
agent), to the holders of the particular Debentures for the payment or
redemption of which such monies have been deposited with the Trustee, of all
sums due and to become due thereon for principal and interest and premium, if
any.
Section 13.3 Paying Agent to Repay Monies Held. Upon the satisfaction
and discharge of this Indenture, all monies then held by any paying agent of the
Debentures (other than the Trustee) shall, upon demand of the Company, be repaid
to it or paid to the Trustee, and thereupon such paying agent shall be released
from all further liability with respect to such monies.
Section 13.4 Return of Unclaimed Monies. Subject to the requirements of
applicable law, any monies deposited with or paid to the Trustee for payment of
the principal of, premium, if any, or interest on Debentures and not applied but
remaining unclaimed by the holders of Debentures for two years after the date
upon which the principal of, premium, if any, or interest on such Debentures, as
the case may be, shall have become due and payable, shall be repaid to the
Company by the Trustee on demand and all liability of the Trustee shall
thereupon cease with respect to such monies; and the holder of any of the
Debentures shall thereafter look only to the Company for any payment which such
holder may be entitled to collect unless an applicable abandoned property law
designates another person.
Section 13.5 Reinstatement. If (i) the Trustee or the paying agent is
unable to apply any money in accordance with Section 13.2 by reason of any order
or judgment of any court or governmental authority enjoining, restraining or
otherwise prohibiting such application and (ii) the holders of at least a
majority in principal amount of the then outstanding Debentures so request by
written notice to the Trustee, the Company's obligations under this Indenture
and the Debentures shall be revived and reinstated as though no deposit had
occurred pursuant to Section 13.1 until such time as the Trustee or the paying
agent is permitted to apply all such money in accordance with Section 13.2;
provided, however, that if the Company makes any payment of interest on or
principal of any Debenture following the reinstatement of its obligations, the
Company shall be subrogated to the rights of the holders of such Debentures to
receive such payment from the money held by the Trustee or paying agent.
ARTICLE XIV
IMMUNITY OF INCORPORATORS, SHAREHOLDERS,
OFFICERS AND DIRECTORS
Section 14.1 Indenture and Debentures Solely Corporate Obligations. No
recourse for the payment of the principal of or premium, if any, or interest on
any Debenture, or for any claim based thereon or otherwise in respect thereof,
and no recourse under or upon any obligation, covenant or agreement of the
Company in this Indenture or in any supplemental indenture or in any Debenture,
or because of the creation of any indebtedness represented thereby, shall be had
against any incorporator, shareholder, employee, agent, officer or director
-61-
<PAGE> 70
or subsidiary, as such, past, present or future, of the Company or of any
successor corporation, either directly or through the Company or any successor
corporation, whether by virtue of any constitution, statute or rule of law, or
by the enforcement of any assessment or penalty or otherwise; it being expressly
understood that all such liability is hereby expressly waived and released as a
condition of, and as a consideration for, the execution of this Indenture and
the issue of the Debentures.
ARTICLE XV
CONVERSION OF DEBENTURES
Section 15.1 Right to Convert. Subject to and upon compliance with the
provisions of this Indenture, the holder of any Debenture shall have, at his
option, the right, at any time on or prior to the close of business on the tenth
anniversary of the Exchange Date (except that, with respect to any Debenture or
portion of a Debenture which shall be called for redemption, such right shall
terminate, except as provided in the fourth paragraph of Section 15.2, at the
close of business on the next Business Day preceding the date fixed for
redemption of such Debenture or portion of a Debenture unless the Company shall
default in payment due upon redemption thereof) to convert the principal amount
of any such Debenture, or any portion of such principal amount which is $1,000
or an integral multiple thereof, into that number of fully paid and
non-assessable shares of Common Stock (as such shares shall then be constituted)
obtained by dividing the principal amount of the Debenture or portion thereof
surrendered for conversion by the Conversion Price in effect at such time, by
surrender of the Debenture so to be converted in whole or in part in the manner
provided in Section 15.2. A holder of Debentures is not entitled to any rights
of a holder of Common Stock until such holder has converted his Debentures to
Common Stock, and only to the extent such Debentures are deemed to have been
converted to Common Stock under this Article XV.
Section 15.2 Exercise of Conversion Privilege; Issuance of Common Stock
on Conversion; No Adjustment for Interest or Dividends. In order to exercise the
conversion privilege with respect to any Debenture, the holder of any such
Debenture to be converted in whole or in part shall surrender such Debenture,
duly endorsed, at an office or agency maintained by the Company pursuant to
Section 5.2, accompanied by the funds, if any, required by the last paragraph of
this Section 15.2, and shall give written notice of conversion in the form
provided on the Debentures (or such other notice which is acceptable to the
Company) to the office or agency that the holder elects to convert such
Debenture or such portion thereof specified in said notice. Such notice shall
also state the name or names (with address) in which the certificate or
certificates for shares of Common Stock which shall be issuable on such
conversion shall be issued, and shall be accompanied by transfer taxes, if
required pursuant to Section 15.7. Each such Debenture surrendered for
conversion shall, unless the shares issuable on conversion are to be issued in
the same name as the registration of such Debenture, be duly endorsed by, or be
accompanied by instruments of transfer in form satisfactory to the Company duly
executed by, the holder or his duly authorized attorney.
-62-
<PAGE> 71
In order to exercise the conversion privilege with respect to any
interest in a Global Debenture, the beneficial holder must complete the
appropriate instruction form for conversion pursuant to the Depositary's
book-entry conversion program, deliver by book-entry delivery an interest in
such Global Debenture, furnish appropriate endorsements and transfer documents
if required by the Company or the Trustee or conversion agent, and pay the
funds, if any, required by the penultimate paragraph of this Section 15.2 and
any transfer taxes, if required pursuant to Section 15.7.
As promptly as practicable after satisfaction of the requirements for
conversion set forth above, the Company shall issue and shall deliver to such
holder or, if shares issuable on conversion are to be issued in a name other
than that of the Debentureholder (as if such transfer were a transfer of the
Debenture or Debentures (or portion thereof) so converted), to such other
person, at the office or agency maintained by the Company for such purpose
pursuant to Section 5.2, a certificate or certificates for the number of full
shares of Common Stock issuable upon the conversion of such Debenture or portion
thereof in accordance with the provisions of this Article and a check or cash in
respect of any fractional interest in respect of a share of Common Stock arising
upon such conversion, as provided in Section 15.3 (which payment, if any, shall
be paid no later than five Business Days after satisfaction of the requirements
for conversion set forth above). In case any Debenture of a denomination greater
than $1,000 shall be surrendered for partial conversion, and subject to Section
2.3, the Company shall execute and the Trustee shall authenticate and deliver to
the holder of the Debenture so surrendered, without charge to him, a new
Debenture or Debentures in authorized denominations in an aggregate principal
amount equal to the unconverted portion of the surrendered Debenture.
Each conversion shall be deemed to have been effected as to any such
Debenture (or portion thereof) on the date on which the requirements set forth
above in this Section 15.2 have been satisfied as to such Debenture (or portion
thereof), and the person in whose name any certificate or certificates for
shares of Common Stock shall be issuable upon such conversion shall be deemed to
have become on said date the holder of record of the shares represented thereby;
provided, however, that if any such surrender occurs on any date when the stock
transfer books of the Company shall be closed, the conversion shall be effected
on the next succeeding day on which such stock transfer books are open, and the
person in whose name the certificates are to be issued shall be the record
holder thereof for all purposes, but such conversion shall be at the Conversion
Price in effect on the date upon which such Debenture shall be surrendered.
Upon the conversion of an interest in a Global Debenture, the Trustee,
or the Custodian at the direction of the Trustee, shall make a notation on such
Global Debenture as to the reduction in the principal amount represented
thereby.
Any Debenture or portion thereof surrendered for conversion during the
period from the close of business on the record date for any interest payment
date through the close of business on the Business Day next preceding such
interest payment date shall (unless such Debenture or
-63-
<PAGE> 72
portion thereof being converted shall have been called for redemption and a
notice of redemption has been sent to the holders of the Debentures pursuant to
Section 3.2) be accompanied by payment, in New York Clearing House funds or
other funds acceptable to the Company, of an amount equal to the interest
otherwise payable on such interest payment date on the principal amount being
converted; provided, however, that no such payment need be made if there shall
exist at the time of conversion a default in the payment of interest on the
Debentures. The Trustee shall not be required to accept for conversion any
Debentures not accompanied by any payment required by the preceding sentence.
Except as provided above in this Section 15.2, no adjustment shall be made for
interest accrued on any Debenture converted or for dividends on any shares
issued upon the conversion of such Debenture as provided in this Article.
Section 15.3 Cash Payments in Lieu of Fractional Shares. No fractional
shares of Common Stock or scrip representing fractional shares shall be issued
upon conversion of Debentures. If more than one Debenture shall be surrendered
for conversion at one time by the same holder, the number of full shares which
shall be issuable upon conversion shall be computed on the basis of the
aggregate principal amount of the Debentures (or specified portions thereof to
the extent permitted hereby) so surrendered for conversion. If any fractional
share of stock otherwise would be issuable upon the conversion of any Debenture
or Debentures, the Company shall make an adjustment therefor in cash at the
current market value thereof to the holder of Debentures. The current market
value of a share of Common Stock shall be the Closing Price on the first Trading
Day immediately preceding the day on which the Debentures (or specified portions
thereof) are deemed to have been converted and such Closing Price shall be
determined as provided in Section 15.5(i).
Section 15.4 Conversion Price. The conversion price shall be as
specified in the form of Debenture (herein called the "Conversion Price")
attached as Exhibit A hereto, subject to adjustment as provided in this Article
XV.
Section 15.5 Adjustment of Conversion Price. The Conversion Price shall
be adjusted from time to time by the Company as follows:
(a) In case the Company shall hereafter pay a dividend or make
a distribution to all holders of the outstanding Common Stock in shares of
Common Stock, the Conversion Price in effect at the opening of business on the
date following the date fixed for the determination of shareholders entitled to
receive such dividend or other distribution shall be reduced by multiplying such
Conversion Price by a fraction of which the numerator shall be the number of
shares of Common Stock outstanding at the close of business on the Record Date
(as defined in Section 15.5(i)) fixed for such determination and the denominator
shall be the sum of such number of shares and the total number of shares
constituting such dividend or other distribution, such reduction to become
effective immediately prior to the opening of business on the day following the
Record Date. If any dividend or distribution of the type described in this
Section 15.5(a) is declared but not so paid or made, the Conversion Price shall
again be
-64-
<PAGE> 73
adjusted to the Conversion Price which would then be in effect if such dividend
or distribution had not been declared.
(b) In case the Company shall issue rights or warrants to all
holders of its outstanding shares of Common Stock entitling them (for a period
expiring within forty-five (45) days after the date fixed for the determination
of shareholders entitled to receive such rights or warrants) to subscribe for or
purchase shares of Common Stock at a price per share less than 95% of the
Current Market Price (as defined in Section 15.5(i)) on the Record Date fixed
for the determination of shareholders entitled to receive such rights or
warrants, the Conversion Price shall be adjusted so that the same shall equal
the price determined by multiplying the Conversion Price in effect at the
opening of business on the date after such Record Date by a fraction of which
the numerator shall be the number of shares of Common Stock outstanding at the
close of business on the Record Date plus the number of shares which the
aggregate offering price of the total number of shares so offered would purchase
at such Current Market Price, and of which the denominator shall be the number
of shares of Common Stock outstanding on the close of business on the Record
Date plus the total number of additional shares of Common Stock so offered for
subscription or purchase. Such adjustment shall become effective immediately
after the opening of business on the day following the Record Date fixed for
determination of shareholders entitled to receive such rights or warrants. To
the extent that shares of Common Stock are not delivered pursuant to such rights
or warrants, upon the expiration or termination of such rights or warrants the
Conversion Price shall be readjusted to the Conversion Price which would then be
in effect had the adjustments made upon the issuance of such rights or warrants
been made on the basis of delivery of only the number of shares of Common Stock
actually delivered. In the event that such rights or warrants are not so issued,
the Conversion Price shall again be adjusted to be the Conversion Price which
would then be in effect if such date fixed for the determination of shareholders
entitled to receive such rights or warrants had not been fixed. In determining
whether any rights or warrants entitle the holders to subscribe for or purchase
shares of Common Stock at less than 95% of such Current Market Price, and in
determining the aggregate offering price of such shares of Common Stock, there
shall be taken into account any consideration received for such rights or
warrants, the value of such consideration, if other than cash, to be determined
by the Board of Directors.
(c) In case the outstanding shares of Common Stock shall be
subdivided into a greater number of shares of Common Stock, the Conversion Price
in effect at the opening of business on the day following the day upon which
such subdivision becomes effective shall be proportionately reduced, and
conversely, in case outstanding shares of Common Stock shall be combined into a
smaller number of shares of Common Stock, the Conversion Price in effect at the
opening of business on the day following the day upon which such combination
becomes effective shall be proportionately increased, such reduction or
increase, as the case may be, to become effective immediately after the opening
of business on the day following the day upon which such subdivision or
combination becomes effective.
-65-
<PAGE> 74
(d) In case the Company shall, by dividend or otherwise,
distribute to all holders of its Common Stock shares of any class of capital
stock of the Company (other than any dividends or distributions to which Section
15.5(a) applies) or evidences of its indebtedness, cash or other assets
(including securities, but excluding (1) any rights or warrants referred to in
Section 15.5(b) or (2) dividends and distributions paid exclusively in cash (the
foregoing hereinafter in this Section 15.5(d) called the "Securities")), then,
in each such case, the Conversion Price shall be reduced so that the same shall
be equal to the price determined by multiplying the Conversion Price in effect
immediately prior to the close of business on the Record Date (as defined in
Section 15.5(i)) with respect to such distribution by a fraction of which the
numerator shall be the Current Market Price (determined as provided in Section
15.5(i)) on such date less the fair market value (as determined by the Board of
Directors, whose determination shall be conclusive and described in a Board
Resolution) on such date of the portion of the Securities so distributed
applicable to one share of Common Stock and the denominator shall be such
Current Market Price, such reduction to become effective immediately prior to
the opening of business on the day following the Record Date; provided, however,
that in the event the then fair market value (as so determined) of the portion
of the Securities so distributed applicable to one share of Common Stock is
equal to or greater than the Current Market Price on the Record Date, in lieu of
the foregoing adjustment, adequate provision shall be made so that each
Debentureholder shall have the right to receive upon conversion of a Debenture
(or any portion thereof) the amount of Securities such holder would have
received had such holder converted such Debenture (or portion thereof)
immediately prior to such Record Date. In the event that such dividend or
distribution is not so paid or made, the Conversion Price shall again be
adjusted to be the Conversion Price which would then be in effect if such
dividend or distribution had not been declared. If the Board of Directors
determines the fair market value of any distribution for purposes of this
Section 15.5(d) by reference to the actual or when issued trading market for any
securities comprising all or part of such distribution, it must in doing so
consider the prices in such market over the same period (the "Reference Period")
used in computing the Current Market Price pursuant to Section 15.5(i) to the
extent possible, unless the Board of Directors in a board resolution determines
in good faith that determining the fair market value during the Reference Period
would not be in the best interest of the Debentureholder.
In the event that the Company implements a
shareholders' rights plan (a "New Rights Plan") or amends any existing
shareholders' rights plan (as amended, an "Amended Rights Plan" and together
with any New Rights Plan, a "Rights Plan"), such Rights Plan shall provide that
upon conversion of the Debentures the holders will receive, in addition to the
Common Stock issuable upon such conversion, the rights under such Rights Plan
(notwithstanding the occurrence of an event causing such rights to separate from
the Common Stock at or prior to the time of conversion). Any distribution of
rights or warrants pursuant to the Rights Plan complying with the requirements
set forth in the immediately preceding sentence of this paragraph shall not
constitute a distribution of rights or warrants for purposes of this Section
15.5(d).
-66-
<PAGE> 75
Rights or warrants distributed by the Company to all
holders of Common Stock entitling the holders thereof to subscribe for or
purchase shares of the Company's capital stock (either initially or under
certain circumstances), which rights or warrants, until the occurrence of a
specified event or events ("Trigger Event"): (i) are deemed to be transferred
with such shares of Common Stock; (ii) are not exercisable; and (iii) are also
issued in respect of future issuances of Common Stock, shall be deemed not to
have been distributed for purposes of this Section 15.5(d) (and no adjustment to
the Conversion Price under this Section 15.5(d) will be required) until the
occurrence of the earliest Trigger Event. If such right or warrant is subject to
subsequent events, upon the occurrence of which such right or warrant shall
become exercisable to purchase different securities, evidences of indebtedness
or other assets or entitle the holder to purchase a different number or amount
of the foregoing or to purchase any of the foregoing at a different purchase
price, then the occurrence of each such event shall be deemed to be the date of
issuance and record date with respect to a new right or warrant (and a
termination or expiration of the existing right or warrant without exercise by
the holder thereof). In addition, in the event of any distribution (or deemed
distribution) of rights or warrants, or any Trigger Event or other event (of the
type described in the preceding sentence) with respect thereto, that resulted in
an adjustment to the Conversion Price under this Section 15.5(d), (1) in the
case of any such rights or warrants which shall all have been redeemed or
repurchased without exercise by any holders thereof, the Conversion Price shall
be readjusted upon such final redemption or repurchase to give effect to such
distribution or Trigger Event, as the case may be, as though it were a cash
distribution, equal to the per share redemption or repurchase price received by
a holder of Common Stock with respect to such rights or warrants (assuming such
holder had retained such rights or warrants), made to all holders of Common
Stock as of the date of such redemption or repurchase, and (2) in the case of
such rights or warrants all of which shall have expired or been terminated
without exercise, the Conversion Price shall be readjusted as if such rights and
warrants had never been issued.
For purposes of this Section 15.5(d) and Sections
15.5(a) and (b), any dividend or distribution to which this Section 15.5(d) is
applicable that also includes shares of Common Stock to which 15.5(a) applies,
or rights or warrants to subscribe for or purchase shares of Common Stock to
which Section 15.5(b) applies (or both), shall be deemed instead to be (1) a
dividend or distribution of the evidences of indebtedness, assets, shares of
capital stock, rights or warrants other than such shares of Common Stock to
which 15.5(a) applies or rights or warrants to which Section 15.5(b) applies
(and any Conversion Price reduction required by this Section 15.5(d) with
respect to such dividend or distribution shall then be made) immediately
followed by (2) a dividend or distribution of such shares of Common Stock or
such rights or warrants (and any further Conversion Price reduction required by
Sections 15.5(a) and (b) with respect to such dividend or distribution shall
then be made, except (A) the Record Date of such dividend or distribution shall
be substituted as "the date fixed for the determination of shareholders entitled
to receive such dividend or other distribution", "Record Date fixed for such
determination" and "Record Date" within the meaning of Section 15.5(a) and as
"the date fixed for the determination of shareholders entitled to receive such
rights or warrants", "the Record Date fixed for the determination of the
shareholders entitled to receive
-67-
<PAGE> 76
such rights or warrants" and "such Record Date" within the meaning of Section
15.5(b) and (B) any shares of Common Stock included in such dividend or
distribution shall not be deemed "outstanding at the close of business on the
date fixed for such determination" within the meaning of Section 15.5(a).
(e) In case the Company shall, by dividend or otherwise,
distribute to all holders of its Common Stock cash (excluding any cash that is
distributed upon a merger or consolidation to which Section 15.6 applies or as
part of a distribution referred to in Section 15.5(d)), in an aggregate amount
that, combined together with (1) the aggregate amount of any other such
distributions to all holders of its Common Stock made exclusively in cash within
the twelve (12) months preceding the date of payment of such distribution, and
in respect of which no adjustment pursuant to this Section 15.5(e) has been
made, and (2) the aggregate of any cash plus the fair market value (as
determined by the Board of Directors, whose determination shall be conclusive
and described in a Board Resolution) of consideration payable in respect of any
tender offer by the Company or any of its subsidiaries for all or any portion of
the Common Stock concluded within the twelve (12) months preceding the date of
payment of such distribution, and in respect of which no adjustment pursuant to
Section 15.5(f) has been made, exceeds 10.0% of the product of the Current
Market Price (determined as provided in Section 15.5(i)) on the Record Date with
respect to such distribution times the number of shares of Common Stock
outstanding on such date, then, and in each such case, immediately after the
close of business on such date, the Conversion Price shall be reduced so that
the same shall equal the price determined by multiplying the Conversion Price in
effect immediately prior to the close of business on such Record Date by a
fraction (i) the numerator of which shall be equal to the Current Market Price
on the Record Date less an amount equal to the quotient of (x) the excess of
such combined amount over such 10.0% and (y) the number of shares of Common
Stock outstanding on the Record Date and (ii) the denominator of which shall be
equal to the Current Market Price on such date, provided, however, that in the
event the portion of the cash so distributed applicable to one share of Common
Stock is equal to or greater than the Current Market Price of the Common Stock
on the Record Date, in lieu of the foregoing adjustment, adequate provision
shall be made so that each Debentureholder shall have the right to receive upon
conversion of a Debenture (or any portion thereof) the amount of cash such
holder would have received had such holder converted such Debenture (or portion
thereof) immediately prior to such Record Date. In the event that such dividend
or distribution is not so paid or made, the Conversion Price shall again be
adjusted to be the Conversion Price which would then be in effect if such
dividend or distribution had not been declared. Any cash distribution to all
holders of Common Stock as to which the Company makes the election permitted by
Section 15.5(n) and as to which the Company has complied with the requirements
of such Section shall be treated as not having been made for all purposes of
this Section 15.5(e).
(f) In case a tender offer made by the Company or any of its
subsidiaries for all or any portion of the Common Stock shall expire and such
tender offer (as amended upon the expiration thereof) shall require the payment
to shareholders (based on the acceptance (up to any maximum specified in the
terms of the tender offer) of Purchased Shares (as defined
-68-
<PAGE> 77
below)) of an aggregate consideration having a fair market value (as determined
by the Board of Directors, whose determination shall be conclusive and described
in a Board Resolution) that combined together with (1) the aggregate of the cash
plus the fair market value (as determined by the Board of Directors, whose
determination shall be conclusive and described in a Board Resolution), as of
the expiration of such tender offer, of consideration payable in respect of any
other tender offers, by the Company or any of its subsidiaries for all or any
portion of the Common Stock expiring within the twelve (12) months preceding the
expiration of such tender offer and in respect of which no adjustment pursuant
to this Section 15.5(f) has been made and (2) the aggregate amount of any
distributions to all holders of the Company's Common Stock made exclusively in
cash within twelve (12) months preceding the expiration of such tender offer and
in respect of which no adjustment pursuant to Section 15.5(e) has been made,
exceeds 10.0% of the product of the Current Market Price (determined as provided
in Section 15.5(i)) as of the last time (the "Expiration Time") tenders could
have been made pursuant to such tender offer (as it may be amended) times the
number of shares of Common Stock outstanding (including any tendered shares) on
the Expiration Time, then, and in each such case, immediately prior to the
opening of business on the day after the date of the Expiration Time, the
Conversion Price shall be adjusted so that the same shall equal the price
determined by multiplying the Conversion Price in effect immediately prior to
close of business on the date of the Expiration Time by a fraction of which the
numerator shall be the number of shares of Common Stock outstanding (including
any tendered shares) on the Expiration Time multiplied by the Current Market
Price of the Common Stock on the Trading Day next succeeding the Expiration Time
and the denominator shall be the sum of (x) the fair market value (determined as
aforesaid) of the aggregate consideration payable to shareholders based on the
acceptance (up to any maximum specified in the terms of the tender offer) of all
shares validly tendered and not withdrawn as of the Expiration Time (the shares
deemed so accepted, up to any such maximum, being referred to as the "Purchased
Shares") and (y) the product of the number of shares of Common Stock outstanding
(less any Purchased Shares) at the Expiration Time and the Current Market Price
of the Common Stock on the Trading Day next succeeding the Expiration Time, such
reduction (if any) to become effective immediately prior to the opening of
business on the day following the Expiration Time. In the event that the Company
is obligated to purchase shares pursuant to any such tender offer, but the
Company is permanently prevented by applicable law from effecting any such
purchases or all such purchases are rescinded, the Conversion Price shall again
be adjusted to be the Conversion Price which would then be in effect if such
tender offer had not been made. If the application of this Section 15.5(f) to
any tender offer would result in an increase in the Conversion Price, no
adjustment shall be made for such tender offer under this Section 15.5(f). Any
cash distribution to all holders of Common Stock as to which the Company has
made the election permitted by Section 15.5(n) and as to which the Company has
complied with the requirements of such Section shall be treated as not having
been made for all purposes of this Section 15.5(f).
(g) In case of a tender or exchange offer made by a person
other than the Company or any Subsidiary for an amount which increases the
offeror's ownership of Common Stock to more than 25% of the Common Stock
outstanding and shall involve the payment by
-69-
<PAGE> 78
such person of consideration per share of Common Stock having a fair market
value (as determined by the Board of Directors, whose determination shall be
conclusive, and described in a resolution of the Board of Directors at the last
time (the "Tender Expiration Time") tenders or exchanges may be made pursuant to
such tender or exchange offer (as it shall have been amended)) that exceeds the
Current Market Price of the Common Stock on the Trading Day next succeeding the
Tender Expiration Time, and in which, as of the Tender Expiration Time the Board
of Directors is not recommending rejection of the offer, the Conversion Price
shall be reduced so that the same shall equal the price determined by
multiplying the Conversion Price in effect immediately prior to the Tender
Expiration Time by a fraction of which the numerator shall be the number of
shares of Common Stock outstanding (including any tendered or exchanged shares)
on the Tender Expiration Time multiplied by the Current Market Price of the
Common Stock on the Trading Day next succeeding the Tender Expiration Time and
the denominator shall be the sum of (x) the fair market value (determined as
aforesaid) of the aggregate consideration payable to shareholders based on the
acceptance (up to any maximum specified in the terms of the tender or exchange
offer) of all shares validly tendered or exchanged and not withdrawn as of the
Tender Expiration Time (the shares deemed so accepted, up to any such maximum,
being referred to as the "Tender Purchased Shares") and (y) the product of the
number of shares of Common Stock outstanding (less any Tender Purchased Shares)
on the Tender Expiration Time and the Current Market Price of the Common Stock
on the Trading Day next succeeding the Tender Expiration Time, such reduction to
become effective immediately prior to the opening of business on the day
following the Tender Expiration Time. In the event that such person is obligated
to purchase shares pursuant to any such tender or exchange offer, but such
person is permanently prevented by applicable law from effecting any such
purchases or all such purchases are rescinded, the Conversion Price shall again
be adjusted to be the Conversion Price which would then be in effect if such
tender or exchange offer had not been made. Notwithstanding the foregoing, the
adjustment described in this Section 15.5(g) shall not be made if, as of the
Tender Expiration Time, the offering documents with respect to such offer
disclose a plan or intention to cause the Company to engage in any transaction
described in Article XII.
(h) In case the Company shall issue Common Stock or securities
convertible into, or exchangeable for, Common Stock at a price per share (or
having a conversion or exchange price per share) that is less than 95% of the
Current Market Price on the date of issuance of such securities (but excluding,
among other things, issuances: (a) pursuant to any bona fide plan for the
benefit of employees, directors or consultants of the Company now or hereafter
in effect; (b) to acquire all or any portion of a business in an arm's-length
transaction between the Company and an unaffiliated third party including, if
applicable, issuances upon exercise of options or warrants assumed in connection
with such an acquisition; (c) in a bona fide public offering pursuant to a firm
commitment underwriting (or a similar type of offering made pursuant to Rule
144A and/or Regulation S under the Securities Act) or sales at the market
pursuant to a continuous offering stock program; (d) pursuant to the exercise of
warrants, rights (including, without limitation, earnout rights) or options, or
upon the conversion of convertible securities, which are issued and outstanding
on the date hereof, or which may be issued in the future at fair value and with
an exercise price or Conversion Price
-70-
<PAGE> 79
at least equal to the Current Market Price on the date of issuance of such
securities; and (e) pursuant to a dividend reinvestment plan or other plan
hereafter adopted for the reinvestment of dividends or interest provided that
such Common Stock is issued at a price at least equal to 95% of the Current
Market Price of the Common Stock at the time of such issuance), the Conversion
Price shall be adjusted so that the same shall equal the price determined by
multiplying (i) the Conversion Price on the day immediately prior to such date
of issuance by (ii) a fraction, the numerator of which shall be the sum of (A)
the number of shares of Common Stock outstanding on such date and (B) the number
of additional shares of Common Stock which the aggregate consideration
receivable by the Company for the total number of shares of Common Stock so
issued (or into which the convertible securities may convert) would purchase at
the Current Market Price as of the trading day immediately preceding the date of
the public announcement of the actual terms (including the pricing terms) of
such issuance (or if there is no such public announcement prior to the effective
date of such issuance, such effective date) and the denominator of which shall
be the sum of (1) the number of shares of Common Stock outstanding on such date
and (2) the number of shares of Common Stock issued (or into which the
convertible securities may convert). An adjustment made pursuant to this
paragraph (h) shall be made on the next Business Day following the date on which
any such issuance is made and shall be effective retroactively immediately after
the close of business on such date. For purposes of this paragraph (h), the
aggregate consideration receivable by the Company in connection with the
issuance of shares of Common Stock or of securities convertible into shares of
Common Stock shall be deemed to be equal to the sum of the aggregate offering
price (before deduction of underwriting discounts or commissions and expenses
payable to third parties) of all such securities plus the minimum aggregate
amount, if any, payable upon conversion of any such convertible securities into
shares of Common Stock.
(i) For purposes of this Section 15.5, the following terms
shall have the meaning indicated:
(1) "Closing Price" with respect to any securities on
any day shall mean the closing sale price regular way on such day or, in case no
such sale takes place on such day, the average of the reported closing bid and
asked prices, regular way, in each case on the Nasdaq National Market or New
York Stock Exchange, as applicable, or, if such security is not listed or
admitted to trading on such National Market or Exchange, on the principal
national security exchange or quotation system on which such security is quoted
or listed or admitted to trading, or, if not quoted or listed or admitted to
trading on any national securities exchange or quotation system, the average of
the closing bid and asked prices of such security on the over-the-counter market
on the day in question as reported by the National Quotation Bureau
Incorporated, or a similar generally accepted reporting service, or if not so
available, in such manner as furnished by any New York Stock Exchange member
firm selected from time to time by the Board of Directors for that purpose, or a
price determined in good faith by the Board of Directors, whose determination
shall be conclusive and described in a Board Resolution.
-71-
<PAGE> 80
(2) "Current Market Price" shall mean the lesser of
(a) the Closing Price per share of Common Stock on the date in question and (b)
the average of the daily Closing Prices per share of Common Stock for the ten
(10) consecutive Trading Days immediately prior to the date in question;
provided, however, that (1) if the "ex" date (as hereinafter defined) for any
event (other than the issuance or distribution or Fundamental Change requiring
such computation) that requires an adjustment to the Conversion Price pursuant
to Section 15.5(a), (b), (c), (d), (e), (f), (g) or (h) occurs during such ten
(10) consecutive Trading Days, the Closing Price for each Trading Day prior to
the "ex" date for such other event shall be adjusted by multiplying such Closing
Price by the same fraction by which the Conversion Price is so required to be
adjusted as a result of such other event, (2) if the "ex" date for any event
(other than the issuance or distribution or Fundamental Change requiring such
computation) that requires an adjustment to the Conversion Price pursuant to
Section 15.5(a), (b), (c), (d), (e), (f), (g) or (h) occurs on or after the "ex"
date for the issuance or distribution or Fundamental Change requiring such
computation and prior to the day in question, the Closing Price for each Trading
Day on and after the "ex" date for such other event shall be adjusted by
multiplying such Closing Price by the reciprocal of the fraction by which the
Conversion Price is so required to be adjusted as a result of such other event,
and (3) if the "ex" date for the issuance, distribution or Fundamental Change
requiring such computation is prior to the day in question, after taking into
account any adjustment required pursuant to clause (1) or (2) of this proviso,
the Closing Price for each Trading Day on or after such "ex" date shall be
adjusted by adding thereto the amount of any cash and the fair market value (as
determined by the Board of Directors in a manner consistent with any
determination of such value for purposes of Section 15.5(d), (f) or (g), whose
determination shall be conclusive and described in a Board Resolution) of the
evidences of indebtedness, shares of capital stock or assets being distributed
applicable to one share of Common Stock as of the close of business on the day
before such "ex" date. For purposes of any computation under Sections 15.5(f) or
(g), the Current Market Price of the Common Stock on any date shall be deemed to
be the average of the daily Closing Prices per share of Common Stock for such
day and the next two succeeding Trading Days; provided, however, that if the
"ex" date for any event (other than the tender offer requiring such computation)
that requires an adjustment to the Conversion Price pursuant to Section 15.5(a),
(b), (c), (d), (e), (f), (g) or (h) occurs on or after the Expiration Time for
the tender or exchange offer requiring such computation and prior to the day in
question, the Closing Price for each Trading Day on and after the "ex" date for
such other event shall be adjusted by multiplying such Closing Price by the
reciprocal of the fraction by which the Conversion Price is so required to be
adjusted as a result of such other event. For purposes of this paragraph, the
term "ex" date, (1) when used with respect to any issuance or distribution or
Fundamental Change, means the first date on which the Common Stock trades
regular way on the relevant exchange or in the relevant market from which the
Closing Price was obtained without the right to receive such issuance or
distribution, (2) when used with respect to any subdivision or combination of
shares of Common Stock, means the first date on which the Common Stock trades
regular way on such exchange or in such market after the time at which such
subdivision or combination becomes effective, and (3) when used with respect to
any tender or exchange offer means the first date on which the Common Stock
trades regular way on such exchange or in such market after the Expiration Time
or Tender Expiration Time, as
-72-
<PAGE> 81
the case may be, of such offer. Notwithstanding the foregoing, whenever
successive adjustments to the Conversion Price are called for pursuant to this
Section 15.5, such adjustments shall be made to the Current Market Price as may
be necessary or appropriate to effectuate the intent of this Section 15.5 and to
avoid unjust or inequitable results as determined in good faith by the Board of
Directors.
(3) "fair market value" shall mean the amount which a
willing buyer would pay a willing seller in an arm's length transaction.
(4) "Record Date" shall mean, with respect to any
dividend, distribution or other transaction or event in which the holders of
Common Stock have the right to receive any cash, securities or other property or
in which the Common Stock (or other applicable security) is exchanged for or
converted into any combination of cash, securities or other property, the date
fixed for determination of shareholders entitled to receive such cash,
securities or other property (whether such date is fixed by the Board of
Directors or by statute, contract or otherwise).
(5) "Trading Day" shall mean (x) if the applicable
security is quoted on the Nasdaq National Market, a day on which trades may be
made thereon or (y) if the applicable security is listed or admitted for trading
on the New York Stock Exchange or another national security exchange, a day on
which the New York Stock Exchange or another national security exchange is open
for business or (z) if the applicable security is not so listed, admitted for
trading or quoted, any day other than a Saturday or Sunday or a day on which
banking institutions in the State of New York are authorized or obligated by law
or executive order to close.
(j) The Company may make such reductions in the Conversion
Price, in addition to those required by Sections 15.5(a), (b), (c), (d), (e),
(f) and (g), as the Board of Directors considers to be advisable to avoid or
diminish any income tax to holders of Common Stock or rights to purchase Common
stock resulting from any dividend or distribution of stock (or rights to acquire
stock) or from any event treated as such for income tax purposes.
To the extent permitted by applicable law, the
Company from time to time may reduce the Conversion Price by any amount for any
period of time if the period is at least twenty (20) days, the reduction is
irrevocable during the period and the Board of Directors shall have made a
determination that such reduction would be in the best interests of the Company,
which determination shall be conclusive and described in a Board Resolution.
Whenever the Conversion Price is reduced pursuant to the preceding sentence, the
Company shall mail to the holder of each Debenture at his last address appearing
on the Debenture register provided for in Section 2.5 a notice of the reduction
at least fifteen (15) days prior to the date the reduced Conversion Price takes
effect, and such notice shall state the reduced Conversion Price and the period
during which it will be in effect.
-73-
<PAGE> 82
(k) No adjustment in the Conversion Price shall be required
unless such adjustment would require an increase or decrease of at least 1% in
such price; provided, however, that any adjustments which by reason of this
Section 15.5(k) are not required to be made shall be carried forward and taken
into account in any subsequent adjustment. All calculations under this Article
XV shall be made by the Company and shall be made to the nearest cent or to the
nearest one hundredth of a share, as the case may be. No adjustment need be made
for a change in the par value or no par value of the Common Stock.
(l) Whenever the Conversion Price is adjusted as herein
provided, the Company shall promptly file with the Trustee and any conversion
agent other than the Trustee an Officers' Certificate setting forth the
Conversion Price after such adjustment and setting forth a brief statement of
the facts requiring such adjustment. Unless and until a Responsible Officer of
the Trustee shall have received such Officers' Certificate, the Trustee shall
not be deemed to have knowledge of any adjustment of the Conversion Price and
may assume without inquiry that the last Conversion Price of which it has
knowledge remains in effect. Promptly after delivery of such certificate, the
Company shall prepare a notice of such adjustment of the Conversion Price
setting forth the adjusted Conversion Price and the date on which each
adjustment becomes effective and shall mail such notice of such adjustment of
the Conversion Price to the holder of each Debenture at his last address
appearing on the Debenture register provided for in Section 2.5, within twenty
(20) days of the effective date of such adjustment. Failure to deliver such
notice shall not effect the legality or validity of any such adjustment.
(m) In any case in which this Section 15.5 provides that an
adjustment shall become effective immediately after a Record Date for an event,
the Company may defer until the occurrence of such event (i) issuing to the
holder of any Debenture converted after such Record Date and before the
occurrence of such event the additional shares of Common Stock issuable upon
such conversion by reason of the adjustment required by such event over and
above the Common Stock issuable upon such conversion before giving effect to
such adjustment and (ii) paying to such holder any amount in cash in lieu of any
fraction pursuant to Section 15.3.
(n) For purposes of this Section 15.5, the number of shares of
Common Stock at any time outstanding shall not include shares held in the
treasury of the Company but shall include shares issuable in respect of scrip
certificates issued in lieu of fractions of shares of Common Stock. The Company
will not pay any dividend or make any distribution on shares of Common Stock
held in the treasury of the Company.
(o) In lieu of making any adjustment to the Conversion Price
pursuant to Section 15.5(e), the Company may elect to reserve an amount of cash
for distribution to the holders of the Debentures upon the conversion of the
Debentures so that any such holder converting Debentures will receive upon such
conversion, in addition to the shares of Common Stock and other items to which
such holder is entitled, the full amount of cash which such holder would have
received if such holder had, immediately prior to the Record Date for such
distribution of cash, converted its Debentures into Common Stock, together with
any interest
-74-
<PAGE> 83
accrued with respect to such amount, in accordance with this Section 15.5(o).
The Company may make such election by providing an Officers' Certificate to the
Trustee to such effect on or prior to the payment date for any such distribution
and depositing with the Trustee on or prior to such date an amount of cash equal
to the aggregate amount the holders of the Debentures would have received if
such holders had, immediately prior to the Record Date for such distribution,
converted all of the Debentures into Common Stock. Any such funds so deposited
by the Company with the Trustee shall be invested by the Trustee in marketable
obligations issued or fully guaranteed by the United States government with a
maturity not more than three (3) months from the date of issuance. Upon
conversion of Debentures by a holder, the holder will be entitled to receive, in
addition to the Common Stock issuable upon conversion, an amount of cash equal
to the amount such holder would have received if such holder had, immediately
prior to the Record Date for such distribution, converted its Debenture into
Common Stock, along with such holder's pro rata share of any accrued interest
earned as a consequence of the investment of such funds. Promptly after making
an election pursuant to this Section 15.5(o), the Company shall give or shall
cause to be given notice to all Debentureholders of such election, which notice
shall state the amount of cash per $1,000 principal amount of Debentures such
holders shall be entitled to receive (excluding interest) upon conversion of the
Debentures as a consequence of the Company having made such election.
Section 15.6 Reclassification, Consolidation, Merger or Sale. If any
transaction shall occur (including, without limitation (a) any recapitalization
or reclassification of shares of Common Stock (other than a change in par value,
or from par value to no par value, or from no par value to par value, or as a
result of a subdivision or combination of Common Stock), (b) any consolidation
of the Company with, or merger of the Company into, any other person, or any
merger of another person into the Company (other than a merger that does not
result in a reclassification, conversion, exchange or cancellation of Common
Stock), (c) any sale, transfer or lease of all or substantially all of the
assets of the Company or (d) any compulsory share exchange) pursuant to which
either shares of Common Stock shall be converted into the right to receive other
securities, cash or other property, or, in the case of a sale or transfer of all
or substantially all of the assets of the Company, the holders of Common Stock
shall be entitled to receive other securities, cash or other property, then the
Company, or such successor or purchasing corporation, as the case may be, shall,
as a condition precedent to such recapitalization, reclassification, change,
consolidation, merger, sale, transfer or share exchange, execute and deliver to
the Trustee a supplemental indenture providing that the holder of each Debenture
then outstanding shall have the right thereafter, to convert such Debenture only
into: (x) in the case of any such transaction that does not constitute a Common
Stock Fundamental Change (as defined in Section 15.11(b)) and subject to funds
being legally available for such purpose under applicable law at the time of
such conversion, the kind and amount of the securities, cash or other property
that would have been receivable upon such recapitalization, reclassification,
consolidation, merger, sale, transfer or share exchange by a holder of the
number of shares of Common Stock issuable upon conversion of such Debentures
immediately prior to such recapitalization, reclassification, consolidation,
merger, sale, transfer or share exchange, after giving effect, in the case of
any Non-Stock Fundamental Change (as
-75-
<PAGE> 84
defined in Section 15.11(b)), to any adjustment in the Conversion Price in
accordance with Section 15.11(a)(i) and (y) in the case of any such transaction
that constitutes a Common Stock Fundamental Change, common stock of the kind
received by holders of Common Stock as a result of such Common Stock Fundamental
Change in an amount determined in accordance with Section 15.11(a)(ii). Such
supplemental indenture shall provide for adjustments that, for events subsequent
to the effective date of such supplemental indenture shall be as nearly
equivalent as may be practicable to the relevant adjustments provided for in
this Article XV. If, in the case of any such consolidation, merger, transfer or
lease, the capital stock and other securities and assets (including cash)
receivable thereupon by a holder of Common stock includes shares of capital
stock or other securities or assets of a corporation other than the successor or
purchasing corporation, as the case may be, in such consolidation, merger,
transfer or lease, then such supplemental indenture shall also be executed by
such other corporation and shall contain such additional provisions to protect
the interests of the holders as the Board of Directors shall reasonably consider
necessary by reason of the foregoing.
The above provisions of this Section shall similarly apply to
successive recapitalizations, consolidations, mergers, sales, transfers or share
exchanges.
In the event the Company shall execute a supplemental indenture
pursuant to this Section 15.6, the Company shall promptly file with the Trustee
an Officers' Certificate briefly stating the reasons therefor, the kind or
amount of shares of capital stock or securities or assets (including cash)
receivable by holders upon the conversion of their Debentures after any such
recapitalization, reclassification, change, consolidation, merger, sale,
transfer or share exchange and any adjustment to be made with respect thereto.
Section 15.7 Taxes on Shares Issued. The issue of stock certificates on
conversions of Debentures shall be made without charge to the converting
Debentureholder for any tax in respect of the issue thereof. The Company shall
not, however, be required to pay any tax which may be payable in respect of any
transfer involved in the issue and delivery of stock in any name other than that
of the holder of any Debenture converted, and the Company shall not be required
to issue or deliver any such stock certificate unless and until the person or
persons requesting the issue thereof shall have paid to the Company the amount
of such tax or shall have established to the satisfaction of the Company that
such tax has been paid.
Section 15.8 Reservation of Shares; Shares to Be Fully Paid; Listing of
Common Stock. The Company shall provide, free from preemptive rights, out of its
authorized but unissued shares or shares held in treasury, sufficient shares to
provide for the conversion of the Debentures from time to time as such
Debentures are presented for conversion, and no Debenture shall be issued unless
such sufficient number of shares has been reserved and are available for
issuance upon conversion of Debentures under this Article XV.
Before taking any action which would cause an adjustment reducing the
Conversion Price below the then par value, if any, of the shares of Common Stock
issuable upon conversion of the Debentures, the Company will take all corporate
action which may, in the
-76-
<PAGE> 85
opinion of its counsel, be necessary in order that the Company may validly and
legally issue shares of such Common Stock at such adjusted Conversion Price.
The Company covenants that all shares of Common Stock issued upon
conversion of Debentures will be fully paid and non-assessable by the Company
and free from all taxes, liens and charges with respect to the issue thereof.
The Company covenants that if any shares of Common Stock to be provided
for the purpose of conversion of Debentures hereunder require registration with
or approval of any governmental authority under any Federal or State law before
such shares may be validly issued upon conversion, the Company will in good
faith and as expeditiously as possible endeavor to secure such registration or
approval, as the case may be.
The Company further covenants that if at any time the Common Stock
shall be listed on the Nasdaq National Market or any other national securities
exchange or automated quotation system the Company will, if permitted by the
rules of such exchange or automated quotation system, list and keep listed, so
long as the Common Stock shall be so listed on such exchange or automated
quotation system, all Common Stock issuable upon conversion of the Debentures.
Section 15.9 Responsibility of Trustee. Except as otherwise expressly
provided for in this Article XV, the Company is solely responsible for
performing the duties and responsibilities contained in this Article XV. The
Trustee and any other conversion agent shall not at any time be under any duty
or responsibility to any holder of Debentures to determine whether any facts
exist which may require any adjustment of the Conversion Price, or with respect
to the nature or extent or calculation of any such adjustment when made, or with
respect to the method employed, or herein or in any supplemental indenture
provided to be employed, in making the same. The Trustee and any other
conversion agent shall not be accountable with respect to the validity or value
(or the kind or amount) of any shares of Common Stock, or of any securities or
property, which may at any time be issued or delivered upon the conversion of
any Debenture; and the Trustee and any other conversion agent make no
representations with respect thereto. Subject to the provisions of Section 8.1,
neither the Trustee nor any conversion agent shall be responsible for any
failure of the Company to issue, transfer or deliver any shares of Common Stock
or stock certificates or other securities or property or cash upon the surrender
of any Debenture for the purpose of conversion or to comply with any of the
duties, responsibilities or covenants of the Company contained in this Article.
Without limiting the generality of the foregoing, neither the Trustee nor any
conversion agent shall be under any responsibility to determine the correctness
of any provisions contained in any supplemental indenture entered into pursuant
to Section 15.6 relating either to the kind or amount of shares of stock or
securities or property (including cash) receivable by Debentureholders upon the
conversion of their Debentures after any event referred to in such Section 15.6
or to any adjustment to be made with respect thereto, but, subject to the
provisions of Section 8.1, may accept as conclusive evidence of the correctness
of any such provisions, and shall be protected in relying upon, the Officers'
Certificate (which
-77-
<PAGE> 86
the Company shall be obligated to file with the Trustee prior to the execution
of any such supplemental indenture) with respect thereto.
Section 15.10 Notice to Holders Prior to Certain Actions. In case:
(a) the Company shall declare a dividend (or any other
distribution) on its Common Stock (that would require an adjustment in the
Conversion Price pursuant to Section 15.5); or
(b) the Company shall authorize the granting to the holders of
its Common Stock of rights or warrants to subscribe for or purchase any share of
any class or any other rights or warrants; or
(c) of any reclassification of the Common Stock of the Company
(other than a subdivision or combination of its outstanding Common Stock, or a
change in par value, or from par value to no par value, or from no par value to
par value), or of any consolidation or merger to which the Company is a party
and for which approval of any shareholders of the Company is required, or of the
sale or transfer of all or substantially all of the assets of the Company; or
(d) of the voluntary or involuntary dissolution, liquidation
or winding-up of the Company;
the Company shall cause to be filed with the Trustee and to be mailed to each
holder of Debentures at his address appearing on the Debenture register,
provided for in Section 2.5 of this Indenture, as promptly as possible but in
any event at least fifteen days prior to the applicable date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for
the purpose of such dividend, distribution or rights or warrants, or, if a
record is not to be taken, the date as of which the holders of Common Stock of
record to be entitled to such dividend, distribution or rights are to be
determined, or (y) the date on which such reclassification, consolidation,
merger, sale, transfer, dissolution, liquidation or winding-up is expected to
become effective or occur, and the date as of which it is expected that holders
of Common Stock of record shall be entitled to exchange their Common Stock for
securities or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer, dissolution, liquidation or winding-up.
Failure to give such notice, or any defect therein, shall not affect the
legality or validity of such dividend, distribution, reclassification,
consolidation, merger, sale, transfer, dissolution, liquidation or winding-up.
Section 15.11 Adjustments to Conversion Price in the Event of a
Fundamental Change.
(a) Notwithstanding any other provision in this Article XV to
the contrary, if any Fundamental Change (as defined below) occurs, then the
Conversion Price in effect will be adjusted immediately following such
Fundamental Change as described below. In addition, in the event of a Common
Stock Fundamental Change, each Debenture shall be convertible
-78-
<PAGE> 87
solely into common stock of the kind received by holders of Common Stock as a
result of such Common Stock Fundamental Change.
For purposes of calculating any adjustment to be made pursuant
to this Section 15.11 in the event of a Fundamental Change, immediately
following such Fundamental Change (and for such purposes a Fundamental Change
shall be deemed to occur on the earlier of (a) the occurrence of such
Fundamental Change, and (b) the date, if any, fixed for determination of
shareholders entitled to receive the cash, securities, property or other assets
distributable in such Fundamental Change to holders of the Common Stock):
(i) in the case of a Non-Stock Fundamental Change,
the Conversion Price of the Debentures immediately following such Non-Stock
Fundamental Change shall be the lower of (A) the Conversion Price in effect
immediately prior to such Non-Stock Fundamental Change, but after giving effect
to any other prior adjustments effected pursuant to this Article XV and (B) the
product of (1) the Applicable Price (as defined in Section 15.11(b)) and (2) a
fraction, the numerator of which is $1000 and the denominator of which is (x)
the amount of the redemption price for each $1,000 principal amount of
Debentures if the redemption date were the date of such Non-Stock Fundamental
Change (or the date of the period commencing on the first date of original
issuance of the Debentures and through August 14, 2000 or the twelve-month
period commencing August 15, 2000, the product of 107.25% and 106.53%,
respectively, times $1000) plus (y) any accrued interest and unpaid interest
thereon to, but excluding, the date of such Non-Stock Fundamental Change; and
(ii) in the case of a Common Stock Fundamental
Change, the Conversion Price of the Debentures immediately following such Common
Stock Fundamental Change shall be the Conversion Price in effect immediately
prior to such Common Stock Fundamental Change, but after giving effect to any
other prior adjustments effected pursuant to Section 15.5 multiplied by a
fraction, the numerator of which is the Purchaser Stock Price (as defined in
Section 15.11(b)) and the denominator of which is the Applicable Price;
provided, however, that in the event of a Common Stock Fundamental Change in
which (A) 100% of the value of the consideration received by a holder of Common
Stock is common stock of the successor, acquiror or other third party (and cash,
if any, paid with respect to any fractional interests in such common stock
resulting from such Common Stock Fundamental Change) and (B) all of the Common
Stock shall have been exchanged for, converted into or acquired for, common
stock of the successor, acquiror or other third party (and any cash with respect
to fractional interests), the Conversion Price immediately following such Common
Stock Fundamental Change shall be the Conversion Price in effect immediately
prior to such Common Stock Fundamental Change multiplied by a fraction, the
numerator of which is one (1) and the denominator of which is the number of
shares of common stock of the successor, acquiror or other third party received
by a holder of one share of Company Common Stock as a result of such Common
Stock Fundamental Change.
(b) For purposes of this Section 15.11, the following terms
shall have the meaning indicated:
-79-
<PAGE> 88
(i) "Applicable Price" means (i) in the event of a
Non-Stock Fundamental Change in which the holders of Common Stock receive only
cash, the amount of cash received by a holder of one share of Common Stock and
(ii) in the event of any other Fundamental Change, the average of the daily
Closing Price (determined as provided in Section 15.5(i)(1)) for one share of
Common Stock during the 10 Trading Days (determined as provided in Section
15.5(i)(5)) immediately prior to the record date for the determination of the
holders of Common Stock entitled to receive cash, securities, property or other
assets in connection with such Fundamental Change or, if there is no such record
date, prior to the date upon which the holders of Common Stock shall have the
right to receive such cash, securities, property or other assets. The Closing
Price on any Trading Day may be subject to adjustment as provided in Section
15.5(i)(1).
(ii) "Common Stock Fundamental Change" means any
Fundamental Change in which more than 50% of the value (as determined in good
faith by the Board of Directors) of the consideration received by holders of
Common Stock consists of common stock that, for the 10 Trading Days immediately
prior to such Fundamental Change, has been admitted for listing or admitted for
listing subject to notice of issuance on a national securities exchange or
quoted on Nasdaq National Market, provided, however, that a Fundamental Change
shall not be a Common Stock Fundamental Change unless either (i) the Company
continues to exist after the occurrence of such Fundamental Change and the
outstanding Debentures continue to exist as outstanding Debentures or (ii) not
later than the occurrence of such Fundamental Change, the outstanding Debentures
are converted into or exchanged for debentures have terms substantially similar
(but no less favorable) to those of the Debentures.
(iii) "Fundamental Change" means the occurrence of
any transaction or event or series of transactions or events pursuant to which
all or substantially all of the Common Stock shall be exchanged for, converted
into, acquired for or shall constitute solely the right to receive cash,
securities, property or other assets (whether by means of an exchange offer,
liquidation, tender offer, consolidation, merger, combination, reclassification,
recapitalization or otherwise); provided, however, in the case of any such
series of transactions or events, for purposes of adjustment of the Conversion
Price, such Fundamental Change shall be deemed to have occurred when
substantially all of the Common Stock shall have been exchanged for, converted
into or acquired for, or shall constitute solely the right to receive, such
cash, securities, property or other assets, but the adjustment shall be based
upon the consideration that the holders of the Common Stock received in the
transaction or event as a result of which more than 50% of the Common Stock
shall have been exchanged for, converted into or acquired for, or shall
constitute solely the right to receive, such cash, securities, property or other
assets.
(iv) "Non-Stock Fundamental Change" means any
Fundamental Change other than a Common Stock Fundamental Change.
-80-
<PAGE> 89
(v) "Purchaser Stock Price" means, with respect to
any Common Stock Fundamental Change, the average of the daily Closing Price for
one share of the common stock received by holders of the Common Stock in such
Common Stock Fundamental Change during the 10 Trading Days immediately prior to
the date fixed for the determination of the holders of the Common Stock entitled
to receive such common stock or, if there is no such date, prior to the date
upon which the holders of the Common Stock shall have the right to receive such
common stock.
ARTICLE XVI
MISCELLANEOUS PROVISIONS
Section 16.1 Provisions Binding on Company's Successors. All the
covenants, stipulations, promises and agreements of the Company in this
Indenture contained shall bind its successors and assigns whether so expressed
or not.
Section 16.2 Official Acts by Successor Corporation. Any act or
proceeding by any provision of this Indenture authorized or required to be done
or performed by any board, committee or officer of the Company shall and may be
done and performed with like force and effect by the like board, committee or
officer of any corporation that shall at the time be the lawful sole successor
of the Company.
Section 16.3 Addresses for Notices, Etc. Any notice or demand which by
any provision of this Indenture is required or permitted to be given or served
by the Trustee or by the holders of Debentures on the Company shall be deemed to
have been sufficiently given or made, for all purposes if given or served by
being deposited postage prepaid by registered or certified mail in a post office
letter box addressed (until another address is filed by the Company with the
Trustee) to 145 Brandywine Parkway, West Chester, PA 19380 Attention: Chief
Financial Officer. Any notice, direction, request or demand hereunder to or upon
the Trustee shall be deemed to have been sufficiently given or made, for all
purposes, if given or served by being deposited postage prepaid by registered or
certified mail in a post office letter box addressed to the Corporate Trust
Office, which office is, at the date as of which this Indenture is dated,
located at 2 Avenue de Lafayette, 5th floor, Boston, MA 02111-1724, Attention:
Corporate Trust Department (Cephalon, Inc. 7.25% Convertible Subordinated
Debentures).
The Trustee, by notice to the Company, may designate additional or
different addresses for subsequent notices or communications.
Any notice or communication mailed to a Debentureholder shall be mailed
to him by first class mail, postage prepaid, at his address as it appears on the
Debenture register and shall be sufficiently given to him if so mailed within
the time prescribed.
-81-
<PAGE> 90
Failure to mail a notice or communication to a Debentureholder or any
defect in it shall not affect its sufficiency with respect to other
Debentureholders. If a notice or communication is mailed in the manner provided
above, it is duly given, whether or not the addressee receives it.
Section 16.4 Governing Law. This Indenture and each Debenture shall be
deemed to be a contract made under the laws of New York, and for all purposes
shall be construed in accordance with the laws of New York, without regard to
the conflict of laws provisions thereof.
Section 16.5 Evidence of Compliance with Conditions Precedent;
Certificates to Trustee. Upon any application or demand by the Company to the
Trustee to take any action under any of the provisions of this Indenture,
including those actions set forth in Section 314(c) of the Trust Indenture Act,
the Company shall furnish to the Trustee an Officers' Certificate stating that
all conditions precedent, if any, provided for in this Indenture relating to the
proposed action have been complied with, and an Opinion of Counsel stating that,
in the opinion of such counsel, all such conditions precedent have been complied
with.
Each certificate or opinion provided for by or on behalf of the Company
in this Indenture and delivered to the Trustee with respect to compliance with a
condition or covenant provided for in this Indenture shall include (1) a
statement that the person making such certificate or opinion has read such
covenant or condition; (2) a brief statement as to the nature and scope of the
examination or investigation upon which the statement or opinion contained in
such certificate or opinion is based; (3) a statement that, in the opinion of
such person, he has made such examination or investigation as is necessary to
enable him to express an informed opinion as to whether or not such covenant or
condition has been complied with; and (4) a statement as to whether or not, in
the opinion of such person, such condition or covenant has been complied with.
Section 16.6 Legal Holidays. In any case where the date of maturity of
interest on or principal of the Debentures or the date fixed for redemption of
any Debenture will not be a Business Day, then payment of such interest on or
principal of the Debentures need not be made on such date, but may be made on
the next succeeding Business Day with the same force and effect as if made on
the date of maturity or the date fixed for redemption, and no interest shall
accrue for the period from and after such date.
Section 16.7 No Security Interest Created. Nothing in this Indenture or
in the Debentures, expressed or implied, shall be construed to constitute a
security interest under the Uniform Commercial Code or similar legislation, as
now or hereafter enacted and in effect, in any jurisdiction.
Section 16.8 Trust Indenture Act. If any provision hereof limits,
qualifies or conflicts with a provision of the Trust Indenture Act that is
required under the Trust Indenture Act to be a part of and govern this
Indenture, the latter provision shall control. If any provision of this
-82-
<PAGE> 91
Indenture modifies or excludes any provision of the Trust Indenture Act that may
be so modified or excluded, the latter provision shall be deemed to apply to
this Indenture as so modified or to be excluded, as the case may be. Until such
time as this Indenture shall be qualified under the Trust Indenture Act, this
Indenture, the Company and the Trustee shall be deemed for all purposes hereof
to be subject to and governed by the Trust Indenture Act to the same extent as
would be the case if this Indenture were so qualified on the date hereof.
Section 16.9 Benefits of Indenture. Nothing in this Indenture or in the
Debentures, expressed or implied, shall give to any person, other than the
parties hereto, any paying agent, any conversion agent, any authenticating
agent, any Debenture registrar and their successors hereunder, the holders of
Debentures and the holders of Senior Indebtedness, any benefit or any legal or
equitable right, remedy or claim under this Indenture.
Section 16.10 Table of Contents, Headings, Etc. The table of contents
and the titles and headings of the articles and sections of this Indenture have
been inserted for convenience of reference only, are not to be considered a part
hereof, and shall in no way modify or restrict any of the terms or provisions
hereof.
Section 16.11 Authenticating Agent. The Trustee may appoint an
authenticating agent which shall be authorized to act on its behalf and subject
to its direction in the authentication and delivery of Debentures in connection
with the original issuance thereof and transfers and exchanges of Debentures
hereunder, including under Sections 2.4, 2.5, 2.6, 2.7 and 3.3, as fully to all
intents and purposes as though the authenticating agent had been expressly
authorized by this Indenture and those Sections to authenticate and deliver
Debentures. For all purposes of this Indenture, the authentication and delivery
of Debentures by the authenticating agent shall be deemed to be authentication
and delivery of such Debentures "by the Trustee" and a certificate of
authentication executed on behalf of the Trustee by an authenticating agent
shall be deemed to satisfy any requirement hereunder or in the Debentures for
the Trustee's certificate of authentication. Such authenticating agent shall at
all times be a person eligible to serve as trustee hereunder pursuant to Section
8.9.
Any corporation into which any authenticating agent may be merged or
converted or with which it may be consolidated, or any corporation resulting
from any merger, consolidation or conversion to which any authenticating agent
shall be a party, or any corporation succeeding to the corporate trust business
of any authenticating agent, shall be the successor of the authenticating agent
hereunder, if such successor corporation is otherwise eligible under this
Section, without the execution or filing of any paper or any further act on the
part of the parties hereto or the authenticating agent or such successor
corporation.
Any authenticating agent may at any time resign by giving written
notice of resignation to the Trustee and to the Company. The Trustee may at any
time terminate the agency of any authenticating agent by giving written notice
of termination to such authenticating agent and to the Company. Upon receiving
such a notice of resignation or upon such a termination, or in case at any time
any authenticating agent shall cease to be eligible under this Section, the
-83-
<PAGE> 92
Trustee shall promptly appoint a successor authenticating agent (which may be
the Trustee), shall give written notice of such appointment to the Company and
shall mail notice of such appointment to all holders of Debentures as the names
and addresses of such holders appear on the Debenture register.
The Trustee agrees to pay to the authenticating agent from time to time
reasonable compensation for its services (to the extent pre-approved by the
Company in writing), and the Trustee shall be entitled to be reimbursed for such
pre-approved payments, subject to Section 8.6.
The provisions of Sections 8.2, 8.3, 8.4, 9.3 and this Section 16.11
shall be applicable to any authenticating agent.
Section 16.12 Execution in Counterparts. This Indenture may be executed
in any number of counterparts, each of which shall be an original, but such
counterparts shall together constitute but one and the same instrument.
State Street Bank and Trust Company hereby accepts the trusts in this
Indenture declared and provided, upon the terms and conditions hereinabove set
forth.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
-84-
<PAGE> 93
IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be
duly signed all as of the date first written above.
CEPHALON, INC.
By:
Title:
STATE STREET BANK AND TRUST COMPANY,
as Trustee
By:
Title:
<PAGE> 94
EXHIBIT A - FORM OF DEBENTURE
[FORM OF FACE OF DEBENTURE]
FORM OF LEGEND FOR GLOBAL NOTE: UNLESS THIS CERTIFICATE IS PRESENTED BY
AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW
YORK CORPORATION ("DTC"), TO THE COMPANY OR ITS AGENT FOR REGISTRATION
OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS
REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS
MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH
AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.
THE DEBENTURE EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE
SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD WITHIN
THE UNITED STATES OR TO, OR FOR, THE ACCOUNT OR BENEFIT OF, U.S.
PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS
ACQUISITION HEREOF, THE HOLDER (1) REPRESENTS THAT (A) IT IS A
"QUALIFIED INSTITUTIONAL BUYER" (AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT) (B) IT IS AN INSTITUTIONAL "ACCREDITED INVESTOR" (AS
DEFINED IN RULE 501(A)(1), (2), (3) OR (7) UNDER THE SECURITIES ACT)
("INSTITUTIONAL ACCREDITED INVESTOR") OR (C) IT IS NOT A U.S. PERSON
AND IS ACQUIRING THE DEBENTURE EVIDENCED HEREBY IN AN OFFSHORE
TRANSACTION; (2) AGREES THAT IT WILL NOT, WITHIN TWO YEARS AFTER THE
ORIGINAL ISSUANCE OF THE PREFERRED STOCK OF WHICH THE DEBENTURE
EVIDENCED HEREBY HAS BEEN ISSUED UPON EXCHANGE THEREFOR, RESELL OR
OTHERWISE TRANSFER THE DEBENTURE EVIDENCED HEREBY OR THE COMMON STOCK
ISSUABLE UPON CONVERSION OF SUCH DEBENTURE EXCEPT (A) TO THE COMPANY OR
ANY SUBSIDIARY THEREOF, (B) TO A QUALIFIED INSTITUTIONAL BUYER IN
COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, (C) TO AN
INSTITUTIONAL ACCREDITED INVESTOR THAT, PRIOR TO SUCH TRANSFER,
FURNISHES TO THE TRUSTEE, A SIGNED LETTER CONTAINING CERTAIN
REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER
OF THE DEBENTURE EVIDENCED HEREBY (THE FORM OF WHICH LETTER CAN BE
OBTAINED FROM SUCH TRUSTEE), (D) PURSUANT TO THE EXEMPTION FROM
REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF
AVAILABLE) OR (E) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BEEN
DECLARED EFFECTIVE UNDER THE SECURITIES ACT (AND
<PAGE> 95
WHICH CONTINUES TO BE EFFECTIVE AT THE TIME OF SUCH TRANSFER); AND (3)
AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THE DEBENTURE
EVIDENCED HEREBY IS TRANSFERRED (OTHER THAN A TRANSFER PURSUANT TO
CLAUSE 2(E)) A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN
CONNECTION WITH ANY TRANSFER OF THE DEBENTURE EVIDENCED HEREBY WITHIN
TWO YEARS AFTER THE ORIGINAL ISSUANCE OF THE PREFERRED STOCK OF WHICH
THE DEBENTURE EVIDENCED HEREBY HAS BEEN ISSUED UPON EXCHANGE THEREFOR
(OTHER THAN A TRANSFER PURSUANT TO CLAUSE 2(E)), THE HOLDER MUST CHECK
THE APPROPRIATE BOX SET FORTH ON THE REVERSE HEREOF RELATING TO THE
MANNER OF SUCH TRANSFER AND SUBMIT THIS CERTIFICATE TO THE TRUSTEE. IF
THE PROPOSED TRANSFEREE IS A PURCHASER WHO IS NOT A U.S. PERSON OR IS
AN INSTITUTIONAL ACCREDITED INVESTOR, THE HOLDER MUST, PRIOR TO SUCH
TRANSFER, FURNISH TO THE TRUSTEE, SUCH CERTIFICATIONS, LEGAL OPINIONS
OR OTHER INFORMATION AS THE COMPANY MAY REASONABLY REQUIRE TO CONFIRM
THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A
TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT. THIS LEGEND WILL BE REMOVED UPON THE EARLIER OF THE
TRANSFER OF THE DEBENTURE EVIDENCED HEREBY PURSUANT TO CLAUSE 2(E)
ABOVE OR THE EXPIRATION OF TWO YEARS FROM THE ORIGINAL ISSUANCE OF THE
PREFERRED STOCK OF WHICH THE DEBENTURE EVIDENCED HEREBY HAS BEEN ISSUED
UPON EXCHANGE THEREFOR.
A-2
<PAGE> 96
No.____________ $_______________
CEPHALON, INC. CUSIP:_______________
7.25% Convertible Subordinated Debenture
Cephalon, Inc., a corporation duly organized and validly existing under
the laws of the State of Delaware (herein called the "Company", which term
includes any successor corporation under the Indenture referred to on the
reverse hereof), for value received hereby promises to pay to _________________,
or registered assigns, the principal sum of ___________________________________
Dollars on ________________, and to pay interest on said principal sum
semi-annually on February 15 and August 15 of each year, commencing on the first
such date after the Exchange Date (as defined in the Indenture), at the rate per
annum specified in the title of this Debenture, accrued from the February 15 or
August 15, as the case may be, next preceding the date of this Debenture to
which interest has been paid or duly provided for, unless the date of this
Debenture is a date to which interest has been paid or duly provided for, in
which case interest shall accrue from the date of this Debenture, or unless no
interest has been paid or duly provided for on this Debenture, in which case
interest shall accrue from the Exchange Date, until payment of said principal
sum has been made or duly provided for. Notwithstanding the foregoing, if the
date hereof is after any February 1 or August 1, as the case may be, and before
the following February 15 or August 15, this Debenture shall bear interest from
such February 15 or August 15, respectively; provided, however, that if the
Company shall default in the payment of interest due on such February 15 or
August 15, then this Debenture shall bear interest from the next preceding
February 15 or August 15 to which interest has been paid or duly provided for
or, if no interest has been paid or duly provided for on this Debenture, from
the Exchange Date. The interest (including Additional Interest, if any) so
payable on any February 15 or August 15 will be paid to the person in whose name
this Debenture (or one or more Predecessor Debentures) is registered at the
close of business on the record date, which shall be the February 1 or August 1
(whether or not a Business Day) next preceding such February 15 or August 15,
respectively, as provided in the Indenture; provided that any such interest not
punctually paid or duly provided for shall be payable as provided in the
Indenture. Payment of the principal of and interest accrued on this Debenture
(including Additional Interest, if any) shall be made at the office or agency of
the Company maintained for that purpose in the Borough of Manhattan, The City of
New York, which shall initially be the office or agency of State Street Bank and
Trust Company, N.A., an Affiliate of the Trustee, or, at the option of the
holder of this Debenture, at the Corporate Trust Office, in such coin or
currency of the United States of America as at the time of payment shall be
legal tender for the payment of public and private debts; provided, however,
that at the option of the Company, payment of interest (including Additional
Interest, if any) may be made by check mailed to the registered address of the
person entitled thereto; provided further that, with respect to any holder of
Debentures with an aggregate principal amount equal to or in excess of
$2,000,000, at the request of such holder in writing to the Company, interest on
such holder's Debentures shall be paid by wire transfer in immediately available
funds in accordance with the wire transfer instruction supplied by such holder
to the Trustee and paying agent (if different from Trustee).
A-3
<PAGE> 97
Reference is made to the further provisions of this Debenture set forth
on the reverse hereof, including, without limitation, provisions subordinating
the payment of principal of and premium, if any, and interest on this Debenture
to the prior payment in full of all Senior Indebtedness as defined in the
Indenture and provisions giving the holder of this Debenture the right to
convert this Debenture into Common Stock of the Company on the terms and subject
to the limitations referred to on the reverse hereof and as more fully specified
in the Indenture. Such further provisions shall for all purposes have the same
effect as though fully set forth at this place.
This Debenture shall be deemed to be a contract made under the laws of
the State of New York, and for all purposes shall be construed in accordance
with and governed by the laws of said State.
This Debenture shall not be valid or become obligatory for any purpose
until the certificate of authentication hereon shall have been manually signed
by the Trustee or a duly authorized authenticating agent under the Indenture.
IN WITNESS WHEREOF, the Company has caused this Debenture to be duly
executed under its corporate seal.
CEPHALON, INC.
Dated By:
-------------------- -------------------------------------
Title:
Attest:
-----------------------------------------
Secretary
A-4
<PAGE> 98
[FORM OF CERTIFICATE OF AUTHENTICATION]
TRUSTEE'S CERTIFICATE OF AUTHENTICATION
This is one of the Debentures described in the within-named Indenture.
STATE STREET BANK AND TRUST COMPANY, as Trustee
By:
---------------------------------------------
Authorized Signatory
A-5
<PAGE> 99
[FORM OF REVERSE OF DEBENTURE]
CEPHALON, INC.
7.25% Convertible Subordinated Debenture
This Debenture is one of a duly authorized issue of Debentures of the
Company, designated as its 7.25% Convertible Subordinated Debentures (herein
called the "Debentures"), limited to the aggregate principal amount of
$125,000,000 all issued or to be issued under and pursuant to an Indenture,
dated as of August 18, 1999 (herein called the "Indenture"), between the Company
and State Street Bank and Trust Company (herein called the "Trustee"), to which
Indenture and all indentures supplemental thereto reference is hereby made for a
description of the rights, limitations of rights, obligations, duties and
immunities thereunder of the Trustee, the Company and the holders of the
Debentures.
In case an Event of Default, as defined in the Indenture, shall have
occurred and be continuing, the principal of and accrued interest on all
Debentures may be declared, and upon said declaration shall become, due and
payable, in the manner, with the effect and subject to the conditions provided
in the Indenture.
The Indenture contains provisions permitting the Company and the
Trustee, with the consent of the holders of not less than a majority of the
aggregate principal amount of the Debentures at the time outstanding, evidenced
as in the Indenture provided, to execute supplemental indentures adding any
provisions to or changing in any manner or eliminating any of the provisions of
the Indenture or of any supplemental indenture or modifying in any manner the
rights of the holders of the Debentures; provided, however, that no such
supplemental indenture shall (i) extend the fixed maturity of any Debenture, or
reduce the rate or extend the time of payment of interest thereon, or reduce the
principal amount thereof or premium, if any, thereon, or reduce any amount
payable on redemption thereof, or impair or adversely affect the right of any
Debentureholder to institute suit for the payment thereof, or make the principal
thereof or interest or premium, if any, thereon payable in any coin or currency
other than that provided in the Debentures, or modify the provisions of the
Indenture with respect to the subordination of the Debentures in a manner
adverse to the Debentureholders, or impair, or change in any respect adverse to
the holders of the Debentures, the right to convert the Debentures into Common
Stock subject to the terms set forth in the Indenture, including Section 15.6
thereof, without the consent of the holder of each Debenture so affected or (ii)
reduce the aforesaid percentage of Debentures, the holders of which are required
to consent to any such supplemental indenture, without the consent of the
holders of all Debentures then outstanding or reduce the percentage of
Debentures, the holder of which are required to consent to any waiver or modify
any of the provisions of Section
A-6
<PAGE> 100
7.7 or Section 11.2 of the Indenture, except to increase any such percentage or
to provide that certain of the provisions of the Indenture cannot be modified or
waived without the consent of the holder of each outstanding Debenture. It is
also provided in the Indenture that, prior to any declaration accelerating the
maturity of the Debentures, the holders of a majority in aggregate principal
amount of the Debentures at the time outstanding may on behalf of the holders of
all of the Debentures waive any past default or Event of Default under the
Indenture and its consequences except (i) a default in the payment of interest
or premium, if any, on, or the principal of, any of the Debentures, (ii) a
failure by the Company to convert any Debentures into Common Stock of the
Company or (iii) a default in respect of a covenant or provision in the
Indenture which cannot be modified or waived without the consent of the holders
of all Debentures then outstanding affected thereby. Any such consent or waiver
by the holder of this Debenture (unless revoked as provided in the Indenture)
shall be conclusive and binding upon such holder and upon all future holders and
owners of this Debenture and any Debentures which may be issued in exchange or
substitution hereof, irrespective of whether or not any notation thereof is made
upon this Debenture or such other Debentures.
The indebtedness evidenced by the Debentures is, to the extent and in
the manner provided in the Indenture, expressly subordinate and subject in right
of payment to the prior payment in full of all Senior Indebtedness of the
Company, as defined in the Indenture, whether outstanding at the date of the
Indenture or thereafter incurred, and this Debenture is issued subject to the
provisions of the Indenture with respect to such subordination. Each holder of
this Debenture, by accepting the same, agrees to and shall be bound by such
provisions and authorizes the Trustee on his behalf to take such action as may
be necessary or appropriate to effectuate the subordination so provided and
appoints the Trustee his attorney in fact for such purpose.
No reference herein to the Indenture and no provision of this Debenture
or of the Indenture shall alter or impair the obligation of the Company, which
is absolute and unconditional, to pay the principal of and any premium and
interest on this Debenture at the place, at the respective times, at the rate
and in the coin or currency herein prescribed.
Interest on the Debentures shall be computed on the basis of a 360-day
year comprised of twelve 30-day months.
The Debentures are issuable in registered form without coupons in
denominations of $1,000 principal amount and integral multiples thereof. At the
office or agency of the Company referred to on the face hereof, and in the
manner and subject to the limitations provided in the Indenture, without payment
of any service charge but with payment of a sum sufficient to cover any tax or
other governmental charge that may be imposed in connection with any
registration or exchange of Debentures, Debentures may be exchanged for a like
aggregate principal amount of Debentures of other authorized denominations.
A-7
<PAGE> 101
The Debentures will not be redeemable at the option of the Company
prior to August 17, 2001. On or after such date and prior to maturity the
Debentures may be redeemed at the option of the Company as a whole, or from time
to time in part, upon mailing a notice of such redemption not less than 20 nor
more than 60 days before the date fixed for redemption to the holders of
Debentures at their last registered addresses, all as provided in the Indenture,
at the following optional redemption prices (expressed as percentages of the
principal amount), together in each case with accrued interest to, but
excluding, the date fixed for redemption.
If redeemed during the 12-month period beginning August 15 (beginning
August 17, 2001 and ending on August 14, 2002, in the case of the first such
period):
<TABLE>
<CAPTION>
YEAR PERCENTAGE
---- ----------
<S> <C>
2001.............................................. 105.80%
2002.............................................. 105.08
2003.............................................. 104.35
2004.............................................. 103.64
2005.............................................. 102.90
2006.............................................. 102.18
2007.............................................. 101.45
2008.............................................. 100.73
</TABLE>
and 100% at August 15, 2009 and thereafter; provided, that if the date fixed for
redemption is a February 15 or August 15, then the interest payable on such date
shall be paid to the holder of record on the next preceding February 1 or August
1.
The Debentures are not subject to redemption through the operation of
any sinking fund.
Subject to the provisions of the Indenture, the holder hereof has, at
its option, the right, at any time or on or prior to the close of business on
the tenth anniversary of the Exchange Date (or, as to all or any portion hereof
called for redemption, prior to the close of business on the next Business Day
preceding the date fixed for redemption (unless the Company shall default in
payment due upon redemption)), to convert the principal hereof or any portion of
such principal which is $1,000 or an integral multiple thereof, into that number
of fully paid and non-assessable shares of Company's Common Stock, as said
shares shall be constituted at the date of conversion, obtained by dividing the
principal amount of this Debenture or portion thereof to be converted by the
conversion price of $17.92 or such conversion price as adjusted from time to
time in the Indenture, upon surrender of this Debenture, together with a
conversion notice as provided in the Indenture and this Debenture, to the
Company at the office or agency of the Company maintained for that purpose in
the Borough of Manhattan, The City of New York, or at the option of such holder,
the Corporate Trust Office, and,
A-8
<PAGE> 102
unless the shares issuable on conversion are to be issued in the same name as
this Debenture, duly endorsed by, or accompanied by instruments of transfer in
form satisfactory to the Company duly executed by, the holder or by his duly
authorized attorney. No adjustment in respect of interest or dividends will be
made upon any conversion; provided, however, that if this Debenture shall be
surrendered for conversion during the period from the close of business on any
record date for the payment of interest through the close of business on the
Business Day next preceding the following interest payment date, this Debenture
(unless it or the portion being converted shall have been called for redemption
and a notice of redemption has been mailed to the holders of the Debentures
pursuant to Section 3.2 of the Indenture) must be accompanied by an amount, in
funds acceptable to the Company, equal to the interest otherwise payable on such
interest payment date on the principal amount being converted. No fractional
shares of Common Stock will be issued upon any conversion, but an adjustment in
cash will be paid to the holder, as provided in the Indenture, in respect of any
fraction of a share which would otherwise be issuable upon the surrender of any
Debenture or Debentures for conversion.
Any Debentures called for redemption, unless surrendered for conversion
on or before the close of business on the date fixed for redemption, may be
deemed to be purchased from the holder of such Debentures at an amount equal to
the applicable redemption price, together with accrued interest to the date
fixed for redemption, by one or more investment bankers or other purchasers who
may agree with the Company to purchase such Debentures from the holders thereof
and convert them into Common Stock of the Company and to make payment for such
Debentures as aforesaid to the Trustee in trust for such holders.
Upon due presentment for registration of transfer of this Debenture at
the office or agency of the Company in the Borough of Manhattan, The City of New
York, which shall initially be State Street Bank and Trust Company, N.A., an
Affiliate of the Trustee, or at the option of the holder of this Debenture, at
the Corporate Trust Office, a new Debenture or Debentures of authorized
denominations for an equal aggregate principal amount will be issued to the
transferee in exchange thereof, subject to the limitations provided in the
Indenture, without charge except for any tax or other governmental charge
imposed in connection therewith, and bearing restrictive legends required by the
Indenture.
The Company, the Trustee, any authenticating agent, any paying agent,
any conversion agent and any Debenture registrar may deem and treat the
registered holder hereof as the absolute owner of this Debenture (whether or not
this Debenture shall be overdue and notwithstanding any notation of ownership or
other writing hereon made by anyone other than the Company or any Debenture
registrar), for the purpose of receiving payment hereof, or on account hereof,
for the conversion hereof and for all other purposes, and neither the Company
nor the Trustee nor any other authenticating agent nor any paying agent nor any
other conversion agent nor any Debenture registrar shall be affected by any
notice to the contrary. All payments made to or upon the order of such
registered holder shall, to
A-9-
<PAGE> 103
the extent of the sum or sums paid, satisfy and discharge liability for monies
payable on this Debenture.
No recourse for the payment of the principal of or any premium or
interest on this Debenture, or for any claim based hereon or otherwise in
respect hereof, and no recourse under or upon any obligation, covenant or
agreement of the Company in the Indenture or any indenture supplemental thereto
or in any Debenture, or because of the creation of any indebtedness represented
thereby, shall be had against any incorporator, shareholder, employee, agent,
officer, director or subsidiary, as such, past, present or future, of the
Company or of any successor corporation, either directly or through the Company
or any successor corporation, whether by virtue of any constitution, statute or
rule of law or by the enforcement of any assessment or penalty or otherwise, all
such liability being, by the acceptance hereof and as part of the consideration
for the issue hereof, expressly waived and released.
Terms used in this Debenture and defined in the Indenture are used
herein as therein defined.
A-10
<PAGE> 104
ABBREVIATIONS
The following abbreviations, when used in the inscription of the face
of this Debenture, shall be construed as though they were written out in full
according to applicable laws or regulations:
<TABLE>
<S> <C> <C>
TEN COM - as tenants in common UNIF GIFT MIN ACT - Custodian
---------------------- ------------------
TEN ENT - as tenants by the (Cust) (Minor)
entireties under Uniform Gifts to Minors
JT TEN - as joint tenants with Act
right of survivorship -------------------------------------
and not as tenants in (State)
common
</TABLE>
Additional abbreviations may also be used
though not in the above list.
A-11
<PAGE> 105
[FORM OF CONVERSION NOTICE]
CONVERSION NOTICE
To:___________________________
The undersigned registered owner of this Debenture hereby irrevocably
exercises the option to convert this Debenture, or the portion hereof (which is
$1,000 principal amount or an integral multiple thereof) below designated, into
shares of Common Stock in accordance with the terms of the Indenture referred to
in this Debenture, and directs that the shares issuable and deliverable upon
such conversion, together with any check in payment for fractional shares and
any Debentures representing any unconverted principal amount hereof, be issued
and delivered to the registered holder hereof unless a different name has been
indicated below. If shares or any portion of this Debenture not converted are to
be issued in the name of a person other than the undersigned, the undersigned
will pay all transfer taxes payable with respect thereto. Any amount required to
be paid to the undersigned on account of interest accompanies this Debenture.
Dated:______________________
_______________________________
_______________________________
Signature(s)
Signature(s) must be guaranteed by an eligible Guarantor Institution (banks,
stock brokers, savings and loan associations and credit unions) with membership
in an approved signature guarantee medallion program pursuant to Securities and
Exchange Commission Rule 17Ad-15 if shares of Common Stock are to be issued, or
Debentures to be delivered, other than to and in the name of the registered
holder.
Signature Guarantee
A-12
<PAGE> 106
Fill in for registration of shares if to be issued, and Debentures if to be
delivered, other than to and in the name of the registered holder:
_____________________________________
(Name)
_____________________________________
(Street Address)
_____________________________________
(City, State and Zip Code)
Please print name and address
Principal amount to be converted (if less than all):
$______,000
____________________________________________________
Social Security or Other Taxpayer Identification
Number
A-13
<PAGE> 107
[FORM OF ASSIGNMENT]
For value received ______________________ hereby sell(s), assign(s) and
transfer(s) unto ____________________ (Please insert social security or Taxpayer
Identification Number of assignee) the Debenture, and hereby irrevocably
constitutes and appoints _________________________ attorney to transfer the said
Debenture on the books of the Company, with full power of substitution in the
premises.
In connection with any transfer of the Debenture occurring within two
years of the original issuance of such Debenture (unless such Debenture is being
transferred pursuant to a registration statement that has been declared
effective under the Securities Act), the undersigned confirms that such
Debenture is being transferred:
|_| To Cephalon, Inc. or a subsidiary thereof; or
|_| To a Qualified Institutional Buyer pursuant to and in
compliance with Rule 144A under the Securities Act of 1933, as
amended; or
|_| To an Institutional Accredited Investor pursuant to and in
compliance with the Securities Act of 1933, as amended; or
|_| Pursuant to and in compliance with Rule 144 under the
Securities Act of 1933, as amended;
A-14
<PAGE> 108
and unless the box below is checked, the undersigned confirms that such
Debenture is not being transferred to an "affiliate" of the Company as defined
in Rule 144 under the Securities Act of 1933, as amended (an "Affiliate").
|_| The transferee is an Affiliate of the Company.
Dated:______________________________
Signature(s)
Signature(s) must be guaranteed by an eligible Guarantor Institution (banks,
stock brokers, savings and loan associations and credit unions) with membership
in an approved signature guarantee medallion program pursuant to Securities and
Exchange Commission Rule 17AD-15 if shares of Common Stock are to be issued, or
Debentures are to be delivered, other than to and in the name of the registered
holder.
Signature Guarantee
NOTICE: The signature on the conversion notice, or the assignment must
correspond with the name as written upon the face of the Debenture in every
particular without alteration or enlargement or any change whatever.
A-15
<PAGE> 109
EXHIBIT B
[FORM OF INSTITUTIONAL ACCREDITED INVESTOR LETTER]
Ladies and Gentlemen:
The undersigned is delivering this letter in connection with the sale
or transfer to the undersigned of Convertible Subordinated Debentures (the
"Debentures), which are convertible into shares of Common Stock, $.01 par value
(the "Common Stock"), of Cephalon, Inc. (the "Company").
The undersigned hereby confirms that:
1. The undersigned is an "accredited investor" within
the meaning of Rule 501(a)(1), (2) or (3) under the Securities Act of
1933 (the "Securities Act") or an entity in which all of the equity
owners are accredited investors within the meaning of Rule 501(a)(1),
(2) or (3) under the Securities Act (an "Institutional Accredited
Investor"):
2. (A) Any purchase of Debentures by the undersigned
will be for the undersigned's own account or for the account of one or
more other Institutional Accredited Investors or as fiduciary for the
account of one or more trusts, each of which is an "accredited
investor" within the meaning of Rule 501(a)(7) under the Securities Act
and for each of which the undersigned exercises sole investment
discretion or (B) the undersigned is a "bank," within the meaning of
Section 3(a)(2) of the Securities Act, or a "savings and loan
association" or other institution described in Section 3(5)(a) of the
Securities Act that is acquiring Debentures as fiduciary for the
account of one or more institutions for which the undersigned exercises
sole investment discretion;
3. In the event that the undersigned purchases any
Debentures, the undersigned will acquire Debentures having a minimum
principal amount of not less than $100,000 for the undersigned's own
account or for any separate account for which the undersigned is
acting;
4. The undersigned has such knowledge and experience
in financial and business matters that the undersigned is capable of
evaluating the merits and risks of purchasing the Debentures; and
5. The undersigned is not acquiring Debentures with a
view to distribution thereof or with any present intention of offering
or selling Debentures or the Common Stock issuable upon conversion
thereof, except as permitted below; provided that the disposition of
<PAGE> 110
the undersigned's property and property of any accounts for which the
undersigned is acting as fiduciary shall remain at all times within the
undersigned's control.
The undersigned understands that the Debentures are being offered in a
transaction not involving any public offering within the United States within
the meaning of the Securities Act and that the Debentures and the shares of
Common Stock issuable upon conversion thereof (collectively, the "Securities")
have not been registered under the Securities Act or any applicable state
securities laws, and the undersigned agrees, on its own behalf and on behalf of
each account for which the undersigned acquires any Debentures, that if in the
future the undersigned decides to resell or otherwise transfer such Securities
may be resold or otherwise transferred only (i) to the Company or any subsidiary
thereof, or (ii) to a person who is a "qualified institutional buyer" (as
defined in Rule 144A under the Securities Act) in a transaction meeting the
requirements of Rule 144A, or (iii) to an Institutional Accredited Investor
that, prior to such transfer, furnishes to the Trustee for the Debentures or
transfer agent for the Common Stock, as the case may be, a signed letter
containing certain representations and agreements relating to the restrictions
on transfer of such securities (the form of which letter can be obtained from
such Trustee or transfer agent, as the case may be), or (iv) pursuant to the
exemption from registration provided by Rule 144 under the Securities Art (if
applicable), or (v) pursuant to a registration statement which has been declared
effective under the Securities Act. The undersigned agrees that any such
transfer of Securities referred to in this paragraph shall be in accordance with
applicable securities laws of any State of the United States or any other
applicable jurisdiction and in accordance with the legends set forth on the
Securities. The undersigned further agrees to provide any person purchasing any
of the Securities from the undersigned a notice advising such purchaser that
resales of such Securities are restricted as stated herein (unless such
Securities have been sold or are being transferred pursuant to a registration
statement that has been declared effective under the Securities Act or otherwise
in a transaction which permits the restrictive legends initially set forth
thereon to be removed). The undersigned understands that the Trustee and
transfer agent for the Securities will not be required to accept for
registration of transfer any Securities (unless such Securities have been sold
or are being transferred pursuant to a registration statement that has been
declared effective under the Securities Act or otherwise in a transaction which
permits the restrictive legends initially set forth thereon to be removed),
except upon presentation of evidence satisfactory to the Company that the
foregoing restrictions on transfer have been complied with. The undersigned
further understands that any Securities will be in the form of definitive
physical certificates and that such certificates will bear a legend (unless the
sale of the Securities has been registered under the Securities Act) reflecting
the substance of this paragraph (unless such Securities have been sold or are
being transferred pursuant to a registration statement that has been declared
effective under the Securities Act or otherwise in a transaction which permits
the restrictive legends initially set forth thereon to be removed).
The undersigned acknowledges that the Company, others and you will rely
upon the undersigned's confirmations, acknowledgments and agreements set forth
herein, and the undersigned
B-2
<PAGE> 111
agrees to notify you promptly in writing if any of our representations or
warranties herein ceases to be accurate and complete.
THIS LETTER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE
INTERNAL LAWS OF THE STATE OF NEW YORK
----------------------------------------
(Name of Purchaser)
By:
-------------------------------------
Name:
Title:
Address:
B-3
<PAGE> 1
EXHIBIT 5.1
Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, PA 19103
October 14, 1999
Cephalon, Inc.
145 Brandywine Parkway
West Chester, PA 19380
Re: Cephalon, Inc. - Registration Statement on Form S-3 Relating to the
Registration of 2,500,000 shares of Convertible Exchangeable Preferred
Stock, $125,000,000 7.25% Subordinated Convertible Debentures and
6,975,447 shares of Common Stock, $.01 par value
Ladies and Gentlemen:
We have acted as counsel to Cephalon, Inc., a Delaware corporation (the
"Company"), in connection with the preparation of the subject Registration
Statement on Form S-3 (the "Registration Statement") to be filed with the
Securities and Exchange Commission (the "Commission") under the Securities Act
of 1933, as amended (the "Act"), relating to (i) 2,500,000 shares of Convertible
Exchangeable Preferred Stock (the "Preferred Stock"), (ii) $125,000,000 7.25%
Subordinated Convertible Debentures (the "Debentures") and (iii) 6,975,447
shares of Common Stock of the Company's common stock, par value $.01 per share
(the "Common Stock") issuable upon the conversion of the Preferred Stock or the
Debentures if issue (the "Conversion Shares"), all of which are to be sold by
certain holders of the Preferred Stock, the Debentures, if issued, or the
Conversion Shares as described in the Registration Statement (the "Selling
Stockholders"). The Debentures will be issued, if at all, under an Indenture
dated as of August 18, 1999 (the "Indenture") by and between the Company and
State Street Bank and Trust Company, as Trustee (the "Trustee").
In rendering the opinion set forth below, we have examined (i) the Registration
Statement and the exhibits thereto, (ii) the Restated Certificate of
Incorporation of the Company (the "Certificate"), (iii) the Indenture, (iv) the
specimen Preferred Stock Certificate and (v) the form of Debenture. We have also
examine certain records of the Company's corporate proceedings as reflected in
its minute books and such statutes, records and other documents as we have
deemed relevant. In our examination, we have assumed the genuineness of
documents submitted to us as originals and the conformity with the originals of
all documents submitted to us as copies thereof.
Based upon and subject to the limitations, qualifications, exceptions and
assumptions set forth herein, we are of the opinion that:
1. The shares of Preferred Stock to be sold by the Selling Stockholders
are duly authorized, legally issued, fully paid and nonassessable.
2. The Debentures, when issued, executed and delivered in exchange for
the Preferred Stock in accordance with the terms of the Certificate
and the Indenture, and when authenticated and
<PAGE> 2
delivered by the Trustee in accordance with the Indenture and assuming
no change in the law from the date of this opinion, will be legally
issued and binding obligation of the Company.
3. The Conversion Shares have been duly authorized by the Company and,
when issued and delivered in accordance with the terms of the
Certificate or the Indenture, as the case may be, will be validly
issued, fully paid and nonassessable, assuming no change in applicable
law.
The opinion set forth above is limited to the General Corporation Law of the
State of Delaware, as amended.
We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration
Statement and to the use of our name under the heading "Legal Opinion" in the
Prospectus. In giving such consent, we do not thereby admit that we are acting
within the category of persons whose consent is required under Section 7 of the
Act and the rules or regulations of the Commission thereunder.
The opinion expressed herein is solely for your benefit and may be relied upon
only by you.
Very truly yours,
/s/ Morgan, Lewis & Bockius LLP
<PAGE> 1
EXHIBIT 12
CEPHALON, INC.
COMPUTATION OF RATIO OF EARNINGS
TO FIXED CHARGES AND PREFERRED STOCK DIVIDENDS
(IN THOUSANDS)
<TABLE>
<CAPTION>
SIX MONTHS
YEAR ENDED DECEMBER 31, ENDED JUNE 30,
----------------------------------------------------------- --------------
1994 1995 1996 1997 1998 1999
---- ---- ---- ---- ---- ----
<S> <C> <C> <C> <C> <C> <C>
Fixed charges and preferred stock
dividends:
Interest expense ....................... $ 1,426 $ 3,112 $ 2,286 $ 3,201 $ 1,874 $ 3,390
Preferred stock dividends .............. -- -- -- -- -- --
-------- -------- -------- -------- -------- --------
Total fixed charges and preferred
stock dividends ........................ $ 1,426 $ 3,112 $ 2,286 $ 3,201 $ 1,874 $ 3,390
======== ======== ======== ======== ======== ========
Net loss ............................... (36,065) (33,003) (53,285) (60,419) (55,407) (31,442)
Fixed charges and preferred stock
dividends .............................. 1,426 3,112 2,286 3,201 1,874 3,390
-------- -------- -------- -------- -------- --------
Deficiency of earnings to cover fixed
charges and preferred stock dividends .. ($34,639) ($29,891) ($50,999) ($57,218) ($53,533) ($28,052)
======== ======== ======== ======== ======== ========
Ratio of earnings to fixed charges and
preferred stock dividends (1)........... -- -- -- -- -- --
</TABLE>
(1) For the fiscal years ended December 31, 1994, 1995, 1996, 1997 and 1998
and for the six months ended June 30, 1999, earnings were insufficient
to cover fixed charges. There were no preferred stock dividends
declared or paid by the Company during any of the fiscal years in the
five year period ended December 31, 1998 nor for the six months ended
June 30, 1999. For these reasons, no ratios are provided.
<PAGE> 1
EXHIBIT 23.2
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation by
reference in this registration statement of our report dated February 25, 1999
included in Cephalon, Inc.'s Form 10-K for the year ended December 31, 1998 and
to all references to our Firm included in this registration statement.
/s/ Arthur Andersen LLP
Philadelphia, PA
October 13, 1999
<PAGE> 1
EXHIBIT 25
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM T-1
STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A
CORPORATION DESIGNATED TO ACT AS TRUSTEE
CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO
SECTION 305(b)(2)
----------------------------------------------------------------------
STATE STREET BANK AND TRUST COMPANY
(Exact Name of Trustee as Specified in its Charter)
04-1867445
(I.R.S. Employer Identification No.)
MASSACHUSETTS
(Jurisdiction of Incorporation if not a U.S. National Bank)
225 FRANKLIN STREET, BOSTON, MASSACHUSETTS
(Address of Principal Executive Offices)
02110
(Zip Code)
Maureen Scannell Bateman, Esq. Executive Vice President and General Counsel
225 Franklin Street, Boston Massachusetts 02110
(617) 654-3253
(Name, Address and Telephone Number of Agent for Service)
CEPHALON, INC.
(Exact Name of Obligor as Specified in its Charter)
DELAWARE
(State or Other Jurisdiction of Incorporation or Organization)
23-2484489
(I.R.S. Employer Identification No.)
145 Brandywine Parkway, West Chester, PA
(Address of Principal Executive Offices)
19380
(Zip Code)
7-1/4% CONVERTIBLE SUBORDINATED DEBENTURES
(Title of Indenture Securities)
----------------------------------------------------------------------
<PAGE> 2
ITEM 1. GENERAL INFORMATION.
FURNISH THE FOLLOWING INFORMATION AS TO THE TRUSTEE:
a) NAME AND ADDRESS OF EACH EXAMINING OR SUPERVISORY AUTHORITY TO WHICH IT
IS SUBJECT:
Department of Banking and Insurance of The Commonwealth of Massachusetts
100 Cambridge Street
Boston, Massachusetts
Board of Governors of the Federal Reserve System
Washington, D.C.
Federal Deposit Insurance Corporation
Washington, D.C.
b) WHETHER IT IS AUTHORIZED TO EXERCISE CORPORATE TRUST POWERS.
Trustee is authorized to exercise corporate trust powers.
ITEM 2. AFFILIATIONS WITH OBLIGOR.
IF THE OBLIGOR IS AN AFFILIATE OF THE TRUSTEE, DESCRIBE EACH SUCH
AFFILIATION.
The obligor is not an affiliate of the trustee or of its parent,
State Street Corporation (see note on page 7).
ITEM 3. VOTING SECURITIES OF THE TRUSTEE.
FURNISH THE FOLLOWING INFORMATION AS TO EACH CLASS OF VOTING SECURITIES
OF THE TRUSTEE:
Not applicable.
ITEM 4. TRUSTEESHIPS UNDER OTHER INDENTURES.
IF THE TRUSTEE IS A TRUSTEE UNDER ANOTHER INDENTURE UNDER WHICH ANY OTHER
SECURITIES, OR CERTIFICATES OF INTEREST OR PARTICIPATION IN ANY OTHER
SECURITIES, OF THE OBLIGOR ARE OUTSTANDING, FURNISH THE FOLLOWING INFORMATION:
Not applicable.
ITEM 5. INTERLOCKING DIRECTORATES AND SIMILAR RELATIONSHIPS WITH THE OBLIGOR
OR UNDERWRITERS.
IF THE TRUSTEE OR ANY OF THE DIRECTORS OR EXECUTIVE OFFICERS OF THE
TRUSTEE IS A DIRECTOR, OFFICER, PARTNER, EMPLOYEE, APPOINTEE, OR REPRESENTATIVE
OF THE OBLIGOR OR OF ANY UNDERWRITER FOR THE OBLIGOR, IDENTIFY EACH SUCH PERSON
HAVING ANY SUCH CONNECTION AND STATE THE NATURE OF EACH SUCH CONNECTION.
Not applicable.
ITEM 6. VOTING SECURITIES OF THE TRUSTEE OWNED BY THE OBLIGOR OR ITS OFFICIALS.
FURNISH THE FOLLOWING INFORMATION AS TO THE VOTING SECURITIES OF THE
TRUSTEE OWNED BENEFICIALLY BY THE OBLIGOR AND EACH DIRECTOR, PARTNER, AND
EXECUTIVE OFFICER OF THE OBLIGOR:
Not applicable.
<PAGE> 3
ITEM 7. VOTING SECURITIES OF THE TRUSTEE OWNED BY UNDERWRITERS OR THEIR
OFFICIALS.
FURNISH THE FOLLOWING INFORMATION AS TO THE VOTING SECURITIES OF THE
TRUSTEE OWNED BENEFICIALLY BY EACH UNDERWRITER FOR THE OBLIGOR AND EACH
DIRECTOR, PARTNER, AND EXECUTIVE OFFICER OF EACH SUCH UNDERWRITER:
Not applicable.
ITEM 8. SECURITIES OF THE OBLIGOR OWNED OR HELD BY THE TRUSTEE.
FURNISH THE FOLLOWING INFORMATION AS TO SECURITIES OF THE OBLIGOR OWNED
BENEFICIALLY OR HELD AS COLLATERAL SECURITY FOR OBLIGATIONS IN DEFAULT BY THE
TRUSTEE:
Not applicable.
ITEM 9. SECURITIES OF UNDERWRITERS OWNED OR HELD BY THE TRUSTEE.
IF THE TRUSTEE OWNS BENEFICIALLY OR HOLDS AS COLLATERAL SECURITY FOR
OBLIGATIONS IN DEFAULT ANY SECURITIES OF AN UNDERWRITER FOR THE OBLIGOR, FURNISH
THE FOLLOWING INFORMATION AS TO EACH CLASS OF SECURITIES OF SUCH UNDERWRITER ANY
OF WHICH ARE SO OWNED OR HELD BY THE TRUSTEE:
Not applicable.
ITEM 10. OWNERSHIP OR HOLDINGS BY THE TRUSTEE OF VOTING SECURITIES OF CERTAIN
AFFILIATES OR SECURITY HOLDERS OF THE OBLIGOR.
IF THE TRUSTEE OWNS BENEFICIALLY OR HOLDS AS COLLATERAL SECURITY FOR
OBLIGATIONS IN DEFAULT VOTING SECURITIES OF A PERSON WHO, TO THE KNOWLEDGE OF
THE TRUSTEE (1) OWNS 10 PERCENT OR MORE OF THE VOTING STOCK OF THE OBLIGOR OR
(2) IS AN AFFILIATE, OTHER THAN A SUBSIDIARY, OF THE OBLIGOR, FURNISH THE
FOLLOWING INFORMATION AS TO THE VOTING SECURITIES OF SUCH PERSON:
Not applicable.
ITEM 11. OWNERSHIP OR HOLDINGS BY THE TRUSTEE OF ANY SECURITIES OF A PERSON
OWNING 50 PERCENT OR MORE OF THE VOTING SECURITIES OF THE OBLIGOR.
IF THE TRUSTEE OWNS BENEFICIALLY OR HOLDS AS COLLATERAL SECURITY FOR
OBLIGATIONS IN DEFAULT ANY SECURITIES OF A PERSON WHO, TO THE KNOWLEDGE OF THE
TRUSTEE, OWNS 50 PERCENT OR MORE OF THE VOTING SECURITIES OF THE OBLIGOR,
FURNISH THE FOLLOWING INFORMATION AS TO EACH CLASS OF SECURITIES OF SUCH PERSON
ANY OF WHICH ARE SO OWNED OR HELD BY THE TRUSTEE:
Not applicable.
ITEM 12. INDEBTEDNESS OF THE OBLIGOR TO THE TRUSTEE.
EXCEPT AS NOTED IN THE INSTRUCTIONS, IF THE OBLIGOR IS INDEBTED TO THE
TRUSTEE, FURNISH THE FOLLOWING INFORMATION:
Not applicable.
<PAGE> 4
ITEM 13. DEFAULTS BY THE OBLIGOR.
(a) STATE WHETHER THERE IS OR HAS BEEN A DEFAULT WITH RESPECT TO THE
SECURITIES UNDER THIS INDENTURE. EXPLAIN THE NATURE OF ANY SUCH DEFAULT.
None.
(b) IF THE TRUSTEE IS A TRUSTEE UNDER ANOTHER INDENTURE UNDER WHICH ANY
OTHER SECURITIES, OR CERTIFICATES OF INTEREST OR PARTICIPATION IN ANY OTHER
SECURITIES, OF THE OBLIGOR ARE OUTSTANDING, OR IS TRUSTEE FOR MORE THAN ONE
OUTSTANDING SERIES OF SECURITIES UNDER THE INDENTURE, STATE WHETHER THERE HAS
BEEN A DEFAULT UNDER ANY SUCH INDENTURE OR SERIES, IDENTIFY THE INDENTURE OR
SERIES AFFECTED, AND EXPLAIN THE NATURE OF ANY SUCH DEFAULT.
None.
ITEM 14. AFFILIATIONS WITH THE UNDERWRITERS.
IF ANY UNDERWRITER IS AN AFFILIATE OF THE TRUSTEE, DESCRIBE EACH SUCH
AFFILIATION.
Not applicable.
ITEM 15. FOREIGN TRUSTEE.
IDENTIFY THE ORDER OR RULE PURSUANT TO WHICH THE TRUSTEE IS AUTHORIZED TO
ACT AS SOLE TRUSTEE UNDER INDENTURES QUALIFIED OR TO BE QUALIFIED UNDER THE
ACT.
Not applicable - trustee is a banking association organized under the laws
of The Commonwealth of Massachusetts.
ITEM 16. LIST OF EXHIBITS.
LIST BELOW ALL EXHIBITS FILED AS PART OF THIS STATEMENT OF ELIGIBILITY.
__1. A copy of articles of association of the trustee as now in effect.
A copy of the Articles of Association of the trustee, as now in
effect, is on file with the Securities and Exchange Commission as
Exhibit 1 to Amendment No. 1 to the Statement of Eligibility and
Qualification of Trustee (Form T-1) filed with the Registration
Statement of Morse Shoe, Inc. (File No. 22-17940) and is incorporated
herein by reference thereto.
__2. A copy of the certificate of authority of the trustee to commence
business, if not contained in the articles of association.
A copy of a Statement from the Commissioner of Banks of
Massachusetts that no certificate of authority for the trustee to
commence business was necessary or issued is on file with the
Securities and Exchange Commission as Exhibit 2 to Amendment No. 1
to the Statement of Eligibility and Qualification of Trustee (Form
T-1) filed with the Registration Statement of Morse Shoe, Inc. (File
No. 22- 17940) and is incorporated herein by reference thereto.
__3. A copy of the authorization of the trustee to exercise corporate
trust powers, if such authorization is not contained in the documents specified
in paragraph (1) or (2) above.
A copy of the authorization of the trustee to exercise corporate
trust powers is on file with the Securities and Exchange Commission
as Exhibit 3 to Amendment No. 1 to the Statement of Eligibility and
Qualification of Trustee (Form T-1) filed with the Registration
Statement of Morse Shoe, Inc. (File No. 22-17940) and is
incorporated
<PAGE> 5
herein by reference thereto.
__4. A copy of the existing by-laws of the trustee or instruments
corresponding thereto.
A copy of the by-laws of the trustee, as now in effect, is on file
with the Securities and Exchange Commission as Exhibit 4 to the
Statement of Eligibility and Qualification of Trustee (Form T-1)
filed with the Registration Statement of Eastern Edison Company
(File No. 33-37823) and is incorporated herein by reference thereto.
__5. A copy of each indenture referred to in Item 4, if the obligor is in
default.
Not Applicable.
/X/ 6. The consents of United States institutional trustees required by
Section 321(b) of the Act.
The consent of the trustee required by Section 321(b) of the Act is
annexed hereto as Exhibit 6 and made a part hereof.
/X/ 7. A copy of the latest report of condition of the trustee published
pursuant to law or the requirements of its supervising or examining authority.
A copy of the latest report of condition of the trustee published
pursuant to law or the requirements of its supervising or examining
authority is annexed hereto as Exhibit 7 and made a part hereof.
__8. A copy of any order pursuant to which the foreign trustee is
authorized to act as sole trustee under indentures qualified or to be qualified
under the Act.
Not Applicable.
__9. Consent to service of process required of foreign trustees pursuant
to Rule 10a-4 under the Act.
Not Applicable.
NOTE
The trustee disclaims responsibility for the accuracy or completeness of
information contained in this Statement of Eligibility and Qualification not
known to the trustee and not obtainable by it through reasonable investigation
and as to which information it has obtained from the obligor and has had to rely
or will obtain from the principal underwriters and will have to rely.
The answer furnished to Item 2. of this Form T-1 will be amended, if
necessary, to reflect any facts which differ from those stated and which would
have been required to be stated if known at the date hereof.
<PAGE> 6
SIGNATURE
Pursuant to the requirements of the Trust Indenture Act of 1939, the
trustee, State Street Bank and Trust Company, a corporation organized and
existing under the laws of The Commonwealth of Massachusetts, has duly caused
this Statement of Eligibility and Qualification to be signed on its behalf by
the undersigned, thereunto duly authorized, all in the City of Boston and The
Commonwealth of Massachusetts, on the 13th day of October, 1999.
STATE STREET BANK AND TRUST COMPANY
/s/ Paul G. Grenier
By: ---------------------------------
Name: Paul G. Grenier
Title: Vice President
EXHIBIT 6
CONSENT OF TRUSTEE
Pursuant to the requirements of Section 321(b) of the Trust Indenture Act
of 1939, and in connection with the issue by Cephalon, Inc. of its 7-1/4%
Convertible Subordinated Debentures, State Street Bank and Trust Company hereby
consents that reports of examinations by Federal, State, Territorial or District
authorities may be furnished by such authorities to the Securities and Exchange
Commission upon request therefor.
STATE STREET BANK AND TRUST COMPANY
/s/ Paul G. Grenier
By: ----------------------------------
Name: Paul G. Grenier
Title: Vice President
Boston, Massachusetts
Dated: October 13, 1999
<PAGE> 7
EXHIBIT 7
Consolidated Report of Condition of State Street Bank and Trust Company,
Massachusetts and foreign and domestic subsidiaries, a state banking institution
organized and operating under the banking laws of this commonwealth and a member
of the Federal Reserve System, at the close of business June 30, 1999, published
in accordance with a call made by the Federal Reserve Bank of this District
pursuant to the provisions of the Federal Reserve Act and in accordance with a
call made by the Commissioner of Banks under General Laws, Chapter 172, Section
22(a).
<TABLE>
<CAPTION>
Thousands of
Dollars
ASSETS
<S> <C> <C>
Cash and balances due from depository institutions:
Noninterest-bearing balances and currency and coin ....................... 1,755,237
Interest-bearing balances ................................................ 14,209,161
Securities ................................................................. 13,027,148
Federal funds sold and securities purchased under agreements to resell in
domestic offices of the bank and its Edge subsidiary ..................... 7,840,413
Loans and lease financing receivables:
Loans and leases, net of unearned income ................................. 8,134,756
Allowance for loan and lease losses ...................................... 88,351
Allocated transfer risk reserve .......................................... 0
Loans and leases, net of unearned income and allowances .................. 8,046,405
Assets held in trading accounts ............................................ 1,753,511
Premises and fixed assets .................................................. 529,247
Other real estate owned .................................................... 0
Investments in unconsolidated subsidiaries ................................. 603
Customers' liability to this bank on acceptances outstanding ............... 76,078
Intangible assets .......................................................... 223,035
Other assets ............................................................... 1,481,250
-----------
Total assets ............................................................... 48,942,088
===========
LIABILITIES
Deposits:
In domestic offices ...................................................... 13,006,374
Noninterest-bearing .................................................... 9,462,505
Interest-bearing ....................................................... 3,543,869
In foreign offices and Edge subsidiary ................................... 19,913,151
Noninterest-bearing .................................................... 444,189
Interest-bearing ....................................................... 19,468,962
Federal funds purchased and securities sold under
agreements to repurchase in domestic offices of
the bank and of its Edge subsidiary ...................................... 10,510,055
Demand notes issued to the U.S. Treasury ................................... 0
Trading liabilities ........................................................ 1,151,604
Other borrowed money ....................................................... 198,253
Subordinated notes and debentures .......................................... 0
Bank's liability on acceptances executed and outstanding ................... 76,078
Other liabilities .......................................................... 1,291,791
Total liabilities .......................................................... 46,147,306
-----------
EQUITY CAPITAL
Perpetual preferred stock and related surplus .............................. 0
Common stock ............................................................... 29,931
Surplus .................................................................... 489,739
Undivided profits and capital reserves/Net unrealized holding gains (losses) 2,313,006
Net unrealized holding gains (losses) on available-for-sale securities ... (25,610)
Cumulative foreign currency translation adjustments ........................ (12,284)
Total equity capital ....................................................... 2,794,782
-----------
Total liabilities and equity capital ....................................... 48,942,088
===========
</TABLE>
<PAGE> 8
I, Rex S. Schuette, Senior Vice President and Comptroller of the above named
bank do hereby declare that this Report of Condition has been prepared in
conformance with the instructions issued by the Board of Governors of the
Federal Reserve System and is true to the best of my knowledge and belief.
Rex S. Schuette
We, the undersigned directors, attest to the correctness of this Report of
Condition and declare that it has been examined by us and to the best of our
knowledge and belief has been prepared in conformance with the instructions
issued by the Board of Governors of the Federal Reserve System and is true and
correct.
David A. Spina
Marshall N. Carter
Truman S. Casner
